duloxetine hydrochloride profile

Duloxetine hydrochloride is a serotonin-norepinephrine reuptake inhibitor (SNRI) used to treat major depressive disorder, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. It works by increasing levels of serotonin and norepinephrine, which are neurotransmitters involved in mood regulation and pain perception. The synthesis of duloxetine hydrochloride involves several steps, including the reaction of a chiral amine with a substituted benzaldehyde to form an imine, followed by reduction with sodium borohydride. The resulting secondary amine is then reacted with a substituted benzoic acid to form the final product. Duloxetine hydrochloride is studied for its potential therapeutic benefits in various conditions, including depression, anxiety, pain, and urinary incontinence. It is an important drug due to its efficacy and safety profile, particularly in managing chronic pain and improving quality of life for patients with fibromyalgia and chronic musculoskeletal pain.'

Duloxetine Hydrochloride: A thiophene derivative and selective NEUROTRANSMITTER UPTAKE INHIBITOR for SEROTONIN and NORADRENALINE (SNRI). It is an ANTIDEPRESSIVE AGENT and ANXIOLYTIC, and is also used for the treatment of pain in patients with DIABETES MELLITUS and FIBROMYALGIA. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

(S)-duloxetine hydrochloride : A duloxetine hydrochloride in which the duloxetine moiety has S configuration. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	60834
CHEMBL ID	1200328
CHEBI ID	31526
MeSH ID	M0473681

Synonym
AC-924
2-thiophenepropanamine, n-methyl-gamma-(1-naphthalenyloxy)-, hydrochloride, (s)-
ariclaim
2-thiophenepropanamine, n-methyl-gamma-(1-naphthalenyloxy)-, hydrochloride, (gammas)-
duloxetine hydrochloride [usan]
xeristar
c18h19nos.hcl
(+)-(s)-n-methyl-gamma-(1-naphthyloxy)-2-thiophenepropylamine hydrochloride
ly-264453
duloxetine hydrochloride
(s)-duloxetine hydrochloride
(3s)-n-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propan-1-amine hydrochloride
cymbalta
CHEBI:31526 ,
(3s)-n-methyl-3-(naphthalen-1-yloxy)-3-(2-thienyl)propan-1-amine hydrochloride
smr000469136
duloxetine hcl
MLS001401452
cpd000469136 ,
136434-34-9
cymbalta (tn)
D01179
yentreve (tn)
duloxetine hydrochloride (jan/usp)
NCGC00164559-01
(3s)-n-methyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine hydrochloride
nsc-759112
duloxetine mylan
ly248686 hcl
CHEMBL1200328
duloxetine (as hydrochloride)
ly-248686 hcl
duloxetine hydrochlorise
nsc744012
nsc-744012
(+)-(s)-n-methyl-.gamma.-(1-naphthyloxy)-2-thiophenepropylamine hydrochloride
dtxcid7026443
dtxsid9046443 ,
cas-136434-34-9
tox21_112188
pharmakon1600-01505387
nsc759112
D4223
(s)-(+)-n-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine hydrochloride
c18h20clnos
CCG-101106
unii-9044sc542w
dulane 20
nsc 759112
ly 248686 hcl
9044sc542w ,
duloxetine boehringer ingelheim
(s)-n-methyl-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propan-1-amine hydrochloride
duloxetine hydrochloride [ep monograph]
duloxetine hydrochloride [orange book]
duloxetine hydrochloride [usp-rs]
duloxetine hydrochloride [mart.]
duloxetine hydrochloride [who-dd]
duloxetine lilly
duloxetine hydrochloride [jan]
duloxetine hydrochloride [usp monograph]
drizalma sprinkle
duloxetine hydrochloride [mi]
2-thiophenepropanamine, n-methyl-.gamma.-(1-naphthalenyloxy)-, hydrochloride, (s)-
S2084
AKOS016340453
(s)-(+)-duloxetine hydrochloride
(s)-(+)-n-methyl-3-(1-naphthalenyloxy)-3-(2-thienyl) propanamine hydrochloride
BFFSMCNJSOPUAY-LMOVPXPDSA-N
duloxetine.hcl
duloxetine (hydrochloride)
CS-1993
HY-B0161A
MLS006010054
(s)-n-methyl-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propan-1-amine hcl
NC00356
NCGC00164559-03
tox21_112188_1
KS-1168
(+)-(s)-n-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propanamine hydrochloride
Q-102508
duloxetine hydrochloride, pharmaceutical secondary standard; certified reference material
(3s)-n-methyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine;hydrochloride
hcl, duloxetine
hydrochloride, duloxetine
ly-248686 hydrochloride
duloxetine hydrochloride, united states pharmacopeia (usp) reference standard
duloxetine for system suitability, european pharmacopoeia (ep) reference standard
duloxetine hydrochloride, european pharmacopoeia (ep) reference standard
(s)-duloxetine hydrochloride, >=98% (hplc)
duloxetine hydrochloride 1.0 mg/ml in methanol (as free base)
SW197393-3
HB1806
(+)-(s)-n-methyl-3-(1-naphthyloxy)- 3-(2-thienyl)propanamine hydrochloride
duloxetine hcl (cymbalta)
AMY12420
(3s)-n-methyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amin hydrochloride.
D-170
(gammas)-n-methyl-gamma-(1-naphthalenyloxy)-2-thiophenepropanamine hydrochloride
methyl[3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propyl]amine hydrochloride
duloxetine for system suitability
BD165546
duloxetine hydrochloride- bio-x
cloridrato de duloxetina
clorhidrato de duloxetina
chlorhydrate de duloxetine
duloxetina cloridrato
(gammas)-2-thiophenepropanamine, n-methyl-gamma-(1-naphthalenyloxy)hydrochloride (1:1)
Z1575081875
duloxetinedr
duloxetine hcldr
duloxetine hydrochloride20 mg
duloxetine hydrochloride (ep monograph)
duloxetine hydrochloride60 mg
duloxetin hydrochloride
duloxetinedelayed-release
duloxetine delayed-releasedelayed-release
duloxetine hydrochloride30 mg
duloxetine delayed-release capsules
duloxetine hydrochloride (usp-rs)
duloxetine hydrochloride (mart.)
duloxetine hydrochloride delayed release
duloxetine hydrochloride (usp monograph)
irenka
(s)-n-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine monohydrochloride
duloxetine.hcl, 1mg/ml in methanol

Excerpt	Reference	Relevance
"Duloxetine hydrochloride (DUL) is a drug used to treat depression and anxiety. "	( Three Spectrophotometric Methods for Quantitative Analysis of Duloxetine in Presence of its Toxic Impurity: 1-Naphthol. Abdelhamid, NS; Anwar, BH; Magdy, MA; Naguib, IA, 2020)	2
"Duloxetine hydrochloride (DH) is a serotonin-norepinephrine reuptake inhibitor (SSNRI) indicated for the treatment of depression. "	( Formulation and optimization of duloxetine hydrochloride buccal films: in vitro and in vivo evaluation. El Sharawy, AM; Elshafeey, AH; Shukr, MH, 2017)	2.18
"Duloxetine hydrochloride is a reuptake inhibitor of 5-hydroxytryptamine and norepinephrine used to treat depression, generalized anxiety disorder, neuropathic pain, and stress incontinence in women. "	( Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials. Derry, S; Gaskell, H; Moore, RA; Sultan, A, 2008)	1.79
"Duloxetine hydrochloride is a balanced selective serotonin and norepinephrine reuptake inhibitor. "	( Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. Cheng, G; Peng, WX; Song, J; Tang, J; Zhao, RK, 2009)	2.12
"Duloxetine hydrochloride (HCl) is an antidepressant drug prescribed for major depressive disorders, pain related to diabetic peripheral neuropathy, and stress urinary incontinence. "	( Stress degradation studies on duloxetine hydrochloride and development of an RP-HPLC method for its determination in capsule formulation. Bhinge, JR; Kumria, R; Sinha, VR, 2009)	2.08
"Duloxetine hydrochloride (1) is an important antidepressant that acts as a serotonin and noradrenaline reuptake inhibitor that has only recently been characterized by single-crystal X-ray diffraction. "	( Polymorphism and a metastable solvate of duloxetine hydrochloride. Bhadbhade, M; Hook, JM; Marjo, CE; Rich, AM, 2011)	2.08
"Duloxetine hydrochloride is a dual reuptake inhibitor of serotonin and norepinephrine and has been licensed by the Food and Drug Administration in the US for major depressive disorder (MDD), generalised anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia and chronic musculoskeletal pain."	( Duloxetine versus other anti-depressive agents for depression. Barbui, C; Cipriani, A; Furukawa, TA; Koesters, M; Nosè, M; Omori, IM; Purgato, M; Trespidi, C, 2012)	1.1
"Duloxetine hydrochloride is a dual reuptake inhibitor of both serotonin and norepinephrine. "	( Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain. D'Souza, DN; Iyengar, S; Pritchett, YL; Raskin, J; Smith, TR; Wernicke, JF; Wong, K, 2006)	1.78

Excerpt	Reference	Relevance
"Duloxetine hydrochloride has recently been approved by the US Food and Drug Administration for the treatment of major depressive disorder (MDD). "	( Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder. Bettinger, TL; Crismon, ML; Hunziker, ME; Suehs, BT, 2005)	3.21

Excerpt	Reference	Relevance
" The reported incidence of treatment-emergent adverse events was somewhat lower with escitalopram than with duloxetine, with the possible exception of sexual dysfunction."	( Newer antidepressants: review of efficacy and safety of escitalopram and duloxetine. Hirschfeld, RM; Vornik, LA, 2004)	0.32
" The most frequently observed adverse events with duloxetine were nausea, dry mouth and somnolence."	( Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression. Cowen, PJ; Gama, J; Ogilvie, AD, 2005)	0.33
" Safety assessments included serious adverse event reports, rates of discontinuation, spontaneously reported treatment-emergent adverse events, changes in vital signs and laboratory values, and electrocardiograms."	( Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials. Hudson, JI; Kajdasz, DK; Mallinckrodt, CH; Martynov, OV; Watkin, JG; Wohlreich, MM, 2005)	0.33
"These results are consistent with those obtained previously from smaller pooled data sets, and suggest that duloxetine is safe and well tolerated in patients with MDD."	( Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials. Hudson, JI; Kajdasz, DK; Mallinckrodt, CH; Martynov, OV; Watkin, JG; Wohlreich, MM, 2005)	0.33
"The database included 1913 women randomized to duloxetine (N=958) or placebo (N=955), examining adverse events (AEs), serious adverse events (SAEs), vital signs, electrocardiograms, and laboratory analytes."	( Duloxetine for the treatment of stress urinary incontinence in women: an integrated analysis of safety. Baygani, SK; Hurley, DJ; Turner, CL; Viktrup, L; Yalcin, I, 2006)	0.33
"Duloxetine was safe and tolerable, although transient AEs were not uncommon."	( Duloxetine for the treatment of stress urinary incontinence in women: an integrated analysis of safety. Baygani, SK; Hurley, DJ; Turner, CL; Viktrup, L; Yalcin, I, 2006)	0.33
" Generally, duloxetine is safe and well-tolerated across indications, with few reported serious side effects."	( Safety and adverse event profile of duloxetine. Gahimer, J; Viktrup, L; Wernicke, JF; Wulster-Radcliffe, M; Yalcin, I, 2005)	0.33
" Safety assessments included rates of discontinuation due to adverse events, spontaneously reported treatment-emergent adverse events, and changes in vital signs."	( Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range. Andorn, AC; Mallinckrodt, CH; Prakash, A; Watkin, JG; Wohlreich, MM, 2006)	0.33
" The rate of discontinuation due to adverse events was 13."	( Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range. Andorn, AC; Mallinckrodt, CH; Prakash, A; Watkin, JG; Wohlreich, MM, 2006)	0.33
"Duloxetine provides safe and effective acute phase treatment of MDD at doses of 40-60 mg/day."	( Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range. Andorn, AC; Mallinckrodt, CH; Prakash, A; Watkin, JG; Wohlreich, MM, 2006)	0.33
"Various unpleasant adverse effects exist, among which nausea is the most frequent, but is mild to moderate and transient in most cases."	( Safety and tolerability of duloxetine in women with stress urinary incontinence. Michel, MC; Oelke, M; Roovers, JP, 2006)	0.33
" Dose escalation combined with patient counselling on the intensity and transient nature of adverse effects may help to further improve the benefit/tolerability ratio of duloxetine in the treatment of SUI."	( Safety and tolerability of duloxetine in women with stress urinary incontinence. Michel, MC; Oelke, M; Roovers, JP, 2006)	0.33
" Discontinuation rates due to adverse events among duloxetine-treated patients were 13."	( Duloxetine in the treatment of major depressive disorder: comparisons of safety and efficacy. Bailey, RK; Mallinckrodt, CH; Plewes, JM; Watkin, JG; Wohlreich, MM, 2006)	0.33
" Safety was assessed using discontinuation rates, spontaneously reported treatment-emergent adverse events, changes in vital signs and laboratory analyses."	( Duloxetine in the treatment of major depressive disorder: comparisons of safety and tolerability in male and female patients. Kornstein, SG; Mallinckrodt, CH; Stewart, DE; Watkin, JG; Wohlreich, MM, 2006)	0.33
"Discontinuation rates due to adverse events among duloxetine-treated patients were 18."	( Duloxetine in the treatment of major depressive disorder: comparisons of safety and tolerability in male and female patients. Kornstein, SG; Mallinckrodt, CH; Stewart, DE; Watkin, JG; Wohlreich, MM, 2006)	0.33
" Adverse event rates were based on spontaneous reports and differential dose-response effects were not evaluated."	( Duloxetine in the treatment of major depressive disorder: comparisons of safety and tolerability in male and female patients. Kornstein, SG; Mallinckrodt, CH; Stewart, DE; Watkin, JG; Wohlreich, MM, 2006)	0.33
" We assessed safety using spontaneously reported treatment-emergent adverse events (TEAEs), changes in vital signs, electrocardiograms (ECGs), laboratory analytes, and visual analogue scales (VAS) for gastrointestinal (GI) disturbance."	( Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation. Carter, WP; Mallinckrodt, CH; Prakash, A; Watkin, JG; Wohlreich, MM, 2007)	0.34
" Discontinuations were primarily due to adverse events, 20."	( Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study. Goldstein, DJ; Pritchett, YL; Raskin, J; Wang, F, )	0.13
" Safety was assessed using discontinuation rates, treatment-emergent adverse events, vital signs, and laboratory analyses."	( Duloxetine in the treatment of major depressive disorder: comparisons of safety and efficacy in U.S. Hispanic and majority Caucasian patients. Blanco, C; Lewis-Fernández, R; Mallinckrodt, CH; Plewes, JM; Watkin, JG; Wohlreich, MM, 2006)	0.33
" Discontinuation rates due to adverse events among duloxetine-treated patients were 14."	( Duloxetine in the treatment of major depressive disorder: comparisons of safety and efficacy in U.S. Hispanic and majority Caucasian patients. Blanco, C; Lewis-Fernández, R; Mallinckrodt, CH; Plewes, JM; Watkin, JG; Wohlreich, MM, 2006)	0.33
" Safety measures included adverse events, laboratory test results, and vital signs."	( Duloxetine in the treatment of women with stress urinary incontinence: results from DESIRE (Duloxetine Efficacy and Safety for Incontinence in Racial and Ethnic populations). Cohen, JS; Liu, C; Meadows, ES; Muram, D; Plouffe, L; Weinstein, DL, 2006)	0.33
" Common adverse events included nausea (21."	( Duloxetine in the treatment of women with stress urinary incontinence: results from DESIRE (Duloxetine Efficacy and Safety for Incontinence in Racial and Ethnic populations). Cohen, JS; Liu, C; Meadows, ES; Muram, D; Plouffe, L; Weinstein, DL, 2006)	0.33
" Evaluated aspects of drug safety included treatment-emergent adverse events (TEAEs), adverse events leading to discontinuation, serious adverse events (SAEs), clinical laboratory tests, vital signs, and electrocardiograms."	( A retrospective pooled analysis of duloxetine safety in 23,983 subjects. Gahimer, J; Ossanna, MJ; Viktrup, L; Wernicke, J; Wulster-Radcliffe, M; Yalcin, I, 2007)	0.34
" The rate of discontinuation due to adverse events (AEs) was higher for the duloxetine group compared with the placebo group (P=."	( Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Ball, S; Detke, MJ; Dinkel, J; Erickson, J; Raskin, J; Rickels, K; Russell, J; Rynn, M, 2008)	0.35
" This study was designed to evaluate the cardiovascular safety profile of the SNRI duloxetine through evaluation of cardiovascular-related parameters and adverse events (AEs)."	( An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies. Kajdasz, DK; Lledó, A; Raskin, J; Wang, F; Wernicke, J, 2007)	0.34
" Tolerability measures included adverse events reported as the reason for discontinuation and treatment-emergent adverse events (TEAEs)."	( The safety and tolerability of duloxetine in depressed elderly patients with and without medical comorbidity. Iosifescu, DV; Raskin, J; Sheridan, M; Wiltse, CG; Wise, TN; Xu, JY, 2007)	0.34
" There were few significant treatment-by-comorbidity subgroup interactions for these efficacy variables, or for adverse events reported as the reason for discontinuation and common TEAEs."	( The safety and tolerability of duloxetine in depressed elderly patients with and without medical comorbidity. Iosifescu, DV; Raskin, J; Sheridan, M; Wiltse, CG; Wise, TN; Xu, JY, 2007)	0.34
" As clinicians face a broader spectrum of efficacious treatments, side-effect profiles play an increasingly important role in the development of a pain management regimen."	( Safety profile of treatment in diabetic peripheral neuropathic pain. Robinson-Papp, J; Simpson, DM, 2007)	0.34
" Treatment-emergent adverse events (>or= 10%) in duloxetine-treated patients were nausea, hyperhidrosis, and dry mouth."	( Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial. Brecht, S; Courtecuisse, C; Croenlein, J; Debieuvre, C; Demyttenaere, K; Desaiah, D; Petit, C; Raskin, J, 2007)	0.34
" Discontinuation rates due to adverse events were similar for duloxetine and placebo (9."	( Safety and tolerability of duloxetine at 60 mg once daily in elderly patients with major depressive disorder. Desaiah, D; Dinkel, JJ; Katona, C; Raskin, J; Walker, DJ; Wiltse, CG, 2008)	0.35
"This study suggests that duloxetine is safe and well tolerated in elderly patients with major depressive disorder."	( Safety and tolerability of duloxetine at 60 mg once daily in elderly patients with major depressive disorder. Desaiah, D; Dinkel, JJ; Katona, C; Raskin, J; Walker, DJ; Wiltse, CG, 2008)	0.35
" Safety was assessed via treatment-emergent adverse events, and changes in vital sign, laboratory, and ECG measures."	( Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Arnold, LM; Chappell, AS; Detke, MJ; Kajdasz, DK; Mease, PJ; Russell, JI; Smith, TR; Walker, DJ; Wohlreich, MM, 2008)	0.35
" The proportion of patients with > or =1 treatment-emergent adverse event (TEAE) was similar with both treatments, but dry mouth, fatigue, constipation, and hyperhidrosis were significantly more common in women taking duloxetine."	( Efficacy and safety of duloxetine in elderly women with stress urinary incontinence or stress-predominant mixed urinary incontinence. Chen, WJ; Jonasson, AF; Lange, RR; Schagen van Leeuwen, JH; Viktrup, L, 2008)	0.35
"Duloxetine is a safe and effective treatment for elderly women with symptoms of SUI or S-MUI."	( Efficacy and safety of duloxetine in elderly women with stress urinary incontinence or stress-predominant mixed urinary incontinence. Chen, WJ; Jonasson, AF; Lange, RR; Schagen van Leeuwen, JH; Viktrup, L, 2008)	0.35
" Safety assessments included discontinuation rates, spontaneously reported treatment-emergent adverse events (TEAEs), changes in vital signs, and changes in lab analytes."	( Safety and tolerability of duloxetine treatment of diabetic peripheral neuropathic pain between patients with and without cardiovascular conditions. Houston, J; Kajdasz, DK; Prakash, A; Wernicke, JF, )	0.13
" Discontinuation due to adverse events was higher for DLX than for PBO in both CV-positive and CV-negative patients (13."	( Safety and tolerability of duloxetine treatment of diabetic peripheral neuropathic pain between patients with and without cardiovascular conditions. Houston, J; Kajdasz, DK; Prakash, A; Wernicke, JF, )	0.13
" Safety and tolerability were assessed via discontinuation rates, treatment-emergent adverse events (TEAEs), and changes in vital signs and laboratory measures."	( Long-term safety, tolerability, and efficacy of duloxetine in the treatment of fibromyalgia. Chappell, AS; Detke, MJ; Kajdasz, DK; Mease, PJ; Russell, IJ; Walker, DJ; Wiltse, CG; Wohlreich, MM, 2010)	0.36
" Groups titrating from placebo to duloxetine showed the highest discontinuation rates due to an adverse event (Study 1, 25%; Study 2, 19%) and TEAE rates (Study 1, 82%; Study 2, 77%)."	( Long-term safety, tolerability, and efficacy of duloxetine in the treatment of fibromyalgia. Chappell, AS; Detke, MJ; Kajdasz, DK; Mease, PJ; Russell, IJ; Walker, DJ; Wiltse, CG; Wohlreich, MM, 2010)	0.36
" The most common (> or =15%) treatment-emergent adverse events (overall phase) were nausea, headache, insomnia, dizziness, constipation, and dry mouth."	( A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia. Chappell, AS; D'Souza, DN; Kajdasz, DK; Littlejohn, G; Moldofsky, H; Scheinberg, M, 2009)	0.35
" Safety measures included treatment-emergent adverse events (TEAEs), adverse events leading to discontinuation, serious adverse events (SAEs), clinical laboratory tests, vital signs, and electrocardiograms."	( Safety and tolerability of duloxetine in the treatment of patients with fibromyalgia: pooled analysis of data from five clinical trials. Chappell, AS; Choy, EH; Crits-Christoph, P; Kajdasz, DK; Mease, PJ; Walker, DJ; Wohlreich, MM, 2009)	0.35
" The safety profile of duloxetine versus placebo with respect to serious adverse events and discontinuation owing to adverse events was similar for FM patients with versus without MDD (P>0."	( Comparisons of the efficacy and safety of duloxetine for the treatment of fibromyalgia in patients with versus without major depressive disorder. Arnold, LM; Chappell, AS; Hudson, JI; Kajdasz, DK; Prakash, A; Wang, F; Wohlreich, MM, )	0.13
" There is insufficient evidence to draw conclusions about rare but severe adverse events."	( The general and comparative efficacy and safety of duloxetine in major depressive disorder: a systematic review and meta-analysis. Gartlehner, G; Gaynes, BN; Hansen, RA; Thaler, K, 2009)	0.35
" Treatment-emergent adverse events were significantly more common during duloxetine treatment (48."	( Short- and long-term efficacy and safety of duloxetine in women with predominant stress urinary incontinence. Beardsworth, A; Cardozo, L; Lange, R; Manning, M; Viktrup, L; Voss, S; Zhao, YD, 2010)	0.36
" Because the patient populations are diverse within these approved indications, and duloxetine is not yet approved for treatment of other conditions, we wanted to determine if adverse event profiles would differ among patients being treated for these various conditions."	( Profile of adverse events with duloxetine treatment: a pooled analysis of placebo-controlled studies. Brunton, S; Crucitti, AS; Edwards, SB; Ossanna, MJ; Robinson, MJ; Walker, DJ; Wang, F, 2010)	0.36
"To provide detailed information on the adverse events associated with duloxetine and to identify differences in the adverse event profile between treatment indications and patient demographic subgroups."	( Profile of adverse events with duloxetine treatment: a pooled analysis of placebo-controlled studies. Brunton, S; Crucitti, AS; Edwards, SB; Ossanna, MJ; Robinson, MJ; Walker, DJ; Wang, F, 2010)	0.36
" The main outcome measures were rates of treatment-emergent adverse events (TEAEs) and adverse events reported as the reason for discontinuation."	( Profile of adverse events with duloxetine treatment: a pooled analysis of placebo-controlled studies. Brunton, S; Crucitti, AS; Edwards, SB; Ossanna, MJ; Robinson, MJ; Walker, DJ; Wang, F, 2010)	0.36
"8%) discontinued because of adverse events (P=0."	( Efficacy and safety of duloxetine in patients with chronic low back pain. Atkinson, JH; Backonja, M; Chappell, AS; Desaiah, D; Detke, MJ; Iyengar, S; Liu-Seifert, H; Skljarevski, V; Zhang, Q, 2010)	0.36
"Frequency/discontinuations due to treatment-emergent adverse events (TEAEs)."	( Safety and tolerability of duloxetine in the acute management of diabetic peripheral neuropathic pain: analysis of pooled data from three placebo-controlled clinical trials. Acharya, N; Crucitti, A; Hall, JA; Oakes, TM; Utterback, BG; Wang, F, 2010)	0.36
" Discontinuations due to adverse events were significantly greater (12."	( Safety and tolerability of duloxetine in the acute management of diabetic peripheral neuropathic pain: analysis of pooled data from three placebo-controlled clinical trials. Acharya, N; Crucitti, A; Hall, JA; Oakes, TM; Utterback, BG; Wang, F, 2010)	0.36
"Duloxetine was generally safe and well tolerated, with the three most commonly reported TEAEs being nausea, somnolence and constipation."	( Safety and tolerability of duloxetine in the acute management of diabetic peripheral neuropathic pain: analysis of pooled data from three placebo-controlled clinical trials. Acharya, N; Crucitti, A; Hall, JA; Oakes, TM; Utterback, BG; Wang, F, 2010)	0.36
" Treatment-emergent adverse events observed with > 10% frequency in both groups were headache and nausea."	( Efficacy and safety of duloxetine 60 mg and 120 mg daily in patients hospitalized for severe depression: a double-blind randomized trial. Brecht, S; Desaiah, D; Guelfi, JD; Marechal, ES; Podhorna, J; Santini, AM, 2011)	0.37
" Safety analyses included treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), AEs reported as reason for discontinuation, and vital signs."	( Long-term safety of duloxetine during open-label compassionate use treatment of patients who completed previous duloxetine clinical trials. Desaiah, D; Detke, MJ; Kennedy, SH; Pangallo, BA; Perahia, DG; Zhang, Q, 2010)	0.36
"3%), adverse event (8."	( Long-term safety of duloxetine during open-label compassionate use treatment of patients who completed previous duloxetine clinical trials. Desaiah, D; Detke, MJ; Kennedy, SH; Pangallo, BA; Perahia, DG; Zhang, Q, 2010)	0.36
"An antidepressant's tolerability, generally captured as the frequency and severity of adverse events (AEs), is often as important as its efficacy in determining treatment success."	( Remission of major depressive disorder without adverse events: a comparison of escitalopram versus serotonin norepinephrine reuptake inhibitors. Ben-Hamadi, R; Dworak, H; Erder, MH; Ramakrishnan, K; Signorovitch, J; Wu, EQ; Yu, AP, 2011)	0.37
" No adverse drug reaction requiring hospitalisation or drug discontinuation was reported in the present study."	( Efficacy, safety and tolerability of duloxetine in idiopathic trigeminal neuralgia. Anand, KS; Dhikav, V; Prasad, A, 2011)	0.37
" Primary outcome measures included treatment-emergent adverse events (TEAEs), vital signs, and Columbia-Suicide Severity Rating Scale (C-SSRS)."	( An open-label safety and pharmacokinetics study of duloxetine in pediatric patients with major depression. Bullok, KE; Emslie, GJ; Kratochvil, CJ; Lobo, E; March, JS; Pangallo, BA; Prakash, A; Quinlan, T; Tamura, RN, 2012)	0.38
"To evaluate the safety and tolerability of duloxetine during routine clinical care in women with stress urinary incontinence (SUI) in Germany, and in particular, to identify previously unrecognized safety issues as uncommon adverse reactions, and the influence of confounding factors present in clinical practice on the safety profile of duloxetine."	( Observational study on safety and tolerability of duloxetine in the treatment of female stress urinary incontinence in German routine practice. Methfessel, HD; Michel, MC; Minarzyk, A; Quail, D; Schwerdtner, I; Weber, HJ, 2013)	0.39
" The main outcome measure was the occurrence of adverse events (AEs)."	( Observational study on safety and tolerability of duloxetine in the treatment of female stress urinary incontinence in German routine practice. Methfessel, HD; Michel, MC; Minarzyk, A; Quail, D; Schwerdtner, I; Weber, HJ, 2013)	0.39
" Discontinuations due to adverse events did not differ significantly between treatment groups; nausea and dry mouth were the only adverse events with a significantly higher incidence with duloxetine versus placebo."	( Efficacy and safety of duloxetine 30 mg/d in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study. Arnold, LM; Pangallo, BA; Zhang, S, )	0.13
" Discontinuation rates because of adverse events, treatment-emergent adverse events, abnormal changes in vital signs and weight, and changes in laboratory analytes were compared between treatments using a Cochran-Mantel-Haenszel test."	( Safety and tolerability of duloxetine in elderly patients with major depressive disorder: a pooled analysis of two placebo-controlled studies. Greist, JH; Katona, C; Liu, P; Oakes, TM; Raskin, J; Robinson, M, 2013)	0.39
"Using safety surveillance and spontaneous adverse events reporting databases, to provide pregnancy outcomes statistics as they relate to duloxetine exposure."	( Duloxetine and pregnancy outcomes: safety surveillance findings. Cheng, Y; Dowsett, SA; Elpers, J; Hoog, SL, 2013)	0.39
"This was an analysis of pregnancy outcome data captured in Lilly Safety System (LSS) (a safety database for the collection, storage, and reporting of adverse events involving Lilly Products), through October 31 2011 and the FDA Adverse Events Reporting System (AERS) database through September 30 2011."	( Duloxetine and pregnancy outcomes: safety surveillance findings. Cheng, Y; Dowsett, SA; Elpers, J; Hoog, SL, 2013)	0.39
" For the AERS database analysis, EB05 was less than one for all clusters of abnormal pregnancy outcomes; there was no disproportionality of reporting adverse pregnancy outcomes for patients treated with duloxetine versus all other drugs or selected antidepressants."	( Duloxetine and pregnancy outcomes: safety surveillance findings. Cheng, Y; Dowsett, SA; Elpers, J; Hoog, SL, 2013)	0.39
" For categorical outcomes such as study discontinuation, adverse events leading to discontinuation, and treatment-emergent adverse events, incidence rates were summarized by race/ethnic subgroups."	( Comparison of safety outcomes among Caucasian, Hispanic, Black, and Asian patients in duloxetine studies of chronic painful conditions. Gaynor, PJ; Liu, P; Weller, MA; Wohlreich, MM, 2013)	0.39
" Older patients are generally at higher risk of adverse drug reactions due to age-related changes in physiology that affect drug disposition, metabolism, and response."	( Safety and efficacy of duloxetine treatment in older and younger patients with osteoarthritis knee pain: a post hoc, subgroup analysis of two randomized, placebo-controlled trials. Ahl, J; Micca, JL; Ruff, D; Wohlreich, MM, 2013)	0.39
" Safety analyses included discontinuation rates, treatment-emergent adverse events, and serious adverse events."	( Safety and efficacy of duloxetine treatment in older and younger patients with osteoarthritis knee pain: a post hoc, subgroup analysis of two randomized, placebo-controlled trials. Ahl, J; Micca, JL; Ruff, D; Wohlreich, MM, 2013)	0.39
" Among treatment-emergent adverse events with duloxetine treatment, only dizziness had a significantly differential treatment effect (p=."	( Safety and efficacy of duloxetine treatment in older and younger patients with osteoarthritis knee pain: a post hoc, subgroup analysis of two randomized, placebo-controlled trials. Ahl, J; Micca, JL; Ruff, D; Wohlreich, MM, 2013)	0.39
" Among the 834 evaluable study participants, treatment-emergent adverse events were reported in 70."	( Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study. Alam, MY; Chen, Y; Jacobsen, PL; Mahableshwarkar, AR; Serenko, M, 2014)	0.4
" In group 1, 20% of patients stopped the study due to adverse effects."	( The efficacy and safety of duloxetine in a multidrug regimen for chronic prostatitis/chronic pelvic pain syndrome. Di Stasi, SM; Giannantoni, A; Gubbiotti, M; Maddonni, S; Porena, M, 2014)	0.4
" Vortioxetine treatment was well tolerated; common adverse events (incidence ≥ 5%) were nausea, headache, diarrhea, dry mouth and dizziness."	( Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Boulenger, JP; Loft, H; Olsen, CK, 2014)	0.4
" We chose the number of patients experiencing = 50% reduction in pain and number of patient withdrawals due to adverse events (AE) as primary outcomes for efficacy and safety, respectively."	( Comparative efficacy and safety of six antidepressants and anticonvulsants in painful diabetic neuropathy: a network meta-analysis. Bansal, D; Bhansali, A; Ghai, B; Gudala, K; Hota, D; Rudroju, N; Talakokkula, ST, )	0.13
"Gabapentin was found to be most efficacious and amitriptyline to be least safe among the treatments included in the study."	( Comparative efficacy and safety of six antidepressants and anticonvulsants in painful diabetic neuropathy: a network meta-analysis. Bansal, D; Bhansali, A; Ghai, B; Gudala, K; Hota, D; Rudroju, N; Talakokkula, ST, )	0.13
" Safety and tolerability was assessed by the occurrence of treatment-emergent adverse events, serious adverse events, laboratory analyses, and vital signs."	( Efficacy and safety of duloxetine in the treatment of older adult patients with generalized anxiety disorder: a randomized, double-blind, placebo-controlled trial. Ahl, J; Alaka, KJ; Ball, S; Bidzan, L; Dorn, B; Dueñas, H; Lenox-Smith, A; Montejo, A; Munshi, A; Noble, W; Strawn, JR, 2014)	0.4
" Treatment-emergent adverse events occurred in ≥5% of duloxetine-treated patients and twice the rate than with placebo including constipation (9% vs."	( Efficacy and safety of duloxetine in the treatment of older adult patients with generalized anxiety disorder: a randomized, double-blind, placebo-controlled trial. Ahl, J; Alaka, KJ; Ball, S; Bidzan, L; Dorn, B; Dueñas, H; Lenox-Smith, A; Montejo, A; Munshi, A; Noble, W; Strawn, JR, 2014)	0.4
" Measures included: Children's Depression Rating Scale-Revised (CDRS-R), treatment-emergent adverse events (TEAEs), and Columbia-Suicide Severity Rating Scale (C-SSRS)."	( A double-blind efficacy and safety study of duloxetine flexible dosing in children and adolescents with major depressive disorder. Atkinson, SD; Bangs, ME; Emslie, GJ; March, JS; Pangallo, BA; Prakash, A; Zhang, Q, 2014)	0.4
" Measures included: Children's Depression Rating Scale-Revised (CDRS-R), treatment-emergent adverse events (TEAEs), and Columbia-Suicide Severity Rating Scale (C-SSRS)."	( A double-blind efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder. Bangs, ME; Emslie, GJ; March, JS; Pangallo, BA; Prakash, A; Zhang, Q, 2014)	0.4
" Discontinuation because of adverse events was significantly greater in the duloxetine (19."	( Comparative safety and tolerability of duloxetine vs. pregabalin vs. duloxetine plus gabapentin in patients with diabetic peripheral neuropathic pain. Irving, G; Malcolm, S; Raskin, J; Risser, RC; Tanenberg, RJ, 2014)	0.4
"Duloxetine, pregabalin and duloxetine plus gabapentin were generally safe and tolerable for the treatment of DPNP."	( Comparative safety and tolerability of duloxetine vs. pregabalin vs. duloxetine plus gabapentin in patients with diabetic peripheral neuropathic pain. Irving, G; Malcolm, S; Raskin, J; Risser, RC; Tanenberg, RJ, 2014)	0.4
"To assess the effects of coding and coding conventions on summaries and tabulations of adverse events data on suicidality within clinical study reports."	( Coding of adverse events of suicidality in clinical study reports of duloxetine for the treatment of major depressive disorder: descriptive study. Gøtzsche, PC; Hróbjartsson, A; Lundh, A; Maund, E; Tendal, B, 2014)	0.4
"Systematic electronic search for adverse events of suicidality in tables, narratives, and listings of adverse events in individual patients within clinical study reports."	( Coding of adverse events of suicidality in clinical study reports of duloxetine for the treatment of major depressive disorder: descriptive study. Gøtzsche, PC; Hróbjartsson, A; Lundh, A; Maund, E; Tendal, B, 2014)	0.4
"Six trials used the medical coding dictionary COSTART (Coding Symbols for a Thesaurus of Adverse Reaction Terms) and three used MedDRA (Medical Dictionary for Regulatory Activities)."	( Coding of adverse events of suicidality in clinical study reports of duloxetine for the treatment of major depressive disorder: descriptive study. Gøtzsche, PC; Hróbjartsson, A; Lundh, A; Maund, E; Tendal, B, 2014)	0.4
"Data on adverse events in tables in clinical study reports may not accurately represent the underlying patient data because of the medical dictionaries and coding conventions used."	( Coding of adverse events of suicidality in clinical study reports of duloxetine for the treatment of major depressive disorder: descriptive study. Gøtzsche, PC; Hróbjartsson, A; Lundh, A; Maund, E; Tendal, B, 2014)	0.4
" Untreated depression is associated with many adverse gestational outcomes."	( The safety of duloxetine during pregnancy and lactation. Andrade, C, 2014)	0.4
" No neonatal adverse events emerged, so far, in the few studies concerning the safety of SNRIs during breastfeeding."	( The safety of serotonin-noradrenaline reuptake inhibitors (SNRIs) in pregnancy and breastfeeding: a comprehensive review. Bellantuono, C; Mandarelli, G; Martini, MG; Nardi, B; Vargas, M, 2015)	0.42
"Available data suggest that venlafaxine is relatively safe during pregnancy, in particular as far as major malformations are concerned, whereas considering the small number of studies published, no definitive conclusions can be drawn on its safety during breastfeeding."	( The safety of serotonin-noradrenaline reuptake inhibitors (SNRIs) in pregnancy and breastfeeding: a comprehensive review. Bellantuono, C; Mandarelli, G; Martini, MG; Nardi, B; Vargas, M, 2015)	0.42
" Safety measures included treatment-emergent adverse events (TEAEs), the Columbia-Suicide Severity Rating Scale, vital signs, electrocardiograms, laboratory samples, and growth (height and weight) assessments."	( Acute and longer-term safety results from a pooled analysis of duloxetine studies for the treatment of children and adolescents with major depressive disorder. Bangs, ME; Emslie, GJ; March, JS; Pangallo, BA; Prakash, A; Wells, TG; Zhang, Q, 2015)	0.42
"Significantly more patients discontinued because of adverse events during duloxetine (8."	( Acute and longer-term safety results from a pooled analysis of duloxetine studies for the treatment of children and adolescents with major depressive disorder. Bangs, ME; Emslie, GJ; March, JS; Pangallo, BA; Prakash, A; Wells, TG; Zhang, Q, 2015)	0.42
" Also, studies with specific data regarding to pain reductions and response rate, Patient Global Impression of Improvement (PGI-I), functional improvement, Western Ontario and McMaster Osteoarthritis Index (WOMAC), adverse events (AEs), treatment-emergent AEs (TEAEs), mortality were included and analyzed, and those with confounding conditions were excluded."	( Efficacy and Safety of Duloxetine on Osteoarthritis Knee Pain: A Meta-Analysis of Randomized Controlled Trials. Chen, F; Chen, H; Li, SJ; Lin, HZ; Lin, JM; Shi, SY; Wang, ZY, 2015)	0.42
"This analysis suggests duloxetine (60/120 mg quaque die (QD)), compared with placebo control, resulted in a greater reduction in pain, improved function and patient-rated impression of improvement, and acceptable adverse effects for the treatment of OAK pain after approximately 10-13 weeks of treatment."	( Efficacy and Safety of Duloxetine on Osteoarthritis Knee Pain: A Meta-Analysis of Randomized Controlled Trials. Chen, F; Chen, H; Li, SJ; Lin, HZ; Lin, JM; Shi, SY; Wang, ZY, 2015)	0.42
" Pain (Brief Pain Inventory severity and interference), quality of life (Patient's Global Impression of Improvement), and safety (primary outcome; adverse events, vital signs, metabolic measures) were measured."	( Efficacy and safety of 40 mg or 60 mg duloxetine in Japanese adults with diabetic neuropathic pain: Results from a randomized, 52-week, open-label study. Alev, L; Baba, Y; Hotta, N; Kashiwagi, A; Kasuga, M; Kawamori, R; Nakajo, K; Yamada, T; Yasuda, H, 2016)	0.43
" Frequently reported adverse events included somnolence (13."	( Efficacy and safety of 40 mg or 60 mg duloxetine in Japanese adults with diabetic neuropathic pain: Results from a randomized, 52-week, open-label study. Alev, L; Baba, Y; Hotta, N; Kashiwagi, A; Kasuga, M; Kawamori, R; Nakajo, K; Yamada, T; Yasuda, H, 2016)	0.43
" Tolerability was based on the nature, incidence and severity of treatment-emergent adverse events (TEAEs) during acute (6/8) week treatment in 11 randomized, double-blind placebo-controlled short-term studies in major depressive disorder: six with an active reference."	( The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies. Baldwin, DS; Chrones, L; Florea, I; Nielsen, R; Nomikos, GG; Palo, W; Reines, E, 2016)	0.43
" Patients' demographic and clinical characteristics, resource utilization data and adverse drug reactions (ADRs) as described in the leaflet were extracted."	( Characteristics, resource utilization and safety profile of patients prescribed with neuropathic pain treatments: a real-world evidence study on general practices in Europe - the role of the lidocaine 5% medicated plaster. Katz, P; Liedgens, H; Pegoraro, V, 2017)	0.46
" Although secondary hypertension is a known side effect of amitriptyline and duloxetine, neither drug has been previously associated with AD."	( Autonomic Dysreflexia as a Potential Adverse Effect of Duloxetine and Amitriptyline Combination Therapy: A Case Report. Parke, SC; Reyes, MR, 2019)	0.51
" Reported incidences of gastrointestinal adverse events were three to four times higher in participants who received duloxetine versus placebo."	( Efficacy and safety of duloxetine in osteoarthritis: a systematic review and meta-analysis. Bannuru, RR; Osani, MC, 2019)	0.51
" EC50 values for duloxetine and econazole enabled to include both drugs within the group of very toxic compounds although econazole showed a higher toxicity than duloxetine and the binary mixture."	( Stability and toxicity studies for duloxetine and econazole on Spirodela polyrhiza using chiral capillary electrophoresis. Amariei, G; Boltes, K; García, MÁ; Marina, ML; Valimaña-Traverso, J, 2019)	0.51
" The percentage of patients reporting at least 1 treatment-emergent adverse event was higher in the duloxetine versus placebo groups (82."	( Efficacy and safety of duloxetine versus placebo in adolescents with juvenile fibromyalgia: results from a randomized controlled trial. Alaka, K; Arnold, LM; Mehta, R; Qiao, M; Upadhyaya, HP; Williams, D, 2019)	0.51
" The most common (>20%) adverse events reported for esketamine/antidepressant were nausea, dissociation, dizziness, vertigo, and headache."	( Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1). Ameele, HVD; Blier, P; Daly, EJ; Drevets, WC; Fava, M; Fedgchin, M; Gaillard, R; Hough, D; Lane, R; Liebowitz, M; Lim, P; Manji, H; Melkote, R; Preskorn, S; Ravindran, A; Singh, JB; Trivedi, M; Vitagliano, D, 2019)	0.51
"Platinum-induced peripheral neurotoxicity (PIPN) is a common side effect of platinum-based chemotherapy that may cause dose reduction and discontinuation, with oxaliplatin being more neurotoxic."	( Platinum-induced peripheral neurotoxicity: From pathogenesis to treatment. Cavaletti, G; Islam, B; Lustberg, M; Psimaras, D; Staff, NP; Tamburin, S, 2019)	0.51
"Taxane-induced peripheral neurotoxicity (TIPN) is the most common non-hematological side effect of taxane-based chemotherapy, and may result in dose reductions and discontinuations, having as such a detrimental effect on patients' overall survival."	( Taxane and epothilone-induced peripheral neurotoxicity: From pathogenesis to treatment. Alberti, P; Argyriou, AA; Demichelis, C; Park, SB; Schenone, A; Tamburin, S, 2019)	0.51
" There were higher rates of treatment-emergent adverse events (TEAEs) (RR = 1."	( The short-term effect and safety of duloxetine in osteoarthritis: A systematic review and meta-analysis. Chen, HY; Gao, SH; Huang, JH; Huo, JB; Li, XW; Pan, QM, 2019)	0.51
"Duloxetine was an effective and safe choice to improve pain and functional outcome in OA patients."	( The short-term effect and safety of duloxetine in osteoarthritis: A systematic review and meta-analysis. Chen, HY; Gao, SH; Huang, JH; Huo, JB; Li, XW; Pan, QM, 2019)	0.51
"Using FDA Adverse Events Reporting System reports from January 1, 2005 to December 31, 2015, we calculated pharmacovigilance signal measures (i."	( Gabapentin drug misuse signals: A pharmacovigilance assessment using the FDA adverse event reporting system. Charnigo, RJ; Havens, JR; Lofwall, MR; Sun, J; Vickers-Smith, R; Walsh, SL, 2020)	0.56
" Patients with breast cancer who received paclitaxel or docetaxel and had a grade 1 or more neuropathy (based on the National Cancer Institute Common Terminology Criteria for Adverse Events version (NCI-CTCAE v4."	( Comparison of the Efficacy and Safety of Pregabalin and Duloxetine in Taxane-Induced Sensory Neuropathy: A Randomized Controlled Trial. Alipour, A; Avan, R; Hendouei, N; Janbabaei, G; Salehifar, E; Tabrizi, N, 2020)	0.56
" Both interventions were tolerated well with mild adverse events."	( Comparison of the Efficacy and Safety of Pregabalin and Duloxetine in Taxane-Induced Sensory Neuropathy: A Randomized Controlled Trial. Alipour, A; Avan, R; Hendouei, N; Janbabaei, G; Salehifar, E; Tabrizi, N, 2020)	0.56
"Duloxetine has been increasingly administered, but the associated cardiovascular adverse event risk is not clearly understood."	( Duloxetine and cardiovascular adverse events: A systematic review and meta-analysis. Kim, S; Ko, YJ; Park, BJ; Park, K, 2020)	0.56
" The aim was to provide an overview of the treatment-emergent adverse events (≥10%) and the serious adverse effects described in clinical trials."	( The safety of medications used to treat peripheral neuropathic pain, part 1 (antidepressants and antiepileptics): review of double-blind, placebo-controlled, randomized clinical trials. Balayssac, D; Busserolles, J; Courteix, C; Cuménal, M; Kerckhove, N; Selvy, M, 2020)	0.56
" Over all studies, the most commonly reported adverse effects were dizziness, drowsiness, nausea, and constipation."	( The safety of medications used to treat peripheral neuropathic pain, part 1 (antidepressants and antiepileptics): review of double-blind, placebo-controlled, randomized clinical trials. Balayssac, D; Busserolles, J; Courteix, C; Cuménal, M; Kerckhove, N; Selvy, M, 2020)	0.56
" No serious adverse events (e."	( Efficacy and safety of the noradrenaline reuptake inhibitor, TAS-303, in women with stress urinary incontinence: Results of a double-blind, randomized, placebo-controlled, early phase II trial. Gotoh, M; Kato, K; Takahashi, S; Takei, M; Yokoyama, O, 2021)	0.62
" Patients with long-lasting CIPN had a higher rate of adverse events (47 vs."	( Duloxetine against symptomatic chemotherapy-induced peripheral neurotoxicity in cancer survivors: a real world, open-label experience. Argyriou, AA; Besora, S; Bruna, J; Calvo, M; Clapés, V; Gil-Gil, M; Izquierdo, C; Jiménez, L; Palmero, R; Pardo, B; Sala, R; Santos, C; Simó, M; Velasco, R, 2021)	0.62
" All adverse events will be recorded and immediately reported to the primary investigator and ethics committee to decide if the patient needs to drop out from the trial."	( Efficacy and safety of duloxetine for postoperative pain after total knee arthroplasty in centrally sensitized patients: study protocol for a randomized controlled trial. Ling, J; Shao, L; Wang, S; Wang, W, 2021)	0.62
" This secondary analysis examines the relationship between adverse events (AE) and patient-perceived benefit, based on patient self-report that the treatment received was beneficial despite side effects."	( Adverse Events and Perception of Benefit From Duloxetine for Treating Aromatase Inhibitor-Associated Arthralgias. Henry, NL; Lustberg, MB; Schnell, PM, 2021)	0.62
"Primary outcomes were postoperative acute pain at rest/during movement (measured on a scale from 0 to 10), number of patients with chronic postsurgical pain (CPSP) and with SSNRI-related adverse events."	( Efficacy and adverse events of selective serotonin noradrenaline reuptake inhibitors in the management of postoperative pain: A systematic review and meta-analysis. Kranke, P; Meißner, M; Meyer-Frießem, CH; Pogatzki-Zahn, EM; Reichl, SU; Schnabel, A; Weibel, S; Zahn, PK, 2021)	0.62
"In antidepressant trials for pediatric patients with depression or anxiety disorders, the risk of suicidal events and other severe psychiatric adverse events such as aggression and agitation is increased with antidepressants relative to placebo."	( Suicidality and other severe psychiatric events with duloxetine: Re-analysis of safety data from a placebo-controlled trial for juvenile fibromyalgia. Hengartner, MP; Plöderl, M, )	0.13
" Both serious adverse events related to psychiatric disorders and adverse events leading to treatment discontinuation were defined as severe treatment-emergent psychiatric adverse events."	( Suicidality and other severe psychiatric events with duloxetine: Re-analysis of safety data from a placebo-controlled trial for juvenile fibromyalgia. Hengartner, MP; Plöderl, M, )	0.13
"We found that a significant portion of adolescents had treatment-emergent suicidal ideation and behaviour as well as other severe psychiatric adverse events with duloxetine, but no such events were recorded on placebo."	( Suicidality and other severe psychiatric events with duloxetine: Re-analysis of safety data from a placebo-controlled trial for juvenile fibromyalgia. Hengartner, MP; Plöderl, M, )	0.13
"Neurotoxicity is a frequent side effect of cisplatin (CisPt)-based anticancer therapy whose pathophysiology is largely vague."	( Cisplatin-induced neurotoxicity involves the disruption of serotonergic neurotransmission. Bornhorst, J; Brinkmann, V; Fritz, G; Honnen, S; Ventura, N; Wellenberg, A, 2021)	0.62
" The results showed that, at the end of the study, duloxetine was significantly superior to gabapentin in terms of the incidence of adverse reactions (RR = 0."	( Comparison of the Efficacy and Safety of Duloxetine and Gabapentin in Diabetic Peripheral Neuropathic Pain: A Meta-Analysis. Cui, J; Jiang, L; Xiong, Y, 2022)	0.72
" Their present status was determined by a telephonic interview which included a subjective assessment of improvement (Likert scale), FIQR (Revised Fibromyalgia Impact Questionnaire), adverse drug effects and compliance."	( Effectiveness and adverse effects of the use of mirtazapine as compared to duloxetine for fibromyalgia: real-life data from a retrospective cohort. Ahmed, S; Basu, A; Mehta, P, 2022)	0.72
" A rare side effect of syndrome of inappropriate antidiuretic hormone (SIADH) secretion has been reported in adults, but not in pediatrics or pediatric oncology patients."	( Hyponatremia with Antidepressant: A Rare Side Effect from Duloxetine in a Child with Acute Leukemia. Baig, MU; Madden, K; Moody, K, 2022)	0.72
" The incidence of adverse drug reactions was 55% in the SFPP group, which is not significantly different from 50% incidence in the control group."	( Comparison of efficacy and safety in the combination therapies of duloxetine and S-flurbiprofen plaster, and of duloxetine and conventional NSAIDs for chronic pain in patients with osteoarthritis (OASIS DUAL study). Koyama, K, 2022)	0.72
"All nine drugs can relieve the pain of CPSP patients to different degrees; among them pregabalin and gabapentin have the most significant effect, and gabapentin and pregabalin also have the most adverse reactions."	( Efficacy and safety of different antidepressants and anticonvulsants in central poststroke pain: A network meta-analysis and systematic review. Chen, KY; Li, RY, 2022)	0.72
"Oxaliplatin-induced peripheral neurotoxicity (OIPN) is a debilitating side effect that afflicts ~90% of patients that is initiated by OCT2-dependent uptake of oxaliplatin in DRG neurons."	( Targeting OCT2 with Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neurotoxicity. DiGiacomo, DF; Gibson, AA; Hu, S; Jin, Y; Li, Y; Lustberg, MB; Nepal, MR; Sparreboom, A; Taheri, H; Talebi, Z; Uddin, ME, 2022)	0.72
" Severe adverse events were rare, whereas nausea, somnolence, dizziness, fatigue, constipation, and decreased appetite were common; approximately, 12."	( Efficacy and safety of duloxetine in painful diabetic peripheral neuropathy: a systematic review and meta-analysis of randomized controlled trials. Huang, YJ; Ko, YC; Lee, CH; Wu, CS, 2023)	0.91
" The rarity of severe adverse events indicates that duloxetine is safe."	( Efficacy and safety of duloxetine in painful diabetic peripheral neuropathy: a systematic review and meta-analysis of randomized controlled trials. Huang, YJ; Ko, YC; Lee, CH; Wu, CS, 2023)	0.91
"This meta-analysis showed that the duloxetine has statistically significant compared with the placebo control, benefits on 24-hour average pain, living quality, physical function, and global impressions and there was no difference in the incidence of serious adverse event."	( Efficacy and safety of duloxetine in chronic musculoskeletal pain: a systematic review and meta-analysis. Guo, Y; Li, G; Ma, X; Sun, J; Sun, W; Wang, L; Zhou, S, 2023)	0.91
" This meta-analysis improved that duloxetine can significantly reduce the pain level of patients, improve depressive symptoms and global impression, and has no obvious serious adverse reactions."	( Efficacy and safety of duloxetine in chronic musculoskeletal pain: a systematic review and meta-analysis. Guo, Y; Li, G; Ma, X; Sun, J; Sun, W; Wang, L; Zhou, S, 2023)	0.91
"A total of 8 randomized controlled trials with 739 patients were included in the literature review of postoperative pain and adverse effects."	( The efficacy and safety of duloxetine for the treatment of patients after TKA or THA: A systematic review and meta-analysis. Cao, Y; Chen, C; Chen, X; Zhou, Y, 2023)	0.91
"Duloxetine could decrease the opioids consumption and relieve early postoperative pain without increasing the risk of adverse medication effects in patients undergoing total knee or hip arthroplasty."	( The efficacy and safety of duloxetine for the treatment of patients after TKA or THA: A systematic review and meta-analysis. Cao, Y; Chen, C; Chen, X; Zhou, Y, 2023)	0.91

Excerpt	Reference	Relevance
" The mean oral clearance, apparent volume of distribution, and half-life values were 114 L/h (range: 44 to 218 L/h), 1943 L (range: 803 to 3531 L), and 12."	( Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. Cerimele, BJ; Goldberg, MJ; Sharma, A, 2000)	0.31
" Following [14C]duloxetine administration, Cmax was reached at a median of 6 h for both duloxetine and total radioactivity."	( Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. Gillespie, TA; Knadler, MP; Kuan, HY; Kuo, F; Lantz, RJ; Rash, TJ; Skinner, M, 2003)	0.32
" Plasma concentration-time data were analysed by noncompartmental pharmacokinetic methods."	( Effect of age on the pharmacokinetics of duloxetine in women. Heathman, M; Knadler, MP; Kuan, HY; O'Brien, L; Reddy, S; Seger, ME; Skerjanec, A; Skinner, MH, 2004)	0.32
" The population pharmacokinetic analysis of Studies 2A and 2B revealed that the CL/F of duloxetine decreased with increasing age."	( Effect of age on the pharmacokinetics of duloxetine in women. Heathman, M; Knadler, MP; Kuan, HY; O'Brien, L; Reddy, S; Seger, ME; Skerjanec, A; Skinner, MH, 2004)	0.32
" Specific pharmacokinetic parameters were assessed statistically using a mixed-effects model."	( Duloxetine pharmacokinetics in cirrhotics compared with healthy subjects. Branch, RA; Gonzales, C; Knadler, MP; Reddy, S; Skinner, MH; Suri, A, 2005)	0.33
" The half-life of duloxetine was about three times longer (47."	( Duloxetine pharmacokinetics in cirrhotics compared with healthy subjects. Branch, RA; Gonzales, C; Knadler, MP; Reddy, S; Skinner, MH; Suri, A, 2005)	0.33
" In this review, we highlight the preclinical pharmacology, pharmacokinetic profile, and effects of duloxetine in the pharmacotherapy of depression."	( The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression. Bymaster, FP; Detke, MJ; Iyengar, S; Knadler, MP; Lee, TC, 2005)	0.33
" A more rapid achievement by venlafaxine of remission and a high-quality pharmacokinetic and pharmacodynamic profile lead to patient compliance and facilitate both fewer relapses and recurrences."	( The role of venlafaxine and duloxetine in the treatment of depression with decremental changes in somatic symptoms of pain, chronic pain, and the pharmacokinetics and clinical considerations of duloxetine pharmacotherapy. Barkin, RL; Barkin, S, )	0.13
"A sensitive and specific method for quantifying duloxetine levels in human plasma has been devised and successfully applied to a clinic pharmacokinetic study of an enteric-coated capsule of duloxetine hydrochloride administered as a single oral dose."	( Determination of duloxetine in human plasma via LC/MS and subsequent application to a pharmacokinetic study in healthy Chinese volunteers. Chen, BM; Feng, S; Li, HD; Ma, N; Wang, F; Xiang, DX; Xu, P; Zhang, BK; Zhu, RH; Zhu, YG, 2007)	0.53
"Duloxetine disposition on oral administration is characterised by a one-compartment pharmacokinetic model."	( Pharmacokinetics and tolerability of duloxetine following oral administration to healthy Chinese subjects. Knadler, MP; Liang, S; Lim, MT; Lobo, ED; Pan, AX; Teng, L; Tianmei, S; Yeo, KP, 2007)	0.34
" This method was successfully applied to pharmacokinetic study of a duloxetine formulation product after oral administration to healthy human subjects."	( Determination of duloxetine in human plasma by liquid chromatography with atmospheric pressure ionization-tandem mass spectrometry and its application to pharmacokinetic study. Gowda, KV; Mandal, U; Pal, TK; Sam Solomon, WD; Senthamil Selvan, P, 2007)	0.34
"The pharmacokinetic meta-analysis dataset was created from one open-label clinical study and four double-blind, placebo-controlled clinical studies."	( Population pharmacokinetics of orally administered duloxetine in patients: implications for dosing recommendation. Heathman, M; Knadler, MP; Lobo, ED; O'Brien, L; Quinlan, T, 2009)	0.35
"Duloxetine pharmacokinetics in patients were described by a one-compartmental pharmacokinetic model."	( Population pharmacokinetics of orally administered duloxetine in patients: implications for dosing recommendation. Heathman, M; Knadler, MP; Lobo, ED; O'Brien, L; Quinlan, T, 2009)	0.35
" Despite being widely used for the treatment of major depressive disorder in China, little information is available on the pharmacokinetic (PK) properties of duloxetine in Chinese subjects."	( Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. Cheng, G; Peng, WX; Song, J; Tang, J; Zhao, RK, 2009)	0.68
"In these healthy Chinese subjects, AUC and Cmax increased proportionally with the dose, whereas t(1/2) was independent of the dose."	( Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. Cheng, G; Peng, WX; Song, J; Tang, J; Zhao, RK, 2009)	0.68
"The aim of this study was to evaluate the effects of varying degrees of renal impairment on duloxetine pharmacokinetics in a single-dose phase I study and using pooled steady-state pharmacokinetic data from phase II/III trials."	( Effects of varying degrees of renal impairment on the pharmacokinetics of duloxetine: analysis of a single-dose phase I study and pooled steady-state data from phase II/III trials. Gonzales, C; Heathman, M; Knadler, MP; Kuan, HY; Lobo, ED; O'Brien, L; Reddy, S; Skinner, M, 2010)	0.36
" Noncompartmental methods (phase I: duloxetine and its metabolites) and population modelling methods (phase II/III: duloxetine) were used to analyse the pharmacokinetic data."	( Effects of varying degrees of renal impairment on the pharmacokinetics of duloxetine: analysis of a single-dose phase I study and pooled steady-state data from phase II/III trials. Gonzales, C; Heathman, M; Knadler, MP; Kuan, HY; Lobo, ED; O'Brien, L; Reddy, S; Skinner, M, 2010)	0.36
" Population pharmacokinetic results indicated that mild or moderate renal impairment, assessed by creatinine clearance (CL(CR)) calculated according to the Cockcroft-Gault formula, did not have a statistically significant effect on pharmacokinetic parameters of duloxetine."	( Effects of varying degrees of renal impairment on the pharmacokinetics of duloxetine: analysis of a single-dose phase I study and pooled steady-state data from phase II/III trials. Gonzales, C; Heathman, M; Knadler, MP; Kuan, HY; Lobo, ED; O'Brien, L; Reddy, S; Skinner, M, 2010)	0.36
" The elimination half-life of duloxetine is approximately 10-12 hours and the volume of distribution is approximately 1640 L."	( Duloxetine: clinical pharmacokinetics and drug interactions. Bergstrom, R; Chappell, J; Knadler, MP; Lobo, E, 2011)	0.37
" Pharmacokinetic samples were collected across all duloxetine doses, and data were analyzed using population modeling."	( An open-label safety and pharmacokinetics study of duloxetine in pediatric patients with major depression. Bullok, KE; Emslie, GJ; Kratochvil, CJ; Lobo, E; March, JS; Pangallo, BA; Prakash, A; Quinlan, T; Tamura, RN, 2012)	0.38
" Body weight and age did not significantly affect duloxetine pharmacokinetic parameters."	( An open-label safety and pharmacokinetics study of duloxetine in pediatric patients with major depression. Bullok, KE; Emslie, GJ; Kratochvil, CJ; Lobo, E; March, JS; Pangallo, BA; Prakash, A; Quinlan, T; Tamura, RN, 2012)	0.38
" Pharmacokinetic results suggested that adjustment of total daily dose based on body weight or age is not warranted for pediatric patients and different total daily doses may not be warranted for pediatric patients relative to adults."	( An open-label safety and pharmacokinetics study of duloxetine in pediatric patients with major depression. Bullok, KE; Emslie, GJ; Kratochvil, CJ; Lobo, E; March, JS; Pangallo, BA; Prakash, A; Quinlan, T; Tamura, RN, 2012)	0.38
" These were evaluated in-vivo for pharmacodynamic studies for depression by forced swimming test and locomotor activity test."	( Intranasal administration of nanostructured lipid carriers containing CNS acting drug: pharmacodynamic studies and estimation in blood and brain. Ahuja, A; Alam, MI; Ali, J; Ali, M; Baboota, S; Sahni, JK, 2012)	0.38
" The purpose of this study was to investigate the pharmacokinetic properties of duloxetine in 20 beagle dogs following a single oral administration of a 30- or 60-mg enteric-coated pellet in a capsule (Cymbalta)."	( Pharmacokinetic analysis of two different doses of duloxetine following oral administration in dogs. Baek, IH; Kang, W; Kwon, KI; Lee, BY, 2013)	0.39
" Pharmacokinetic parameters were analyzed using both noncompartmental and compartmental approaches."	( Pharmacokinetic analysis of two different doses of duloxetine following oral administration in dogs. Baek, IH; Kang, W; Kwon, KI; Lee, BY, 2013)	0.39
" The one compartment model with first-order absorption and a lag time was used successfully for pharmacokinetic analysis of duloxetine following a single oral administration of Cymbalta 30 mg or 60 mg."	( Pharmacokinetic analysis of two different doses of duloxetine following oral administration in dogs. Baek, IH; Kang, W; Kwon, KI; Lee, BY, 2013)	0.39
"In pharmacokinetic (PK)/pharmacodynamic (PD) modelling and simulations (M&S), omitting dropouts can cause inaccuracies in parameter estimation and clinical trial simulations (CTS)."	( Handling missing data in a duloxetine population pharmacokinetic/pharmacodynamic model - imputation methods and selection models. Aarons, L; Gueorguieva, I; Yuen, E, 2014)	0.4
"The analyses meta-dataset was created from pharmacokinetic and demographic data available from one phase II (open-label) and two phase III (randomized, double-blind) clinical trials of duloxetine in children and adolescents."	( Pharmacokinetics of orally administered duloxetine in children and adolescents with major depressive disorder. Lobo, ED; Prakash, A; Quinlan, T, 2014)	0.4
" Typical values of CL/F, V d/F, and half-life (t 1/2) at 60 mg/day of duloxetine were 79."	( Pharmacokinetics of orally administered duloxetine in children and adolescents with major depressive disorder. Lobo, ED; Prakash, A; Quinlan, T, 2014)	0.4
" Pharmacokinetic and pharmacodynamic data were obtained from healthy subjects (n = 160) from 5 clinical trials."	( Pharmacodynamics of norepinephrine reuptake inhibition: Modeling the peripheral and central effects of atomoxetine, duloxetine, and edivoxetine on the biomarker 3,4-dihydroxyphenylglycol in humans. Kielbasa, W; Lobo, E, 2015)	0.42
" The present study aimed to investigate chiral pharmacology differences of 071031B enantiomers, S-071031B and R-071031B, and disclose mechanisms underlying the behavioral differences based on target profiles and pharmacokinetic profiles."	( Pharmacokinetic profiles contribute to the differences in behavioral pharmacology of 071031B enantiomers as novel serotonin and norepinephrine reuptake inhibitors. Fan, SY; He, XH; Jin, ZL; Li, NM; Li, Y; Li, YF; Xue, R; Yuan, L; Zhang, TT; Zhang, YZ; Zheng, AP; Zhong, BH, 2017)	0.46
"The aim of this work was to predict the extent of Cytochrome P450 2D6 (CYP2D6)-mediated drug-drug interactions (DDIs) in different CYP2D6 genotypes using physiologically-based pharmacokinetic (PBPK) modeling."	( Physiologically-Based Pharmacokinetic Modeling for the Prediction of CYP2D6-Mediated Gene-Drug-Drug Interactions. Daali, Y; Desmeules, J; Storelli, F, 2019)	0.51
" The developed formulations were subjected to pharmacokinetic studies and results showed about 8 to 11."	( Pharmacokinetic and pharmacodynamic evaluation of Solid self-nanoemulsifying delivery system (SSNEDDS) loaded with curcumin and duloxetine in attenuation of neuropathic pain in rats. Bhatia, A; Garg, V; Gulati, M; Kumar, B; Melkani, I; Pandey, NK; Prakash, T; Singh, S; Singh, SK, 2021)	0.62
" Pharmacokinetic analysis of pregabalin or combination (pregabalin + amitriptyline or pregabalin + duloxetine) in the plasma were performed by ultraperformance liquid chromatography tandem mass spectrometry."	( Investigation of the Combination of Pregabalin with Duloxetine or Amitriptyline on the Pharmacokinetics and Antiallodynic Effect During Neuropathic Pain in Rats. Barros, CM; Boralli, VB; Costa, LH; Galdino, G; Kawano, T; Placido, RV; Podesta, MHMC; Rodrigues, RF; Santos, RS, 2021)	0.62
"The pharmacokinetic disposition of pregabalin was changed in the association with amitriptyline, presenting a clearance reduction and consequently an increase in bioavailability."	( Investigation of the Combination of Pregabalin with Duloxetine or Amitriptyline on the Pharmacokinetics and Antiallodynic Effect During Neuropathic Pain in Rats. Barros, CM; Boralli, VB; Costa, LH; Galdino, G; Kawano, T; Placido, RV; Podesta, MHMC; Rodrigues, RF; Santos, RS, 2021)	0.62
" Here, we investigated the roles of Cyp1a2 and Cyp2d on DLX pharmacokinetic profile and tissue distribution using a Cyp1a2 knockout (Cyp1a2-KO) mouse model together with a Cyp2d inhibitor (propranolol)."	( The roles of Cyp1a2 and Cyp2d in pharmacokinetic profiles of serotonin and norepinephrine reuptake inhibitor duloxetine and its metabolites in mice. Barzi, M; Bissig, KD; Boyd, SR; Hakenjos, JM; Li, F; MacKenzie, KR; Qin, X; Xie, C; Young, DW, 2023)	0.91
" Biopharmaceutical and pharmacokinetic characteristics comparison suggested that low intestinal permeability and small systemic elimination rate of duloxetine hinders the clear impact of different dissolution profile on its in vivo performance."	( Lowly-buffered biorelevant dissolution testing is not necessarily biopredictive of human bioequivalence study outcome: Relationship between dissolution and pharmacokinetics. Matsui, K; Nakamichi, K; Nakatani, M; Yamashita, S; Yokota, S; Yoshida, H, 2023)	0.91
" A population pharmacokinetic (PK) model was developed with plasma steady-state duloxetine concentrations from Japanese pediatric patients with MDD in an open-label long-term extension trial in Japan (ClinicalTrials."	( Population pharmacokinetics of duloxetine in Japanese pediatric patients with major depressive disorder. Kaibara, A; Kubota, R; Shibata, RY; Uenaka, K; Wajima, T, 2023)	0.91

Excerpt	Reference	Relevance
"The aim of this study was to describe a potential drug-drug interaction between duloxetine and acenocoumarol in a patient with Alzheimer's disease."	( Potential drug-drug interaction between duloxetine and acenocoumarol in a patient with Alzheimer's disease. Camarda, C; Camarda, R; Monastero, R, 2007)	0.34
"This case report suggests a possible drug-drug interaction between duloxetine and acenocoumarol."	( Potential drug-drug interaction between duloxetine and acenocoumarol in a patient with Alzheimer's disease. Camarda, C; Camarda, R; Monastero, R, 2007)	0.34
" Here a duloxetine overdose case, in combination with other antidepressants and benzodiazepines, is reported and the chemical-clinical correlations discussed; this is probably the first detailed report of such a case."	( Non-fatal overdose of duloxetine in combination with other antidepressants and benzodiazepines. Gozzi, BF; Menchetti, M; Mercolini, L; Petio, C; Raggi, MA; Saracino, MA, 2009)	0.35
"A number of antidepressants inhibit the activity of the cytochrome P450 2D6 enzyme system, which can lead to drug-drug interactions."	( An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects. Burczynski, ME; Connolly, SM; Fatato, P; Guico-Pabia, C; Isler, JA; Jiang, Q; Nichols, AI; Patroneva, A; Paul, J; Pedersen, R, 2008)	0.35
"The purpose of this study was to determine whether duloxetine [a serotonin (5-HT)-norepinephrine reuptake inhibitor] combined with transcutaneous foot stimulation or WAY-100635 (a 5-HT1A antagonist) can enhance inhibition of bladder overactivity in cats."	( Inhibition of bladder overactivity by duloxetine in combination with foot stimulation or WAY-100635 treatment in cats. de Groat, WC; Matsuta, Y; Roppolo, JR; Schwen, Z; Shen, B; Tai, C; Wang, J, 2013)	0.39
"The frequency and financial impact of potential drug-drug interactions (DDIs) and drug-condition interactions (DCIs) in patients with painful diabetic peripheral neuropathy (DPN) treated with either pregabalin or duloxetine were compared."	( Cost comparison of drug-drug and drug-condition interactions in patients with painful diabetic peripheral neuropathy treated with pregabalin versus duloxetine. Cappelleri, JC; Chu, BC; Johnson, BH; Johnston, SS; Shrady, G; Silverman, SL; Udall, M, 2013)	0.39
"Potential DDI measured using clinical software that identifies co-prescription of medications that potentially interact with pregabalin or duloxetine."	( Potential drug-drug and drug-condition interactions among fibromyalgia patients initiating pregabalin or duloxetine: prevalence and health care expenditure impact. Cappelleri, JC; Chu, BC; Johnson, BH; Johnston, SS; Shrady, G; Silverman, SL; Udall, M, 2014)	0.4
"Anticipating and controlling drug-drug interactions (DDIs) in older patients with painful diabetic peripheral neuropaty (pDPN) presents a significant challenge to providers."	( A retrospective, matched cohort study of potential drug-drug interaction prevalence and opioid utilization in a diabetic peripheral neuropathy population initiated on pregabalin or duloxetine. Cappelleri, JC; Ellis, JJ; Mudumby, P; Ndehi, L; Parsons, B; Sadosky, AB; Suehs, BT; Ten Eyck, LL, 2015)	0.42
" However, sitagliptin was observed to have no effect when administered alone or in combination with the other three drugs."	( Drug combinations in diabetic neuropathic pain: an experimental validation. Mehta, AK; Tripathi, CD; Yadav, AM, 2016)	0.43
" The magnitude of drug-drug interaction between dextromethorphan and paroxetine was higher in homozygous than in heterozygous subjects (14."	( Impact of CYP2D6 Functional Allelic Variations on Phenoconversion and Drug-Drug Interactions. Daali, Y; Desmeules, J; Lenglet, S; Matthey, A; Storelli, F; Thomas, A, 2018)	0.48
"The aim of this work was to predict the extent of Cytochrome P450 2D6 (CYP2D6)-mediated drug-drug interactions (DDIs) in different CYP2D6 genotypes using physiologically-based pharmacokinetic (PBPK) modeling."	( Physiologically-Based Pharmacokinetic Modeling for the Prediction of CYP2D6-Mediated Gene-Drug-Drug Interactions. Daali, Y; Desmeules, J; Storelli, F, 2019)	0.51
" However, evidence regarding the efficacy of IA injection of HA+CS combined with duloxetine for pain management in patients with OA of the knee is lacking."	( Duloxetine combined with intra-articular injection versus intra-articular injection alone for pain relief in knee osteoarthritis: a study protocol for a randomised controlled trial. Han, R; Li, DY; Luo, F; Zhao, ZG, 2020)	0.56
" The participants will be randomly allocated to receive either a single IA injection of HA+CS combined with duloxetine or a single IA injection of HA+CS alone, and both groups will complete a 24-week follow-up to assess pain and functional improvements."	( Duloxetine combined with intra-articular injection versus intra-articular injection alone for pain relief in knee osteoarthritis: a study protocol for a randomised controlled trial. Han, R; Li, DY; Luo, F; Zhao, ZG, 2020)	0.56
"This randomized study was aimed at evaluating the additional analgesic effect of Okada Purifying Therapy (OPT) when administered in combination with duloxetine in patients with Temporomandibular Disorders (TMDs) and Fibromyalgia (FM)."	( Okada Purifying Therapy in combination with duloxetine vs. duloxetine alone in patients with TMD and fibromyalgia: a randomized clinical study. Atencio, MR; Bruti, G; D'Urso, A; Di Giacomo, P; Di Paolo, C, 2020)	0.56
" Since activated microglia, impaired serotonergic and noradrenergic neurotransmission and overexpressed sodium channels are implicated in oxaliplatin-induced pain, this in vivo study assessed the effect of minocycline, a microglial activation inhibitor used alone or in combination with ambroxol, a sodium channel blocker, or duloxetine, a serotonin and noradrenaline reuptake inhibitor, on oxaliplatin-induced tactile allodynia and cold hyperalgesia."	( The Microglial Activation Inhibitor Minocycline, Used Alone and in Combination with Duloxetine, Attenuates Pain Caused by Oxaliplatin in Mice. Furgała-Wojas, A; Sałat, K; Sałat, R, 2021)	0.62
" It is worth noting that doses of drug combination in FST and TST did not change the motor activities of mice in the open-field test (OFT)."	( The Potential Antidepressant Action of Duloxetine Co-Administered with the TAAR1 Receptor Agonist SEP-363856 in Mice. Chen, Y; Liang, L; Ren, X; Xiong, J; Zhang, G, 2022)	0.72
"To observe the clinical effect of flunarizine combined with duloxetine in the treatment of chronic migraine with comorbid depression and anxiety disorders and to provide a reference for clinical treatment."	( Clinical effect of flunarizine combined with duloxetine in the treatment of chronic migraine comorbidity of depression and anxiety disorder. Chen, J; Zhang, K; Zhu, J, 2022)	0.72
" The control group was treated with flunarizine combined with loxoprofen sodium, and the observation group was treated with flunarizine combined with duloxetine."	( Clinical effect of flunarizine combined with duloxetine in the treatment of chronic migraine comorbidity of depression and anxiety disorder. Chen, J; Zhang, K; Zhu, J, 2022)	0.72
"Flunarizine combined with duloxetine in the treatment of chronic migraine with depression and anxiety disorder can effectively improve neuroelectrophysiological indexes, reduce inflammation, and reduce depression and anxiety."	( Clinical effect of flunarizine combined with duloxetine in the treatment of chronic migraine comorbidity of depression and anxiety disorder. Chen, J; Zhang, K; Zhu, J, 2022)	0.72
" Therefore, we investigated the effect of an antimuscarinic (oxybutynin) on OSA severity when administered with either duloxetine or milnacipran, two dual noradrenergic/serotonergic reuptake inhibiters."	( A single dose of noradrenergic/serotonergic reuptake inhibitors combined with an antimuscarinic does not improve obstructive sleep apnoea severity. Adam, M; Beatty, CJ; Cheung, T; Edwards, BA; Hamilton, GS; Joosten, SA; Landry, SA; Mann, DL; Thomson, LDJ; Wong, AM, 2022)	0.72

Excerpt	Reference	Relevance
" The observed plasma concentration-time data at all three dose levels were adequately described by a one-compartment model with a first-order absorption rate constant."	( Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. Cerimele, BJ; Goldberg, MJ; Sharma, A, 2000)	0.31
" In the presence of fluvoxamine, the oral bioavailability of duloxetine increased from 42."	( In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine. Bergstrom, RF; Chappell, J; Hong, Q; Knadler, MP; Lobo, ED; Quinlan, T; Reddy, S; Ring, B, 2008)	0.35
" In vivo study was conducted by quantitating the effect of orally administered DLX on the bioavailability of talinolol."	( In vitro and in vivo evaluation of the effects of duloxetine on P-gp function. Junhua, C; Ruike, Z; Wenxing, P, 2010)	0.36
" In the in vivo study, co-administration of DLX increased the bioavailability of talinolol."	( In vitro and in vivo evaluation of the effects of duloxetine on P-gp function. Junhua, C; Ruike, Z; Wenxing, P, 2010)	0.36
" In view of the importance of formulation processing and bioavailability characteristics of the crystalline forms of 1, a comprehensive structural study of 1(acetone) was carried out using single-crystal and powder X-ray diffraction, infrared and Raman spectroscopies, and solid-state NMR spectroscopy."	( Polymorphism and a metastable solvate of duloxetine hydrochloride. Bhadbhade, M; Hook, JM; Marjo, CE; Rich, AM, 2011)	0.64
" Alteration of the gastrointestinal tract by this procedure suggests a potential for clinically significant alterations in the bioavailability of ingested medications including antidepressants."	( A comparison of duloxetine plasma levels in postbariatric surgery patients versus matched nonsurgical control subjects. Cao, L; Crosby, RD; Mitchell, JE; Roerig, JL; Steffen, KJ; Zimmerman, C, 2013)	0.39
" The effects on absorption rate and type of drug delivery systems (nanocarriers and drug solution) for nose to brain/blood permeation were assessed."	( Intranasal infusion of nanostructured lipid carriers (NLC) containing CNS acting drug and estimation in brain and blood. Ahuja, A; Alam, MI; Ali, J; Ali, M; Baboota, S; Sahni, JK, 2013)	0.39
" The pharmacokinetic evaluation of ZBH2012001 indicated that the absolute bioavailability value was 60."	( Antidepressant-like Effects of ZBH2012001, a Novel Potent Serotonin and Norepinephrine Reuptake Inhibitor. Fan, QY; Fan, SY; He, XH; Li, J; Li, Y; Li, YF; Xue, R; Zhang, TT; Zhang, YZ; Zhong, BH, 2016)	0.43
" Duloxetine suffers from reduced oral bioavailability (≈50%) due to hepatic metabolism."	( Formulation and optimization of duloxetine hydrochloride buccal films: in vitro and in vivo evaluation. El Sharawy, AM; Elshafeey, AH; Shukr, MH, 2017)	0.74
"8 times increment in bioavailability in comparison to duloxetine suspension."	( Duloxetine loaded-microemulsion system to improve behavioral activities by upregulating serotonin and norepinephrine in brain for the treatment of depression. Ali, J; Baboota, S; Iqbal, B; Kumar, S; Sindhu, P, 2018)	0.48
" The study was aimed to develop a thiomer gel containing duloxetine proniosomes for the intranasal delivery, improving its bioavailability and brain delivery through olfactory system."	( Development and Evaluation of Optimized Thiolated Chitosan Proniosomal Gel Containing Duloxetine for Intranasal Delivery. Amin, U; Khan, GM; Khatoon, M; Shah, KU; Shahnaz, G; Sohail, MF; Ullah, N; Ur Rehman, A; Ur Rehman, F, 2019)	0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" The mean fed and fasting pharmacokinetic parameters and drug-related adverse events from the 2 studies were compared in order to assess the effect of food on the duloxetine bioavailability and respectively, tolerability."	( The Effect of Food on the Single-Dose Bioavailability and Tolerability of the Highest Marketed Strength of Duloxetine. Chirila, M; Duna, SN; Ghita, A; Iordachescu, A; Rizea-Savu, S, 2020)	0.56
"The present investigation is focused on improving oral bioavailability of poorly soluble and lipophilic drugs, curcumin (CRM) and duloxetine (DXH), through the solid self-nanoemulsifying drug delivery system (S-SNEDDS) and identifying their potential against attenuation of NP in chronic constriction injury (CCI)-induced rats through the solid self-nanoemulsifying drug delivery system (S-SNEDDS)."	( Pharmacokinetic and pharmacodynamic evaluation of Solid self-nanoemulsifying delivery system (SSNEDDS) loaded with curcumin and duloxetine in attenuation of neuropathic pain in rats. Bhatia, A; Garg, V; Gulati, M; Kumar, B; Melkani, I; Pandey, NK; Prakash, T; Singh, S; Singh, SK, 2021)	0.62
" Developing a prolonged release parenteral nanosphere formulation of DLX would be overcoming pitfalls like acid-labile degradation, first-pass metabolism and erratic bioavailability along with long-term therapeutic benefit in the treatment of depression."	( Polymer-based prolonged-release nanoformulation of duloxetine: fabrication, characterization and neuropharmacological assessments. Ali, W; Kuhad, A; Prasad, P; Sarwal, A; Sharma, S; Singh, G, 2021)	0.62
"Duloxetine (DLX) is dual serotonin and norepinephrine reuptake inhibitor suffering from limited bioavailability (≈ 40%) due to extensive hepatic metabolism."	( Brain Targeting of Duloxetine HCL via Intranasal Delivery of Loaded Cubosomal Gel: In vitro Characterization, ex vivo Permeation, and in vivo Biodistribution Studies. Abdelbary, GA; Elsayed, I; Elsenosy, FM; Elshafeey, AH; Fares, AR, 2020)	0.56
"Accordingly, intranasal DLX in situ cubo-gel can be considered as an innovative nano-carrier delivery system for bioavailability enhancement and efficient brain targeting of DLX to maximize its effect."	( Brain Targeting of Duloxetine HCL via Intranasal Delivery of Loaded Cubosomal Gel: In vitro Characterization, ex vivo Permeation, and in vivo Biodistribution Studies. Abdelbary, GA; Elsayed, I; Elsenosy, FM; Elshafeey, AH; Fares, AR, 2020)	0.56
"The data demonstrated that combined therapy of pregabalin plus amitriptyline improved the bioavailability of pregabalin and potentiated the efficacy of the antiallodynic effect of pregabalin alone, proving to be advantageous for the treatment of sciatic neuropathic pain."	( Investigation of the Combination of Pregabalin with Duloxetine or Amitriptyline on the Pharmacokinetics and Antiallodynic Effect During Neuropathic Pain in Rats. Barros, CM; Boralli, VB; Costa, LH; Galdino, G; Kawano, T; Placido, RV; Podesta, MHMC; Rodrigues, RF; Santos, RS, 2021)	0.62
" Following its extensive hepatic metabolism, acid-labile nature, and limited aqueous solubility, DXH has poor oral bioavailability (40%)."	( Glycerosomal thermosensitive in situ gel of duloxetine HCl as a novel nanoplatform for rectal delivery: in vitro optimization and in vivo appraisal. Ali, AA; El-Ela, FIA; Khallaf, RA; Rabea, YK; Salem, HF, 2022)	0.72
" Alterations caused by RYGB could modify drug bioavailability and cause potential subtherapeutic plasma concentrations, increasing the risk of depressive relapse."	( The Influence of a Roux-en-Y Gastric Bypass on Plasma Concentrations of Antidepressants. Eap, CB; Favre, L; Frantz, J; Garin, P; Vandenberghe, F; Vionnet, N, 2023)	0.91

Excerpt	Relevance	Reference
"Duloxetine hydrochloride ((S)-N-methyl-3-(1-naphthalenyloxy)-2-thiophenepropanamine hydrochloride) has been found to react with polymer degradation products or residual free acids present in the enteric polymers hydroxypropyl methylcellulose acetate succinate (HPMCAS) and hydroxypropyl methylcellulose phthalate (HPMCP) in dosage formulations to form succinamide and phthalamide impurities, respectively."	( Characterization of impurities formed by interaction of duloxetine HCl with enteric polymers hydroxypropyl methylcellulose acetate succinate and hydroxypropyl methylcellulose phthalate. Baertschi, SW; Jansen, PJ; Kemp, CA; Maple, SR; Oren, PL, 1998)	1.74
" TYR PD30 increased significantly with desipramine dosing (p<0."	( Duloxetine increases serotonin and norepinephrine availability in healthy subjects: a double-blind, controlled study. Bieck, PR; Bymaster, FP; Chalon, SA; Granier, LA; Hirth, C; Joliat, MJ; Potter, WZ; Vandenhende, FR, 2003)	0.32
" These findings suggest that there should not be a need for routine adjustment of tolterodine dosage in the presence of duloxetine."	( Effect of duloxetine on tolterodine pharmacokinetics in healthy volunteers. Chan, C; Gonzales, CR; Hua, TC; Knadler, MP; Pan, A; Poo, YK; Skinner, MH; Wise, SD, 2004)	0.32
" The dose of intravenous tyramine required to raise systolic blood pressure by 30 mm Hg (PD30) increased dose-dependently with duloxetine and was significant at the end of the 120-mg/d dosage (P<0."	( Clinical assessment of norepinephrine transporter blockade through biochemical and pharmacological profiles. Bieck, PR; Black, BK; Bymaster, FP; Garland, EM; Gonzales, C; Loghin, C; Potter, WZ; Robertson, D; Vincent, S, 2004)	0.32
" In this study, the effects of two dosing regimens of duloxetine on sleep electroencephalography (EEG) were investigated at steady-state plasma concentrations in young, healthy, male subjects."	( Comparative effects of duloxetine and desipramine on sleep EEG in healthy subjects. Chalon, S; Granier, LA; Lainey, E; Pereira, A; Staner, L; Vandenhende, F; Watkin, JG, 2005)	0.33
" While approved dosing ranges have not yet been determined, studies support the efficacy and safety of 40-60 mg twice daily for the treatment of acute MDD."	( Duloxetine: a dual reuptake inhibitor. Dugan, SE; Fuller, MA, 2004)	0.32
"The rate of duloxetine elimination is reduced for cirrhotic subjects, making dosage adjustments appropriate."	( Duloxetine pharmacokinetics in cirrhotics compared with healthy subjects. Branch, RA; Gonzales, C; Knadler, MP; Reddy, S; Skinner, MH; Suri, A, 2005)	0.33
"Duloxetine exhibits linear, dose-dependent pharmacokinetics across the approved oral dosage range of 40 to 60 mg/d."	( Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder. Bettinger, TL; Crismon, ML; Hunziker, ME; Suehs, BT, 2005)	1.77
"The pharmacology, pharmacokinetics, efficacy, safety, drug interactions, dosage and administration, cost, and place in therapy of duloxetine for major depression, pain from diabetic peripheral neuropathy, and stress urinary incontinence are reviewed."	( Duloxetine: a balanced and selective norepinephrine- and serotonin-reuptake inhibitor. Gayken, J; Haight, R; Westanmo, AD, 2005)	0.33
" The recommended dosage of duloxetine is 40-80 mg daily, depending on the indication, preferably split into two doses per day."	( Duloxetine: a balanced and selective norepinephrine- and serotonin-reuptake inhibitor. Gayken, J; Haight, R; Westanmo, AD, 2005)	0.33
"Positron emission tomography (PET) has been utilized for determining the dosage of antipsychotic drugs."	( A dose-finding study of duloxetine based on serotonin transporter occupancy. Ikoma, Y; Kosaka, J; Nozaki, S; Ota, M; Suhara, T; Suzuki, K; Takano, A; Tanada, S, 2006)	0.33
" Adverse event rates were based on spontaneous reports and differential dose-response effects were not evaluated."	( Duloxetine in the treatment of major depressive disorder: comparisons of safety and tolerability in male and female patients. Kornstein, SG; Mallinckrodt, CH; Stewart, DE; Watkin, JG; Wohlreich, MM, 2006)	0.33
" Whereas the target dose for the majority of patients is 60 mg/day, higher duloxetine doses (up to 120 mg/day) have been studied using a twice-daily dosing schedule."	( Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation. Carter, WP; Mallinckrodt, CH; Prakash, A; Watkin, JG; Wohlreich, MM, 2007)	0.34
" An evaluation of increments in effect size between doses consistently showed that the most notable gain in effect size for efficacy was the 40-60mg/day dosage range."	( Use of effect size to determine optimal dose of duloxetine in major depressive disorder. Berzon, RA; Corey-Lisle, PK; Desaiah, D; Detke, MJ; Marciniak, MD; Pritchett, YL, )	0.13
" The varying sensitivity of scales that measure the severity of depression is one of the many factors affecting the evaluation of the dose-response relationship with antidepressants."	( Dose-response relationship of duloxetine in placebo-controlled clinical trials in patients with major depressive disorder. Bech, P; Kajdasz, DK; Porsdal, V, 2006)	0.33
" Duloxetine, in a dosage of 60 mg x 1 or x 2 daily, significantly reduces, from the first week of administration, the pain of DPN, when compared with a placebo."	( [Duloxetine, a new therapeutic option for diabetic peripheral neuropathic pain]. Ziegler, D, 2006)	0.33
" The patient took 20 mg daily for five days and then decided, on her own, to decrease the dosage after experiencing insomnia, a common adverse effect of duloxetine."	( Facial flushing associated with duloxetine use. Ezzo, DC; Patel, PN, 2007)	0.34
"Data were combined from two similarly designed, multicenter, randomized, double-blind, parallel group studies in which patients with major depressive disorder were randomized to either duloxetine 60 mg/day or venlafaxine extended release (XR) 150 mg/day (75 mg/day for the first 2 weeks) for a 6-week fixed dosing period followed by an additional 6 weeks of treatment in which the dose could be increased up to 120 mg/day for duloxetine and 225 mg/day for venlafaxine."	( A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. Bauer, M; Froud, DM; Jain, R; Kajdasz, DK; Perahia, DG; Pritchett, YL; Raskin, J; Russell, JM; Spencer, KA; Thase, ME; Walker, DJ, 2008)	0.35
"047) experienced sustained elevations of systolic blood pressure during the fixed dosing period."	( A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. Bauer, M; Froud, DM; Jain, R; Kajdasz, DK; Perahia, DG; Pritchett, YL; Raskin, J; Russell, JM; Spencer, KA; Thase, ME; Walker, DJ, 2008)	0.35
" Duloxetine produced increases in supine systolic and diastolic blood pressures, which reached maximums of approximately 12 mm Hg and approximately 7 mm Hg above baseline, respectively, during dosing at 120 mg BID and then stabilized."	( The effects of supratherapeutic doses of duloxetine on blood pressure and pulse rate. Callaghan, JT; Chappell, JC; Derby, MA; Ereshefsky, L; Gonzales, CR; Hoelscher, D; Leese, PT; Leibowitz, M; Mitchell, MI; Zhang, L, 2007)	0.34
" Significant improvements versus placebo in core emotional symptoms as well as painful physical symptoms associated with depression, were seen in most, but not all, appropriately designed studies; results of meta-analyses suggested that improvements in these efficacy measures were apparent after 1-2 weeks' treatment with the highest recommended dosage of 60 mg once daily."	( Duloxetine: a review of its use in the treatment of major depressive disorder. Frampton, JE; Plosker, GL, 2007)	0.34
"Duloxetine pharmacokinetics in healthy Chinese subjects given a 60 mg once-daily dosing regimen were well characterised and consistent with known duloxetine pharmacokinetics in healthy Caucasian and Japanese subjects."	( Pharmacokinetics and tolerability of duloxetine following oral administration to healthy Chinese subjects. Knadler, MP; Liang, S; Lim, MT; Lobo, ED; Pan, AX; Teng, L; Tianmei, S; Yeo, KP, 2007)	0.34
"Participants in a major depressive episode (N=249) began duloxetine treatment at 30 or 60 mg daily for the first week, followed by up to 11 weeks of flexibly dosed duloxetine (60, 90, or 120 mg daily)."	( The efficacy and tolerability of duloxetine in the treatment of anxious versus non-anxious depression: a post-hoc analysis of an open-label outpatient study. Brown, E; Chen, L; Fava, M; Greist, J; Marangell, LB; Martinez, JM; Wohlreich, MM, )	0.13
" A secondary analysis of dose-response relationships indicated that this advantage was not attributable to the studies using higher doses of duloxetine."	( Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder. Detke, MJ; Ossanna, MJ; Pritchett, YL; Swindle, RW; Thase, ME; Xu, J, 2007)	0.34
"14]) but did not resolve urinary incontinence, with no significant dose-response association."	( Systematic review: randomized, controlled trials of nonsurgical treatments for urinary incontinence in women. Kane, RL; Shamliyan, TA; Wilt, TJ; Wyman, J, 2008)	0.35
"Fifty-five women with PMDD were treated with a 60 mg/day dosage of duloxetine for two menstrual cycles."	( Duloxetine for premenstrual dysphoric disorder: a pilot study. Bria, P; Catalano, V; Harnic, D; Janiri, L; Mazza, M, 2008)	0.35
" Duloxetine was administered in dosage 60 mg per day during 8 weeks to 40 patients."	( [Efficacy of duloxetine in the treatment of chronic daily headache]. Artemenko, AR; Filatova, EG; Kurenkov, AL, 2007)	0.34
" Cymbalta was used as a monotherapy in dosage 60 mg daily during 6 weeks simultaneously with traditional non-pharmacological therapy."	( [Treatment of chronic back pain with antidepressant cymbalta: an experimental study]. Kaverina, IV; Leonova, AR; Voznesenskaia, TG, 2007)	0.34
" Adverse effects were evaluated using the Dosage Record Treatment Emergent Symptom Scale."	( Efficacy and tolerability of duloxetine in the treatment of patients with borderline personality disorder: a pilot study. Bellino, S; Bogetto, F; Bozzatello, P; Paradiso, E, 2010)	0.36
" Fifteen individuals with panic disorder with or without agoraphobia received 8 weeks of open label duloxetine flexibly dosed from 60 to 120 mg per day."	( Open-label support for duloxetine for the treatment of panic disorder. Herlands, NN; Hoge, EA; Kaufman, RE; Owens, ME; Pollack, MH; Simon, NM; Worthington, JJ, 2009)	0.35
" Patients received cymbalta in dosage 60 mg daily during 2 months."	( [Cymbalta (duloxetine) in the treatment of anxiety-depressive disorders in patients with discirculatory encephalopathy]. Bobrova, MV; Listopadov, IuI; Rzheusskaia, GV; Umrudina, AG, 2009)	0.35
"The objectives of this analysis were to characterize the pharmacokinetics of duloxetine at steady state in patients, estimate the variability, identify significant covariates that may influence duloxetine pharmacokinetics and provide appropriate dosing recommendations for patients on duloxetine treatment."	( Population pharmacokinetics of orally administered duloxetine in patients: implications for dosing recommendation. Heathman, M; Knadler, MP; Lobo, ED; O'Brien, L; Quinlan, T, 2009)	0.35
" Covariates including bodyweight, age, sex, ethnicity, smoking status, disease condition, dose, dosing regimen and creatinine clearance were tested for their influence on duloxetine pharmacokinetics."	( Population pharmacokinetics of orally administered duloxetine in patients: implications for dosing recommendation. Heathman, M; Knadler, MP; Lobo, ED; O'Brien, L; Quinlan, T, 2009)	0.35
" The significant improvements in efficacy that occurred in patients with fibromyalgia during 8 weeks of open-label treatment with duloxetine 60 mg/day were generally maintained during 52 weeks of subsequent blinded treatment at the same dosage in a phase III trial."	( Duloxetine: in patients with fibromyalgia. Curran, MP, 2009)	0.35
"This study evaluated the pharmacodynamics and pharmacokinetics of once-daily dosing of warfarin at steady state when taken concomitantly with once-daily doses of duloxetine."	( Effects of duloxetine on the pharmacodynamics and pharmacokinetics of warfarin at steady state in healthy subjects. Chappell, J; He, J; Knadler, MP; Lee, D; Lobo, E; Mitchell, M, 2009)	0.35
"Many women received lower duloxetine doses than expected based on evidence-based dosing recommendations."	( How are women with SUI-symptoms treated with duloxetine in real life practice? - preliminary results from a large observational study in Germany. Gotsch, U; Gross, A; Manning, M; Methfessel, HD; Michel, MC; Minarzyk, A; Pages, I; Quail, D, 2009)	0.35
" At week 7, the duloxetine dosage was increased, in a blinded fashion, to 120-mg QD in patients reporting < 30% pain reduction."	( A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee. Belenkov, Y; Brown, JP; Chappell, AS; Desaiah, D; Liu-Seifert, H; Skljarevski, V; Zhang, S, )	0.13
" Opioid utilization including total days, number of prescriptions filled, and morphine equivalent dosage was assessed for overall, long-acting, and short-acting opioids."	( Opioid utilization and health-care costs among patients with diabetic peripheral neuropathic pain treated with duloxetine vs. other therapies. Boulanger, L; Chen, SY; Fraser, KA; Hallett, LA; Patel, CK; Wu, N; Zhao, Y, )	0.13
" This study examined the association between initial prescription dosage of duloxetine and its adherence and persistence."	( Initial duloxetine prescription dose and treatment adherence and persistence in patients with major depressive disorder. Able, SL; Faries, DE; Gelwicks, S; Liu, X, 2010)	0.36
" The author reviews the major medications used, dosing schedules, and data from randomized controlled trials."	( Treatment of neuropathic pain. Jefferies, K, 2010)	0.36
" A month after the aripiprazole dosage was increased to 50 mg daily, the patient developed confusion and loss of coordination."	( Increased aripiprazole concentrations in an HIV-positive male concurrently taking duloxetine, darunavir, and ritonavir. Aung, GL; Kawamoto, LS; O'Brien, JG; Tien, PG, 2010)	0.36
"A reproducible gradient reversed-phase ultra-performance liquid chromatographic method is developed for quantitative determination of duloxetine hydrochloride in pharmaceutical dosage forms."	( Analysis of duloxetine hydrochloride and its related compounds in pharmaceutical dosage forms and in vitro dissolution studies by stability indicating UPLC. Chakole, D; Mukkanti, K; Rao, DD; Reddy, AM; Reddy, YR; Sait, SS, 2010)	0.94
"A stability-indicating HPLC assay method was developed for the quantitative determination of duloxetine (DLX) in a pharmaceutical dosage form in the presence of its degradation products, and kinetic determinations were evaluated in acid conditions and UV-C radiation exposure."	( Stress degradation studies and kinetic determinations of duloxetine enteric-coated pellets by HPLC. Gomes, P; Paim, CS; Schapoval, EE; Steppe, M; Wingert, NR, )	0.13
" However, given that the study had several limitations, including the lack of a comparison group and a flexible dosage design, further research is needed to replicate and extend these findings."	( Clinical and demographic predictors of improvement during duloxetine treatment in patients with major depression: an open-label study. Chiesa, A; De Ronchi, D; Mencacci, C; Nasso, ED; Serretti, A, 2011)	0.37
"It is necessary to warn patients who take benzodiazepines in therapy that reinforcement of irritability may occur in case of higher dosage of benzodiazepines, which may be misinterpreted as worsening in mental condition."	( Reinforcement of irritability during therapy with benzodiazepines. Kozumplik, O; Uzun, S, 2011)	0.37
" We described a patient with tremor, mydriatic pupils, clonus, and ataxia after a single dose of duloxetine; on the dosage of admission."	( Serotonin syndrome due to duloxetine. Gelener, P; Gorgulu, U; Inan, LE; Kutlu, G; Ucler, S, )	0.13
" The CGI-Improvement, CGI-Effectiveness Index and Dosage Record Treatment Emergent Symptom Scale were administered at T1 and T2."	( Duloxetine for the treatment of mood disorder in cancer patients: a 12-week case-control clinical trial. Borio, R; Castelli, L; Leombruni, P; Torta, R, )	0.13
"To examine medication dosing patterns of duloxetine and pregabalin among patients with fibromyalgia."	( Medication dosing patterns associated with duloxetine and pregabalin among patients with fibromyalgia. Sun, P; Watson, P; Zhao, Y; Zhao, Z, 2011)	0.37
"Among patients with fibromyalgia, duloxetine and pregabalin initiators had different dosing patterns."	( Medication dosing patterns associated with duloxetine and pregabalin among patients with fibromyalgia. Sun, P; Watson, P; Zhao, Y; Zhao, Z, 2011)	0.37
"The purpose of our study was to examine dosing patterns and pretreatment predictors of high-dose duloxetine therapy for patients with MDD in the usual clinical setting."	( Dosing patterns for duloxetine and predictors of high-dose prescriptions in patients with major depressive disorder: analysis from a United States third-party payer perspective. Ball, T; Cui, Z; Faries, DE; Johnstone, B; Liu, X; Niu, L, 2011)	0.37
" Dosing patterns and predictors of high-dose therapy with duloxetine were examined."	( Dosing patterns for duloxetine and predictors of high-dose prescriptions in patients with major depressive disorder: analysis from a United States third-party payer perspective. Ball, T; Cui, Z; Faries, DE; Johnstone, B; Liu, X; Niu, L, 2011)	0.37
" Nonblinded, flexibly dosed treatment was used to mimic clinical practice."	( A pragmatic 12-week, randomized trial of duloxetine versus generic selective serotonin-reuptake inhibitors in the treatment of adult outpatients in a moderate-to-severe depressive episode. Edwards, SE; Greist, JH; Katon, W; Kroenke, K; Marangell, LB; Martinez, JM; Meyers, AL; Shoemaker, S; Swindle, R; Thase, ME, 2012)	0.38
"Study limitations include a short timeframe and using data from different dosage schemes for GBP and PGB."	( Economic evaluation of duloxetine as a first-line treatment for painful diabetic peripheral neuropathy in Mexico. Carlos, F; Dueñas, H; Galindo-Suárez, RM; Ramírez-Gámez, J; Ramos, E, 2012)	0.38
"To compare medication dosing patterns of duloxetine and pregabalin among patients with diabetic peripheral neuropathic pain (DPNP)."	( Dosing pattern comparison between duloxetine and pregabalin among patients with diabetic peripheral neuropathic pain. Bernauer, M; Sun, P; Watson, P; Zhao, Y; Zhao, Z, 2012)	0.38
" healthcare claims database, we examined the dosing patterns of duloxetine and pregabalin among commercially insured patients with DPNP aged 18 to 64 who initiated (a 90-day medication gap) duloxetine or pregabalin therapy in 2006."	( Dosing pattern comparison between duloxetine and pregabalin among patients with diabetic peripheral neuropathic pain. Bernauer, M; Sun, P; Watson, P; Zhao, Y; Zhao, Z, 2012)	0.38
"The commercially insured patients with DPNP who initiated duloxetine or pregabalin therapy had different dosing patterns."	( Dosing pattern comparison between duloxetine and pregabalin among patients with diabetic peripheral neuropathic pain. Bernauer, M; Sun, P; Watson, P; Zhao, Y; Zhao, Z, 2012)	0.38
" We here review the evidence for the efficacy of 60 mg once-daily dosing of duloxetine for chronic pain conditions."	( A review of duloxetine 60 mg once-daily dosing for the management of diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain due to chronic osteoarthritis pain and low back pain. Langley, P; Nalamachu, S; Pergolizzi, JV; Raffa, RB; Rodriguez, G; Taylor, R, 2013)	0.39
"The studies reviewed report that duloxetine 60 mg once-daily dosing is an effective option for the management of diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain due to chronic OA pain and chronic LBP."	( A review of duloxetine 60 mg once-daily dosing for the management of diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain due to chronic osteoarthritis pain and low back pain. Langley, P; Nalamachu, S; Pergolizzi, JV; Raffa, RB; Rodriguez, G; Taylor, R, 2013)	0.39
"The Tekscan(®) WB measurement system was used in MIA rats to examine the acute and chronic dosing effects of drugs that targeted different mechanisms."	( Pharmacological validation of early and late phase of rat mono-iodoacetate model using the Tekscan system. Elmes, SJ; McIntosh, F; Perkins, MN; Rashid, MH; Theberge, Y, 2013)	0.39
" Rates of change (slopes) were estimated from the fitted model and differences in the cost trajectory among dosing cohorts were tested using the F-test."	( Longitudinal analysis of healthcare costs: a case study of patients with major depressive disorder treated with duloxetine. Able, SL; Cui, Z; Faries, DE; Novick, D; Shen, W, 2013)	0.39
" Duloxetine has a generally favorable side effect profile and dosing is simple."	( [Duloxetine for chronic pain management: pharmacology and clinical use]. Itoh, M; Masuda, R; Suzuki, T, 2013)	0.39
" Concerning the emotional pain responses revealed with USVs, we assumed that the antinociceptive effects were almost completely derived from duloxetine, since celecoxib was ineffective when administered alone or reduced the dosage of duloxetine when given in combination."	( Synergistic analgesia of duloxetine and celecoxib in the mouse formalin test: a combination analysis. Dong, YL; Gu, ZX; Lu, GJ; Sun, YH; Wang, W; Wang, YT; Wu, SX; Yang, J; Zhao, GL, 2013)	0.39
" The results of this study indicate that the analgesic effect of repeated dosing of AS1069562 but not duloxetine is persistent even after a 1-week drug discontinuation in STZ-induced diabetic rats."	( AS1069562, the (+)-isomer of indeloxazine, but not duloxetine has a curative-like analgesic effect in a rat model of streptozotocin-induced diabetic neuropathy. Aoki, T; Hamakawa, N; Matsuoka, N; Murai, N; Tamura, S; Yamamoto, H, 2014)	0.4
"Mean median daily dosage over 6 months was 53."	( Effectiveness of duloxetine compared with pregabalin and gabapentin in diabetic peripheral neuropathic pain: results from a German observational study. Birklein, F; Boess, FG; Happich, M; Schacht, A; Schneider, E; Wilhelm, S; Ziegler, D, 2014)	0.4
" Rates of treatment-emergent sexual dysfunction (TESD) in the vortioxetine dosing groups were similar to placebo."	( A randomised, double-blind, placebo-controlled, duloxetine-referenced study of the efficacy and tolerability of vortioxetine in the acute treatment of adults with generalised anxiety disorder. Chen, Y; Jacobsen, PL; Mahableshwarkar, AR; Simon, JS, 2014)	0.4
" Here, the in vivo effects of dosing with duloxetine 60 mg once daily for 11 days in healthy subjects were assessed in 2 studies: (1) centrally (n = 11), by measuring concentrations of 5-hydroxyindoleacetic acid, 3,4-dihydroxyphenylglycol (DHPG), and NE in cerebrospinal fluid, and (2) versus escitalopram 20 mg/d (n = 32) in a 2-period crossover study by assessing the ΔDHPG/ΔNE ratio in plasma during orthostatic testing and by pharmacokinetic/pharmacodynamic modeling of reuptake inhibition using subjects' serum in cell lines expressing cloned human 5-HTT or NET."	( Effects of duloxetine on norepinephrine and serotonin transporter activity in healthy subjects. Chappell, JC; Dean, RA; Detke, MJ; Eisenhofer, G; Haber, H; Iyengar, S; Knadler, MP; Lachno, DR; Lobo, ED; Mitchell, MI; Nemeroff, CB; Owens, MJ; Pangallo, B, 2014)	0.4
" The methods were successfully applied for the determination of this drug in pharmaceutical dosage form."	( Development of sensitive spectrofluorimetric and spectrophotometric methods for the determination of duloxetine in capsule and spiked human plasma. Önal, A; Sagirli, O; Toker, SE, 2014)	0.4
" However, cost-analysis is only part of the equation when treating chronic pain patients and undervalues the relationships of enhanced compliance due to single-daily dosing and stable and reliable pharmacokinetics associated with extended-duration preparations using either retentive technologies or delayed absorption strategies."	( Can Chronic Pain Patients Be Adequately Treated Using Generic Pain Medications to the Exclusion of Brand-Name Ones? Anantamongkol, U; Candido, KD; Chiweshe, J; Knezevic, NN, )	0.13
" By univariate and multivariate analysis, the patient's age, tumor origin, regimen of chemotherapy, accumulated doses of paclitaxel or carboplatin, previous medication, maintenance dosage and timing of treatment with duloxetine were found not to be associated with the effectiveness of duloxetine treatment."	( Usefulness of duloxetine for Paclitaxel-induced peripheral neuropathy treatment in gynecological cancer patients. Egawa-Takata, T; Fujita, M; Isobe, A; Kimura, T; Kobayashi, E; Mabuchi, S; Matsuzaki, S; Otake, A; Sawada, K; Ueda, Y; Yoshino, K, 2015)	0.42
" Effects of orally dosed standard analgesics on CRANE were examined 48 h following bilateral CFA injection."	( Complete Freund's adjuvant-induced reduction of exploratory activity in a novel environment as an objective nociceptive endpoint for sub-acute inflammatory pain model in rats. Bannon, AW; Joshi, SK; Zhu, CZ, 2015)	0.42
"Youth aged 7 through 17 years with a primary diagnosis of GAD were treated with flexibly dosed duloxetine (30-120 mg daily, n = 135) or placebo (n = 137) for 10 weeks, followed by open-label duloxetine (30-120mg daily) for 18 weeks."	( A randomized, placebo-controlled study of duloxetine for the treatment of children and adolescents with generalized anxiety disorder. Cai, N; Findling, RL; Pangallo, BA; Prakash, A; Strawn, JR; Stroud, CE; Zhang, Q, 2015)	0.42
" Systemic intraperitoneal injections at a higher dosage (10 mg) had smaller analgesic effects (reduced by approximately 53%-69%), whereas contralateral SC injections (10 mg) were ineffective."	( R-Duloxetine and N-Methyl Duloxetine as Novel Analgesics Against Experimental Postincisional Pain. Russell, G; Strichartz, GR; Wang, CF; Wang, GK; Wang, SY, 2016)	0.43
" Then, duloxetine dosage was reduced to 30 mg/day."	( Duloxetine-induced Sleep Bruxism in Fibromyalgia Successfully Treated With Amitriptyline. Malas, FÜ; Şahin Onat, S, )	0.13
" The mean dosage of duloxetine was 55 mg/day (range 40-60 mg/day) and the mean dosage of sertraline was 146 mg/day (range 50-200 mg/day)."	( Comparing the Effects of Sertraline with Duloxetine for Depression Severity and Symptoms: A Double-Blind, Randomized Controlled Trial. Dastgheib, SA; Mowla, A; Razeghian Jahromi, L, 2016)	0.43
" The aim of this article was to characterize the relevant classification of drug impurities and to review the methods of impurities determination for atorvastatin (ATV) and duloxetine (DLX) (both in active pharmaceutical ingredients and in different dosage forms)."	( Impurities in Drug Products and Active Pharmaceutical Ingredients. Frankowski, M; Kątny, M, 2017)	0.46
" The mean dosage of duloxetine was 44."	( Duloxetine Augmentation in Resistant Obsessive-Compulsive Disorder: A Double-Blind Controlled Clinical Trial. Boostani, S; Dastgheib, SA; Mowla, A, 2016)	0.43
" The patients in the duloxetine group received doxazosin 4 mg + duloxetine 30 mg once a day, and the dosage of duloxetine was increased to 60 mg after a week."	( Clinical study of duloxetine hydrochloride combined with doxazosin for the treatment of pain disorder in chronic prostatitis/chronic pelvic pain syndrome: An observational study. Dong, D; Ji, Z; Li, H; Yan, S; Zhang, M, 2017)	0.79
" Thus, taking into account the observed high interindividual variability of SCD, our findings suggest that for MDD patients treated with duloxetine, SCD could be a useful tool to guide the treatment by optimizing the oral dosage in order to increase the AR rate."	( Duloxetine plasma level and antidepressant response. Conca, A; De Donatis, D; Florio, V; Mercolini, L; Porcelli, S; Saria, A; Serretti, A, 2019)	0.51
" Unlike the selective serotonin (5-HT) reuptake inhibitors (SSRIs), most of these antidepressants have an ascending rather than a flat dose-response curve."	( Serotonin and Norepinephrine Reuptake Inhibitors. Shelton, RC, 2019)	0.51
" This study compared the efficacy and safety of switching patients with treatment-resistant depression from an ineffective antidepressant to flexibly dosed esketamine nasal spray plus a newly initiated antidepressant or to a newly initiated antidepressant (active comparator) plus placebo nasal spray."	( Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. Bajbouj, M; Cooper, K; Daly, EJ; Drevets, WC; Hough, D; Lane, R; Lim, P; Manji, H; Mazzucco, C; Molero, P; Popova, V; Shelton, RC; Singh, JB; Thase, ME; Trivedi, M; Vieta, E, 2019)	0.51
"Eighteen healthy women signed informed consent, however, one dropped out before dosing and one dropped out after the first period, therefore, 16 subjects completed the study."	( Effect of a 5-HT Cernus, D; Klarskov, N; Sawyer, W; Van Till, O, 2019)	0.51
" However, further studies are still needed to find out the optimal dosage for OA and examine its long-term efficacy and safety."	( The short-term effect and safety of duloxetine in osteoarthritis: A systematic review and meta-analysis. Chen, HY; Gao, SH; Huang, JH; Huo, JB; Li, XW; Pan, QM, 2019)	0.51
"To raise awareness and demonstrate the importance of a thorough assessment of smoking status, we present a case in which the temporal relationship of smoking cessation to the emergence of nausea, vomiting, and tachycardia 3 days later (day 3); the development of myoclonic jerks by day 5; and the resolution of symptoms on reduction of duloxetine dosage on day 44 implicates duloxetine toxicity in a patient with ischemic cardiomyopathy awaiting implantation of a left ventricular assist device."	( Smoking cessation and duloxetine toxicity: A case report. Kohli, N; Tancredi, N, )	0.13
" Baseline paw withdrawal thresholds (PWTs) were determined in the ipsilateral (injured side) and contralateral hindpaws immediately prior to dosing and at scheduled times for 3 h post dosing in individual animals."	( Assessment of the anti-allodynic efficacy of a glycine transporter 2 inhibitor relative to pregabalin and duloxetine in a rat model of prostate cancer-induced bone pain. Corradini, L; Imam, MZ; Kuo, A; Nicholson, JR; Smith, MT, 2020)	0.56
"Aim of the study was to reduce the dose and dosing frequency of duloxetine HCl (DXT) by complexation with sulfobutylether-β-cyclodextrin (SBEβCD), an anionic cyclodextrin through permeation enhancement for more effective management of depression."	( Transdermal delivery of duloxetine-sulfobutylether-β-cyclodextrin complex for effective management of depression. Dahiya, L; Kumar, R; Sarwal, A; Sinha, VR, 2021)	0.62
" The mechanism underpinning pain relief induced by the GlyT2 inhibitor at 10 mg/kg is likely due to increased glycinergic inhibition in the lumbar spinal cord, although the bell-shaped dose-response curve warrants further translational considerations."	( Assessment of the Anti-Allodynic and Anti-Hyperalgesic Efficacy of a Glycine Transporter 2 Inhibitor Relative to Pregabalin, Duloxetine and Indomethacin in a Rat Model of Cisplatin-Induced Peripheral Neuropathy. Corradini, L; Kuo, A; Nicholson, JR; Smith, MT, 2021)	0.62
" Western blot and immunohistochemistry suggested that a cumulative dosage of PTX (8 mg/kg) upregulated TRPV1 expression in the lumbar DRG and spinal dorsal horn (SDH) at day 14 post treatment."	( Participation of transient receptor potential vanilloid 1 in the analgesic effect of duloxetine for paclitaxel induced peripheral neuropathic pain. Feng, S; Mao, M; Wang, J; Wang, X; Zhang, S; Zhou, F, 2022)	0.72

Role	Description
antidepressant	Antidepressants are mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
duloxetine hydrochloride
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
glp-1 receptor, partial	Homo sapiens (human)	Potency	11.2202	0.0184	6.8060	14.1254	AID624417
RAR-related orphan receptor gamma	Mus musculus (house mouse)	Potency	19.3351	0.0060	38.0041	19,952.5996	AID1159521; AID1159523
Fumarate hydratase	Homo sapiens (human)	Potency	35.4813	0.0030	8.7949	48.0869	AID1347053
TDP1 protein	Homo sapiens (human)	Potency	19.3486	0.0008	11.3822	44.6684	AID686978; AID686979
GLI family zinc finger 3	Homo sapiens (human)	Potency	3.2937	0.0007	14.5928	83.7951	AID1259369; AID1259392
AR protein	Homo sapiens (human)	Potency	21.3567	0.0002	21.2231	8,912.5098	AID1259243; AID1259247; AID743035; AID743042; AID743054; AID743063
Smad3	Homo sapiens (human)	Potency	22.3872	0.0052	7.8098	29.0929	AID588855
caspase 7, apoptosis-related cysteine protease	Homo sapiens (human)	Potency	33.4915	0.0133	26.9810	70.7614	AID1346978
estrogen receptor 2 (ER beta)	Homo sapiens (human)	Potency	9.4392	0.0006	57.9133	22,387.1992	AID1259378
nuclear receptor subfamily 1, group I, member 3	Homo sapiens (human)	Potency	26.9434	0.0010	22.6508	76.6163	AID1224838; AID1224839; AID1224893
progesterone receptor	Homo sapiens (human)	Potency	33.4915	0.0004	17.9460	75.1148	AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	9.2451	0.0123	7.9835	43.2770	AID1346984; AID1645841
glucocorticoid receptor [Homo sapiens]	Homo sapiens (human)	Potency	22.5978	0.0002	14.3764	60.0339	AID720691; AID720692
retinoic acid nuclear receptor alpha variant 1	Homo sapiens (human)	Potency	22.0846	0.0030	41.6115	22,387.1992	AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alpha	Homo sapiens (human)	Potency	9.5205	0.0008	17.5051	59.3239	AID1159527; AID1159531
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	33.4915	0.0015	30.6073	15,848.9004	AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptor	Homo sapiens (human)	Potency	30.0450	0.3758	27.4851	61.6524	AID743217; AID743220
pregnane X nuclear receptor	Homo sapiens (human)	Potency	20.2855	0.0054	28.0263	1,258.9301	AID1346982; AID1346985
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	22.0444	0.0002	29.3054	16,493.5996	AID1259248; AID743069; AID743078; AID743079; AID743080; AID743091
cytochrome P450 2D6	Homo sapiens (human)	Potency	0.4365	0.0010	8.3798	61.1304	AID1645840
polyprotein	Zika virus	Potency	35.4813	0.0030	8.7949	48.0869	AID1347053
peroxisome proliferator-activated receptor delta	Homo sapiens (human)	Potency	30.0450	0.0010	24.5048	61.6448	AID743212; AID743215
peroxisome proliferator activated receptor gamma	Homo sapiens (human)	Potency	20.5256	0.0010	19.4141	70.9645	AID743094; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptor	Homo sapiens (human)	Potency	10.6822	0.0237	23.2282	63.5986	AID743223
caspase-3	Homo sapiens (human)	Potency	33.4915	0.0133	26.9810	70.7614	AID1346978
IDH1	Homo sapiens (human)	Potency	16.3601	0.0052	10.8652	35.4813	AID686970
aryl hydrocarbon receptor	Homo sapiens (human)	Potency	11.8832	0.0007	23.0674	1,258.9301	AID743085
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a	Homo sapiens (human)	Potency	33.4915	0.0017	23.8393	78.1014	AID743083
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a	Homo sapiens (human)	Potency	16.9301	19.7391	45.9784	64.9432	AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)	Homo sapiens (human)	Potency	15.4521	0.0578	21.1097	61.2679	AID1159526; AID1159528
potassium voltage-gated channel subfamily H member 2 isoform d	Homo sapiens (human)	Potency	5.0119	0.0178	9.6374	44.6684	AID588834
thyroid hormone receptor beta isoform 2	Rattus norvegicus (Norway rat)	Potency	7.6445	0.0003	23.4451	159.6830	AID743065; AID743067
heat shock protein beta-1	Homo sapiens (human)	Potency	26.6011	0.0420	27.3789	61.6448	AID743210
importin subunit beta-1 isoform 1	Homo sapiens (human)	Potency	29.0929	5.8048	36.1306	65.1308	AID540253
snurportin-1	Homo sapiens (human)	Potency	29.0929	5.8048	36.1306	65.1308	AID540253
nuclear factor erythroid 2-related factor 2 isoform 1	Homo sapiens (human)	Potency	16.7842	0.0006	27.2152	1,122.0200	AID743202
GTP-binding nuclear protein Ran isoform 1	Homo sapiens (human)	Potency	29.0929	5.8048	16.9962	25.9290	AID540253
urokinase-type plasminogen activator precursor	Mus musculus (house mouse)	Potency	10.0000	0.1585	5.2879	12.5893	AID540303
plasminogen precursor	Mus musculus (house mouse)	Potency	10.0000	0.1585	5.2879	12.5893	AID540303
urokinase plasminogen activator surface receptor precursor	Mus musculus (house mouse)	Potency	10.0000	0.1585	5.2879	12.5893	AID540303
geminin	Homo sapiens (human)	Potency	12.4438	0.0046	11.3741	33.4983	AID624296; AID624297
Interferon beta	Homo sapiens (human)	Potency	21.0071	0.0033	9.1582	39.8107	AID1347407
Cellular tumor antigen p53	Homo sapiens (human)	Potency	31.6704	0.0023	19.5956	74.0614	AID651631; AID720552
Alpha-synuclein	Homo sapiens (human)	Potency	5.6234	0.5623	9.3985	25.1189	AID652106
Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus	Potency	14.1254	0.0096	10.5250	35.4813	AID1479145
ATPase family AAA domain-containing protein 5	Homo sapiens (human)	Potency	23.7101	0.0119	17.9420	71.5630	AID651632
Ataxin-2	Homo sapiens (human)	Potency	23.7101	0.0119	12.2221	68.7989	AID651632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	133.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	133.0000	0.2000	5.6774	10.0000	AID1473741
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	133.0000	0.1100	7.1903	10.0000	AID1473738
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	133.0000	2.4100	6.3433	10.0000	AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle G2/M phase transition	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
ER overload response	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
in utero embryonic development	Cellular tumor antigen p53	Homo sapiens (human)
somitogenesis	Cellular tumor antigen p53	Homo sapiens (human)
release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic progenitor cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
T cell proliferation involved in immune response	Cellular tumor antigen p53	Homo sapiens (human)
B cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
T cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
response to ischemia	Cellular tumor antigen p53	Homo sapiens (human)
nucleotide-excision repair	Cellular tumor antigen p53	Homo sapiens (human)
double-strand break repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
protein import into nucleus	Cellular tumor antigen p53	Homo sapiens (human)
autophagy	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
Ras protein signal transduction	Cellular tumor antigen p53	Homo sapiens (human)
gastrulation	Cellular tumor antigen p53	Homo sapiens (human)
neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
protein localization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA replication	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
determination of adult lifespan	Cellular tumor antigen p53	Homo sapiens (human)
mRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
rRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
response to salt stress	Cellular tumor antigen p53	Homo sapiens (human)
response to inorganic substance	Cellular tumor antigen p53	Homo sapiens (human)
response to X-ray	Cellular tumor antigen p53	Homo sapiens (human)
response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of gene expression	Cellular tumor antigen p53	Homo sapiens (human)
cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
viral process	Cellular tumor antigen p53	Homo sapiens (human)
glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
cerebellum development	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell growth	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
mitotic G1 DNA damage checkpoint signaling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of telomere maintenance via telomerase	Cellular tumor antigen p53	Homo sapiens (human)
T cell differentiation in thymus	Cellular tumor antigen p53	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
regulation of tissue remodeling	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV	Cellular tumor antigen p53	Homo sapiens (human)
multicellular organism growth	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of mitochondrial membrane permeability	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
entrainment of circadian clock by photoperiod	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial DNA repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
transcription initiation-coupled chromatin remodeling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of proteolysis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
response to antibiotic	Cellular tumor antigen p53	Homo sapiens (human)
fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
circadian behavior	Cellular tumor antigen p53	Homo sapiens (human)
bone marrow development	Cellular tumor antigen p53	Homo sapiens (human)
embryonic organ development	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Cellular tumor antigen p53	Homo sapiens (human)
protein stabilization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of helicase activity	Cellular tumor antigen p53	Homo sapiens (human)
protein tetramerization	Cellular tumor antigen p53	Homo sapiens (human)
chromosome organization	Cellular tumor antigen p53	Homo sapiens (human)
neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic stem cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
type II interferon-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
cardiac septum morphogenesis	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of programmed necrotic cell death	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	Cellular tumor antigen p53	Homo sapiens (human)
thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
necroptotic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to xenobiotic stimulus	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to ionizing radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV-C	Cellular tumor antigen p53	Homo sapiens (human)
stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to actinomycin D	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
replicative senescence	Cellular tumor antigen p53	Homo sapiens (human)
oxidative stress-induced premature senescence	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
oligodendrocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of execution phase of apoptosis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of G1 to G0 transition	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of miRNA processing	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of pentose-phosphate shunt	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
regulation of fibroblast apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
calcium ion homeostasis	Alpha-synuclein	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Alpha-synuclein	Homo sapiens (human)
microglial cell activation	Alpha-synuclein	Homo sapiens (human)
positive regulation of receptor recycling	Alpha-synuclein	Homo sapiens (human)
positive regulation of neurotransmitter secretion	Alpha-synuclein	Homo sapiens (human)
negative regulation of protein kinase activity	Alpha-synuclein	Homo sapiens (human)
fatty acid metabolic process	Alpha-synuclein	Homo sapiens (human)
neutral lipid metabolic process	Alpha-synuclein	Homo sapiens (human)
phospholipid metabolic process	Alpha-synuclein	Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process	Alpha-synuclein	Homo sapiens (human)
mitochondrial membrane organization	Alpha-synuclein	Homo sapiens (human)
adult locomotory behavior	Alpha-synuclein	Homo sapiens (human)
response to xenobiotic stimulus	Alpha-synuclein	Homo sapiens (human)
response to iron(II) ion	Alpha-synuclein	Homo sapiens (human)
regulation of phospholipase activity	Alpha-synuclein	Homo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathway	Alpha-synuclein	Homo sapiens (human)
regulation of glutamate secretion	Alpha-synuclein	Homo sapiens (human)
regulation of dopamine secretion	Alpha-synuclein	Homo sapiens (human)
synaptic vesicle exocytosis	Alpha-synuclein	Homo sapiens (human)
synaptic vesicle priming	Alpha-synuclein	Homo sapiens (human)
regulation of transmembrane transporter activity	Alpha-synuclein	Homo sapiens (human)
negative regulation of microtubule polymerization	Alpha-synuclein	Homo sapiens (human)
receptor internalization	Alpha-synuclein	Homo sapiens (human)
protein destabilization	Alpha-synuclein	Homo sapiens (human)
response to magnesium ion	Alpha-synuclein	Homo sapiens (human)
negative regulation of transporter activity	Alpha-synuclein	Homo sapiens (human)
response to lipopolysaccharide	Alpha-synuclein	Homo sapiens (human)
negative regulation of monooxygenase activity	Alpha-synuclein	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation	Alpha-synuclein	Homo sapiens (human)
response to type II interferon	Alpha-synuclein	Homo sapiens (human)
cellular response to oxidative stress	Alpha-synuclein	Homo sapiens (human)
SNARE complex assembly	Alpha-synuclein	Homo sapiens (human)
positive regulation of SNARE complex assembly	Alpha-synuclein	Homo sapiens (human)
regulation of locomotion	Alpha-synuclein	Homo sapiens (human)
dopamine biosynthetic process	Alpha-synuclein	Homo sapiens (human)
mitochondrial ATP synthesis coupled electron transport	Alpha-synuclein	Homo sapiens (human)
regulation of macrophage activation	Alpha-synuclein	Homo sapiens (human)
positive regulation of apoptotic process	Alpha-synuclein	Homo sapiens (human)
negative regulation of apoptotic process	Alpha-synuclein	Homo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic process	Alpha-synuclein	Homo sapiens (human)
negative regulation of neuron apoptotic process	Alpha-synuclein	Homo sapiens (human)
positive regulation of endocytosis	Alpha-synuclein	Homo sapiens (human)
negative regulation of exocytosis	Alpha-synuclein	Homo sapiens (human)
positive regulation of exocytosis	Alpha-synuclein	Homo sapiens (human)
regulation of long-term neuronal synaptic plasticity	Alpha-synuclein	Homo sapiens (human)
synaptic vesicle endocytosis	Alpha-synuclein	Homo sapiens (human)
synaptic vesicle transport	Alpha-synuclein	Homo sapiens (human)
positive regulation of inflammatory response	Alpha-synuclein	Homo sapiens (human)
regulation of acyl-CoA biosynthetic process	Alpha-synuclein	Homo sapiens (human)
protein tetramerization	Alpha-synuclein	Homo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosol	Alpha-synuclein	Homo sapiens (human)
neuron apoptotic process	Alpha-synuclein	Homo sapiens (human)
dopamine uptake involved in synaptic transmission	Alpha-synuclein	Homo sapiens (human)
negative regulation of dopamine uptake involved in synaptic transmission	Alpha-synuclein	Homo sapiens (human)
negative regulation of serotonin uptake	Alpha-synuclein	Homo sapiens (human)
regulation of norepinephrine uptake	Alpha-synuclein	Homo sapiens (human)
negative regulation of norepinephrine uptake	Alpha-synuclein	Homo sapiens (human)
excitatory postsynaptic potential	Alpha-synuclein	Homo sapiens (human)
long-term synaptic potentiation	Alpha-synuclein	Homo sapiens (human)
positive regulation of inositol phosphate biosynthetic process	Alpha-synuclein	Homo sapiens (human)
negative regulation of thrombin-activated receptor signaling pathway	Alpha-synuclein	Homo sapiens (human)
response to interleukin-1	Alpha-synuclein	Homo sapiens (human)
cellular response to copper ion	Alpha-synuclein	Homo sapiens (human)
cellular response to epinephrine stimulus	Alpha-synuclein	Homo sapiens (human)
positive regulation of protein serine/threonine kinase activity	Alpha-synuclein	Homo sapiens (human)
supramolecular fiber organization	Alpha-synuclein	Homo sapiens (human)
negative regulation of mitochondrial electron transport, NADH to ubiquinone	Alpha-synuclein	Homo sapiens (human)
positive regulation of glutathione peroxidase activity	Alpha-synuclein	Homo sapiens (human)
positive regulation of hydrogen peroxide catabolic process	Alpha-synuclein	Homo sapiens (human)
regulation of synaptic vesicle recycling	Alpha-synuclein	Homo sapiens (human)
regulation of reactive oxygen species biosynthetic process	Alpha-synuclein	Homo sapiens (human)
positive regulation of protein localization to cell periphery	Alpha-synuclein	Homo sapiens (human)
negative regulation of chaperone-mediated autophagy	Alpha-synuclein	Homo sapiens (human)
regulation of presynapse assembly	Alpha-synuclein	Homo sapiens (human)
amyloid fibril formation	Alpha-synuclein	Homo sapiens (human)
synapse organization	Alpha-synuclein	Homo sapiens (human)
chemical synaptic transmission	Alpha-synuclein	Homo sapiens (human)
xenobiotic metabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
negative regulation of gene expression	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bile acid and bile salt transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
heme catabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic export from cell	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transepithelial transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
leukotriene transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
monoatomic anion transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell population proliferation	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of B cell proliferation	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
nuclear DNA replication	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
signal transduction in response to DNA damage	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
isotype switching	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of DNA replication	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of isotype switching to IgG isotypes	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA clamp unloading	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
regulation of mitotic cell cycle phase transition	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of cell cycle G2/M phase transition	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
negative regulation of receptor internalization	Ataxin-2	Homo sapiens (human)
regulation of translation	Ataxin-2	Homo sapiens (human)
RNA metabolic process	Ataxin-2	Homo sapiens (human)
P-body assembly	Ataxin-2	Homo sapiens (human)
stress granule assembly	Ataxin-2	Homo sapiens (human)
RNA transport	Ataxin-2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
transcription cis-regulatory region binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
core promoter sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
TFIID-class transcription factor complex binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
protease binding	Cellular tumor antigen p53	Homo sapiens (human)
p53 binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity	Cellular tumor antigen p53	Homo sapiens (human)
mRNA 3'-UTR binding	Cellular tumor antigen p53	Homo sapiens (human)
copper ion binding	Cellular tumor antigen p53	Homo sapiens (human)
protein binding	Cellular tumor antigen p53	Homo sapiens (human)
zinc ion binding	Cellular tumor antigen p53	Homo sapiens (human)
enzyme binding	Cellular tumor antigen p53	Homo sapiens (human)
receptor tyrosine kinase binding	Cellular tumor antigen p53	Homo sapiens (human)
ubiquitin protein ligase binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase regulator activity	Cellular tumor antigen p53	Homo sapiens (human)
ATP-dependent DNA/DNA annealing activity	Cellular tumor antigen p53	Homo sapiens (human)
identical protein binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase binding	Cellular tumor antigen p53	Homo sapiens (human)
protein heterodimerization activity	Cellular tumor antigen p53	Homo sapiens (human)
protein-folding chaperone binding	Cellular tumor antigen p53	Homo sapiens (human)
protein phosphatase 2A binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Cellular tumor antigen p53	Homo sapiens (human)
14-3-3 protein binding	Cellular tumor antigen p53	Homo sapiens (human)
MDM2/MDM4 family protein binding	Cellular tumor antigen p53	Homo sapiens (human)
disordered domain specific binding	Cellular tumor antigen p53	Homo sapiens (human)
general transcription initiation factor binding	Cellular tumor antigen p53	Homo sapiens (human)
molecular function activator activity	Cellular tumor antigen p53	Homo sapiens (human)
promoter-specific chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
fatty acid binding	Alpha-synuclein	Homo sapiens (human)
phospholipase D inhibitor activity	Alpha-synuclein	Homo sapiens (human)
SNARE binding	Alpha-synuclein	Homo sapiens (human)
magnesium ion binding	Alpha-synuclein	Homo sapiens (human)
transcription cis-regulatory region binding	Alpha-synuclein	Homo sapiens (human)
actin binding	Alpha-synuclein	Homo sapiens (human)
protein kinase inhibitor activity	Alpha-synuclein	Homo sapiens (human)
copper ion binding	Alpha-synuclein	Homo sapiens (human)
calcium ion binding	Alpha-synuclein	Homo sapiens (human)
protein binding	Alpha-synuclein	Homo sapiens (human)
phospholipid binding	Alpha-synuclein	Homo sapiens (human)
ferrous iron binding	Alpha-synuclein	Homo sapiens (human)
zinc ion binding	Alpha-synuclein	Homo sapiens (human)
lipid binding	Alpha-synuclein	Homo sapiens (human)
oxidoreductase activity	Alpha-synuclein	Homo sapiens (human)
kinesin binding	Alpha-synuclein	Homo sapiens (human)
Hsp70 protein binding	Alpha-synuclein	Homo sapiens (human)
histone binding	Alpha-synuclein	Homo sapiens (human)
identical protein binding	Alpha-synuclein	Homo sapiens (human)
alpha-tubulin binding	Alpha-synuclein	Homo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic process	Alpha-synuclein	Homo sapiens (human)
tau protein binding	Alpha-synuclein	Homo sapiens (human)
phosphoprotein binding	Alpha-synuclein	Homo sapiens (human)
molecular adaptor activity	Alpha-synuclein	Homo sapiens (human)
dynein complex binding	Alpha-synuclein	Homo sapiens (human)
cuprous ion binding	Alpha-synuclein	Homo sapiens (human)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
protein binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
ATP binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
ATP hydrolysis activity	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA clamp unloader activity	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
RNA binding	Ataxin-2	Homo sapiens (human)
epidermal growth factor receptor binding	Ataxin-2	Homo sapiens (human)
protein binding	Ataxin-2	Homo sapiens (human)
mRNA binding	Ataxin-2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
nuclear body	Cellular tumor antigen p53	Homo sapiens (human)
nucleus	Cellular tumor antigen p53	Homo sapiens (human)
nucleoplasm	Cellular tumor antigen p53	Homo sapiens (human)
replication fork	Cellular tumor antigen p53	Homo sapiens (human)
nucleolus	Cellular tumor antigen p53	Homo sapiens (human)
cytoplasm	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrion	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial matrix	Cellular tumor antigen p53	Homo sapiens (human)
endoplasmic reticulum	Cellular tumor antigen p53	Homo sapiens (human)
centrosome	Cellular tumor antigen p53	Homo sapiens (human)
cytosol	Cellular tumor antigen p53	Homo sapiens (human)
nuclear matrix	Cellular tumor antigen p53	Homo sapiens (human)
PML body	Cellular tumor antigen p53	Homo sapiens (human)
transcription repressor complex	Cellular tumor antigen p53	Homo sapiens (human)
site of double-strand break	Cellular tumor antigen p53	Homo sapiens (human)
germ cell nucleus	Cellular tumor antigen p53	Homo sapiens (human)
chromatin	Cellular tumor antigen p53	Homo sapiens (human)
transcription regulator complex	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex	Cellular tumor antigen p53	Homo sapiens (human)
platelet alpha granule membrane	Alpha-synuclein	Homo sapiens (human)
extracellular region	Alpha-synuclein	Homo sapiens (human)
extracellular space	Alpha-synuclein	Homo sapiens (human)
nucleus	Alpha-synuclein	Homo sapiens (human)
cytoplasm	Alpha-synuclein	Homo sapiens (human)
mitochondrion	Alpha-synuclein	Homo sapiens (human)
lysosome	Alpha-synuclein	Homo sapiens (human)
cytosol	Alpha-synuclein	Homo sapiens (human)
plasma membrane	Alpha-synuclein	Homo sapiens (human)
cell cortex	Alpha-synuclein	Homo sapiens (human)
actin cytoskeleton	Alpha-synuclein	Homo sapiens (human)
membrane	Alpha-synuclein	Homo sapiens (human)
inclusion body	Alpha-synuclein	Homo sapiens (human)
axon	Alpha-synuclein	Homo sapiens (human)
growth cone	Alpha-synuclein	Homo sapiens (human)
synaptic vesicle membrane	Alpha-synuclein	Homo sapiens (human)
perinuclear region of cytoplasm	Alpha-synuclein	Homo sapiens (human)
postsynapse	Alpha-synuclein	Homo sapiens (human)
supramolecular fiber	Alpha-synuclein	Homo sapiens (human)
protein-containing complex	Alpha-synuclein	Homo sapiens (human)
cytoplasm	Alpha-synuclein	Homo sapiens (human)
axon terminus	Alpha-synuclein	Homo sapiens (human)
neuronal cell body	Alpha-synuclein	Homo sapiens (human)
virion membrane	Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
Elg1 RFC-like complex	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
nucleus	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
cytoplasm	Ataxin-2	Homo sapiens (human)
Golgi apparatus	Ataxin-2	Homo sapiens (human)
trans-Golgi network	Ataxin-2	Homo sapiens (human)
cytosol	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
membrane	Ataxin-2	Homo sapiens (human)
perinuclear region of cytoplasm	Ataxin-2	Homo sapiens (human)
ribonucleoprotein complex	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID511218	Binding affinity to human serum albumin at pH 8.5	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	Study on the binding of chiral drug duloxetine hydrochloride to human serum albumin.
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID511217	Binding affinity to human serum albumin at pH 7.4	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	Study on the binding of chiral drug duloxetine hydrochloride to human serum albumin.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (0.06)	18.7374
1990's	25 (1.43)	18.2507
2000's	536 (30.72)	29.6817
2010's	890 (51.00)	24.3611
2020's	293 (16.79)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	441 (23.37%)	5.53%
Reviews	382 (20.24%)	6.00%
Case Studies	258 (13.67%)	4.05%
Observational	10 (0.53%)	0.25%
Other	796 (42.18%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (352)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Effects of Duloxetine on Postoperative Wound Complication of Total Knee Arthroplasty(TKA) in Central Sensitization Patient [NCT03880916]		80 participants (Anticipated)	Interventional	2019-03-30	Not yet recruiting
Duloxetine (Cymbalta) in the Reduction of Pain Severity in Patient With Systemic Lupus Erythematosus: A Pilot Study [NCT01269866]		26 participants (Actual)	Interventional	2010-12-31	Completed
Randomized Double-blind Study Comparing the Efficacy of Duloxetine With Placebo in Patients With Chronic Low Back Pain With a Radicular Component [NCT01166048]	Phase 4	41 participants (Actual)	Interventional	2010-05-31	Completed
A Pilot Study of Duloxetine in Psychological Resilience and Its Correlation With Blockade of Serotonin and Norepinephrine Transporter [NCT00331799]	Phase 2	18 participants (Actual)	Interventional	2007-04-30	Completed
Mechanism-based Choice of Therapy for Neuropathic Pain: Can Treatments Success in Neuropathic Post-operative Pain be Coupled to Psychophysical Pain Modulation Profile? [NCT01359514]		32 participants (Actual)	Interventional	2008-04-30	Completed
Duloxetine(Cymbalta) for Fibromyalgia: An Open-Label Pilot Study to Assess Potential Mechanisms for Fibromyalgia in Peripheral Tissue Innervation That Could Predict Therapeutic Responsiveness to Duloxetine [NCT01127490]		25 participants (Actual)	Interventional	2010-05-05	Completed
Capsaicin 179 mg Patch Versus Oral Duloxetine in Patients With Chemotherapy-induced Peripheral Neuropathy : a Phase 3 Randomized Multicentric Open-label Study. [NCT05840562]	Phase 3	274 participants (Anticipated)	Interventional	2023-09-30	Not yet recruiting
A Double-blind, Randomised, Multicenter, Comparative Study of Escitalopram and Duloxetine in Outpatients With Major Depressive Disorder [NCT01148472]	Phase 4	294 participants (Actual)	Interventional	2005-09-30	Completed
A Novel Drug Combination for Alcohol-Use Disorders: A Human Laboratory Study [NCT03575403]	Phase 1	19 participants (Actual)	Interventional	2018-09-01	Completed
A PHASE IV, SINGLE-DOSE, OPEN-LABEL, RANDOMIZED, 2-WAY CROSSOVER STUDY TO DETERMINE THE BIOEQUIVALENCE OF DULOXETINE HYDROCHLORIDE HARD GELATINOUS CAPSULE WITH DELAYED RELEASE MICROGRANULES (60 MG; PFIZER S.R.L - ARGENTINA.) COMPARED TO CYMBALTA (REGISTER [NCT03794154]	Phase 4	0 participants (Actual)	Interventional	2020-03-30	Withdrawn(stopped due to This study has been cancelled prior to FSFV due to business reasons)
Pre-emptive Effect of Duloxetine in the Second Knee in Staged Total Knee Arthroplasty: A Randomized Controlled Study [NCT03792828]	Phase 4	90 participants (Anticipated)	Interventional	2019-01-31	Not yet recruiting
A PHASE IV, SINGLE-DOSE, OPEN-LABEL, RANDOMIZED, 2-WAY CROSSOVER STUDY TO DETERMINE THE BIOEQUIVALENCE OF DULOXETINE HYDROCHLORIDE HARD GELATINOUS CAPSULE WITH DELAYED RELEASE MICROGRANULES (60 MG; PFIZER S.R.L - ARGENTINA) COMPARED WITH CYMBALTA(REGISTER [NCT03729284]	Phase 4	0 participants (Actual)	Interventional	2020-03-30	Withdrawn(stopped due to This study has been cancelled prior to FSFV due to business reasons)
Efficacy, Safety, Tolerability and Pharmacokinetics of Concomitant Administration of Tramadol With Duloxetine or Pregabalin: a Randomized Controlled Flexible-dose Study in Patients With Neuropathic Pain [NCT01116531]	Phase 4	0 participants (Actual)	Interventional	2010-04-30	Withdrawn
Mechanism-based Choice of Therapy: Can Treatments Success in Fibromyalgia Patients be Coupled to Psychophysical Pain Modulation Profile? [NCT01268631]		150 participants (Anticipated)	Interventional	2011-01-31	Not yet recruiting
Pretreatment Identification of Duloxetine Success in Neuropathic Pain Patients Based on Assessment of Endogenous Analgesia Capabilities [NCT01363284]		51 participants (Actual)	Interventional	2010-06-30	Completed
EEG Signal Processing as a Predictor of Antidepressant Response [NCT01369290]		150 participants (Anticipated)	Observational	2009-10-31	Recruiting
A Long-term Safety Study of Duloxetine Hydrochloride in the Treatment of Japanese Children and Adolescents With Depressive Disorder [NCT03395353]	Phase 3	151 participants (Actual)	Interventional	2018-01-29	Terminated(stopped due to Business decision)
A Double-blind, Efficacy and Safety Study of Duloxetine Hydrochloride Versus Placebo in the Treatment of Japanese Children and Adolescents With Depressive Disorder [NCT03315793]	Phase 3	149 participants (Actual)	Interventional	2017-12-04	Completed
A Prospective, Triple-Blind, Randomized Controlled Trial Evaluating Duloxetine on Post-Operative Outcomes Following Primary Total Knee Arthroplasty in Patients With and Without Central Sensitization [NCT05086393]	Phase 4	504 participants (Anticipated)	Interventional	2021-11-01	Recruiting
Effect of Preoperative Duloxetine on Quality of Recovery After Outpatient Laparoscopic Surgery [NCT02351440]	Phase 4	0 participants (Actual)	Interventional	2016-04-30	Withdrawn
Clinical Psychopharmacology Division,Institute of Mental Health,Peking University [NCT03148522]		120 participants (Anticipated)	Interventional	2017-06-01	Recruiting
Effect of Duloxetine on Opioid Use After Total Knee Arthroplasty: A Double-blinded Randomized Control Trial [NCT03271151]	Phase 4	160 participants (Actual)	Interventional	2017-09-28	Completed
Brain Morphometric Study in Knee Osteoarthritis Patients Treated With Duloxetine [NCT02903238]		21 participants (Actual)	Interventional	2011-07-31	Completed
A Randomized Phase II Study Comparing Lorcaserin Versus Duloxetine for the Treatment of Chemotherapy-Induced Peripheral Neuropathy Produced by Oxaliplatin [NCT03812523]	Phase 2	50 participants (Anticipated)	Interventional	2019-06-30	Not yet recruiting
Effects of Duloxetine on Postoperative Pain Control and Knee Rehabilitation After Open Reduction Internal Fixation of Tibial Plateau Fractures [NCT04639011]	Phase 4	0 participants (Actual)	Interventional	2022-10-31	Withdrawn(stopped due to Study was not conducted because funding was not obtained.)
Maintenance Therapies in Late-Life Depression: MTLD III [NCT00177671]	Phase 4	220 participants (Actual)	Interventional	2003-12-31	Completed
Analgesic Efficacy of Duloxetine in Patients Undergoing Lumbar Discectomy: Randomized Trial [NCT03549026]		70 participants (Anticipated)	Interventional	2018-01-05	Recruiting
The BEST Trial: Biomarkers for Evaluating Spine Treatments [NCT05396014]	Phase 4	820 participants (Anticipated)	Interventional	2022-09-12	Recruiting
A Randomized, Double-Blind, Active-Controlled, International, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Flexibly-dosed Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New S [NCT03852160]	Phase 3	0 participants (Actual)	Interventional	2019-12-01	Withdrawn(stopped due to New design was developed to better fit company strategy, a new study has replaced 5413541TRD3011 study)
Psychiatric Orders in Psychoanalytic Treatment of ASD [NCT05930912]		1 participants (Actual)	Observational	2023-06-01	Active, not recruiting
A Feasibility and Pilot Study of Combined Treatment Protocol Using Aerobic Exercise and Duloxetine in Older Adults With Symptomatic Knee Osteoarthritis and Comorbid Depression [NCT04111627]	Phase 2	30 participants (Anticipated)	Interventional	2021-10-07	Recruiting
An Open-label Feasibility Study of Duloxetine in Adolescents With Juvenile Primary Fibromyalgia Syndrome: A Pilot Study [NCT01089621]	Phase 4	0 participants (Actual)	Interventional	2010-03-31	Withdrawn(stopped due to Terminated due to study design changes; zero patients enrolled.)
Initial Severity and Antidepressant Efficacy for Anxiety Disorders: an Individual Patient Data Meta-analysis [NCT02476136]		8,800 participants (Anticipated)	Observational	2015-05-31	Active, not recruiting
Comparing Effectiveness of Duloxetine and Desipramine in Patients With Chronic Pain: A Pragmatic Trial Using Point of Care Randomization [NCT03548454]	Phase 4	320 participants (Anticipated)	Interventional	2018-09-20	Recruiting
A Ten-week, Randomized, Double-blind Study Evaluating the Efficacy of Duloxetine 60 mg Once Daily Versus Placebo in Outpatients With Major Depressive Disorder and Pain (EU-Pain Enriched Study) [NCT02232555]	Phase 3	327 participants	Interventional	2005-05-31	Completed
A Multicenter, Randomized, Double-Blind, Active Controlled, Comparative, Fixed-Dose, Dose Response Study of the Efficacy and Safety of BMS-820836 in Patients With Treatment Resistant Major Depression (TRD). [NCT01369095]	Phase 2	976 participants (Actual)	Interventional	2011-07-31	Completed
Single Dose Crossover Comparative Bioavailability Study of Duloxetine Delayed-Release Capsules 60 mg in Healthy Adult Human Subjects Under Fasting Conditions [NCT02291367]	Phase 1	76 participants (Actual)	Interventional	2008-05-31	Completed
A Multi-center, Randomized, Double-blind, Double-simulation, Duloxetine Hydrochloride Enteric-coated Positive-control Phase III Study of Desvenlafaxine Succinate Sustained-Release in the Treatment of Major Depressive Disorder. [NCT04364997]	Phase 3	420 participants (Actual)	Interventional	2020-06-18	Completed
A Prediction Study of Multiple Indexes of the Effect of Different Mechanisms of Antidepressants Treatment on Depression [NCT03623711]	Early Phase 1	200 participants (Anticipated)	Interventional	2018-08-01	Recruiting
A Prospective Randomized Controlled Study Comparing the Efficacy of Pelvic Floor Muscle Training and Oral Duloxetine in the Recovery of Continence After Robotic Assisted Radical Prostatectomy [NCT02367404]	Phase 3	240 participants (Anticipated)	Interventional	2015-05-31	Recruiting
A Randomized, Double-blind, Multicenter, Active-Controlled Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Treatment-resistant Depression [NCT02493868]	Phase 3	719 participants (Actual)	Interventional	2015-10-01	Completed
The Clinical Effect of Pregabalin on Neuropathic Pain in Central Sensitized Patients Who Are Treated With Duloxetine After Total Knee Arthroplasty: Randomized Controlled Trial. [NCT05254652]		90 participants (Anticipated)	Interventional	2022-05-31	Not yet recruiting
The Effect of Preoperative Duloxetine on the Occurance of Postoperative Delirium in Patients Undergoing Cancer Surgery . [NCT05949229]	Phase 1/Phase 2	42 participants (Anticipated)	Interventional	2023-08-31	Not yet recruiting
The Cymbalta Pregnancy Registry [NCT01074151]		144 participants (Actual)	Observational	2009-07-31	Completed
Tolerability and Safety of 40 mg and 100 mg Duloxetine BID Given Over 7 Days in Healthy Female Subjects. A Randomised, Placebo-controlled Double-blind Trial. [NCT02232542]	Phase 1	32 participants (Actual)	Interventional	2003-06-30	Completed
Comparison of the Efficacy and Safety of Duloxetine Augmented With Gabapentin and Duloxetine Augmented With Amitriptyline vs Duloxetine Alone in Chemotherapy -Induced Neuropathy: A Randomized Controlled Trial [NCT06091553]	Phase 2	160 participants (Anticipated)	Interventional	2023-10-20	Not yet recruiting
A Novel Drug Combination as a Pharmacotherapeutic for Methamphetamine-Use Disorder [NCT04178993]	Phase 1	8 participants (Actual)	Interventional	2019-09-01	Completed
Risk of Phenoconversion in Genetic Extensive Metabolizers Healthy Volunteers Carriers of One Fully-Functional and One Non-Functional Allele Versus Carriers of Two Fully-Functional Alleles [NCT03054220]		34 participants (Actual)	Interventional	2016-07-31	Completed
Duloxetine Potentiates the Analgesic Efficacy of Intrathecal Morphine in Major Abdominal Cancer Surgery [NCT03560427]		60 participants (Actual)	Interventional	2018-09-10	Completed
University of Michigan Mechanistic Research Center -The Back Pain Consortium Research Program [NCT04870957]	Phase 4	500 participants (Anticipated)	Interventional	2021-06-09	Recruiting
A Global, Multicenter, Randomized, Double-Blind Placebo Controlled Study Comparing the Safety and Efficacy of ABT-894, Duloxetine and Placebo in Subjects With Diabetic Neuropathic Pain [NCT00507936]	Phase 2	280 participants (Actual)	Interventional	2007-08-31	Completed
A Randomized, Double-blind, Placebo Controlled, Dose Escalation Pilot Study Evaluating the Efficacy of Two Doses of Duloxetine and Amitriptyline in Interstitial Lung Disease-related Cough [NCT05120934]	Phase 2	25 participants (Anticipated)	Interventional	2021-11-01	Recruiting
Functional Brain Imaging to Understand the Mechanisms of Pain Relief in Knee Osteoarthritis [NCT02208778]	Phase 4	77 participants (Actual)	Interventional	2014-12-31	Completed
An Eight-week, Randomized, Double-blind, Two Parallel Groups, Study to Assess Clinical Response of Duloxetine 60 mg and 120 mg Per Day in Patients Hospitalized for Severe Depression [NCT02229825]	Phase 4	339 participants (Actual)	Interventional	2007-02-09	Completed
Open Label Duloxetine Compassionate Use in Patients Who Have Completed a Previous Neuroscience Duloxetine Clinical Trial [NCT00071708]		0 participants	Expanded Access		No longer available
A Randomized, Double-blind, Placebo-controlled, Dose-escalation Study Evaluating the Efficacy of Two Doses of Duloxetine & Amitriptyline in Subjects With Refractory Chronic Cough [NCT05110144]	Phase 2	50 participants (Anticipated)	Interventional	2021-11-01	Recruiting
Serotonin-norepinephrine Reuptake Inhibitors and Acute Kidney Injury [NCT02320240]		3,255,526 participants (Actual)	Observational	2013-06-30	Completed
Sensation and Psychiatry: Linking Age-Related Hearing Loss to Late-Life Depression and Cognitive Decline [NCT03321006]	Phase 4	25 participants (Actual)	Interventional	2018-05-30	Completed
Continuation Electroconvulsive Therapy Associated With Pharmacotherapy Versus Pharmacotherapy Alone for Relapse Prevention in Major Depression. A Clinical, Controlled, Prospective and Randomized Trial [NCT01305707]	Phase 4	104 participants (Actual)	Interventional	2009-07-31	Terminated(stopped due to Difficulties in recruiting)
Duloxetine Versus Placebo in the Acute Treatment of Patients With Major Depressive Disorder and Associated Painful Physical Symptoms [NCT01070329]	Phase 4	527 participants (Actual)	Interventional	2010-03-31	Completed
Effect of Duloxetine 30/60 mg Once Daily Versus Placebo in Adolescents With Juvenile Primary Fibromyalgia Syndrome [NCT01237587]	Phase 3	184 participants (Actual)	Interventional	2011-03-31	Completed
A Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Women With Early Stage Breast Cancer [NCT01598298]	Phase 3	299 participants (Actual)	Interventional	2013-05-15	Completed
A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Generalized Anxiety Disorder [NCT01226511]	Phase 3	281 participants (Actual)	Interventional	2011-06-30	Completed
An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder [NCT00961298]	Phase 4	17 participants (Actual)	Interventional	2009-09-30	Completed
A Phase 4 Comparison of Duloxetine Dosing Strategies in the Treatment of Korean Patients With Major Depressive Disorder [NCT00960986]	Phase 4	249 participants (Actual)	Interventional	2009-08-31	Completed
A Multidisciplinary Approach to Manage Gait Difficulty in Parkinson Patients [NCT02857244]	Phase 2	0 participants (Actual)	Interventional	2016-11-30	Withdrawn(stopped due to Site did not obtain LIRB approval due to medication usage.)
A Phase 4, 8-Week, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy of Duloxetine 60 mg Once Daily in Outpatients With Major Depressive Disorder and Associated Painful Physical Symptoms [NCT01000805]	Phase 4	528 participants (Actual)	Interventional	2009-11-30	Completed
TRY FIRST: A 12-Week, Randomized, Open-Label Trial of Duloxetine Versus Generic SSRIs in the Treatment of a Severe Depressive Episode [NCT00666757]	Phase 4	750 participants (Actual)	Interventional	2008-05-31	Completed
A Superiority Study of LY248686 Versus Placebo in the Treatment of Patients With Diabetic Peripheral Neuropathic Pain - Extension Phase [NCT00641719]	Phase 3	258 participants (Actual)	Interventional	2008-03-31	Completed
A Randomized, Double-Blind Comparison of Duloxetine 30 mg QD and Placebo in Adult Patients With Fibromyalgia [NCT00965081]	Phase 4	308 participants (Actual)	Interventional	2009-09-30	Completed
A Mechanism Based Proof of Concept Study of the Effects of Duloxetine in the Treatment of Patients With Osteoarthritic Knee Pain [NCT04224584]	Phase 2	40 participants (Actual)	Interventional	2020-01-01	Completed
A Multicenter, Randomized, Double-blind, Active-Controlled Study of the Efficacy and Safety of Flexibly-Dosed BMS-820836 in Patients With Treatment Resistant Major Depression [NCT01309945]	Phase 2	889 participants (Actual)	Interventional	2011-04-30	Completed
Duloxetine Versus Placebo in the Treatment of Patients With Generalized Anxiety Disorder in China [NCT00803361]	Phase 3	210 participants (Actual)	Interventional	2008-12-31	Completed
Clinical Psychopharmacology Division [NCT03294525]		400 participants (Anticipated)	Observational	2016-01-31	Recruiting
A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Subjects With Treatment-resistant Depression [NCT02422186]	Phase 3	139 participants (Actual)	Interventional	2015-08-20	Completed
Comparisons of the Impact of Duloxetine Versus Imipramine on Therapeutic Efficacy, Psychological Distress, Sexual Function, Urethral and Bladder Wall Structure and Blood Flow in Women With Stress Urinary Incontinence: a Randomized Controlled Study [NCT04412876]	Phase 3	0 participants (Actual)	Interventional	2020-05-31	Withdrawn(stopped due to Failed to pass the Ministry of Science and Technology.)
A Comparison Between Qutenza and Duloxetine for the Treatment of Painful Chemotherapy-induced Peripheral Neuropathy: a Pragmatic Randomized Controlled Trial [NCT05560516]		102 participants (Anticipated)	Interventional	2022-12-01	Recruiting
The Effect of Duloxetine on Bone Metabolism [NCT05550506]		102 participants (Anticipated)	Observational	2022-07-27	Recruiting
Duloxetine for Social Anxiety Disorder: Prediction of Long Term Outcome [NCT00114127]	Phase 3	28 participants (Actual)	Interventional	2004-06-30	Completed
Duloxetine for Patients With Low Back Pain Who Fail to Improve With Oral NSAIDs. A Randomized Placebo-controlled Exploratory Study [NCT05851976]	Phase 4	120 participants (Anticipated)	Interventional	2023-10-04	Recruiting
A Open Single-dose and Multiple-dose Study to Evaluate the Pharmacokinetics and Safety of Duloxetine in Chinese Han Healthy Subjects [NCT00933452]	Phase 1	36 participants (Anticipated)	Interventional	2009-07-31	Completed
A Sequenced Strategy for Improving Outcomes in People With Knee Osteoarthritis Pain [NCT04504812]	Phase 3	2,700 participants (Anticipated)	Interventional	2021-02-01	Recruiting
A Phase III Double Blind Trial of Oral Duloxetine for Treatment of Pain Associated With Chemotherapy-Induced Peripheral Neuropathy [NCT00489411]	Phase 3	231 participants (Actual)	Interventional	2008-04-30	Completed
"Cardiac Transfer of SARS-CoV-2 Spike Protein Circulation Techniques - Medicine Induced Hemodialysis on Vaccinated Immune Attacks" [NCT05711810]	Phase 4	1 participants (Actual)	Interventional	2023-01-02	Completed
Switching to Duloxetine to Ameliorate SSRI-Induced Sexual Dysfunction [NCT00398632]	Phase 4	6 participants (Actual)	Interventional	2006-11-30	Terminated(stopped due to Unable to recruit subjects)
A Randomised, Double-blind, Parallel-group, Placebo-controlled, Duloxetine-referenced, Fixed-dose Study Evaluating the Efficacy and Safety of Three Dosages of [Vortioxetine] Lu AA21004, in Acute Treatment of Major Depressive Disorder [NCT00635219]	Phase 3	766 participants (Actual)	Interventional	2008-02-29	Completed
Effect of Duloxetine 60 mg to 120 mg Once Daily in Patients With Chronic Low Back Pain [NCT00424593]	Phase 3	236 participants (Actual)	Interventional	2007-01-31	Completed
Single Dose Crossover Comparative Bioavailability Study of Duloxetine Delayed-Release Capsules 60 mg in Healthy Adult Human Subjects Under Fed Conditions [NCT02291341]	Phase 1	76 participants (Actual)	Interventional	2008-05-31	Completed
Duloxetine for the Treatment of Major Depression in Midlife Women: Effects on Brain Structure and Functioning, Mood, and Quality of Life [NCT00889369]	Phase 4	70 participants (Anticipated)	Interventional	2009-05-31	Recruiting
A 12-Week, Double-Blind, Placebo-Controlled, Trial of Duloxetine Versus Placebo in the Treatment of Binge Eating Disorder and Comorbid Depressive Disorder. [NCT00607789]	Phase 4	40 participants (Actual)	Interventional	2006-10-31	Completed
Pain Response Evaluation of a Combined Intervention to Cope Effectively (PRECICE) [NCT04395001]	Phase 4	280 participants (Anticipated)	Interventional	2021-02-24	Recruiting
Assessment of Cognitive Functioning Before and After Treatment With Duloxetine [NCT00933439]		30 participants (Actual)	Interventional	2005-02-28	Completed
A Single-Blind Placebo Run-in Study of Duloxetine for Activity-Limiting Osteoarthritis Pain [NCT00609557]	Phase 4	25 participants (Actual)	Interventional	2004-09-30	Completed
Effects of Duloxetine on Pain Relief After Total Knee Arthroplasty in Central Sensitization Patient : A Randomized, Controlled, Double-Blind Trial [NCT02600247]		100 participants (Anticipated)	Interventional	2015-11-30	Not yet recruiting
Pilot Study of the Efficacy of Duloxetine in Treating Adults With Attention Deficit Hyperactivity Disorder: a Randomized, Controlled Trial. [NCT00940693]	Phase 2	40 participants (Anticipated)	Interventional	2009-08-31	Completed
Shifting Pain Modulation From Pro-to Anti-nociceptive: Individualized Prevention of Post Operative Pain [NCT02672202]		9 participants (Actual)	Interventional	2016-02-29	Terminated(stopped due to Recruitment rate was slow so we could not complete the study.)
Pharmacological Interaction Between Duloxetine and 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy): Pharmacodynamics (PD) and Pharmacokinetics (PK) [NCT00990067]	Phase 1	16 participants (Actual)	Interventional	2009-11-30	Completed
Qualification of Single Dose Administration of Analgesic Therapy in the Treatment of Chronic Neuropathic Pain in Patients With Painful Diabetic Neuropathy [NCT00837941]	Phase 2	0 participants (Actual)	Interventional	2009-04-30	Withdrawn
A Phase 3, Randomized, Double-Blind Study Comparing the Efficacy and Safety of SAGE-217 Plus an Antidepressant Versus Placebo Plus an Antidepressant in Adults With Major Depressive Disorder [NCT04476030]	Phase 3	440 participants (Actual)	Interventional	2020-11-09	Completed
An Open-Label, Randomized Comparison of Duloxetine, Pregabalin, and the Combination of Duloxetine and Gabapentin Among Patients With Inadequate Response to Gabapentin for the Management of Diabetic Peripheral Neuropathic Pain [NCT00385671]	Phase 4	407 participants (Actual)	Interventional	2006-09-30	Completed
Duloxetine Versus Placebo in the Treatment of Patients With Diabetic Peripheral Neuropathic Pain in China [NCT00408993]	Phase 3	215 participants (Actual)	Interventional	2006-12-31	Completed
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Duloxetine-Referenced, Parallel-Group Study to Evaluate the Efficacy and Safety of 2 Fixed Doses (50mg, 100mg) of Desvenlafaxine Sustained-Release Tablets in Adult Outpatients With Major Depress [NCT00384033]	Phase 3	638 participants (Actual)	Interventional	2006-09-30	Completed
Duloxetine Versus Placebo in Patients With Major Depressive Disorder (MDD): Assessment of Energy and Vitality in MDD [NCT00536471]	Phase 4	776 participants (Actual)	Interventional	2007-09-30	Completed
Therapeutic Drug Monitoring (TDM) in Child & Adolescent Psychiatry [NCT01057329]		200 participants (Actual)	Observational	2010-01-31	Completed
Comparison of Two Different Treatment Strategies in Patients With Major Depressive Disorder Not Exhibiting Improvement on Escitalopram Treatment: Early vs. Delayed Intervention Strategy [NCT00810069]	Phase 4	840 participants (Actual)	Interventional	2008-11-30	Completed
Cymbalta for Depression as a Complication of Bereavement [NCT00658931]	Phase 4	20 participants (Anticipated)	Interventional	2008-04-30	Active, not recruiting
A 12 Weeks Open Label Two Parallel Groups Study to Assess the Efficacy of Orally Administered Duloxetine 60 mg and 120 mg Per Day on Treatment Outcomes in Patients With Diabetic Peripheral Neuropathic Pain With and Without Co-morbid Major Depressive Disor [NCT00844194]	Phase 4	108 participants (Actual)	Interventional	2009-02-28	Completed
An Open Label Pilot Study on the Tolerability of Duloxetine in the Treatment of Depressed Patients With Parkinson's Disease [NCT00437125]	Phase 4	151 participants (Actual)	Interventional	2007-03-31	Completed
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Duloxetine and Methadone for the Treatment of HIV-Associated Painful Peripheral Neuropathy [NCT00863057]	Phase 2	15 participants (Actual)	Interventional	2009-05-31	Terminated(stopped due to Due to slow rate of enrollment, which compromised the ability to meet study objectives in a timely manner.)
The Depression and Memory Trial [NCT02590874]	Phase 4	19 participants (Actual)	Interventional	2016-01-31	Completed
Efficacy and Safety of Duloxetine Compared With Placebo in Subjects With Stress Urinary Incontinence [NCT00475358]	Phase 3	120 participants	Interventional	2003-04-30	Completed
A Phase 2a, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Multicenter Study to Assess the Safety and Efficacy of ADL5859 100 mg BID in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy [NCT00603265]	Phase 2	226 participants (Actual)	Interventional	2007-11-30	Completed
A Randomised, Double-blind, Parallel-group, Placebo-controlled, Duloxetine-referenced, Fixed-dose Study Evaluating the Efficacy and Safety of Lu AA21004 (15 and 20 mg/Day) in the Acute Treatment of Adult Patients With Major Depressive Disorder [NCT01140906]	Phase 3	607 participants (Actual)	Interventional	2010-05-31	Completed
A Phase 3b Study to Assess the Efficacy of Duloxetine 60 mg Once Daily Compared With Placebo on the Reduction of Pain Caused by Osteoarthritis of the Knee, in a 13-week, Double-blind, Randomized Study [NCT00945945]	Phase 3	424 participants (Actual)	Interventional	2009-07-31	Completed
Phase 4 Study of Development of Pharmacogenomic Method to Predict Antidepressant Responsiveness [NCT00817011]		1,000 participants (Anticipated)	Interventional	2006-04-30	Recruiting
Duloxetine 60 to 120 mg Versus Placebo in the Treatment of Patients With Osteoarthritis Knee Pain [NCT00408421]	Phase 3	231 participants (Actual)	Interventional	2006-11-30	Completed
A Randomized, Placebo-Controlled Trial of Duloxetine Added to Nonsteroidal Anti-inflammatory Drugs in Patients With Knee Pain Due to Osteoarthritis Who Have Had Suboptimal Response to Nonsteroidal Anti-inflammatory Drug Treatment. [NCT01018680]	Phase 3	524 participants (Actual)	Interventional	2009-11-30	Completed
Three Way Interaction Between Gabapentin, Duloxetine, and Donepezil in Patients With Diabetic Neuropathy [NCT00619983]	Phase 4	22 participants (Actual)	Interventional	2008-02-29	Terminated(stopped due to Study terminated due to low enrollment)
Inflammatory Markers and Cognitive Function in Major Depression:a Pilot Study [NCT01391221]	Phase 4	20 participants (Anticipated)	Interventional	2011-07-31	Recruiting
Flexible Dosed Duloxetine Versus Placebo in the Treatment of Fibromyalgia [NCT00673452]	Phase 4	530 participants (Actual)	Interventional	2008-06-30	Completed
Maintenance of Effect of Duloxetine 60 mg Once Daily in Patients With Diabetic Peripheral Neuropathic Pain [NCT00322621]	Phase 4	216 participants (Actual)	Interventional	2006-04-30	Completed
Effects of Duloxetine on Fear Conditioning in PTSD [NCT00763178]	Early Phase 1	26 participants (Actual)	Interventional	2007-02-28	Completed
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Referenced, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder [NCT00672620]	Phase 3	611 participants (Actual)	Interventional	2008-04-30	Completed
Randomised, Double-blind, Parallel-group, Placebo-controlled, Duloxetine-referenced, Fixed Dose Study Comparing the Efficacy and Safety of [Vortioxetine] Lu AA21004 in Acute Treatment of Major Depressive Disorder in Elderly Patients [NCT00811252]	Phase 3	453 participants (Actual)	Interventional	2009-01-31	Completed
Duloxetine in Patients With Central Neuropathic Pain Due to Multiple Sclerosis. [NCT00755807]	Phase 3	239 participants (Actual)	Interventional	2008-10-31	Completed
Randomized Clinical Trial: 03 (Methylphenidate and Duloxetine) [NCT02700711]	Phase 1	13 participants (Actual)	Interventional	2016-02-29	Completed
Pain Relieving Potentials of Preoperative Combination of Single Dose Oral Duloxetine and Intravenous Magnesium Sulphate in Acute and Chronic Post Mastectomy Pain: A Randomized Controlled Trial [NCT06087211]	Phase 4	90 participants (Anticipated)	Interventional	2023-10-10	Recruiting
An Open Trial of Duloxetine on Comorbid Major Depression and Chronic Headache [NCT00531895]	Phase 4	30 participants (Actual)	Interventional	2006-04-30	Completed
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Referenced, Fixed-Dose Study Comparing the Efficacy and Safety of 3 Doses of Lu AA21004 in Acute Treatment of Adults With Generalized Anxiety Disorder [NCT00730691]	Phase 3	781 participants (Actual)	Interventional	2008-06-30	Completed
Long-Term Monitoring of Safety in Subjects Treated With Duloxetine for Stress Urinary Incontinence [NCT00190632]	Phase 3	600 participants	Interventional	2001-03-31	Completed
The Effectiveness of Duloxetine Compared With Placebo in the Treatment of Predominant Stress Urinary Incontinence [NCT00190827]	Phase 3	500 participants	Interventional	2003-09-30	Completed
Study of Duloxetine HCl in Women of Different Demographic Characteristics and Co-Morbidities With Stress Urinary Incontinence: Evaluation of Efficacy and Safety [NCT00190905]	Phase 4	4,000 participants	Interventional	2004-02-29	Completed
A Comparison of Duloxetine Dosing Strategies in The Treatment of Patients With Major Depression [NCT00191061]	Phase 4	640 participants	Interventional	2004-10-31	Completed
Protocol F1J-MC-HMFG Duloxetine 60 to 120 mg Versus Placebo in the Treatment of Patients With Osteoarthritis Knee Pain [NCT00433290]	Phase 3	256 participants (Actual)	Interventional	2007-02-28	Completed
Protocol F1J-MC-HMEO Duloxetine Versus Placebo in the Treatment of Chronic Low Back Pain [NCT00408876]	Phase 3	404 participants (Actual)	Interventional	2006-12-31	Completed
Duloxetine Versus Placebo in the Long-Term Treatment of Patients With Late-Life Major Depression [NCT00406848]	Phase 4	370 participants (Actual)	Interventional	2006-11-30	Completed
An Eight-Week, Randomized, Double Blind, Two Parallel Groups, Study to Assess Clinical Response of Duloxetine 60 mg and 120 Per Day in Patients Hospitalized for Severe Depression [NCT00422162]	Phase 4	339 participants (Actual)	Interventional	2007-02-28	Completed
An Open-Label Trial of Duloxetine for the Treatment of Irritable Bowel Syndrome Without Comorbid Major Depressive Disorder [NCT00401258]	Phase 4	15 participants (Actual)	Interventional	2006-11-30	Completed
A Double-blind, Randomized, Placebo Controlled Clinical Trial on Comparing Escitalopram and Duloxetine add-on for Negative Symptoms in Schizophrenic Subjects With Neuregulin-1 (NRG1) Risk Genotype [NCT01078870]	Phase 4	75 participants (Anticipated)	Interventional	2010-02-28	Active, not recruiting
Duloxetine 60/120mg Versus Placebo in the Treatment of Fibromyalgia Syndrome [NCT00233025]	Phase 3	320 participants	Interventional	2005-09-30	Completed
A Double-Blind, Stratified, Randomised, Parallel, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy and Safety of Duloxetine (20 mg Bid for 2 Weeks Escalating to 40 mg Bid) for up to 12 Weeks, Compared to Placebo, in Community-Dwelling Elderly [NCT00244296]	Phase 4	276 participants	Interventional	2005-10-31	Completed
Effects of Escitalopram vs. Duloxetine on Heart Rate Variability and Autonomic Cardiovascular Control [NCT00215228]	Phase 2/Phase 3	26 participants (Anticipated)	Interventional	2005-07-31	Completed
Comparison of Opioid and Duloxetine for Postoperative Pain Control After Total Knee Arthroplasty: Randomized Controlled Trial [NCT04719585]		160 participants (Anticipated)	Interventional	2021-01-31	Not yet recruiting
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Active Controlled, Parallel Group, Multicenter Study to Assess the Safety and Efficacy of 2 Fixed Dose Groups of TC-5214 (S-mecamylamine) as Monotherapy Treatment in Patients With Major Depressive [NCT01288079]	Phase 2	145 participants (Actual)	Interventional	2011-02-28	Terminated
[NCT02020122]		5 participants (Actual)	Interventional	2014-01-31	Completed
The Effect of Transcutaneous Posterior Tibial Nerve Stimulation on Pain and Quality of Life in Patients With Fibromyalgia: a Single-blind, Randomized Controlled Trial [NCT05937711]		64 participants (Actual)	Interventional	2020-11-02	Completed
Duloxetine for Post Operative Analgesia After Modified Radical Mastectomy:A Randomized Controlled Study [NCT05442268]		40 participants (Anticipated)	Interventional	2022-07-16	Recruiting
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Duloxetine-Referenced, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (15 and 20 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder [NCT01153009]	Phase 3	614 participants (Actual)	Interventional	2010-06-30	Completed
Prophylactic Duloxetine Administration During Acute Herpes Zoster Prevents Postherpetic Neuralgia [NCT04313335]		750 participants (Anticipated)	Interventional	2021-03-01	Recruiting
A Phase IIa, Multi-centre, Randomized, Double-Blind, Double-Dummy, Active and Placebo Controlled, Parallel Group Study to Assess the Effectiveness and Safety of AZD2066 After 6 Weeks of Treatment in Patients With Major Depressive Disorder - D0475C00020 [NCT01145755]	Phase 2	131 participants (Actual)	Interventional	2010-05-31	Terminated
A Study of the Effectiveness and Tolerability of Duloxetine (Cymbalta) in the Treatment of PTSD. [NCT00583193]	Phase 3	20 participants (Anticipated)	Interventional	2005-12-31	Recruiting
Pilot Study of the Efficacy and Tolerability of Duloxetine in Patients With Suspected Functional Pancreatic/Biliary Pain (Sphincter of Oddi Dysfunction). [NCT00471315]	Phase 3	18 participants (Actual)	Interventional	2006-07-31	Completed
Comparison of the Efficacy of Duloxetine and Pregabalin in Patients With Knee Osteoarthritis With Mix Type Pain [NCT04532684]	Phase 4	66 participants (Actual)	Interventional	2016-10-31	Completed
Mechanisms of Neuromuscular Fatigue Post Stroke [NCT01688570]	Early Phase 1	27 participants (Actual)	Interventional	2011-08-31	Completed
Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies [NCT02893371]		1,037,352 participants (Actual)	Observational	2016-09-30	Completed
Attributes of Response in Depressed Patients Switched to Treatment With Duloxetine (ARDENT Study) [NCT00696774]	Phase 4	242 participants (Actual)	Interventional	2008-06-30	Completed
F1J-MC-HMFN (a) An Open-Label Study of Tolerability, Safety, and Pharmacokinetics of Duloxetine in the Treatment of Children and Adolescents With Major Depressive Disorder [NCT00529789]	Phase 2	72 participants (Actual)	Interventional	2007-08-31	Completed
A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Major Depressive Disorder [NCT00849693]	Phase 3	463 participants (Actual)	Interventional	2009-03-31	Completed
Duloxetine in the Treatment of Postpartum-onset and Non-Postpartum Onset Major Depressive Disorder [NCT00617045]		0 participants (Actual)	Interventional	2007-07-31	Withdrawn(stopped due to poor patient recruitment)
"Use of Duloxetine or Pregabalin in Monotherapy Versus Combination Therapy of Both Drugs in Patients With Painful Diabetic Neuropathy The COMBO - DN (COmbination vs Monotherapy of pregaBalin and dulOxetine in Diabetic Neuropathy) Study" [NCT01089556]	Phase 3	811 participants (Actual)	Interventional	2010-03-31	Completed
Duloxetine for Menopausal Depression [NCT01117857]	Phase 4	29 participants (Actual)	Interventional	2009-08-31	Completed
Treatment of Patients With Diabetic Peripheral Neuropathic Pain in China: Duloxetine Versus Placebo [NCT01179672]	Phase 3	405 participants (Actual)	Interventional	2011-04-30	Completed
[NCT02711215]	Phase 4	80 participants (Anticipated)	Interventional	2015-05-31	Active, not recruiting
Efficacy of Perioperative Duloxetine as a Part of Multimodal Analgesia in Laparoscopic Colorectal Cancer Surgery [NCT04294953]	Phase 2	60 participants (Anticipated)	Interventional	2020-03-01	Not yet recruiting
Predicting Treatment Outcome in Major Depressive Disorder [NCT02869035]	Phase 1	100 participants (Anticipated)	Interventional	2016-08-31	Completed
The Role of Central Serotonergic and Adrenergic Systems in the Effectiveness of DNIC (Diffuse Noxious Inhibitory Control [NCT00660751]		64 participants (Actual)	Interventional	2007-08-31	Completed
UMCC 2008.62: Prospective Pilot Study Evaluating the Use of Duloxetine for Treatment of Aromatase Inhibitor-associated Musculoskeletal Symptoms in Breast Cancer Patients [NCT01028352]		35 participants (Actual)	Interventional	2008-10-31	Completed
Pain Management in Osteoarthritis Using the Centrally Acting Analgesics Duloxetine and Pregabalin [NCT02612233]	Phase 4	81 participants (Actual)	Interventional	2013-09-30	Completed
A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Major Depressive Disorder [NCT00849901]	Phase 3	337 participants (Actual)	Interventional	2009-03-31	Completed
Duloxetine Versus Placebo in the Treatment of Elderly Patients With Generalized Anxiety Disorder [NCT01118780]	Phase 4	291 participants (Actual)	Interventional	2010-10-31	Completed
DULOPLASM Study: Pilot Study on Mechanisms of Analgesic Action of Duloxetine: Effective Dosage of Duloxetine at the Peak and at the Lowest Plasma Concentrations [NCT02846701]	Phase 4	8 participants (Actual)	Interventional	2016-11-17	Completed
Predicting Medication Response in Obsessive Compulsive Disorder [NCT01404871]		26 participants (Actual)	Interventional	2009-04-30	Completed
Duloxetine in the Treatment of Melancholic Depression: An 8-Week Open-Label Dose Study [NCT00191685]	Phase 3	200 participants	Interventional	2004-05-31	Completed
Pilot, Opened, Randomized Clinical Trial to Assess the Efficacy of Duloxetine in the Treatment of Fibromialgy in Patients With Infection by HIV 1+ [NCT00552682]	Phase 3	10 participants (Actual)	Interventional	2007-01-31	Completed
[NCT01425827]		288 participants (Actual)	Interventional	2010-11-30	Completed
Combining Data Sources to Identify Effect Moderation for Personalized Mental Health [NCT05267873]		14,146 participants (Anticipated)	Observational	2015-01-01	Active, not recruiting
A Double-blind, Double-dummy, Placebo-controlled, Incomplete Block, Two Period Crossover Study of the Histamine H3 Antagonist GSK189254 and Duloxetine in the Electrical Hyperalgesia Model of Central Sensitisation in Healthy Volunteers [NCT00387413]	Phase 1	40 participants (Actual)	Interventional	2006-10-02	Completed
Efficacy of Duloxetine in Conjunction With Tramadol for Chronic Cancer Pain [NCT05311774]		400 participants (Anticipated)	Interventional	2022-04-30	Not yet recruiting
Effect of Duloxetine 60 mg Once Daily Versus Placebo in Patients With Chronic Low Back Pain [NCT00767806]	Phase 3	401 participants (Actual)	Interventional	2008-09-30	Completed
Bioavailability of a Formulation of Duloxetine 60 mg Capsules With Enteric Coated Granules With Regards to the Marketed Reference Product [NCT04723238]	Phase 1	36 participants (Actual)	Interventional	2021-01-23	Completed
A Comparison of Duloxetine Hydrochloride, Venlafaxine Extended Release, and Placebo in the Treatment of Generalized Anxiety Disorder [NCT00122837]	Phase 3	560 participants	Interventional	2005-04-30	Completed
Efficacy and Safety of Duloxetine Compared With Placebo in Subjects Electing Surgery for Severe Pure Genuine Stress Incontinence [NCT00190619]	Phase 3	100 participants	Interventional	2001-05-31	Completed
Efficacy and Safety of Duloxetine Compared With Placebo in Women With Symptoms of Mixed Urinary Incontinence. [NCT00190814]	Phase 3	600 participants	Interventional	2003-09-30	Completed
Effect of Duloxetine on Valsalva Leak Point Pressure and Quantitative Rhabdosphincter Electromyography Measures in Women With Stress Urinary Incontinence [NCT00190853]	Phase 3	93 participants	Interventional	2005-01-31	Completed
Long Term Monitoring of Safety in Subjects Treated With Duloxetine for Stress Urinary Incontinence [NCT00191204]	Phase 3	363 participants	Interventional	2001-09-30	Completed
Open-Label Duloxetine Extension Phase in Patients Who Have Completed the HMDG Clinical Trial [NCT00191594]	Phase 3	105 participants	Interventional	2005-03-31	Completed
A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder, the Orion Trial [NCT01360866]	Phase 3	2,944 participants (Actual)	Interventional	2011-10-31	Completed
A Preliminary Comparison of the Effect of Roux-en-Y Bariatric Surgery on Blood Levels of Duloxetine [NCT00989157]	Phase 3	20 participants (Actual)	Interventional	2009-09-30	Completed
Comparison of Aripiprazole Augmentation vs Switching to Different Class of Antidepressants for Patients With MDD Who Are Partially/Minimally Responsive to Current Antidepressants:Randomized, Rater-blinded, Prospective Study [NCT01488266]		90 participants (Anticipated)	Interventional	2011-11-30	Active, not recruiting
RCT of Duloxetine & Pregabalin for the Treatment of Gulf War Illness in Veterans [NCT01846182]	Phase 2	112 participants (Actual)	Interventional	2015-06-24	Terminated(stopped due to Terminated by Funder)
Neurobiological Correlates of Antidepressant Response After Duloxetine Hydrochloride Treatment in Subjects With Major Depressive Disorder [NCT01051466]	Phase 4	60 participants (Actual)	Interventional	2010-01-31	Completed
Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder [NCT00105989]	Phase 3	514 participants (Actual)	Interventional	2005-03-31	Completed
Randomised, Double-blind, Parallel-group, Placebo-controlled, Active-referenced, Dose-finding Study of Lu AA24530 in Major Depressive Disorder [NCT00599911]	Phase 2	652 participants (Actual)	Interventional	2007-10-31	Completed
Effects of Duloxetine on Pathological Worry in Patients With Generalized Anxiety Disorder: A fMRI Study [NCT00491348]		23 participants (Actual)	Interventional	2007-04-30	Terminated(stopped due to Change of MRI mode)
Comparative Evaluation of Vortioxetine Versus Other Antidepressants With Pregabalin Augmentation in Treatment-resistant Burning Mouth Syndrome: a Prospective Longitudinal Clinical Trial With Treatment Response Prediction [NCT06025474]	Phase 3	203 participants (Anticipated)	Interventional	2023-01-01	Recruiting
Optimizing Neurofeedback to Treat Chemotherapy Induced Peripheral Neuropathy [NCT04560673]	Phase 2	380 participants (Anticipated)	Interventional	2020-07-10	Recruiting
[NCT02934035]		10,000 participants (Anticipated)	Observational	2016-09-30	Active, not recruiting
Impact of Therapeutical Strategies on Emotional Processing in Depression: Neurofunctional and Clinical Issues in the Context of Affective Bias [NCT00596986]		30 participants (Anticipated)	Interventional	2008-10-31	Active, not recruiting
'Fix the Dysfunction' Concept for Mechanism-based Pharmacological Treatment of Neuropathic Pain by Drug [NCT03276689]		300 participants (Actual)	Interventional	2017-10-19	Completed
"Preoperative Oral Duloxetine: Does it Affect Duration of Spinal Anesthesia and Early Postoperative Pain After Arthroscopic ACL Repair? a Prospective, Randomized, Double-blind Controlled Trial" [NCT05050656]	Phase 4	70 participants (Actual)	Interventional	2021-03-15	Completed
A Double-blind, Randomised, Parallel Groups Investigation Into the Effects of Pregabalin, Duloxetine and Amitriptyline on Aspects of Pain, Sleep, and Next Day Performance in Patients Suffering From Diabetic Peripheral Neuropathy [NCT00370656]	Phase 2/Phase 3	90 participants (Anticipated)	Interventional	2007-02-28	Completed
Efficacy of Duloxetine Compared to NSIADs in Osteoarthritis of Knee: A Randomized Open Labelled Clinical Trial [NCT05486026]	Phase 2	200 participants (Actual)	Interventional	2022-08-20	Completed
[NCT01470339]		200 participants (Actual)	Interventional	2011-12-31	Completed
[NCT01470352]		179 participants (Actual)	Interventional	2011-11-16	Completed
Comparison of Duloxetine Versus Pregabalin in Post-mastectomy Pain Syndrome: a Randomized Controlled Trial [NCT04727502]	Phase 2	70 participants (Anticipated)	Interventional	2020-12-20	Recruiting
Comparative Responses to 15 Different Antidepressants in Major Depressive Disorder - Results From a Long-term Nation-wide Population-based Study Emulating a Randomized Trial [NCT05952713]		73,336 participants (Actual)	Observational	2022-10-01	Completed
A Comparison of Duloxetine Hydrochloride, Venlafaxine Extended Release, and Placebo in the Treatment of Generalized Anxiety Disorder. [NCT00122850]	Phase 3	480 participants	Interventional	2004-10-31	Completed
A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled and Active-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained-Release (SEROQUEL®) as Monotherapy in the Treatment of Patients With MDD [NCT00321490]	Phase 3	600 participants	Interventional	2006-04-30	Completed
A 1-Year Safety Study of Duloxetine in Patients With Fibromyalgia Syndrome [NCT00125892]	Phase 3	320 participants	Interventional	2005-07-31	Completed
A Study of the Effects of Paroxetine vs. Duloxetine on Heart Rate Variability and Autonomic Cardiovascular Control [NCT00136383]	Phase 2/Phase 3	40 participants (Anticipated)	Interventional	2005-03-31	Completed
A Multi-Centre, Double-Blind, Randomised, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SRTM) in Combination With an Antidepressant in the Treatment of Patients With Major [NCT00351910]	Phase 3	494 participants (Actual)	Interventional	2006-05-31	Completed
Long-Term Monitoring of Safety in Subjects Treated With Duloxetine for Bladder Overactivity [NCT00475696]	Phase 2	300 participants	Interventional	2002-11-30	Completed
Duloxetine Hydrochloride Once Daily Compared With Placebo in the Treatment of Generalized Anxiety Disorder [NCT00475969]	Phase 3	327 participants	Interventional	2004-08-31	Completed
Duloxetine Versus Placebo in the Treatment of Fibromyalgia Patients With or Without Major Depressive Disorder [NCT00489073]	Phase 3	345 participants	Interventional	2002-11-30	Completed
Duloxetine Versus Paroxetine in the Acute Treatment of Major Depression [NCT00489775]	Phase 3	480 participants	Interventional	2004-01-31	Completed
Duloxetine Versus Duloxetine Plus Non-Pharmacological Intervention in the Treatment of Depression [NCT00494377]	Phase 4	940 participants	Interventional	2004-02-29	Completed
Identifying and Treating Depression in the Orthopaedic Trauma Population [NCT05976347]	Phase 4	100 participants (Anticipated)	Interventional	2024-02-29	Not yet recruiting
The Role of SNRI's in the Prophylaxis of Depression in the First Year Following Lower Extremity Fragility Fractures in Geriatric Patients [NCT05851898]	Phase 4	100 participants (Anticipated)	Interventional	2024-02-29	Not yet recruiting
A Single-Center, Open Label Pilot Study Examining The Use Of Duloxetine In The Prevention Of Episodic Migraine [NCT00443352]	Phase 4	27 participants (Actual)	Interventional	2007-08-31	Completed
Evaluation of the Effect of Duloxetine on the Pharmacodynamics of Warfarin at Steady-State in Healthy Subjects [NCT00533026]	Phase 1	60 participants (Actual)	Interventional	2007-07-31	Completed
Dose Response Study of Duloxetine Versus Placebo in the Treatment of Fibromyalgia Syndrome [NCT00190866]	Phase 3	210 participants	Interventional	2005-06-30	Completed
A Ten-Week, Randomized, Double-Blind Study Evaluating the Efficacy of Duloxetine 60mg Once Daily Versus Placebo in Outpatients With Major Depressive Disorder and Pain [NCT00191919]	Phase 3	310 participants	Interventional	2005-05-31	Completed
Long-Term Monitoring of Safety in Subjects Treated With Duloxetine for Stress Urinary Incontinence. [NCT00191087]	Phase 3	458 participants	Interventional	2001-04-30	Completed
Duloxetine Combined With Intra-articular Injection of Corticosteroid and Hyaluronic Acid Reduces Pain in the Treatment of Knee Osteoarthritis Patients [NCT04117893]	Phase 4	150 participants (Actual)	Interventional	2019-10-01	Completed
Efficacy and Safety of Duloxetine Compared With Placebo in Subjects With Stress Urinary Incontinence [NCT00475397]	Phase 3	120 participants	Interventional	2003-12-31	Completed
Lilly's Emotional and Physical Symptoms of Depression Study [NCT00479726]	Phase 4	8,000 participants	Interventional	2004-08-31	Completed
Duloxetine for Perimenopausal Depression [NCT00517985]	Phase 4	7 participants (Actual)	Interventional	2007-02-28	Completed
An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression [NCT02497287]	Phase 3	802 participants (Actual)	Interventional	2015-09-30	Completed
A Randomised, Controlled Trial to Investigate the Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment. [NCT05973786]	Phase 4	418 participants (Anticipated)	Interventional	2023-11-01	Not yet recruiting
Open-Label Treatment With Duloxetine Hydrochloride Once-Daily Dosing for Evaluation of Stabilization Dose in Patients With Major Depression [NCT00042562]	Phase 3	0 participants	Interventional	2002-12-31	Completed
[NCT00399022]		40 participants (Anticipated)	Interventional		Withdrawn(stopped due to Funding was not recieved)
Duloxetine Versus Venlafaxine Extended Release in the Treatment of Major Depressive Disorder [NCT00067912]	Phase 4	480 participants	Interventional	2003-04-30	Completed
Duloxetine Versus Venlafaxine Extended Release in the Treatment of Major Depressive Disorder [NCT00071695]	Phase 4	320 participants	Interventional	2003-07-31	Completed
Duloxetine Versus Escitalopram and Placebo in the Treatment of Patients With Major Depression [NCT00073411]	Phase 3	675 participants	Interventional	2003-11-30	Completed
Duloxetine Versus Placebo in the Prevention of Relapse of Major Depressive Disorder [NCT00036309]	Phase 3	0 participants	Interventional	2002-05-31	Completed
Duloxetine Versus Placebo in the Treatment of Patients With Painful Diabetic Neuropathy [NCT00058968]	Phase 3	660 participants	Interventional	2002-10-31	Completed
Duloxetine Versus Placebo in the Treatment of Elderly Patients With Major Depressive Disorder [NCT00062673]	Phase 3	311 participants	Interventional	2003-03-31	Completed
Duloxetine Hydrochloride (LY248686) Protocol F1J-US-HMCB Duloxetine Once-Daily Dosing Versus Placebo in Patients With Major Depression and Pain [NCT00036335]	Phase 3	286 participants	Interventional	2002-03-31	Completed
Protocol F1J-US-HMBY Dose Escalation, Double-Blind Treatment With Duloxetine Hydrochloride Once Daily Dosing for Evaluation of Safety in Major Depression [NCT00042575]	Phase 3	120 participants	Interventional	2002-06-30	Completed
Duloxetine Hydrochloride 60 mg or 120 mg Once Daily Compared With Placebo in Patients With Generalized Anxiety Disorder. [NCT00122824]	Phase 3	480 participants	Interventional	2004-06-30	Completed
Duloxetine 60 to 120 mg Once Daily Compared With Placebo in the Prevention of Relapse in Generalized Anxiety Disorder [NCT00122863]	Phase 3	380 participants	Interventional	2005-01-31	Completed
"The CHRONOS Study: Can the Sleep-deprivation Induced Antidepressive Effect in Patients With Major Depression be Sustained by Correction of Diurnal Rhythms, Long Term Light Treatment and Duloxetine Treatment?" [NCT00149110]		75 participants (Actual)	Interventional	2005-09-30	Completed
Duloxetine for the Treatment of Dysthymia [NCT00185575]		24 participants (Anticipated)	Interventional	2004-09-30	Completed
Biomechanical Effects of Duloxetine on Bladder Function and Sphincter Resistance During the Emptying Phase and on Urethral Function During the Filling Phase of the Micturition Cycle in Women With Pure Genuine Stress Incontinence [NCT00190567]	Phase 2	50 participants	Interventional	2001-10-31	Completed
Efficacy and Safety of Duloxetine Compared With Placebo,Pelvic Floor Muscle Training, and Combined Duloxetine/Pelvic Floor Muscle Training in Subjects With Moderate to Sever Stress Urinary Incontinence [NCT00190606]	Phase 2	200 participants	Interventional	2002-01-31	Completed
Long-Term Monitoring of Safety in Subjects Treated With Duloxetine for Stress Urinary Incontinence [NCT00190645]	Phase 3	600 participants	Interventional	2001-02-28	Completed
The Safety and Effectiveness of Duloxetine Compared With Placebo and Its Long-Term Safety and Efficacy in the Treatment of Predominant Stress Urinary Incontinence [NCT00190996]	Phase 3	2,765 participants	Interventional	2003-01-31	Completed
Switching to Duloxetine From Other Antidepressants: A Regional Multicentre Trial Comparing Two Switching Techniques [NCT00191932]	Phase 4	360 participants	Interventional	2004-08-31	Completed
Treatment of Major Depressive Episodes During the Course of Psychotic Disorders With Duloxetine [NCT00224302]	Phase 4	20 participants (Anticipated)	Interventional	2005-08-31	Completed
A Randomized, Placebo-Controlled, Double-Blind Trial of Duloxetine in the Treatment of Patients With Chronic Fatigue Syndrome [NCT00375973]	Phase 2/Phase 3	60 participants (Actual)	Interventional	2006-09-30	Completed
The Efficacy and Tolerability of Duloxetine for the Treatment of Panic Disorder [NCT00438971]	Phase 4	15 participants (Actual)	Interventional	2006-08-31	Completed
Leveraging EEG for Antidepressant Prediction With Duloxetine and Bupropion (LEAP-DB): A Multicenter, Randomized, Blinded Outcome Study of EEG-guided Treatment With Duloxetine Versus Bupropion in Adults With Major Depressive Disorder [NCT04388189]	Phase 4	0 participants (Actual)	Interventional	2020-10-15	Withdrawn(stopped due to No participants enrolled)
Optimizing Outcomes in Older Adults With Low Back Pain and Depression [NCT00696293]	Phase 4	30 participants (Actual)	Interventional	2007-05-31	Completed
[NCT03110172]	Phase 1/Phase 2	32 participants (Anticipated)	Interventional	2017-01-31	Active, not recruiting
A Randomized, Open-Label, Crossover, Drug Interaction Study to Evaluate the Effects of DVS SR And Duloxetine on the Pharmacokinetics of Desipramine in Healthy Subjects [NCT00366652]	Phase 3	20 participants (Anticipated)	Interventional	2006-09-30	Completed
Comparative Clinical Study Evaluating the Possible Efficacy of Duloxetine, Gabapentin and Lacosamide on Oxaliplatin-Induced Peripheral Neuropathy in Cancer Patients [NCT05510856]	Phase 4	90 participants (Anticipated)	Interventional	2022-09-01	Recruiting
[NCT02655354]		635 participants (Actual)	Interventional	2015-10-31	Completed
A Comparison of Strategies for Switching Patients From Amitriptyline to Duloxetine for the Management of Diabetic Peripheral Neuropathic Pain [NCT00266643]	Phase 4	205 participants	Interventional	2005-12-31	Completed
Post-Marketing Surveillance Study on the Safety and Efficacy of Cymbalta (Duloxetine) on Diabetic Peripheral Neuropathic Pain Among Filipino Patients [NCT02215798]		269 participants (Actual)	Observational	2006-07-31	Completed
Evaluation of the Effects of Duloxetine on Norepinephrine Transporter Inhibition in Healthy Subjects [NCT00414323]	Phase 1	35 participants (Actual)	Interventional	2006-11-30	Completed
A Pilot Study Assessing Duloxetine's Efficacy in Atypical Depression [NCT00296699]	Phase 4	20 participants (Actual)	Interventional	2005-03-31	Completed
Evaluation of the Role of the Noradrenergic System in Pain Perception in Parkinson's Disease [NCT01504178]	Phase 3	28 participants (Actual)	Interventional	2011-05-31	Completed
Duloxetine (Cymbalta): for Fibromyalgia: An Open Label Study to Assess Potential Mechanisms for Fibromyalgia in Peripheral Tissue Innervation That Could Predict Therpeutic Responsiveness to Duloxetine. [NCT01619566]	Phase 4	0 participants (Actual)	Interventional	2012-06-30	Withdrawn(stopped due to Sponsor related)
A Randomized Trial of Sequenced Treatment Using Placebo Without Deception Followed by Open-Label Antidepressant Versus Immediate Open-Label Antidepressant Treatment for Major Depressive Disorder [NCT01650740]		1 participants (Actual)	Interventional	2012-08-31	Terminated(stopped due to Poor recruitment results.)
Efficacy of Variable Doses of Pregabalin Vs Duloxetine in Diabetic Peripheral Neuropathic Pain: A Comparative Study [NCT05292066]	Early Phase 1	126 participants (Anticipated)	Interventional	2022-10-31	Not yet recruiting
Algorithm Guided Treatment Strategies for Major Depressive Disorder [NCT01764867]	Phase 4	1,080 participants (Anticipated)	Interventional	2012-06-30	Recruiting
Antidepressant Treatments During Pregnancy and Lactation: Prediction of Drug Exposure Through Breastfeeding and Evaluation of Drug Effect on the Neonatal Adaptation and the Development of the Young Child [NCT01796132]	Phase 4	500 participants (Anticipated)	Interventional	2012-08-31	Recruiting
Efficacy of Pregabalin and Duloxetine in Patients With Painful Diabetic Peripheral Neuropathy (PDPN): the Effect of Pain on Cognitive Function, Sleep and Quality of Life (BLOSSOM) [NCT04246619]	Phase 4	254 participants (Actual)	Interventional	2019-11-12	Terminated(stopped due to The statistical analysis will still provide relevant results with the same statistical power as initially planned.COVID-19 pandemic prolonged the recruiting period and consequently affected the costs of the clinical trial.)
Intravenous Lidocaine Infusion Versus Oral Duloxetine For The Prevention And Treatment Of Chemotherapy Induced Peripheral Neuropathy Among Breast Cancer Patients [NCT04732455]		60 participants (Actual)	Interventional	2021-01-15	Completed
Hyperbaric Oxygen vs. Standard Pharmaceutical Therapies for Fibromyalgia Syndrome - Prospective, Randomized Crossover Clinical Trial [NCT03325959]		76 participants (Actual)	Interventional	2017-03-01	Completed
Brain Morphometries in OA Patients Treated With Duloxetine [NCT01558700]	Phase 4	40 participants (Actual)	Interventional	2012-03-31	Completed
Does Duloxetine Reduce Sub-Acute Pain After Knee Arthroplasty? [NCT02005601]	Phase 4	106 participants (Actual)	Interventional	2013-11-30	Completed
Prevention of Depression and Enhancement of Cognitive Recovery Following Traumatic Brain Injury With Duloxetine [NCT01223001]	Phase 2	8 participants (Actual)	Interventional	1996-09-30	Terminated(stopped due to Most potential subjects had already been prescribed Cymbalta.)
[NCT01443520]	Phase 4	12 participants (Actual)	Interventional	2011-10-31	Completed
A Randomised, Controlled Trial to Investigate the Effect of an Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment. [NCT05603104]	Phase 3	1,254 participants (Anticipated)	Interventional	2023-08-01	Not yet recruiting
The Efficacy and Safety of the Shugan Dingtong Decoction in the Treatment of Fibromyalgia [NCT05508516]	Early Phase 1	72 participants (Anticipated)	Interventional	2022-09-01	Not yet recruiting
Duloxetine Role in Reducing Opioid Consumption After Thoracotomy [NCT03618225]	Phase 4	60 participants (Actual)	Interventional	2018-08-15	Completed
Duloxetine as an Analgesic Agent in Patients Undergoing Elective Spine Surgery [NCT02535000]	Phase 4	60 participants (Actual)	Interventional	2014-01-01	Completed
Does Duloxetine Reduce Chronic Pain After Total Knee Arthroplasty? [NCT02307305]	Phase 2	168 participants (Anticipated)	Interventional	2014-08-31	Recruiting
Duloxetine for Treatment of Painful Temporomandibular Joint Disorder [NCT00981149]		24 participants (Actual)	Interventional	2009-05-31	Completed
Biomarkers for Prediction of Analgesic Efficacy Based on Interrelations Between Pain Modulation and EEG vs. Drugs' Mode of Action in Knee OA [NCT05256342]		100 participants (Anticipated)	Interventional	2021-12-30	Recruiting
Efficacy of Interpersonal Psychotherapy in Treatment Resistant Depression [NCT01896349]		74 participants (Anticipated)	Interventional	2013-04-30	Recruiting
Evaluating Duloxetine's Analgesic Effectiveness in Chronic Pelvic Pain [NCT01451606]	Phase 4	34 participants (Actual)	Interventional	2011-07-11	Terminated(stopped due to Adequate recruitment was not achieved in the time frame allowed.)
The Effect of Duloxetine on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients [NCT02443194]	Phase 3	50 participants (Actual)	Interventional	2015-05-31	Terminated(stopped due to principle investigator decision due to many adverse events in patients)
An Open Treatment Trial of Duloxetine in Elderly Patients With Dysthymic Disorder [NCT01852383]	Phase 4	30 participants (Actual)	Interventional	2006-01-31	Completed
A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects With Treatment-resistant Depression [NCT02418585]	Phase 3	236 participants (Actual)	Interventional	2015-08-07	Completed
Effect of Combination of Duloxetine and Pregabalin to Improve Pain After Liposuction Surgery [NCT04862845]	Phase 1	72 participants (Anticipated)	Interventional	2021-05-15	Not yet recruiting
A Randomized Controlled, Single-blind, Esketamine Adjuvant Therapy for the Efficacy and Safety of Patients With Chronic Visceral Pain Comorbid Major Depressive Disorder [NCT04847245]		80 participants (Anticipated)	Interventional	2021-05-01	Not yet recruiting
Comparisons of the Impact of Duloxetine Versus Imipramine on Therapeutic Efficacy in Women With Stress Urinary Incontinence: a Randomized Controlled Study. [NCT05677295]	Phase 3	90 participants (Anticipated)	Interventional	2023-04-18	Recruiting
A Japan Post-Marketing, Randomized, Double-Blind, Parallel-Group, Flexible Dose Comparative Study to Assess the Non-Inferiority of Duloxetine Compared With Pregabalin in Patients With Diabetic Peripheral Neuropathic Pain [NCT02417935]	Phase 4	304 participants (Actual)	Interventional	2015-04-30	Completed
Investigation Into the Diversity and Dynamic Succession of Gut Flora Pre- and Post-remission in Major Depressive Disorder [NCT04347577]		40 participants (Anticipated)	Observational	2020-04-10	Recruiting
A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled Study Comparing the Analgesic Efficacy and Safety of ABT-652 to Placebo in Subjects With Diabetic Neuropathic Pain [NCT01579279]	Phase 2	1 participants (Actual)	Interventional	2012-04-30	Terminated(stopped due to Study Stopped)
Effect of Combined Morphine and Duloxetine on Chronic Pain [NCT03249558]	Phase 4	81 participants (Actual)	Interventional	2018-03-12	Completed
Duloxetine for Acute Post-mastectomy Pain: Placebo Controlled Dose Ranging Study [NCT03468348]		88 participants (Actual)	Interventional	2018-04-01	Completed
Effect of Duloxetine 60 mg Versus Placebo in Patients With Chronic Low Back Pain in Japan [NCT01855919]	Phase 3	458 participants (Actual)	Interventional	2013-05-31	Completed
Antidepressant Response in Older Adults With Comorbid PTSD and MDD [NCT04697693]	Phase 4	1 participants (Actual)	Interventional	2021-03-03	Terminated(stopped due to Unable to recruit participants in a timely fashion due to COVID pandemic)
Functional Change and Efficacy of Duloxetine in Patients With Major Depression and Co-Morbid Soft Tissue Discomfort Symptoms [NCT01035073]	Phase 4	22 participants (Actual)	Interventional	2006-04-30	Completed
A Comparative Study Of Botulinum Toxin Type A Versus Conventional Oral Therapy As A Second Line Treatment Of Diabetic Neuropathy [NCT05296759]	Phase 4	30 participants (Actual)	Interventional	2021-02-01	Completed
Comparison of Antidepressants in the Real-World: Retrospective Cohort Study Using Big Data [NCT04446039]		405,349 participants (Actual)	Observational	2022-07-04	Completed
A Study to Identify Predictors of Response to Duloxetine in Breast Cancer Patients With Chronic Pain [NCT01912612]	Phase 2	82 participants (Actual)	Interventional	2013-10-30	Completed
An Open Label Extension Study of Phase 3 Trial of Duloxetine in Patients With Osteoarthritis and Knee Pain [NCT02335346]	Phase 3	93 participants (Actual)	Interventional	2015-01-31	Completed
Antidepressant Response in the Treatment of Depressive Symptoms and Frailty Characteristics in Older Adults [NCT01973283]	Phase 4	100 participants (Actual)	Interventional	2014-02-19	Completed
Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS) [NCT02260388]	Phase 4	402 participants (Actual)	Interventional	2014-10-31	Completed
A Superiority Study of LY248686 Versus Placebo in the Treatment of Patients With Diabetic Peripheral Neuropathic Pain [NCT00552175]	Phase 3	339 participants (Actual)	Interventional	2007-11-30	Completed
Impact of Duloxetine on Male Fertility [NCT03038867]	Phase 2	69 participants (Actual)	Interventional	2016-12-12	Completed
Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD) a Multicentre Open-label Randomized Controlled Trial Protocol [NCT05814640]	Phase 1/Phase 2	520 participants (Anticipated)	Interventional	2023-02-20	Recruiting
Investigation of the Effect of Initial Central Sensitization Severity on Treatment Response in Patients With Fibromyalgia [NCT05020600]		40 participants (Anticipated)	Observational	2021-08-19	Recruiting
Hyperbaric Oxygen Therapy vs. Pharmaceutical Therapy in Patients Suffering From Fibromyalgia That Was Induced by Emotional Trauma: Prospective, Randomized, Two Active Arms Clinical Trial [NCT04316702]		60 participants (Anticipated)	Interventional	2020-03-01	Active, not recruiting
A Phase III Clinical Trial of Duloxetine in Participants With Fibromyalgia [NCT01552057]	Phase 3	393 participants (Actual)	Interventional	2012-03-31	Completed
Predictors of Antidepressant Treatment Response: The Emory CIDAR [NCT00360399]		344 participants (Actual)	Interventional	2006-08-31	Completed
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Referenced, Flexible Dose Study on the Efficacy of Lu AA21004 on Cognitive Dysfunction in Adult Subjects With Major Depressive Disorder (MDD) [NCT01564862]	Phase 2	602 participants (Actual)	Interventional	2012-04-30	Completed
Altering The Transition From Acute to Chronic Pain (ATTAC-Pain): A Randomized Clinical Trial of Duloxetine for the Treatment and Prevention of Musculoskeletal Pain [NCT03315533]	Phase 2	76 participants (Actual)	Interventional	2018-01-19	Completed
Neurobiology of Non-Specific and Specific Treatment Responses in Major Depression [NCT03068247]	Phase 3	0 participants (Actual)	Interventional	2021-11-30	Withdrawn(stopped due to Institution was unable to manufacture radiotracer that was central to the protocol. Study transferred to another institution.)
A Single-Center, Single-Arm Clinical Trail Evaluating Efficacy and Safety of Duloxetine in Chinese Solid Tumor Patients With Taxanes-induced Painful Peripheral Neuropathy [NCT04970121]	Phase 2	100 participants (Anticipated)	Interventional	2021-08-21	Recruiting
Effectiveness of the Norepinephrine and Serotonin Reuptake Inhibitor Levomilnacipran in Healthy Males [NCT03249311]	Phase 4	36 participants (Actual)	Interventional	2018-03-02	Active, not recruiting
Postoperative Duloxetine Impact on Pain Control and Patient Outcomes Following Lateral Lumbar Interbody Fusion: A Randomized Controlled Trial [NCT05611749]	Phase 2	130 participants (Anticipated)	Interventional	2022-11-15	Not yet recruiting
Efficacy of Hydroxyzine Versus Treatment as Usual for Panic Disorder: An Eight-Week, Open Label, Pilot, Randomized Controlled Trial. [NCT05737511]	Phase 4	80 participants (Anticipated)	Interventional	2023-12-30	Not yet recruiting
Pharmacovigilance in Gerontopsychiatric Patients [NCT02374567]	Phase 3	407 participants (Actual)	Interventional	2015-01-31	Terminated
Incorporating Drug Metabolism by the Human Gut Microbiome Into Personalized Medicine [NCT05065671]	Phase 1	14 participants (Anticipated)	Interventional	2022-02-01	Recruiting
Bioavailability of a Formulation of Duloxetine 60 mg Enteric Coated Granules With Regards to Reference Product in Feeding Conditions [NCT04751318]	Phase 1	36 participants (Actual)	Interventional	2021-02-27	Completed
A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects With Treatment-resistant Depression [NCT02417064]	Phase 3	346 participants (Actual)	Interventional	2015-08-10	Completed
A Phase 4, 8-week, Double-blind, Randomized Study Comparing Switching to Duloxetine or Escitalopram in Patients With Major Depressive Disorder and Residual Apathy in the Absence of Depressed Mood [NCT00985504]	Phase 4	483 participants (Actual)	Interventional	2009-09-30	Completed
Pilot Study of Use of Duloxetine for the Treatment of Phantom Limb Pain [NCT00425230]		15 participants (Anticipated)	Interventional	2007-01-31	Terminated(stopped due to No patients were enrolled in this study. The study onset was delayed due to problems with drug acquisition.)
Effectiveness of Adding Duloxetine to Pregabalin in Treatment of Acute Postoperative and Prevention of Chronic Pain Following Thoracotomy Surgeries; Randomized Controlled Study [NCT04782310]	Phase 4	75 participants (Anticipated)	Interventional	2021-03-10	Recruiting
Factors of Treatment Response in Major Depressive Disorder [NCT00200902]	Phase 4	88 participants (Actual)	Interventional	2005-08-31	Completed
Duloxetine for Chronic Depression: a Double-blind Study [NCT00360724]	Phase 4	65 participants (Actual)	Interventional	2006-08-31	Completed
Duloxetine for the Treatment of Obsessive Compulsive Disorder [NCT00464698]	Phase 4	20 participants (Actual)	Interventional	2005-12-31	Completed
Functional MRI Neural Correlates of Medication Efficacy in Patients With Chronic Low Back Pain [NCT00388414]		14 participants (Actual)	Interventional	2006-09-30	Completed
Duloxetine Effects on Brain fMRI Response to Emotionally Valenced Pictures in the Treatment of Patients With Major Depression [NCT00532480]	Phase 4	10 participants (Actual)	Interventional	2007-09-30	Completed
A Comparison of Non-Surgical Treatment Methods for Patients With Lumbar Spinal Stenosis [NCT01943435]		259 participants (Actual)	Interventional	2013-11-20	Completed
Duloxetine Versus Pregabalin for Alcohol Dependence [NCT00929344]	Phase 2	150 participants (Actual)	Interventional	2009-07-31	Completed
Effects of Treatment on Decision-making in Major Depression [NCT01916824]	Phase 4	53 participants (Actual)	Interventional	2013-08-31	Completed
Impact of Duloxetine on Succinylcholine-induced Postoperative Myalgia During Direct Microlaryngoscopic Surgeries: Randomized Controlled Double-blind Study [NCT03037073]	Phase 2/Phase 3	70 participants (Actual)	Interventional	2017-04-15	Completed
Phase 3 Clinical Study of Duloxetine Hydrochloride in Patients With CLBP - Open Label Long Term Extension Study [NCT01914666]	Phase 3	151 participants (Actual)	Interventional	2013-09-30	Completed
A Randomized Placebo Controlled Trial of Duloxetine for Central Pain in Multiple Sclerosis [NCT00457730]	Phase 2/Phase 3	38 participants (Actual)	Interventional	2007-01-31	Completed
A Phase 1, Single-center, Open-label, Sequential Drug Interaction Study Between AVP-786 (Deuterated [d6] Dextromethorphan Hydrobromide [DM]/Quinidine Sulfate [Q]) and Paroxetine and Between AVP-786 and Duloxetine in Healthy Subjects [NCT02174822]	Phase 1	56 participants (Actual)	Interventional	2014-01-31	Completed
Open Trial of Duloxetine in Outpatients With Irritable Bowel Syndrome Symptoms and Co-Morbid Major Depression [NCT01754493]	Phase 4	17 participants (Actual)	Interventional	2008-12-31	Completed
Perioperative Duloxetine for Pain Management After Laparoscopic Hysterectomy: A Prospective Randomized Placebo-controlled Study [NCT03350334]		100 participants (Actual)	Interventional	2017-12-04	Completed
Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD) [NCT04245748]	Phase 4	84 participants (Anticipated)	Interventional	2020-03-01	Recruiting
Acute, Double-blind, Adaptively Randomized Treatment With Duloxetine or Escitalopram, Followed by Open-label Naturalistic Follow-up. [NCT04245436]	Phase 4	60 participants (Anticipated)	Interventional	2020-01-01	Recruiting
Proof of Concept Study to Treat Negative Affect in Chronic Low Back Pain [NCT04747314]	Phase 2/Phase 3	300 participants (Anticipated)	Interventional	2021-03-31	Recruiting
Efficacy and Safety of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression: A Multicenter, Randomized, Double-blind, Double-dummy, Active- and Placebo-controlled, Parallel-group, Phase II Study [NCT05018013]	Phase 2	240 participants (Anticipated)	Interventional	2021-08-21	Recruiting
Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study [NCT04137107]	Phase 2/Phase 3	348 participants (Anticipated)	Interventional	2020-05-01	Suspended(stopped due to Protocol-specified safety stopping rule)
Comparative Efficacy of Duloxetine vs Escitalopram in Patients With Fibromyalgia [NCT03487211]	Phase 2/Phase 3	200 participants (Actual)	Interventional	2018-04-09	Completed
Effect of Duloxetine 60 mg Versus Placebo in Patients With Chronic Osteoarthritis and Knee Pain in Japan [NCT02248480]	Phase 3	354 participants (Actual)	Interventional	2014-10-31	Completed
Duloxetine Efficacy and Tolerability for Pain Management in Patients Undergoing Laparoscopic Cholecystectomy [NCT05115123]	Phase 2	60 participants (Actual)	Interventional	2022-03-02	Completed
Genetic Variants Associated With the Occurrence of Localized Low Back Pain or Low Back Pain With Widespread Pain Symptoms, and Their Response to Treatment With Duloxetine or Propranolol [NCT03364075]	Phase 2	10 participants (Actual)	Interventional	2017-09-01	Terminated(stopped due to Recruitment issue)
Efficacy and Safety of Duloxetine Among Individuals With Depressive Disorder in a 12 Weeks Trial [NCT03121573]		30 participants (Actual)	Interventional	2014-12-15	Completed
A Randomized, Double-blind, Multicenter Active-controlled Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects With Treatment-resistant Depressio [NCT03434041]	Phase 3	252 participants (Actual)	Interventional	2018-05-25	Completed
Preoperative Duloxetine to Prevent Postoperative Shoulder Pain After Gynecological Laparoscopies [NCT03249168]	Phase 3	60 participants (Actual)	Interventional	2017-10-01	Completed
An Open Label Extension Study of Phase 3 Trial of Duloxetine in Patients With Fibromyalgia [NCT01621191]	Phase 3	149 participants (Actual)	Interventional	2012-06-30	Completed
Effect of Duloxetine 60mg Once Daily in Patients With Chronic Pain Due to Osteoarthritis in China [NCT01931475]	Phase 3	407 participants (Actual)	Interventional	2013-09-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00105989 (67) [back to overview]	Change From Baseline to Endpoint in Arizona Sexual Experience Scale (ASEX) - Acute and Continuation Phases (Males)
NCT00105989 (67) [back to overview]	Recurrence Count
NCT00105989 (67) [back to overview]	Mean Values at Endpoint in Patient's Global Impressions of Improvement (PGI-I) - Maintenance Phase
NCT00105989 (67) [back to overview]	Vital Signs - Change From Baseline to Endpoint in Weight - Acute and Continuation Phases
NCT00105989 (67) [back to overview]	Vital Signs - Change From Baseline to Endpoint in Pulse - Acute and Continuation Phases
NCT00105989 (67) [back to overview]	Vital Signs - Change From Baseline to Endpoint in Blood Pressure - Maintenance Phase
NCT00105989 (67) [back to overview]	Vital Signs - Change From Baseline to Endpoint in Blood Pressure - Acute and Continuation Phases
NCT00105989 (67) [back to overview]	Treatment-Emergent Adverse Events Occurring in at Least 5 Percent of the Participants -- Open-Label Continuation Phase
NCT00105989 (67) [back to overview]	Treatment-Emergent Adverse Events Occurring in at Least 5 Percent of Participants -- Open-Label Acute Therapy Phase
NCT00105989 (67) [back to overview]	Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Uric Acid - Acute Phase
NCT00105989 (67) [back to overview]	Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Total Protein - Continuation Phase
NCT00105989 (67) [back to overview]	Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Total Protein - Acute Phase
NCT00105989 (67) [back to overview]	Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Sodium - Acute Phase
NCT00105989 (67) [back to overview]	Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Platelet Count - Acute Phase
NCT00105989 (67) [back to overview]	Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Monocytes - Continuation Phase
NCT00105989 (67) [back to overview]	Mean Values at Endpoint in Patient's Global Impressions of Improvement (PGI-I) - Acute and Continuation Phases
NCT00105989 (67) [back to overview]	Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Chloride - Acute Phase
NCT00105989 (67) [back to overview]	Loss of Response at Any Time
NCT00105989 (67) [back to overview]	Change From Baseline to Endpoint in Symptom Questionnaire-Somatic Subscale (SQ-SS) - Maintenance Phase
NCT00105989 (67) [back to overview]	Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Mean Cell Volume (MCV) - Continuation Phase
NCT00105989 (67) [back to overview]	Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Mean Cell Hemoglobin - Continuation Phase
NCT00105989 (67) [back to overview]	Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Low Density Lipoprotein (LDL) Cholesterol (Direct) - Continuation Phase
NCT00105989 (67) [back to overview]	Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Leukocyte Count - Continuation Phase
NCT00105989 (67) [back to overview]	Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Hemoglobin - Continuation Phase
NCT00105989 (67) [back to overview]	Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Hemoglobin - Acute Phase
NCT00105989 (67) [back to overview]	Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Hematocrit - Continuation Phase
NCT00105989 (67) [back to overview]	Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Hematocrit - Acute Phase
NCT00105989 (67) [back to overview]	Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Glucose - Maintenance Phase
NCT00105989 (67) [back to overview]	Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Gamma-Glutamyl Transferase - Continuation Phase
NCT00105989 (67) [back to overview]	Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Gamma-Glutamyl Transferase - Acute Phase
NCT00105989 (67) [back to overview]	Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Erythrocyte Count - Continuation Phase
NCT00105989 (67) [back to overview]	Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Eosinophils - Acute Phase
NCT00105989 (67) [back to overview]	Change From Baseline to Endpoint in Clinical Global Impressions (CGI) Severity Scale - Maintenance Phase
NCT00105989 (67) [back to overview]	Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Calcium - Maintenance Phase
NCT00105989 (67) [back to overview]	Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Calcium - Continuation Phase
NCT00105989 (67) [back to overview]	Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Calcium - Acute Phase
NCT00105989 (67) [back to overview]	Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Bilirubin, Total - Continuation Phase
NCT00105989 (67) [back to overview]	Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Bilirubin, Direct - Continuation Phase
NCT00105989 (67) [back to overview]	Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Bicarbonate, HCO3 - Continuation Phase
NCT00105989 (67) [back to overview]	Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Albumin - Continuation Phase
NCT00105989 (67) [back to overview]	Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Albumin - Acute Phase
NCT00105989 (67) [back to overview]	Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Alanine Aminotransferase (ALT) - Maintenance Phase
NCT00105989 (67) [back to overview]	Resource Utilization and Hospitalization Module - Visits to Health Care Providers - Maintenance Phase
NCT00105989 (67) [back to overview]	Resource Utilization and Hospitalization Module - Visits to Health Care Providers - Acute and Continuation Phases
NCT00105989 (67) [back to overview]	Resource Utilization and Hospitalization Module - Change From Baseline to Endpoint in Number of Missed Paid Work Hours - Acute and Continuation Phase
NCT00105989 (67) [back to overview]	Resource Utilization and Hospitalization Module - Change From Baseline to Endpoint in Average Number of Hours Worked in a Week - Acute and Continuation Phases
NCT00105989 (67) [back to overview]	Percentage of Participants With Greater Than or Equal to 50% Worsening After Time (t) in Days
NCT00105989 (67) [back to overview]	Percentage of Participants With Depressive Recurrence After Time (t) in Days
NCT00105989 (67) [back to overview]	Change From Baseline to Endpoint in Visual Analog Scales (VAS) for Pain - Maintenance Phase
NCT00105989 (67) [back to overview]	Change From Baseline to Endpoint in Visual Analog Scales (VAS) for Pain - Acute and Continuation Phase
NCT00105989 (67) [back to overview]	Change From Baseline to Endpoint in Symptom Questionnaire-Somatic Subscale (SQ-SS) - Acute and Continuation Phases
NCT00105989 (67) [back to overview]	Change From Baseline to Endpoint in Sheehan Disability Scale (SDS) - Maintenance Phase
NCT00105989 (67) [back to overview]	Change From Baseline to Endpoint in Sheehan Disability Scale (SDS) - Acute and Continuation Phases
NCT00105989 (67) [back to overview]	Change From Baseline to Endpoint in Hamilton Depression Rating Scale Subscales, Including the Core, Maier, Anxiety/Somatization, Retardation/Somatization, and Sleep Subscales, and the Depressed Mood Item - Maintenance Phase
NCT00105989 (67) [back to overview]	Change From Baseline to Endpoint in Hamilton Depression Rating Scale Subscales, Including the Core, Maier, Anxiety/Somatization, Retardation/Somatization, and Sleep Subscales, and the Depressed Mood Item - Acute and Continuation Phases
NCT00105989 (67) [back to overview]	Change From Baseline to Endpoint in Clinical Global Impressions (CGI) Severity Scale - Acute and Continuation Phases
NCT00105989 (67) [back to overview]	Change From Baseline to Endpoint in Arizona Sexual Experience Scale (ASEX) - Maintenance Phase (Males)
NCT00105989 (67) [back to overview]	Change From Baseline to Endpoint in Arizona Sexual Experience Scale (ASEX) - Maintenance Phase (Females)
NCT00105989 (67) [back to overview]	Change From Baseline to Endpoint in 17-Item Hamilton Depression Rating Scale (HAMD-17) Total Score - Maintenance Phase
NCT00105989 (67) [back to overview]	Change From Baseline to Endpoint in Arizona Sexual Experience Scale (ASEX) - Acute and Continuation Phases (Females)
NCT00105989 (67) [back to overview]	Change From Baseline to Endpoint in 36-item Short-Form Health Survey (SF-36) - Maintenance Phase
NCT00105989 (67) [back to overview]	Change From Baseline to Endpoint in 36-item Short-Form Health Survey (SF-36) - Acute and Continuation Phase
NCT00105989 (67) [back to overview]	Change From Baseline to Endpoint in 17-Item Hamilton Depression Rating Scale (HAMD-17) Total Score - Acute and Continuation Phases
NCT00105989 (67) [back to overview]	Vital Signs - Change From Baseline to Endpoint in Weight - Maintenance Phase
NCT00105989 (67) [back to overview]	Vital Signs - Change From Baseline to Endpoint in Pulse - Maintenance Phase
NCT00105989 (67) [back to overview]	Resource Utilization and Hospitalization Module - Change From Baseline to Endpoint in Number of Missed Paid Work Hours - Maintenance Phase
NCT00105989 (67) [back to overview]	Resource Utilization and Hospitalization Module - Change From Baseline to Endpoint in Average Number of Hours Worked in a Week - Maintenance Phase
NCT00114127 (2) [back to overview]	Anxiety Symptoms as Assessed by Liebowitz Social Anxiety Scale
NCT00114127 (2) [back to overview]	CGI-S
NCT00177671 (4) [back to overview]	Number of Participants With Recurrence of Major Depression
NCT00177671 (4) [back to overview]	Cognitive Instrumental Activities of Daily Living (IADL)
NCT00177671 (4) [back to overview]	Global Cognitive Performance
NCT00177671 (4) [back to overview]	Percentage of Participants With Mild Cognitive Impairment Converting to Dementia.
NCT00200902 (3) [back to overview]	Response as Assessed by Participants' Change in Depression Rating
NCT00200902 (3) [back to overview]	Average Change in 3 Weeks of Participant Treatment Expectations
NCT00200902 (3) [back to overview]	Change in Hamilton Depression Assessment Score
NCT00322621 (41) [back to overview]	Maintenance Arm: Change From Baseline (Week 8) in Brief Pain Inventory Interference Score: Sleep at Week 34 Endpoint
NCT00322621 (41) [back to overview]	Rescue Arm: Patient's Global Impressions of Improvement (PGI-I) at Week 34 Endpoint
NCT00322621 (41) [back to overview]	Rescue Arm: Change From Baseline (Week 8) in Brief Pain Inventory Least Pain Score at Week 34 Endpoint
NCT00322621 (41) [back to overview]	Maintenance Arm: Change From Baseline (Week 8) in Brief Pain Inventory Interference Score: Walking Ability at Week 34 Endpoint
NCT00322621 (41) [back to overview]	Number of Participants Discontinuing in Maintenance / Rescue Phase
NCT00322621 (41) [back to overview]	Change From Baseline (Week 0) in Vital Signs: Diastolic Blood Pressure at Week 34 Endpoint
NCT00322621 (41) [back to overview]	Change From Baseline (Week 0) in Vital Signs: Systolic Blood Pressure at Week 34 Endpoint
NCT00322621 (41) [back to overview]	Change From Baseline (Week 0) in Vital Signs: Weight at Week 34 Endpoint
NCT00322621 (41) [back to overview]	Change From Baseline (Week 8) in Brief Pain Inventory (BPI) 24-hour Average Pain Item Score at Week 34 Endpoint
NCT00322621 (41) [back to overview]	Change From Baseline in Vital Signs: Heart Rate at Week 34 Endpoint
NCT00322621 (41) [back to overview]	Maintenance Arm: Change From Baseline (Week 8) in Beck Depression Inventory-II (BDI-II) Total Score at Week 34 Endpoint
NCT00322621 (41) [back to overview]	Maintenance Arm: Change From Baseline (Week 8) in Brief Pain Inventory Average Interference at Week 34 Endpoint
NCT00322621 (41) [back to overview]	Maintenance Arm: Change From Baseline (Week 8) in Brief Pain Inventory Average Pain Score at Week 34 Endpoint
NCT00322621 (41) [back to overview]	Maintenance Arm: Change From Baseline (Week 8) in Brief Pain Inventory Interference Score: Enjoyment of Life at Week 34 Endpoint
NCT00322621 (41) [back to overview]	Maintenance Arm: Change From Baseline (Week 8) in Brief Pain Inventory Interference Score: General Activity at Week 34 Endpoint
NCT00322621 (41) [back to overview]	Maintenance Arm: Change From Baseline (Week 8) in Brief Pain Inventory Interference Score: Mood at Week 34 Endpoint
NCT00322621 (41) [back to overview]	Maintenance Arm: Change From Baseline (Week 8) in Brief Pain Inventory Interference Score: Normal Work at Week 34 Endpoint
NCT00322621 (41) [back to overview]	Maintenance Arm: Change From Baseline (Week 8) in Brief Pain Inventory Interference Score: Relations With Other People at Week 34 Endpoint
NCT00322621 (41) [back to overview]	Maintenance Arm: Patient's Global Impressions of Improvement (PGI-I) at Week 34 Endpoint
NCT00322621 (41) [back to overview]	Maintenance Arm: Number of Patients With a ≥50% Reduction From Baseline (Week 0) in Brief Pain Inventory 24-hour Average Pain Item
NCT00322621 (41) [back to overview]	Maintenance Arm: Change From Baseline (Week 8) in Sensory Portion of the Short-Form McGill Pain Questionnaire at Week 34 Endpoint
NCT00322621 (41) [back to overview]	Maintenance Arm: Change From Baseline (Week 8) in Clinical Global Impressions of Severity (CGI-S) at Week 34 Endpoint
NCT00322621 (41) [back to overview]	Maintenance Arm: Change From Baseline (Week 8) in Brief Pain Inventory Worst Pain Score at Week 34 Endpoint
NCT00322621 (41) [back to overview]	Maintenance Arm: Change From Baseline (Week 8) in Brief Pain Inventory Pain Right Now Score at Week 34 Endpoint
NCT00322621 (41) [back to overview]	Maintenance Arm: Change From Baseline (Week 8) in Brief Pain Inventory Least Pain Score at Week 34 Endpoint
NCT00322621 (41) [back to overview]	Rescue Arm: Change From Baseline (Week 8) in Brief Pain Inventory Interference Score: Normal Work at Week 34 Endpoint
NCT00322621 (41) [back to overview]	Rescue Arm: Change From Baseline (Week 8) in Beck Depression Inventory-II (BDI-II) Total Score at Week 34 Endpoint
NCT00322621 (41) [back to overview]	Rescue Arm: Change From Baseline (Week 8) in Brief Pain Inventory Average Interference at Week 34 Endpoint
NCT00322621 (41) [back to overview]	Rescue Arm: Change From Baseline (Week 8) in Brief Pain Inventory Average Pain Score at 34 Week Endpoint
NCT00322621 (41) [back to overview]	Rescue Arm: Change From Baseline (Week 8) in Brief Pain Inventory Interference Score: Enjoyment of Life at Week 34 Endpoint
NCT00322621 (41) [back to overview]	Number of Participants Discontinuing in the Acute Phase
NCT00322621 (41) [back to overview]	Rescue Arm: Change From Baseline (Week 8) in Brief Pain Inventory Interference Score: General Activity at Week 34 Endpoint
NCT00322621 (41) [back to overview]	Rescue Arm: Change From Baseline (Week 8) in Brief Pain Inventory Interference Score: Mood at Week 34 Endpoint
NCT00322621 (41) [back to overview]	Rescue Arm: Change From Baseline (Week 8) in Brief Pain Inventory Interference Score: Relations With Other People at Week 34 Endpoint
NCT00322621 (41) [back to overview]	Rescue Arm: Change From Baseline (Week 8) in Brief Pain Inventory Interference Score: Sleep at Week 34 Endpoint
NCT00322621 (41) [back to overview]	Rescue Arm: Change From Baseline (Week 8) in Brief Pain Inventory Interference Score: Walking Ability at 34 Week Endpoint
NCT00322621 (41) [back to overview]	Rescue Arm: Change From Baseline (Week 8) in Brief Pain Inventory Pain Right Now Score at Week 34 Endpoint
NCT00322621 (41) [back to overview]	Rescue Arm: Change From Baseline (Week 8) in Brief Pain Inventory Worst Pain Score at Week 34 Endpoint
NCT00322621 (41) [back to overview]	Rescue Arm: Change From Baseline (Week 8) in Clinical Global Impressions of Severity (CGI-S) at Week 34 Endpoint
NCT00322621 (41) [back to overview]	Rescue Arm: Change From Baseline (Week 8) in Sensory Portion of the Short-Form McGill Pain Questionnaire at Week 34 Endpoint
NCT00322621 (41) [back to overview]	Rescue Arm: Number of Patients With a ≥50% Reduction From Baseline (Week 0) in Brief Pain Inventory 24-hour Average Pain Item
NCT00331799 (1) [back to overview]	Change in Connor Davidson Resilience Scale (CD-RISC) From Baseline to 8 Weeks
NCT00360399 (6) [back to overview]	Remission From Major Depressive Episode Among Participants Who Completed the Intervention
NCT00360399 (6) [back to overview]	Remission From Major Depressive Episode in Intent to Treat Sample
NCT00360399 (6) [back to overview]	Number of Participants Experiencing Depression Recurrence Following Remission to Monotherapy Treatment
NCT00360399 (6) [back to overview]	Number of Participants in Each Category of Response to Treatment of Depressive Symptoms, Among Participants Who Completed the Intervention
NCT00360399 (6) [back to overview]	Number of Participants in Each Category of Response to Treatment of Depressive Symptoms, in Intent to Treat Sample
NCT00360399 (6) [back to overview]	Number of Participants Achieving Remission From Major Depressive Episode After 12 Weeks of Combined Treatment, for Those Patients Who do Not Achieve Remission With Monotherapy
NCT00360724 (11) [back to overview]	Beck Depression Inventory (BDI)
NCT00360724 (11) [back to overview]	Beck Depression Inventory (BDI)
NCT00360724 (11) [back to overview]	Clinical Global Impressions Improvement(CGI-I)
NCT00360724 (11) [back to overview]	Cornell Dysthymia Rating Scale (CDRS)
NCT00360724 (11) [back to overview]	Cornell Dysthymia Rating Scale (CDRS)
NCT00360724 (11) [back to overview]	Global Assessment of Functioning Scale (GAF)
NCT00360724 (11) [back to overview]	Global Assessment of Functioning Scale (GAF)
NCT00360724 (11) [back to overview]	Hamilton Depression Rating Scale (HDRS) - 24 Total Score
NCT00360724 (11) [back to overview]	Resting-state Functional Connectivity Magnetic Resonance Imaging(fMRI)
NCT00360724 (11) [back to overview]	Resting-state Functional Connectivity Magnetic Resonance Imaging(fMRI)
NCT00360724 (11) [back to overview]	Hamilton Depression Rating Scale (HDRS) - 24 Total Score
NCT00375973 (7) [back to overview]	Change From Baseline in the Clinical Global Impression of Severity (CGI-S)
NCT00375973 (7) [back to overview]	Change From Baseline in Brief Pain Inventory (BPI) --Average Pain Severity Score
NCT00375973 (7) [back to overview]	Number of Participants Who Discontinued Use of Treatment Due to Adverse Events
NCT00375973 (7) [back to overview]	Patient Global Impression of Improvement (PGI-I)
NCT00375973 (7) [back to overview]	Change From Baseline in Multidimensional Fatigue Inventory (MFI)--General Fatigue Subscale Score
NCT00375973 (7) [back to overview]	Number of Participants Who Discontinued the Study for Any Reason
NCT00375973 (7) [back to overview]	Change From Baseline in the Hospital Anxiety and Depression Scale (HADS) --Depression Subscale
NCT00384033 (9) [back to overview]	Change From Baseline in HAM-D17 Total Score at Week 8 or Final On-therapy (FOT) Evaluation
NCT00384033 (9) [back to overview]	Change From Baseline in Montgomery and Asberg Depression Rating Scale (MADRS) Total Score at Week 8 or FOT Evaluation
NCT00384033 (9) [back to overview]	Change From Baseline in the HAM-D Energy Subscale Score at Week 8 or FOT Evaluation
NCT00384033 (9) [back to overview]	Change From Baseline in the Lassitude Item of the MADRS Scale at Week 8 or FOT Evaluation
NCT00384033 (9) [back to overview]	Change From Baseline in Visual Analog Scale-Pain Intensity (VAS-PI) Overall and Subcomponent Score at Week 8 or FOT Evaluation
NCT00384033 (9) [back to overview]	Number of Participants With Categorical Scores on CGI-Improvement (CGI-I) Score at Week 8 or FOT Evaluation
NCT00384033 (9) [back to overview]	Change From Baseline in Mean CGI-S Score at Week 8 or FOT Evaluation
NCT00384033 (9) [back to overview]	Change From Baseline in Covi Anxiety Scale at Week 8 or FOT Evaluation
NCT00384033 (9) [back to overview]	Change From Baseline in HAM-D6 Total Score at Week 8 or FOT Evaluation
NCT00385671 (48) [back to overview]	Categorical Change From Baseline to 12 Weeks in Sexual Functioning Questionnaire (CSFQ) Total Score and Subscale Scores
NCT00385671 (48) [back to overview]	Categorical Change From Baseline to 12 Weeks in Number of Patients Using Health Care as Measured by the Resource Utilization Scale
NCT00385671 (48) [back to overview]	Categorial Change From Baseline to 12 Weeks in Portland Neurotoxicity Scale - Total Score and Subscale Scores
NCT00385671 (48) [back to overview]	Time to First ≥ 30% Reduction in Weekly Mean 24 Hour Average Pain Score
NCT00385671 (48) [back to overview]	Time to First ≥ 2 Points Reduction in Weekly Mean 24 Hour Average Pain Score
NCT00385671 (48) [back to overview]	Summary of Number of Participants Who Discontinued
NCT00385671 (48) [back to overview]	Patient's Global Impression of Improvement Scale (PGI - Improvement) at 12 Weeks
NCT00385671 (48) [back to overview]	Discontinuations for Abnormal Laboratory Analytes, Vital Signs, Overall and for Each Measure
NCT00385671 (48) [back to overview]	Number of Participants With Treatment-Emergent Elevated Heart Rate
NCT00385671 (48) [back to overview]	Number of Participants With a ≥ 2-points Reduction on the Weekly Average of the Daily 24-hour Average Pain Scale at 12 Weeks
NCT00385671 (48) [back to overview]	Number of Participants With ≥ 30% Reduction in the Weekly Mean 24 Hour Average Pain Score at 12 Weeks
NCT00385671 (48) [back to overview]	Mean Change From Baseline to 12 Weeks in Weekly Mean of the Daily Worst Pain Severity Score
NCT00385671 (48) [back to overview]	Mean Change From Baseline to 12 Weeks in Weekly Mean of Nighttime Pain Severity
NCT00385671 (48) [back to overview]	Mean Change From Baseline to 12 Weeks in Weekly Mean of Daily 24 Hour Average Pain Score, Pregabalin Compared With Duloxetine
NCT00385671 (48) [back to overview]	Mean Change From Baseline to 12 Weeks in Weekly Mean of Daily 24 Hour Average Pain Score, Duloxetine Compared With Duloxetine+Gabapentin
NCT00385671 (48) [back to overview]	Number of Patients With a Reduction of ≥ 50% in Weekly Mean of 24 Hour Average Pain Score
NCT00385671 (48) [back to overview]	Mean Change From Baseline to 12 Weeks in Body Weight
NCT00385671 (48) [back to overview]	Mean Change From Baseline to 12 Weeks in Beck Depression Inventory II (BDI-II) Total Score
NCT00385671 (48) [back to overview]	Mean Change From Baseline to 12 Weeks in Brief Pain Inventory (BPI) - Interference With Sleep
NCT00385671 (48) [back to overview]	Mean Change From Baseline to 12 Weeks in Brief Pain Inventory (BPI) - Interference With Relations With Other People
NCT00385671 (48) [back to overview]	Mean Change From Baseline to 12 Weeks in Brief Pain Inventory (BPI) - Interference With Normal Work
NCT00385671 (48) [back to overview]	Mean Change From Baseline to 12 Weeks in Brief Pain Inventory (BPI) - Interference With Mood
NCT00385671 (48) [back to overview]	Mean Change From Baseline to 12 Weeks in Brief Pain Inventory (BPI) - Interference With Enjoyment of Life
NCT00385671 (48) [back to overview]	Mean Change From Baseline to 12 Weeks in Blood Pressure
NCT00385671 (48) [back to overview]	Mean Change From Baseline to 12 Weeks in Heart Rate
NCT00385671 (48) [back to overview]	Mean Change From Baseline to 12 Weeks in Brief Pain Inventory (BPI) - Severity: Least Pain
NCT00385671 (48) [back to overview]	Weekly Mean Change in 24 Hour Average Pain Severity by Week by Gabapentin Exposure Subgroup (de Novo Versus Prior Use)
NCT00385671 (48) [back to overview]	Weekly Mean Change From Baseline to 12 Weeks in 24 Hour Average Pain Severity - Only Participants Who Adhered to Key Protocol Requirements (Per-Protocol Population)
NCT00385671 (48) [back to overview]	Summary of Adverse Events and Serious Adverse Events Leading to Discontinuation
NCT00385671 (48) [back to overview]	Path Analysis of Improvement in Pain Through Improvement in Depressive Symptoms
NCT00385671 (48) [back to overview]	Number of Patients With Treatment-Emergent Elevated Laboratory Analytes
NCT00385671 (48) [back to overview]	Number of Participants With Treatment-emergent Elevated Blood Pressure
NCT00385671 (48) [back to overview]	Number of Participants With Treatment-Emergent Changes in Body Weight
NCT00385671 (48) [back to overview]	Mean Change From Baseline to 12 Weeks in Total Bilirubin
NCT00385671 (48) [back to overview]	Mean Change From Baseline to 12 Weeks in Sheehan Disability Scale (SDS) - Total Score and Scores for Items 1 to 3
NCT00385671 (48) [back to overview]	Mean Change From Baseline to 12 Weeks in Sexual Functioning Questionnaire (CSFQ) Total Score and Subscale Scores
NCT00385671 (48) [back to overview]	Mean Change From Baseline to 12 Weeks in Portland Neurotoxicity Scale - Total Score and Subscale Scores
NCT00385671 (48) [back to overview]	Mean Change From Baseline to 12 Weeks in Leeds Sleep Evaluation Questionnaire (LSEQ) Subscales of Ease of Going to Sleep (GTS), Awakening (AFS), and Behavior Following Wakefulness (BFW), Quality of Sleep (QOS)
NCT00385671 (48) [back to overview]	Mean Change From Baseline to 12 Weeks in Hepatic Enzyme Serum Levels
NCT00385671 (48) [back to overview]	Mean Change From Baseline to 12 Weeks in Hemoglobin A1C
NCT00385671 (48) [back to overview]	Mean Change From Baseline to 12 Weeks in Fasting Plasma Glucose
NCT00385671 (48) [back to overview]	Mean Change From Baseline to 12 Weeks in Clinical Global Impression of Severity Scale (CGI Severity)
NCT00385671 (48) [back to overview]	Mean Change From Baseline to 12 Weeks in Brief Pain Inventory (BPI) - Severity: Worst Pain
NCT00385671 (48) [back to overview]	Mean Change From Baseline to 12 Weeks in Brief Pain Inventory (BPI) - Severity: Pain Right Now
NCT00385671 (48) [back to overview]	Mean Change From Baseline to 12 Weeks in Brief Pain Inventory (BPI) - Severity: 24-hour Average Pain
NCT00385671 (48) [back to overview]	Mean Change From Baseline to 12 Weeks in Brief Pain Inventory (BPI) - Mean Interference Score
NCT00385671 (48) [back to overview]	Mean Change From Baseline to 12 Weeks in Brief Pain Inventory (BPI) - Interference: With General Activity
NCT00385671 (48) [back to overview]	Mean Change From Baseline to 12 Weeks in Brief Pain Inventory (BPI) - Interference With Walking Ability
NCT00388414 (2) [back to overview]	Pain
NCT00388414 (2) [back to overview]	Neural Correlates of Pain Relief
NCT00398632 (2) [back to overview]	Global Clinical Impressions Improvement Score re Sexual Functioning
NCT00398632 (2) [back to overview]	Count of Patients With Remission of Depressive Symptoms According to the Inventory for Depressive Symptomology-Clinician Rated (IDS-C) at End of Study
NCT00401258 (8) [back to overview]	Brief Pain Inventory
NCT00401258 (8) [back to overview]	Short Form McGill Pain Questionnaire
NCT00401258 (8) [back to overview]	Irritable Bowel Syndrome-Quality of Life Scale
NCT00401258 (8) [back to overview]	Hamilton Depression Rating Scale
NCT00401258 (8) [back to overview]	Clinical Global Impression Scale
NCT00401258 (8) [back to overview]	Hamilton Anxiety Rating Scale
NCT00401258 (8) [back to overview]	Sheehan Disability Scale
NCT00401258 (8) [back to overview]	Abdominal Pain, as Determined by Daily Pain Diaries (Patterned After Item 3 From the Brief Pain Inventory; Cleeland and Ryan, 1994).
NCT00406848 (28) [back to overview]	Probability of Remission as Measured by the HAMD-17 Total Score ≤7 and ≤10
NCT00406848 (28) [back to overview]	Patient's Global Impression of Improvement (PGI-I) at 13 Weeks and 25 Weeks
NCT00406848 (28) [back to overview]	Number of Participants With Successful Treatment Outcome
NCT00406848 (28) [back to overview]	Number of Participants With Abnormal Vital Signs and Weight at Any Time During the Study
NCT00406848 (28) [back to overview]	Number of Participants With Abnormal Laboratory Values - Low Leukocyte Count
NCT00406848 (28) [back to overview]	Number of Participants Experiencing Sustained Hypertension (SH) or Orthostatic Hypotension (OH)
NCT00406848 (28) [back to overview]	Change From Baseline on the 30-item Geriatric Depression Scale (GDS)
NCT00406848 (28) [back to overview]	Change From Baseline on Cognitive Test Scores: Verbal Learning and Recall Test (VLRT), Symbol Digit Substitution Test (SDST), Trail Making Test (Part B), 2-Digit Cancellation Test (2DCT), and the Composite Cognitive Score Derived From the Above Scores
NCT00406848 (28) [back to overview]	Change From Baseline in Weight
NCT00406848 (28) [back to overview]	Change From Baseline in the Quality of Life, Enjoyment, and Satisfaction Questionnaire (Q-LES-Q-SF)
NCT00406848 (28) [back to overview]	Change From Baseline in the Mini-Mental State Exam (MMSE)
NCT00406848 (28) [back to overview]	Change From Baseline in the HAMD-17 Total Score, Subscales, and Individual Items
NCT00406848 (28) [back to overview]	Change From Baseline in the Clinical Global Impression-Severity (CGI-S)
NCT00406848 (28) [back to overview]	Change From Baseline in the Brief Pain Inventory (BPI) Severity and Interference Scores
NCT00406848 (28) [back to overview]	Change From Baseline in Supine Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
NCT00406848 (28) [back to overview]	Change From Baseline in Pulse Rate
NCT00406848 (28) [back to overview]	Change From Baseline in Laboratory Values - Uric Acid
NCT00406848 (28) [back to overview]	Change From Baseline in Laboratory Values - Platelet Count
NCT00406848 (28) [back to overview]	Change From Baseline in Laboratory Values - Hemoglobin, Mean Cell Hemoglobin Concentration (MCHC)
NCT00406848 (28) [back to overview]	Change From Baseline in Laboratory Values - Erythrocyte Count
NCT00406848 (28) [back to overview]	Change From Baseline in Laboratory Values - Chloride and Fasting Glucose
NCT00406848 (28) [back to overview]	Change From Baseline in Electrocardiograms
NCT00406848 (28) [back to overview]	Probability of Efficacy Onset as Measured by at Least 20% Sustained Reduction From Baseline in the HAMD-17 Maier Subscale at Week 3
NCT00406848 (28) [back to overview]	Change From Baseline to 13 Weeks in Hamilton Depression Rating Scale (HAMD-17) Maier Subscale
NCT00406848 (28) [back to overview]	Change From Baseline in the Numeric Rating Scales (NRS) for Pain Item Scores
NCT00406848 (28) [back to overview]	Summary of Adverse Events and Serious Adverse Events Leading to Discontinuation
NCT00406848 (28) [back to overview]	Probability of Response at Endpoint as Measured by ≥50% Improvement in the HAMD-17 Total Score
NCT00406848 (28) [back to overview]	Probability of Remission as Measured by the HAMD-17 Total Score ≤7 and ≤10 by Medical Comorbidity Severity as Assessed by the Cumulative Illness Rating Scale-Geriatric Version (CIRS-G)
NCT00408421 (35) [back to overview]	Weekly Change From Baseline in the 24-Hour Average Pain Rating Using an 11-Point Numerical Likert Scale Patient Diary
NCT00408421 (35) [back to overview]	Change From Baseline to 13 Week Endpoint in Brief Pain Inventory Interference Score - Sleep
NCT00408421 (35) [back to overview]	Change From Baseline to 13 Week Endpoint in Brief Pain Inventory Interference Score - Walking Ability
NCT00408421 (35) [back to overview]	Change From Baseline to 13 Week Endpoint in Clinical Global Impression of Severity
NCT00408421 (35) [back to overview]	Change From Baseline to 13 Week Endpoint in Euro-Quality of Life - 5 Dimensions (EQ-5D): US Based Index Score
NCT00408421 (35) [back to overview]	Change From Baseline to 13 Week Endpoint in Hospital Anxiety and Depression Scale (HADS) - Anxiety Subscale
NCT00408421 (35) [back to overview]	Change From Baseline to 13 Week Endpoint in Medical Outcomes Study Short Form-36 (SF-36) - Mental Health Component Summary
NCT00408421 (35) [back to overview]	Change From Baseline to 13 Week Endpoint in Medical Outcomes Study Short Form-36 (SF-36) - Physical Component Summary
NCT00408421 (35) [back to overview]	Change From Baseline to 13 Week Endpoint in Vital Signs - Blood Pressure (BP) Systolic
NCT00408421 (35) [back to overview]	Change From Baseline to 13 Week Endpoint in Vital Signs - Pulse Rate
NCT00408421 (35) [back to overview]	Change From Baseline to 13 Week Endpoint in Brief Pain Inventory Interference Score - Enjoyment of Life
NCT00408421 (35) [back to overview]	Change From Baseline to 13 Week Endpoint in Brief Pain Inventory Interference Score - General Activity
NCT00408421 (35) [back to overview]	Change From Baseline to 13 Week Endpoint in Vital Signs - Weight
NCT00408421 (35) [back to overview]	Change From Baseline to 13 Week Endpoint in Brief Pain Inventory Interference Score - Mood
NCT00408421 (35) [back to overview]	Change From Baseline to 13 Week Endpoint in Weekly Mean of 24-Hour Average Pain in the Re-Randomized Treatment Phase
NCT00408421 (35) [back to overview]	Change From Baseline to 13 Week Endpoint in Weekly Mean of the 24-Hour Worst Pain Score
NCT00408421 (35) [back to overview]	Change From Baseline to 13 Week Endpoint in Western Ontario and McMaster Osteoarthritis Index (WOMAC) - Pain Subscale
NCT00408421 (35) [back to overview]	Change From Baseline to 13 Week Endpoint in Western Ontario and McMaster Osteoarthritis Index (WOMAC) - Physical Function Subscale
NCT00408421 (35) [back to overview]	Change From Baseline to 13 Week Endpoint in Western Ontario and McMaster Osteoarthritis Index (WOMAC) - Stiffness Subscale
NCT00408421 (35) [back to overview]	Weekly Change From Baseline in the 24-Hour Worst Pain Score
NCT00408421 (35) [back to overview]	Change From Baseline to 13 Week Endpoint in Western Ontario and McMaster Osteoarthritis Index (WOMAC) - Total Score
NCT00408421 (35) [back to overview]	Change From Baseline to 13 Week Endpoint in Vital Signs - Blood Pressure (BP) Diastolic
NCT00408421 (35) [back to overview]	Statistically Significant Change From Baseline to 13 Week Endpoint in Laboratory Data - Chemistry Analytes: Alkaline Phosphatase
NCT00408421 (35) [back to overview]	Statistically Significant Change From Baseline to 13 Week Endpoint in Laboratory Data - Chemistry Analytes: Uric Acid
NCT00408421 (35) [back to overview]	Response to Treatment - The Number of Participants With a >=30% Reduction of Weekly Mean in 24-Hour Average Pain Severity Ratings in the Re-Randomized Treatment Phase
NCT00408421 (35) [back to overview]	Response to Treatment - The Number of Participants With a >= 30% Reduction of Weekly Mean in 24-Hour Average Pain Severity Ratings
NCT00408421 (35) [back to overview]	Patient Global Impression of Improvement at 13 Week Endpoint
NCT00408421 (35) [back to overview]	Change From Baseline to 13 Week Endpoint in Brief Pain Inventory Interference Score - Normal Work
NCT00408421 (35) [back to overview]	Change From Baseline to 13 Week Endpoint in Brief Pain Inventory Interference Score - Relations With Other People
NCT00408421 (35) [back to overview]	Change From Baseline to 13 Week Endpoint in Brief Pain Inventory Average Interference
NCT00408421 (35) [back to overview]	Change From Baseline to 13 Week Endpoint in Brief Pain Inventory (BPI) - Worst Pain Score
NCT00408421 (35) [back to overview]	Change From Baseline to 13 Week Endpoint in Brief Pain Inventory - Pain Right Now Score
NCT00408421 (35) [back to overview]	Change From Baseline to 13 Week Endpoint in Brief Pain Inventory - Least Pain Score
NCT00408421 (35) [back to overview]	Change From Baseline to 13 Week Endpoint in Brief Pain Inventory - Average Pain Score
NCT00408421 (35) [back to overview]	Change From Baseline to 13 Week Endpoint in Beck Depression Inventory-II - Total Score
NCT00408876 (61) [back to overview]	Change From Baseline to Week 13 Endpoint in Brief Pain Inventory Severity (BPI-S) - Least Pain Score
NCT00408876 (61) [back to overview]	Response to Treatment, as Defined by a 50% Reduction of Weekly Mean Score in 24-hour Average Pain Severity Ratings, Last Observation Carried Forward
NCT00408876 (61) [back to overview]	Change From Baseline to Week 13 Endpoint in Brief Pain Inventory Severity (BPI-S) - Pain Right Now Score
NCT00408876 (61) [back to overview]	Change From Baseline to Week 13 Endpoint in Brief Pain Inventory Severity (BPI-S) - Worst Pain Score
NCT00408876 (61) [back to overview]	Adverse Events Reported as Reason for Discontinuation
NCT00408876 (61) [back to overview]	Change From Baseline to Week 2 in Weekly Mean of the 24-Hour Average Pain Scores
NCT00408876 (61) [back to overview]	Change From Baseline to Week 13 Endpoint in Weekly Mean of the 24-Hour Average Pain Scores
NCT00408876 (61) [back to overview]	Change From Baseline to Week 13 Endpoint in Vital Signs - Weight
NCT00408876 (61) [back to overview]	Change From Baseline to Week 13 Endpoint in Vital Signs - Systolic Blood Pressure
NCT00408876 (61) [back to overview]	Change From Baseline to Week 13 Endpoint in Vital Signs - Pulse Rate
NCT00408876 (61) [back to overview]	Change From Baseline to Week 13 Endpoint in Vital Signs - Diastolic Blood Pressure
NCT00408876 (61) [back to overview]	Change From Baseline to Week 13 Endpoint in the Euro-Quality of Life Questionnaire - 5 Dimension - US Based Index Score
NCT00408876 (61) [back to overview]	Change From Baseline to Week 13 Endpoint in the 36-item Short-Form Health Survey (SF36)- Mental Component Summary (MCS)
NCT00408876 (61) [back to overview]	Change From Baseline to Week 13 Endpoint in the 11-point Likert Scale, Weekly Mean of Worst Pain Score
NCT00408876 (61) [back to overview]	Change From Baseline to Week 13 Endpoint in the 11-point Likert Scale, Weekly Mean 24-Hour Night Pain Score
NCT00408876 (61) [back to overview]	Change From Baseline to Week 13 Endpoint in Beck Depression Inventory-II Total Score
NCT00408876 (61) [back to overview]	Change From Baseline to Week 13 Endpoint in Roland-Morris Disability Questionnaire (RMDQ) Total Score
NCT00408876 (61) [back to overview]	Change From Baseline to Week 13 Endpoint in Laboratory Assessments - Alkaline Phosphatase
NCT00408876 (61) [back to overview]	Change From Baseline to Week 13 Endpoint in Laboratory Assessment - Potassium
NCT00408876 (61) [back to overview]	Change From Baseline to Week 13 Endpoint in Laboratory Assessment - Creatinine
NCT00408876 (61) [back to overview]	Change From Baseline to Week 13 Endpoint in Laboratory Assessment - Cholesterol
NCT00408876 (61) [back to overview]	Change From Baseline to Week 13 Endpoint in Laboratory Assessment - Chloride
NCT00408876 (61) [back to overview]	Change From Baseline to Week 13 Endpoint in Laboratory Assessment - Bilirubin, Total
NCT00408876 (61) [back to overview]	Change From Baseline to Week 13 Endpoint in Laboratory Assessment - Bilirubin, Direct
NCT00408876 (61) [back to overview]	Change From Baseline to Week 13 Endpoint in Laboratory Assessment - Bicarbonate, HCO3
NCT00408876 (61) [back to overview]	Change From Baseline to Week 13 Endpoint in Hospital Anxiety and Depression Scale (HADS) Anxiety Subscale
NCT00408876 (61) [back to overview]	Change From Baseline to Week 13 Endpoint in Clinical Global Impression of Severity
NCT00408876 (61) [back to overview]	Change From Baseline to Week 13 Endpoint in Laboratory Assessment - Uric Acid
NCT00408876 (61) [back to overview]	Change From Baseline to Week 8 in Weekly Mean of the 24-Hour Average Pain Scores
NCT00408876 (61) [back to overview]	Change From Baseline to Week 7 in Weekly Mean of the 24-Hour Average Pain Scores
NCT00408876 (61) [back to overview]	Change From Baseline to Week 6 in Weekly Mean of the 24-Hour Average Pain Scores
NCT00408876 (61) [back to overview]	Change From Baseline to Week 5 in Weekly Mean of the 24-Hour Average Pain Scores
NCT00408876 (61) [back to overview]	Change From Baseline to Week 4 in Weekly Mean of the 24-Hour Average Pain Scores
NCT00408876 (61) [back to overview]	Change From Baseline to Week 3 in Weekly Mean of the 24-Hour Average Pain Scores
NCT00408876 (61) [back to overview]	Change From Baseline to Week 13 Endpoint in Brief Pain Inventory Severity (BPI-S) - Average Pain Score
NCT00408876 (61) [back to overview]	Change From Baseline to Week 13 Endpoint in Brief Pain Inventory Interference (BPI-I) Score - Walking Ability
NCT00408876 (61) [back to overview]	Change From Baseline to Week 13 Endpoint in Brief Pain Inventory Interference (BPI-I) Score - Sleep
NCT00408876 (61) [back to overview]	Change From Baseline to Week 13 Endpoint in Brief Pain Inventory Interference (BPI-I) Score - Relations With Other People
NCT00408876 (61) [back to overview]	Change From Baseline to Week 13 Endpoint in Brief Pain Inventory Interference (BPI-I) Score - Normal Work
NCT00408876 (61) [back to overview]	Change From Baseline to Week 13 Endpoint in Brief Pain Inventory Interference (BPI-I) Score - Mood
NCT00408876 (61) [back to overview]	Change From Baseline to Week 13 Endpoint in Brief Pain Inventory Interference (BPI-I) Score - General Activity
NCT00408876 (61) [back to overview]	Change From Baseline to Week 13 Endpoint in Brief Pain Inventory Interference (BPI-I) Score - Enjoyment of Life
NCT00408876 (61) [back to overview]	Change From Baseline to Week 13 Endpoint in Brief Pain Inventory Interference (BPI-I) Score - Average Interference
NCT00408876 (61) [back to overview]	Change From Baseline to Week 13 Endpoint in Athens Insomnia Scale
NCT00408876 (61) [back to overview]	Change From Baseline to Week 13 Endpoint in 36-Item Short-Form Health Survey (SF36) - Vitality
NCT00408876 (61) [back to overview]	Change From Baseline to Week 13 Endpoint in 36-Item Short-Form Health Survey (SF36) - Social Functioning
NCT00408876 (61) [back to overview]	Change From Baseline to Week 13 Endpoint in 36-Item Short-Form Health Survey (SF36) - Role-Physical
NCT00408876 (61) [back to overview]	Change From Baseline to Week 13 Endpoint in 36-Item Short-Form Health Survey (SF36) - Role-Emotional
NCT00408876 (61) [back to overview]	Change From Baseline to Week 13 Endpoint in 36-Item Short-Form Health Survey (SF36) - Physical Functioning
NCT00408876 (61) [back to overview]	Change From Baseline to Week 13 Endpoint in 36-Item Short-Form Health Survey (SF36) - Physical Component Summary (PCS)
NCT00408876 (61) [back to overview]	Change From Baseline to Week 13 Endpoint in 36-Item Short-Form Health Survey (SF36) - Mental Health
NCT00408876 (61) [back to overview]	Change From Baseline to Week 13 Endpoint in 36-Item Short-Form Health Survey (SF36) - General Health
NCT00408876 (61) [back to overview]	Change From Baseline to Week 13 Endpoint in 36-Item Short-Form Health Survey (SF36) - Bodily Pain
NCT00408876 (61) [back to overview]	Change From Baseline to Week 12 in Weekly Mean of the 24-Hour Average Pain Scores
NCT00408876 (61) [back to overview]	Change From Baseline to Week 11 in Weekly Mean of the 24-Hour Average Pain Scores
NCT00408876 (61) [back to overview]	Change From Baseline to Week 10 in Weekly Mean of the 24-Hour Average Pain Scores
NCT00408876 (61) [back to overview]	Change From Baseline to Week 1 in Weekly Mean of the 24-hour Average Pain Scores
NCT00408876 (61) [back to overview]	Change From Baseline to 13 Week Endpoint in Laboratory Assessments - Alanine Transaminase
NCT00408876 (61) [back to overview]	Response to Treatment, as Defined by a 30% Reduction of Weekly Mean Score in 24-hour Average Pain Severity Ratings, Last Observation Carried Forward
NCT00408876 (61) [back to overview]	Patient's Global Impression - Improvement (PGI-I) at Week 13 Endpoint
NCT00408876 (61) [back to overview]	Change From Baseline to Week 9 in Weekly Mean of the 24-Hour Average Pain Scores
NCT00408993 (13) [back to overview]	Change From Baseline to 12 Week Endpoint in Athens Insomnia Scale 8-item and 5-item
NCT00408993 (13) [back to overview]	Number of Participants Discontinuing Due to Adverse Events
NCT00408993 (13) [back to overview]	Change From Baseline to 12 Week Endpoint in EuroQoL Questionnaire - 5 Dimensions (EQ-5D) (US Based Index Score)
NCT00408993 (13) [back to overview]	Change From Baseline to 12 Week Endpoint in Clinical Global Impression of Severity
NCT00408993 (13) [back to overview]	Change From Baseline to 12 Week Endpoint in Brief Pain Inventory 24-hour Average Pain Score
NCT00408993 (13) [back to overview]	Vital Signs - Weight
NCT00408993 (13) [back to overview]	Time Course of Change in Patient Global Impression - Improvement Scale
NCT00408993 (13) [back to overview]	Vital Signs - Blood Pressure
NCT00408993 (13) [back to overview]	Change From Baseline to 12 Week Endpoint in Brief Pain Inventory (BPI) Worst Pain, Least Pain, and Current Pain Severity and Average Interference Scores
NCT00408993 (13) [back to overview]	Vital Signs - Pulse Rate
NCT00408993 (13) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events Reported in >5% of Either Treatment Group by Time of Dosing (Morning or Evening)
NCT00408993 (13) [back to overview]	Statistically Significant Change From Baseline to 12 Week Endpoint in Laboratory Measures - Chloride, High Density Lipoprotein, Sodium, and Triglycerides
NCT00408993 (13) [back to overview]	Statistically Significant Change From Baseline to 12 Week Endpoint in Laboratory Measures - Uric Acid
NCT00422162 (16) [back to overview]	Utilization of Allowed Hypnotic and/or Anxiolytic Co-Medication
NCT00422162 (16) [back to overview]	Reason for Living (RFL) Questionnaire Mean Scores at Baseline and Week 8
NCT00422162 (16) [back to overview]	Percentage of Responders
NCT00422162 (16) [back to overview]	Change in 6-Item Hamilton Depression Scale (HAMD-6) Total Scores From Baseline
NCT00422162 (16) [back to overview]	Patients Reaching Remission
NCT00422162 (16) [back to overview]	Patient Global Impression of Improvement (PGI-I) Score at Each Visit
NCT00422162 (16) [back to overview]	Number of Patients With Potentially Clinically Significant Laboratory Findings
NCT00422162 (16) [back to overview]	Number of Participants Experiencing High Values for Vital Signs at Any Time During the Study
NCT00422162 (16) [back to overview]	Hamilton Anxiety Scale (HAMA) Score at Baseline and Weeks 4 and 8
NCT00422162 (16) [back to overview]	Evaluation of Rescue Options Based on Changes in the Montgomery-Asberg Depression Rating Scale (MADRS) and the 6-Item Hamilton Depression Scale (HAMD-6)
NCT00422162 (16) [back to overview]	Discontinuations Due to Adverse Events (AE)
NCT00422162 (16) [back to overview]	Clinical Global Impression of Severity (CGI-S) Scores at Each Visit
NCT00422162 (16) [back to overview]	Clinical Global Impression of Improvement (CGI-I) at Each Visit
NCT00422162 (16) [back to overview]	Change From Baseline to 4 Week Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
NCT00422162 (16) [back to overview]	Change in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score From Baseline
NCT00422162 (16) [back to overview]	Change From Baseline to Week 4 and Week 8 in Weight
NCT00424593 (21) [back to overview]	Change From Baseline to Week 13 and Week 54 Endpoints in Vital Signs: Blood Pressure
NCT00424593 (21) [back to overview]	Change From Baseline to Week 13 and Week 54 Endpoints in Vital Signs: Pulse Rate
NCT00424593 (21) [back to overview]	Change From Baseline to Week 13 and Week 54 Endpoints in Vital Signs: Weight
NCT00424593 (21) [back to overview]	Change From Baseline to Week 13 and Week 54 Endpoints in Work Productivity and Activity Impairment Instrument (WPAI) Scores
NCT00424593 (21) [back to overview]	Change From Baseline to Week 13 Endpoint in 36-Item Short-Form Health Survey (SF-36)
NCT00424593 (21) [back to overview]	Change From Baseline to Week 13 Endpoint in EuroQoL Questionnaire - 5 Dimension (EQ-5D)
NCT00424593 (21) [back to overview]	Change From Baseline to Week 13 Endpoint in Hospital Anxiety and Depression Scale (HADS) Scores
NCT00424593 (21) [back to overview]	Change From Baseline to Week 13 Endpoint in Weekly Mean of 24-hour Average Pain, Night Pain and Worst Pain by 11-Point Likert Scale
NCT00424593 (21) [back to overview]	Laboratory Assessments That Were Statistically Significantly Different Between Treatment Groups in Change From Baseline to Week 13 Endpoint: Bicarbonate
NCT00424593 (21) [back to overview]	Laboratory Assessments That Were Statistically Significantly Different Between Treatment Groups in Change From Baseline to Week 13 Endpoint: Uric Acid
NCT00424593 (21) [back to overview]	Serious Adverse Events During the Dose-Blind Extension Phase
NCT00424593 (21) [back to overview]	Treatment-Emergent Adverse Events Occurring in at Least 5 Percent of Patients During the Dose-Blind Extension Phase
NCT00424593 (21) [back to overview]	Change From Baseline to Week 13 and Week 54 Endpoints in Beck Depression Inventory (BDI-II) Total Scores
NCT00424593 (21) [back to overview]	Change From Baseline to Week 13 in Brief Pain Inventory (BPI), 24-hour Average Pain Scores
NCT00424593 (21) [back to overview]	Number of Participants Who Responded to Treatment at Week 13 Endpoint Based on 30% Score Reduction Criteria
NCT00424593 (21) [back to overview]	Number of Participants Who Responded to Treatment at Week 13 Endpoint Based on 50% Score Reduction Criteria
NCT00424593 (21) [back to overview]	Patient's Global Impression of Improvement (PGI-I)
NCT00424593 (21) [back to overview]	Change From Baseline to Week 13 and Week 54 Endpoints in Athens Insomnia Scale
NCT00424593 (21) [back to overview]	Change From Baseline to Week 13 and Week 54 Endpoints in Brief Pain Inventory - Severity (BPI-S) and Interference (BPI-I) Scores
NCT00424593 (21) [back to overview]	Change From Baseline to Week 13 and Week 54 Endpoints in Clinical Global Impression of Severity (CGI-Severity)
NCT00424593 (21) [back to overview]	Change From Baseline to Week 13 and Week 54 Endpoints in Roland Morris Disability Questionnaire-24 Item (RMDQ-24) Total Score
NCT00433290 (33) [back to overview]	Change From Baseline to 13 Week Endpoint in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Stiffness Subscale
NCT00433290 (33) [back to overview]	Change From Baseline to 13 Week Endpoint in Brief Pain Inventory Interference: Sleep
NCT00433290 (33) [back to overview]	Change From Baseline to 13 Week Endpoint in Clinical Global Impression of Severity (CGI-S)
NCT00433290 (33) [back to overview]	Mean Values at 13 Week Endpoint in Patient Global Impression of Improvement (PGI-I)
NCT00433290 (33) [back to overview]	Number of Nonresponders at Week 7 Who Responded at Week 13 Endpoint
NCT00433290 (33) [back to overview]	Number of Participants Who Responded to Treatment at 13 Week Endpoint
NCT00433290 (33) [back to overview]	Change From Baseline to 13 Week Endpoint in Vital Signs - Weight
NCT00433290 (33) [back to overview]	Change From Baseline to 13 Week Endpoint in Hospital Anxiety and Depression Scale - Anxiety Subscale (HADS-A)
NCT00433290 (33) [back to overview]	Change From Baseline to 13 Week Endpoint in Brief Pain Inventory Interference: Relations With Other People
NCT00433290 (33) [back to overview]	Adverse Events Reported as Reason for Discontinuation
NCT00433290 (33) [back to overview]	Change From Baseline to 13 Week Endpoint in Brief Pain Inventory Interference: Average Interference
NCT00433290 (33) [back to overview]	Adverse Events Reported as Reason for Discontinuation in Nonresponders
NCT00433290 (33) [back to overview]	Change From Baseline to 13 Week Endpoint in Beck Depression Inventory - II (BDI-II)
NCT00433290 (33) [back to overview]	Change From Baseline to 13 Week Endpoint in Brief Pain Inventory (BPI) Severity: Worst Pain Score
NCT00433290 (33) [back to overview]	Change From Baseline to 13 Week Endpoint in Brief Pain Inventory Interference: Normal Work
NCT00433290 (33) [back to overview]	Change From Baseline to 13 Week Endpoint in Brief Pain Inventory Interference: Mood
NCT00433290 (33) [back to overview]	Statisically Significant Change From Baseline to 13 Week Endpoint in Laboratory Analytes
NCT00433290 (33) [back to overview]	Statisically Significant Change From Baseline to 13 Week Endpoint in Chloride
NCT00433290 (33) [back to overview]	Mean Change From Baseline to 13 Week Endpoint in Medical Outcomes Study Short Form-36 (SF-36) Medical Component Summary (MCS), Physical Component Summary (PCS), and Domain Scores
NCT00433290 (33) [back to overview]	Change in Brief Pain Inventory (BPI) 24-hour Average Rating
NCT00433290 (33) [back to overview]	Change From Baseline to 13 Week Endpoint in Brief Pain Inventory Interference: General Activity
NCT00433290 (33) [back to overview]	Change From Baseline to 13 Week Endpoint in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale
NCT00433290 (33) [back to overview]	Change From Baseline to 13 Week Endpoint in Western Ontario and McMaster Osteoarthritis Index (WOMAC) Physical Function Subscale
NCT00433290 (33) [back to overview]	Change From Baseline to 13 Week Endpoint in Weekly Mean of the 24-Hour Average Pain and Worst Pain Scores
NCT00433290 (33) [back to overview]	Change From Baseline to 13 Week Endpoint in Brief Pain Inventory - Average Pain Score in Nonresponders
NCT00433290 (33) [back to overview]	Change From Baseline to 13 Week Endpoint in Vital Signs - Heart Rate
NCT00433290 (33) [back to overview]	Change From Baseline to 13 Week Endpoint in Vital Signs - Blood Pressure
NCT00433290 (33) [back to overview]	Change From Baseline to 13 Week Endpoint in Brief Pain Inventory Interference: Enjoyment of Life
NCT00433290 (33) [back to overview]	Change From Baseline to 13 Week Endpoint in EuroQoL Questionnaire - 5 Dimension (EQ-5D)
NCT00433290 (33) [back to overview]	Change From Baseline to 13 Week Endpoint in Brief Pain Inventory Severity: Pain Right Now Score
NCT00433290 (33) [back to overview]	Change From Baseline to 13 Week Endpoint in Brief Pain Inventory Severity: Least Pain Score
NCT00433290 (33) [back to overview]	Change From Baseline to 13 Week Endpoint in Brief Pain Inventory Severity: Average Pain Score
NCT00433290 (33) [back to overview]	Change From Baseline to 13 Week Endpoint in Brief Pain Inventory Interference: Walking Ability
NCT00437125 (15) [back to overview]	Average Change From Baseline to 12 Weeks in Blood Pressure
NCT00437125 (15) [back to overview]	Average Change From Baseline to 12 Weeks in Heart Rate
NCT00437125 (15) [back to overview]	Patient's Global Impression-Improvement at Week 12
NCT00437125 (15) [back to overview]	Change From Baseline to 12 Weeks on the Unified Parkinson's Disease Rating Scale (UPDRS) Total Score
NCT00437125 (15) [back to overview]	Change From Baseline to 12 Weeks on the UKU (Udvalg for Kliniske Undersogelser: Committee for Clinical Investigations) Side Effect Rating Scale
NCT00437125 (15) [back to overview]	Change From Baseline to 12 Weeks in Parkinson Disease Questionnaire - 39 Item Version (PDQ-39) Total Score
NCT00437125 (15) [back to overview]	Change From Baseline to 12 Weeks in Visual Analog Scale (VAS)
NCT00437125 (15) [back to overview]	Change From Baseline to 12 Weeks on the 17-item Hamilton Depression Rating Scale (HAMD-17) Total Score
NCT00437125 (15) [back to overview]	Change From Baseline to 12 Weeks on the Clinical Global Impression-Severity Scale
NCT00437125 (15) [back to overview]	Change From Baseline on the Pittsburgh Sleep Quality Index (PSQI)
NCT00437125 (15) [back to overview]	Number of Participants With Abnormal Electrocardiograms (ECG) During the 12 Week Study
NCT00437125 (15) [back to overview]	Number of Participants Who Responded to Treatment by 12 Weeks
NCT00437125 (15) [back to overview]	Number of Participants Who Reached Remission by 12 Weeks
NCT00437125 (15) [back to overview]	Number of Participants Reporting Serious Adverse Events or Other Adverse Events Leading Either to Discontinuation or to Death
NCT00437125 (15) [back to overview]	Change From Baseline to 12 Weeks in Beck Depression Inventory (BDI) Total Score
NCT00438971 (8) [back to overview]	Panic Attack Scale (PAS)
NCT00438971 (8) [back to overview]	Sheehan Disability Scale (SDS)
NCT00438971 (8) [back to overview]	Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q)
NCT00438971 (8) [back to overview]	Panic Disorder Severity Scale (PDSS)
NCT00438971 (8) [back to overview]	Montgomery Asberg Depression Rating Scale (MADRS)
NCT00438971 (8) [back to overview]	Longitudinal Interval Follow-up Evaluation Range of Impaired Functioning Tool (LIFE-RIFT)
NCT00438971 (8) [back to overview]	Clinical Global Impression of Severity Scale (CGI-S)
NCT00438971 (8) [back to overview]	Beck Anxiety Inventory (BAI)
NCT00443352 (1) [back to overview]	Change in Frequency of Migraine Days During the Last 28 Day Interval of the Treatment Period as Compared to the 28 Day Baseline Period.
NCT00457730 (3) [back to overview]	Percent Change in Worst Pain Score
NCT00457730 (3) [back to overview]	Percent Change in Average Pain Score.
NCT00457730 (3) [back to overview]	Global Impression of Change
NCT00464698 (5) [back to overview]	QLESQ (Quality of Life, Enjoyment, and Satisfaction Questionnaire) - First and Last Visit (Week 0 and Week 17)
NCT00464698 (5) [back to overview]	Clinical Global Impressions Scale at Week 3 and Week 17
NCT00464698 (5) [back to overview]	BDI (Beck Depression Inventory) - First and Last Visit (Week 0 and Week 17).
NCT00464698 (5) [back to overview]	BAI (Beck Anxiety Inventory) - First and Last Visit (Week 0 and Week 17)
NCT00464698 (5) [back to overview]	Y-BOCS Scores at 1st and Last Visit
NCT00471315 (2) [back to overview]	The Primary Outcome Measure Was a Patient Global Assessment of Change (PGIC) Scale.
NCT00471315 (2) [back to overview]	Toleration of the Medication as Measured by the Duloxetine Compliance Rate
NCT00489411 (4) [back to overview]	Change in Average Pain From Week 1 to Week 5, as Measured by the BPI-SF Average Pain Severity Item
NCT00489411 (4) [back to overview]	Change in Average Pain From Week 8 to Week 12, as Measured by the BPI-SF Average Pain Severity Item
NCT00489411 (4) [back to overview]	Change in Pain-related Functional Interference Score From Week 1 to Week 5, as Measured by the BPI-SF Interference Score
NCT00489411 (4) [back to overview]	Change in the Total Score of the FACT/COG-NTX From Week 1 to Week 5
NCT00529789 (14) [back to overview]	Change From Baseline to 18 Weeks and 30 Weeks in Children's Depression Rating Scale-Revised (CDRS-R) Total Score
NCT00529789 (14) [back to overview]	Adverse Events Leading to Discontinuation
NCT00529789 (14) [back to overview]	Change From Baseline to 18 Weeks and 30 Weeks in Clinical Global Impressions of Severity Scale (CGI-S)
NCT00529789 (14) [back to overview]	Number of Participants Experiencing Suicidal Ideation or Suicidal Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) During Period IV
NCT00529789 (14) [back to overview]	Number of Participants Meeting Criteria for Potentially Clinically Significant (PCS) Laboratory Analyte Values at Any Time During Period II/III
NCT00529789 (14) [back to overview]	Number of Participants Meeting Criteria for Potentially Clinically Significant (PCS) Laboratory Analyte Values at Any Time During Period IV
NCT00529789 (14) [back to overview]	Number of Participants Meeting Criteria for Potentially Clinically Significant Electrocardiograms at Any Time in Period II/III
NCT00529789 (14) [back to overview]	Number of Participants Meeting Criteria for Potentially Clinically Significant Vital Sign Values at Any Time During Period II/III
NCT00529789 (14) [back to overview]	Number of Participants Meeting Criteria for Potentially Clinically Significant Vital Sign Values at Any Time During Period IV
NCT00529789 (14) [back to overview]	Pharmacokinetics: Summary of Observed Duloxetine Plasma Concentrations Stratified by Duloxetine Dose
NCT00529789 (14) [back to overview]	Number of Participants With Potentially Clinically Significant Electrocardiograms at Any Time in Period IV
NCT00529789 (14) [back to overview]	Number of Participants With Emergence of Suicidal Ideation During Period II/III
NCT00529789 (14) [back to overview]	Number of Participants With Emergence of Suicidal Ideation During Period IV
NCT00529789 (14) [back to overview]	Number of Participants Experiencing Suicidal Ideation or Suicidal Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) During Period II/III
NCT00532480 (1) [back to overview]	17-item Hamilton Depression Rating Scale
NCT00536471 (61) [back to overview]	Change From Baseline to 9 Month Endpoint in Sheehan Disability Scale (SDS) Total Score and Subscores
NCT00536471 (61) [back to overview]	Path Analysis of BPOMS Total Score to Overall Improvement in HAMD-24 Item 7
NCT00536471 (61) [back to overview]	Path Analysis of BPOMS Total Score to Overall Improvement in HAMD-24 Item 7 - Percent of Total Effect
NCT00536471 (61) [back to overview]	Path Analysis of BPOMS Total Score to Overall Improvement in SDS Total Score - Percent of Total Effect
NCT00536471 (61) [back to overview]	Path Analysis of BPOMS Total Score to Overall Improvement in Sheehan Disability Scale (SDS) Total Score
NCT00536471 (61) [back to overview]	Probability of Remission at 12 Week Endpoint and Sustained Remission at 9 Month Endpoint
NCT00536471 (61) [back to overview]	Probability of Response at 12 Week Endpoint
NCT00536471 (61) [back to overview]	Statistically Significant Abnormal Laboratory Values at 9 Month Endpoint
NCT00536471 (61) [back to overview]	Statistically Significant Abnormal Laboratory Values at Anytime During 9 Months
NCT00536471 (61) [back to overview]	Statistically Significant Abnormal Laboratory Values at Anytime/12 Week Endpoint
NCT00536471 (61) [back to overview]	Statistically Significant Changes in Baseline to 12 Week and 9 Month Endpoints Laboratory Values - Bilirubin, Creatinine, Uric Acid
NCT00536471 (61) [back to overview]	Statistically Significant Changes in Baseline to 12 Week and 9 Month Endpoints Laboratory Values - Chloride, Urea Nitrogen, Cholesterol, Sodium
NCT00536471 (61) [back to overview]	Statistically Significant Changes in Baseline to 12 Week and 9 Month Endpoints Laboratory Values - Hematocrit
NCT00536471 (61) [back to overview]	Statistically Significant Changes in Baseline to 12 Week and 9 Month Endpoints Laboratory Values - Mean Cell Volume (MCV)
NCT00536471 (61) [back to overview]	Statistically Significant Changes in Baseline to 12 Week and 9 Month Endpoints Laboratory Values - Platelet Count
NCT00536471 (61) [back to overview]	Summary of Adverse Events Leading to Discontinuation
NCT00536471 (61) [back to overview]	Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 21:Obsessional and Compulsive Symptoms
NCT00536471 (61) [back to overview]	Change From Baseline to 8 Weeks in 24-Item Hamilton Depression Rating Scale (HAMD-24) Item 7 (Work and Activities)
NCT00536471 (61) [back to overview]	Change From Baseline to 9 Month Endpoint in HAMD-24 - Item 7:Work and Activities
NCT00536471 (61) [back to overview]	Statistically Significant Changes in Baseline to 9 Month Endpoint Laboratory Values - Alkaline Phosphatase
NCT00536471 (61) [back to overview]	Statistically Significant Changes in Baseline to 9 Month Endpoint Laboratory Values - Hemoglobin
NCT00536471 (61) [back to overview]	Abnormal Vital Signs at 12 Week Endpoint
NCT00536471 (61) [back to overview]	Abnormal Vital Signs at 9 Month Endpoint
NCT00536471 (61) [back to overview]	Abnormal Vital Signs at Anytime Over 12 Weeks
NCT00536471 (61) [back to overview]	Abnormal Vital Signs at Anytime Over 9 Months
NCT00536471 (61) [back to overview]	Change From Baseline to 12 Week and 9 Month Endpoint in the Clinical Global Impression-Severity Scale (CGI-S)
NCT00536471 (61) [back to overview]	Change From Baseline to 12 Week and 9 Month Endpoints in 16-Item Quick Inventory of Depressive Symptomatology Self Report (QIDS16SR) Total Score
NCT00536471 (61) [back to overview]	Change From Baseline to 12 Week and 9 Month Endpoints in Blood Pressure
NCT00536471 (61) [back to overview]	Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 10:Anxiety (Psychic)
NCT00536471 (61) [back to overview]	Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 11:Anxiety (Somatic)
NCT00536471 (61) [back to overview]	Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 12:Somatic Symptoms/Gastrointestinal
NCT00536471 (61) [back to overview]	Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 13:Somatic Symptoms/General
NCT00536471 (61) [back to overview]	Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 14:Genital Symptoms
NCT00536471 (61) [back to overview]	Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 15:Hypochondriasis
NCT00536471 (61) [back to overview]	Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 16:Loss of Weight
NCT00536471 (61) [back to overview]	Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 17:Insight
NCT00536471 (61) [back to overview]	Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 18A:Diurnal Variation
NCT00536471 (61) [back to overview]	Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 18B:Diurnal Variation-Severity
NCT00536471 (61) [back to overview]	Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 19: Depersonalization and Derealization
NCT00536471 (61) [back to overview]	Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 2:Feelings of Guilt
NCT00536471 (61) [back to overview]	Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 20:Paranoid Symptoms
NCT00536471 (61) [back to overview]	Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 22B:Helplessness
NCT00536471 (61) [back to overview]	Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 23B:Hopelessness
NCT00536471 (61) [back to overview]	Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 24B:Worthlessness
NCT00536471 (61) [back to overview]	Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 3:Suicide
NCT00536471 (61) [back to overview]	Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 4:Insomnia Early
NCT00536471 (61) [back to overview]	Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 5:Insomnia Middle
NCT00536471 (61) [back to overview]	Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 6:Insomnia Late
NCT00536471 (61) [back to overview]	Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 8:Retardation
NCT00536471 (61) [back to overview]	Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 9:Agitation
NCT00536471 (61) [back to overview]	Change From Baseline to 12 Week and 9 Month Endpoints in Pain Numerical Rating Scale (NRS)
NCT00536471 (61) [back to overview]	Change From Baseline to 12 Week and 9 Month Endpoints in Pulse Rate
NCT00536471 (61) [back to overview]	Change From Baseline to 12 Week and 9 Month Endpoints in the 17-Item Hamilton Depression Rating Scale (HAMD-17) Total Score and HAMD-24 Subscales (8 Week Endpoint for Maier Subscale)
NCT00536471 (61) [back to overview]	Change From Baseline to 12 Week and 9 Month Endpoints in the HAMD-24 Item 1:Depressed Mood
NCT00536471 (61) [back to overview]	Change From Baseline to 12 Week and 9 Month Endpoints in the HAMD-24 Total Score
NCT00536471 (61) [back to overview]	Change From Baseline to 12 Week and 9 Month Endpoints in the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (MGH-CPFQ)
NCT00536471 (61) [back to overview]	Change From Baseline to 12 Week and 9 Month Endpoints in the Social Adaptation Self-evaluation Scale (SASS) Total Score
NCT00536471 (61) [back to overview]	Change From Baseline to 12 Week and 9 Month Endpoints in Weight
NCT00536471 (61) [back to overview]	Change From Baseline to 12 Week Endpoint in 30-Item Brief Profile of Mood States (BPOMS) Scale and Subscales (Tension-Anxiety, Depression-Dejection, Anger-Hostility, Vigor-Activity, Fatigue-Inertia, and Confusion-Bewilderment).
NCT00536471 (61) [back to overview]	Change From Baseline to 12 Week Endpoint in Sheehan Disability Scale (SDS) Total Score and Subscores
NCT00536471 (61) [back to overview]	Change From Baseline to 9 Month Endpoint in 30-Item Brief Profile of Mood States (BPOMS) Scale and Subscales (Tension-Anxiety, Depression-Dejection, Anger-Hostility, Vigor-Activity, Fatigue-Inertia, and Confusion-Bewilderment)
NCT00552175 (12) [back to overview]	Change From Baseline at Week 12 in Average Pain Severity Rating Using Diaries for the Combined Duloxetine Arms (40 mg + 60 mg)
NCT00552175 (12) [back to overview]	Change From Baseline in Beck Depression Inventory-II (BDI-II) Total Score at Week 12
NCT00552175 (12) [back to overview]	Change From Baseline in Beck Depression Inventory-II (BDI-II) Total Score at Week 12 for the Combined Duloxetine Arms (40 mg + 60 mg)
NCT00552175 (12) [back to overview]	Patient Global Impression of Improvement Scale at Week 12
NCT00552175 (12) [back to overview]	Patient Global Impression of Improvement Scale at Week 12 in Combined Duloxetine Arms (40 mg + 60 mg)
NCT00552175 (12) [back to overview]	Change From Baseline at Week 12 in Worst Pain Severity Score and Night Pain Severity Score Using Diaries
NCT00552175 (12) [back to overview]	Change From Baseline at Week 12 in Average Pain Severity Rating Score Using Diaries
NCT00552175 (12) [back to overview]	Change From Baseline at Week 12 in Worst Pain Severity Score and Night Pain Severity Score Using Diaries for the Combined Duloxetine Arms (40 mg + 60 mg)
NCT00552175 (12) [back to overview]	Change From Baseline in Brief Pain Inventory Interference Scores at Week 12
NCT00552175 (12) [back to overview]	Change From Baseline in Brief Pain Inventory Interference Scores at Week 12 for the Combined Duloxetine Arms (40 mg + 60 mg)
NCT00552175 (12) [back to overview]	Change From Baseline in Brief Pain Inventory Severity Scores at Week 12
NCT00552175 (12) [back to overview]	Change From Baseline in Brief Pain Inventory Severity Scores at Week 12 for the Combined Duloxetine Arms (40 mg + 60 mg)
NCT00603265 (7) [back to overview]	Change From Baseline in Mean Numeric Pain Rating Scale (NPRS) Score
NCT00603265 (7) [back to overview]	Change From Baseline in the Evening Assessment of the 24-hour Overall Mean Pain Intensity Score
NCT00603265 (7) [back to overview]	Change in Sleep Interference Scale (SIS) From Baseline
NCT00603265 (7) [back to overview]	Percentage of Responders
NCT00603265 (7) [back to overview]	Change From Baseline in NPRS After Walking 50 Feet in the Clinic
NCT00603265 (7) [back to overview]	Change From Baseline in NPRS at Rest in the Clinic
NCT00603265 (7) [back to overview]	Patient Global Impression of Change (PGIC)
NCT00607789 (2) [back to overview]	Binge Eating Days
NCT00607789 (2) [back to overview]	Weekly Episodes
NCT00619983 (1) [back to overview]	Visual Analog Scale for Pain
NCT00635219 (10) [back to overview]	Change From Baseline in HAM-A Total Score After 8 Weeks of Treatment
NCT00635219 (10) [back to overview]	Change From Baseline in ASEX Total Score After 8 Weeks of Treatment
NCT00635219 (10) [back to overview]	Change From Baseline in CGI-S Score After 8 Weeks of Treatment
NCT00635219 (10) [back to overview]	Change From Baseline in HAM-D-24 Total Score After 8 Weeks of Treatment
NCT00635219 (10) [back to overview]	Change From Baseline in HAM-D-24 Total Score After 8 Weeks of Treatment in Patients With Baseline HAM-A Total Score >=20
NCT00635219 (10) [back to overview]	Change From Baseline in MADRS Total Score After 8 Weeks of Treatment
NCT00635219 (10) [back to overview]	Change From Baseline in SDS Total Score After 8 Weeks of Treatment
NCT00635219 (10) [back to overview]	Change in Clinical Status Using CGI-I Score at Week 8
NCT00635219 (10) [back to overview]	Proportion of Remitters at Week 8 (Remission Defined as a MADRS Total Score <=10)
NCT00635219 (10) [back to overview]	Proportion of Responders at Week 8 (Response Defined as a >=50% Decrease in the MADRS Total Score From Baseline)
NCT00641719 (9) [back to overview]	Number of Participants Who Experienced an Adverse Event (AE)
NCT00641719 (9) [back to overview]	Change From Baseline to One Year Endpoint in Brief Pain Inventory (BPI) Interference Scores
NCT00641719 (9) [back to overview]	Change From Baseline to One Year Endpoint in Brief Pain Inventory (BPI) Severity Scores
NCT00641719 (9) [back to overview]	Brief Pain Inventory (BPI) Severity Scores at One Year Endpoint
NCT00641719 (9) [back to overview]	Brief Pain Inventory (BPI) Interference Scores at One Year Endpoint
NCT00641719 (9) [back to overview]	Patient Global Impression of Improvement (PGI-I) Scale at One Year Endpoint.
NCT00641719 (9) [back to overview]	Change From Baseline to One Year Endpoint in Beck Depression Inventory-II (BDI-II) Total Score
NCT00641719 (9) [back to overview]	Change From Baseline to One Year Endpoint for Patient Global Impression of Improvement (PGI-I) Scale
NCT00641719 (9) [back to overview]	Beck Depression Inventory-II (BDI-II) Total Score at One Year Endpoint
NCT00666757 (25) [back to overview]	Change From Baseline in Sheehan Disability Scale (SDS) Global Functional Impairment Score at 12-Week Endpoint (Functional Outcome Measure)
NCT00666757 (25) [back to overview]	Change From Baseline in Sheehan Disability Scale (SDS) Family/Home Item Score at Week-12 Endpoint (Functional Outcome Measure)
NCT00666757 (25) [back to overview]	Change From Baseline in SDS Work/School Item Score at 12-Week Endpoint (Functional Outcome Measure)
NCT00666757 (25) [back to overview]	Change From Baseline in QIDS-SR Total Score at 12-Week Endpoint (Mood Measure)
NCT00666757 (25) [back to overview]	Change From Baseline in Pulse Rate at Week-12 Endpoint
NCT00666757 (25) [back to overview]	Change From Baseline in HAMD-17 Total Score at 12-Week Endpoint (Mood Measure)
NCT00666757 (25) [back to overview]	Change From Baseline in HAMD-17 Sleep Subscale Score at 12-Week Endpoint (Mood Measure)
NCT00666757 (25) [back to overview]	Change From Baseline in HAMD-17 Retardation Subscale Score at 12-Week Endpoint (Mood Measure)
NCT00666757 (25) [back to overview]	Change From Baseline in HAMD-17 Maier Subscale Score at 12-Week Endpoint (Mood Measure)
NCT00666757 (25) [back to overview]	Change From Baseline in HAMD-17 Bech Subscale Score at 12-Week Endpoint (Mood Measure)
NCT00666757 (25) [back to overview]	Change From Baseline in HAMD-17 Anxiety/Somatization Subscale Score at 12-Week Endpoint (Mood Measure)
NCT00666757 (25) [back to overview]	Change From Baseline in Diastolic Blood Pressure at Week-12 Endpoint
NCT00666757 (25) [back to overview]	Change From Baseline in Brief Pain Inventory (BPI) Average 24-hour Pain Score, in Particpants With a Baseline BPI Average 24-hour Pain Score of 3 or Greater, at 12-Week Endpoint (Pain Measure)
NCT00666757 (25) [back to overview]	Change From Baseline in BPI Average 24 Hour Pain Score at 12-Week Endpoint (Pain Measure)
NCT00666757 (25) [back to overview]	Change From Baseline in SDS Social Item Score at 12-Week Endpoint (Functional Outcome Measure)
NCT00666757 (25) [back to overview]	Change From Baseline in World Health Organization Health and Work Performance Questionnaire, Clinical Trials 7-Day Version (HPQ), Presenteeism Score, at Week-12 Endpoint
NCT00666757 (25) [back to overview]	Change From Baseline in World Health Organization Health and Work Performance Questionnaire, Clinical Trials 7-Day Version (HPQ), Dollars of Income Lost Due to Work Presenteeism (WP)Score, at Week-12 Endpoint
NCT00666757 (25) [back to overview]	Change From Baseline in World Health Organization Health and Work Performance Questionnaire, Clinical Trials 7-Day Version (HPQ), Dollars of Income Lost Due to Work Absenteeism Score at Week-12 Endpoint
NCT00666757 (25) [back to overview]	Change From Baseline in World Health Organization Health and Work Performance Questionnaire, Clinical Trials 7-Day Version (HPQ), Absenteeism at 12-Week Endpoint
NCT00666757 (25) [back to overview]	Change From Baseline in Weight at Week-12 Endpoint
NCT00666757 (25) [back to overview]	Change From Baseline in Systolic Blood Pressure at Week-12 Endpoint
NCT00666757 (25) [back to overview]	Probability of Response [QIDS-SR Total Score (Mood Measure) Greater Than Or Equal To 50 Percent Reduction From Baseline To 12 Week Endpoint]
NCT00666757 (25) [back to overview]	Probability of Response [HAMD-17 Total Score (Mood Measure) Greater Than Or Equal To 50 Percent Reduction From Baseline To 12 Week Endpoint]
NCT00666757 (25) [back to overview]	Probability of Remission [17-item Hamilton Depression Rating Scale (HAMD-17) (Mood Measure) Less Than or Equal to 7 at 12-Week Endpoint]
NCT00666757 (25) [back to overview]	Probability of Remission [16-item Quick Inventory of Depressive Symptomatology (QIDS-SR) Score Less Than or Equal to 5 at 12-Week Endpoint]
NCT00672620 (12) [back to overview]	Change From Baseline in the Clinical Global Impression Scale-Severity of Illness Scale
NCT00672620 (12) [back to overview]	Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score
NCT00672620 (12) [back to overview]	Percentage of Participants With a Sustained Response in HAM-D24
NCT00672620 (12) [back to overview]	Clinical Global Impression Scale-Global Improvement Scale
NCT00672620 (12) [back to overview]	Change From Baseline in Montgomery-Åsberg Depression Rating Scale - Self-assessment (MADRS-S)
NCT00672620 (12) [back to overview]	Healthcare Resource Utilization as Assessed by the Health Economic Assessment Questionnaire
NCT00672620 (12) [back to overview]	Change From Baseline in the 24-item Hamilton Depression Scale Total Score at Other Weeks Assessed
NCT00672620 (12) [back to overview]	Change From Baseline in the Montgomery Åsberg Depression Rating Scale (MADRS) Total Score
NCT00672620 (12) [back to overview]	Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 8
NCT00672620 (12) [back to overview]	Percentage of Responders in HAM-D 24 Total Score by Study Visit
NCT00672620 (12) [back to overview]	Change From Baseline in the 24-item Hamilton Depression Scale Total Score at Week 8
NCT00672620 (12) [back to overview]	Percentage of Participants in MADRS Remission at Week 8
NCT00673452 (15) [back to overview]	Change From Baseline in Blood Pressure at 12 Week Endpoint
NCT00673452 (15) [back to overview]	Change From Baseline in 36-Item Short-form Health Survey (SF-36) at 12 Weeks
NCT00673452 (15) [back to overview]	Number of Responders: 50% Improvement in Brief Pain Inventory Average Pain Score at 12 Week Endpoint
NCT00673452 (15) [back to overview]	Number of Responders: 30% Improvement in Brief Pain Inventory Average Pain at 12 Week Endpoint
NCT00673452 (15) [back to overview]	Change From Baseline in Weight at 12 Week Endpoint
NCT00673452 (15) [back to overview]	Change From Baseline in Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (MGH-CPFQ) Total Score at 12 Week Endpoint
NCT00673452 (15) [back to overview]	Change From Baseline in Heart Rate at 12 Week Endpoint
NCT00673452 (15) [back to overview]	Change From Baseline in Clinical Global Impressions of Severity (CGI-S) at 12 Week Endpoint
NCT00673452 (15) [back to overview]	Change From Baseline in Beck Depression Inventory-II (BDI-II) at 12 Week Endpoint
NCT00673452 (15) [back to overview]	Change From Baseline in Beck Anxiety Inventory (BAI) at 12 Week Endpoint
NCT00673452 (15) [back to overview]	Change From Baseline in Brief Pain Inventory (BPI) (Modified Short Form) at 12 Week Endpoint
NCT00673452 (15) [back to overview]	Change From Baseline in Multidimensional Fatigue Inventory (MFI) at 12 Week Endpoint
NCT00673452 (15) [back to overview]	Change From Baseline in the Mood, Anxiety, Pain, Sleep, and Stiffness Likert Scale at 12 Week Endpoint
NCT00673452 (15) [back to overview]	Number of Patients With Columbia Suicide Severity Rating Scale (CSSR-S) Events (Behaviors, Ideations, Acts)
NCT00673452 (15) [back to overview]	Patient's Global Impressions of Improvement (PGI-I) at Week 12
NCT00696293 (2) [back to overview]	Change in Montgomery Asberg Depression Rating Scale(MADRS) Score From Baseline and 12 Weeks
NCT00696293 (2) [back to overview]	Change in McGill Pain Questionaire, Short Form, Score From Baseline and 12 Weeks
NCT00696774 (15) [back to overview]	Change From Baseline HAMD-17 Sleep Subscale at 8 Weeks
NCT00696774 (15) [back to overview]	Change From Baseline HAMD-17 Anxiety/Somatization Subscale at 8 Weeks
NCT00696774 (15) [back to overview]	Change From Baseline HAMD-17 Core Subscale at 8 Weeks
NCT00696774 (15) [back to overview]	Change From Baseline HAMD-17 Maier Subscale at 8 Weeks
NCT00696774 (15) [back to overview]	Change From Baseline HAMD-17 Retardation/Somatization Subscale at 8 Weeks
NCT00696774 (15) [back to overview]	Change From Baseline in the Sexual Functioning Questionnaire Clinical Version (CSFQ) at 4 and 8 Weeks
NCT00696774 (15) [back to overview]	Change From Baseline HAMD-17 Total Score at 8 Weeks
NCT00696774 (15) [back to overview]	Change From Baseline in the Sheehan Disability Scale (SDS) at 4 and 8 Weeks
NCT00696774 (15) [back to overview]	Change From Baseline in the Treatment Satisfaction Questionnaire for Medication (TSQM) at 4 and 8 Weeks
NCT00696774 (15) [back to overview]	Change From Baseline in Brief Pain Inventory-Modified Short Form (BPI-SF) Interference Score Between Responder and Non-Responder Participants at 4 Weeks
NCT00696774 (15) [back to overview]	Change From Baseline in Patient Global Impression - Improvement (PGI-I) Scale Score at 8 Weeks
NCT00696774 (15) [back to overview]	Change From Baseline in the Brief Pain Inventory - Modified Short Form (BPI-SF) Average Pain Score at 8 Weeks
NCT00696774 (15) [back to overview]	Change From Baseline in the Clinical Global Impression - Severity (CGI-Severity) Scale at 8 Weeks
NCT00696774 (15) [back to overview]	Change From Baseline in the Hamilton Anxiety Rating Scale (HAMA) at 8 Weeks
NCT00696774 (15) [back to overview]	Percentage of Participants Meeting Criteria for Response on the 17-Item Hamilton Depression Rating Scale (HAMD-17) Maier Subscale at 4 and 8 Weeks
NCT00730691 (16) [back to overview]	Percentage of Participants in HAM-A Remission at Each Week Assessed
NCT00730691 (16) [back to overview]	Change From Baseline in Hospital Anxiety and Depression (HAD) - Anxiety Subscale at Other Weeks Assessed
NCT00730691 (16) [back to overview]	Change From Baseline in Clinical Global Impression Scale-Severity of Illness (CGI-S)
NCT00730691 (16) [back to overview]	Percentage of Responders in HAM-A Total Score at Week 8
NCT00730691 (16) [back to overview]	Mean Clinical Global Impression Scale-Global Improvement (CGI-I) at Week 8
NCT00730691 (16) [back to overview]	Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Week 8 in Participants With Baseline HAM-A ≥25
NCT00730691 (16) [back to overview]	Change From Baseline in the Hamilton Anxiety (HAM-A) Scale Total Score at Week 8
NCT00730691 (16) [back to overview]	Change From Baseline in Sheehan Disability Scale (SDS) at Week 8
NCT00730691 (16) [back to overview]	Change From Baseline in Hospital Anxiety and Depression (HAD) - Anxiety Subscale at Week 8
NCT00730691 (16) [back to overview]	Change From Baseline in Hamilton Anxiety Scale (HAM-A) Total Score at Other Weeks Assessed
NCT00730691 (16) [back to overview]	Percentage of Responders in HAM-A Total Score at Other Weeks Assessed
NCT00730691 (16) [back to overview]	Mean Clinical Global Impression Scale-Global Improvement (CGI-I) at Other Weeks Assessed
NCT00730691 (16) [back to overview]	Health Care Resource Utilization Assessed by the Health Economic Assessment Questionnaire
NCT00730691 (16) [back to overview]	Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Other Weeks Assessed in Participants With Baseline HAM-A ≥25
NCT00730691 (16) [back to overview]	Change From Baseline in Sheehan Disability Scale (SDS) at Other Weeks Assessed
NCT00730691 (16) [back to overview]	Change From Baseline in Hospital Anxiety and Depression (HAD) - Depression Subscale at All Weeks Assessed
NCT00755807 (36) [back to overview]	Number of Participants With Adverse Events (AEs) Resulting in Discontinuation During the Open-label Extension Phase
NCT00755807 (36) [back to overview]	Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the Open-label Extension Phase
NCT00755807 (36) [back to overview]	Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the Acute Phase
NCT00755807 (36) [back to overview]	Change in the Weekly Mean of the Night Pain Scores From Week 6 Through Week 18 (Open-label Extension Phase)
NCT00755807 (36) [back to overview]	Number of Participants Who Discontinued During the Open-label Extension Phase (by Week 18)
NCT00755807 (36) [back to overview]	Number of Participants With Suicidal Behaviors, Ideations, and Acts Based on The Columbia Suicide Severity Rating Scale (C-SSRS) at Week 6
NCT00755807 (36) [back to overview]	Patient Global Impressions of Improvement Scale (PGI-I) at 6 Weeks
NCT00755807 (36) [back to overview]	Patient Global Impressions of Improvement Scale (PGI-I) Score at 18 Weeks
NCT00755807 (36) [back to overview]	Change From Baseline in Bicarbonate (HCO3) at Week 6 (Acute Phase)
NCT00755807 (36) [back to overview]	Change From Baseline in Blood Pressure at Week 18 (Open-label Extension Phase)
NCT00755807 (36) [back to overview]	Change From Baseline in Blood Pressure at Week 6 (Acute Phase)
NCT00755807 (36) [back to overview]	Change From Baseline in Brief Pain Inventory Severity and Interference Scores (BPI-S/BPI-I) at Week 18
NCT00755807 (36) [back to overview]	Change From Baseline in Inorganic Phosphorus at Week 6 (Acute Phase)
NCT00755807 (36) [back to overview]	Change From Baseline in Creatinine at Week 6 (Acute Phase)
NCT00755807 (36) [back to overview]	Change From Baseline in Monocytes at Week 18 (Open-label Extension Phase)
NCT00755807 (36) [back to overview]	Change From Baseline in Multiple Sclerosis Quality of Life-54 Instrument (MS-QOL-54) at Week 18 (Open-label Extension Phase)
NCT00755807 (36) [back to overview]	Change From Baseline in Sodium at Week 18 (Open-label Extension Phase)
NCT00755807 (36) [back to overview]	Change From Baseline in the Brief Pain Inventory Severity and Interference Scores (BPI-S/BPI-I) at Week 6 (Acute Phase)
NCT00755807 (36) [back to overview]	Change From Baseline in the Multiple Sclerosis Quality of Life-54 Instrument (MS-QOL-54) at 6 Weeks (Acute Phase)
NCT00755807 (36) [back to overview]	Change From Baseline in the Platelet Count at Week 6 (Acute Phase)
NCT00755807 (36) [back to overview]	Change From Baseline in the Weekly 24-Hour Average Pain Scores up to Week 6 (Acute Phase)
NCT00755807 (36) [back to overview]	Change From Baseline in Total Protein at Week 18 (Open-label Extension Phase)
NCT00755807 (36) [back to overview]	Number of Participants With Suicidal Behaviors, Ideations, and Acts Based on The Columbia Suicide Severity Rating Scale (C-SSRS) at Week 18
NCT00755807 (36) [back to overview]	Number of Participants With Adverse Events (AEs) Resulting in Discontinuation From Baseline During the Acute Phase
NCT00755807 (36) [back to overview]	Change From Baseline in Uric Acid at Week 6 (Acute Phase)
NCT00755807 (36) [back to overview]	Number of Participants Who Discontinued During the Acute Phase (by Week 6)
NCT00755807 (36) [back to overview]	Change From Baseline in Weight at Week 6 (Acute Phase)
NCT00755807 (36) [back to overview]	Change From Baseline in Weight at Week 18 (Open-label Extension Phase)
NCT00755807 (36) [back to overview]	Change From Baseline in the Weekly Mean of Night Pain Scores at Week 6 (Acute Phase)
NCT00755807 (36) [back to overview]	Change From Baseline in the Weekly 24-Hour Average Pain Scores at Week 6 (Acute Phase)
NCT00755807 (36) [back to overview]	Change From Baseline in the Clinical Global Impression of Severity Scale (CGI-S) Score at Week 18 (Open-label Extension Phase)
NCT00755807 (36) [back to overview]	Change From Baseline in the Clinical Global Impression of Severity Scale (CGI-S) at 6 Weeks (Acute Phase)
NCT00755807 (36) [back to overview]	Change From Baseline in the Beck Depression Inventory II (BDI-II) Question #9 at Week 6 (Acute Phase)
NCT00755807 (36) [back to overview]	Change From Baseline in Pulse Rate at Week 6 (Acute Phase)
NCT00755807 (36) [back to overview]	Change From Baseline in Pulse Rate at Week 18 (Open-label Extension Phase)
NCT00755807 (36) [back to overview]	Change From Baseline in Beck Depression Inventory II (BDI-II), Question #9 at Week 18 (Open-label Extension Phase)
NCT00767806 (26) [back to overview]	Number of Responders: 50 Percent (%) or Greater Reduction of the Brief Pain Inventory (BPI) Average Pain Severity Rating at 12 Week Endpoint
NCT00767806 (26) [back to overview]	Number of Responders: 30 Percent (%) or Greater Reduction of the Brief Pain Inventory (BPI) Average Pain Severity Rating at 12 Week Endpoint
NCT00767806 (26) [back to overview]	Number of Participants With Suicidal Ideation or Suicidal Behaviors According to the Columbia Suicide Severity Rating Scale
NCT00767806 (26) [back to overview]	Change From Baseline to 12 Weeks in Profile of Mood States - Brief Form
NCT00767806 (26) [back to overview]	Change From Baseline to 12 Weeks in Weekly Mean of 24-hour Average Pain, Worst Pain, and Night Pain Rating
NCT00767806 (26) [back to overview]	Change From Baseline to 12 Weeks in Work Productivity and Activity Impairment Instrument (WPAI)
NCT00767806 (26) [back to overview]	Change From Baseline to 12 Week Endpoint in Albumin
NCT00767806 (26) [back to overview]	Change From Baseline to 12 Week Endpoint in Alkaline Phosphatase
NCT00767806 (26) [back to overview]	Change From Baseline to 12 Week Endpoint in Aspartate Aminotransferase
NCT00767806 (26) [back to overview]	Change From Baseline to 12 Week Endpoint in Creatinine
NCT00767806 (26) [back to overview]	Change From Baseline to 12 Week Endpoint in Total Protein
NCT00767806 (26) [back to overview]	Change From Baseline to 12 Week Endpoint in Weight
NCT00767806 (26) [back to overview]	Change From Baseline to 12 Weeks Endpoint in Clinical Global Impressions of Severity (CGI-S)
NCT00767806 (26) [back to overview]	Change From Baseline to 12 Week Endpoint in Alanine Aminotransferase
NCT00767806 (26) [back to overview]	Patient's Global Impression of Improvement (PGI-I) at 12 Weeks
NCT00767806 (26) [back to overview]	Change From Baseline to 12 Week Endpoint in Pulse Rate
NCT00767806 (26) [back to overview]	Change From Baseline to 12 Weeks in Brief Pain Inventory 24-hour Average Pain Score
NCT00767806 (26) [back to overview]	Change From Baseline to 12 Weeks in Roland Morris Disability Questionnaire
NCT00767806 (26) [back to overview]	Change From Baseline to 12 Weeks in Uric Acid
NCT00767806 (26) [back to overview]	Number of Participants Reaching Each Threshold of of BPI Average Pain Score Reduction During the Study - Cumulative Distribution
NCT00767806 (26) [back to overview]	Change From Baseline to 12 Weeks on the Brief Pain Inventory - Severity (BPI-S) and Interference (BPI-I)
NCT00767806 (26) [back to overview]	Change From Baseline to 12 Weeks in European Quality of Life Questionnaire - 5 Dimension
NCT00767806 (26) [back to overview]	Change From Baseline to 12 Weeks in Blood Pressure
NCT00767806 (26) [back to overview]	Change From Baseline to 12 Weeks in 36-item Short-Form (SF-36) Health Survey
NCT00767806 (26) [back to overview]	Participants Who Discontinued From Baseline to 12 Weeks
NCT00767806 (26) [back to overview]	Number of Sustained Responders at 12 Week Endpoint
NCT00803361 (7) [back to overview]	Change From Baseline in Brief Pain Inventory (BPI) - Short Form Severity (BPI-S) and Interference (BPI-I) Scores at Endpoint
NCT00803361 (7) [back to overview]	Mean Clinical Global Impressions (CGI) Improvement Score at Endpoint
NCT00803361 (7) [back to overview]	Change From Baseline in Visual Analogue Scale (VAS) for Pain at Endpoint
NCT00803361 (7) [back to overview]	Change From Baseline in the Hospital Anxiety and Depression Scale (HADS) Depression Subscale Score at Endpoint
NCT00803361 (7) [back to overview]	Change From Baseline in the Hospital Anxiety and Depression Scale (HADS) Anxiety Subscale Score at Endpoint
NCT00803361 (7) [back to overview]	Change From Baseline in the Hamilton Anxiety (HAMA) Rating Scale Total Score at Endpoint
NCT00803361 (7) [back to overview]	Change From Baseline in Sheehan Disability Scale (SDS) at Endpoint, Global Functioning Scores
NCT00810069 (18) [back to overview]	Estimated Probability of Not Reaching Confirmed Remission at 12 Weeks Based on the Survival Function for the Time to Confirmed Remission
NCT00810069 (18) [back to overview]	Visual Analog Scale (VAS) - Overall Pain Severity
NCT00810069 (18) [back to overview]	Sheehan Disability Scale (SDS) Normal Functioning Total Score
NCT00810069 (18) [back to overview]	Resource Utilisation - Number of Work Hours Missed in the Last 4 Weeks
NCT00810069 (18) [back to overview]	Resource Utilisation - Number of Work Hours Missed Due to Depression in the Last 4 Weeks
NCT00810069 (18) [back to overview]	Resource Utilisation - Number of Visits to Primary Healthcare Provider Due to Depression in the Last 4 Weeks
NCT00810069 (18) [back to overview]	Resource Utilisation - Number of Visits to Other Specialists Due to Depression in the Last 4 Weeks
NCT00810069 (18) [back to overview]	Resource Utilisation - Number of Hours Worked Per Week
NCT00810069 (18) [back to overview]	Resource Utilisation - Has the Participant Been Hospitalized Due to Depression in the Last 4 Weeks - Number of Participants With a Yes Response
NCT00810069 (18) [back to overview]	Number of Participants With Adverse Events (AEs)
NCT00810069 (18) [back to overview]	Euro Quality of Life Questionnaire-5 Dimensions (EQ-5D) Scale - United Kingdom (UK) Population Based Index Score
NCT00810069 (18) [back to overview]	Euro Quality of Life Questionnaire-5 Dimensions (EQ-5D) Scale - Health State Score
NCT00810069 (18) [back to overview]	Clinical Global Impressions of Severity (CGI-S) Scale
NCT00810069 (18) [back to overview]	Time to Confirmed Response by ≥ 50% Change From Baseline Reduction in the Hamilton Depression Rating Scale-17 Items (HAMD-17)
NCT00810069 (18) [back to overview]	Time to Confirmed Response as Defined by ≥ 50% Reduction From Baseline Reduction in the 16-Item Quick Inventory of Depressive Symptomatology Self Report (QIDS16SR) That is Reported for Two Consecutive Visits
NCT00810069 (18) [back to overview]	Time to Confirmed Remission by a Hamilton Depression Rating Scale-17 Items (HAMD-17) Score of ≤ 7 That is Maintained for Two Consecutive Visits
NCT00810069 (18) [back to overview]	Time to Confirmed Remission as Defined by a 16-Item Quick Inventory of Depressive Symptomatology Self Report (QIDS16SR) Score of ≤ 5 That is Maintained for Two Consecutive Visits.
NCT00810069 (18) [back to overview]	Estimated Probability of Not Reaching Confirmed Response at 12 Weeks Based on the Survival Function for the Time to Confirmed Response
NCT00811252 (13) [back to overview]	Change From Baseline in HAM-A Total Score After 8 Weeks of Treatment
NCT00811252 (13) [back to overview]	Change From Baseline in GDS Total Score After 8 Weeks of Treatment
NCT00811252 (13) [back to overview]	Risk of Suicidality Using C-SSRS Scores
NCT00811252 (13) [back to overview]	Change From Baseline in HAM-D-24 Total Score After 8 Weeks of Treatment
NCT00811252 (13) [back to overview]	Change in Clinical Status Using CGI-I Score at Week 8
NCT00811252 (13) [back to overview]	Proportion of Responders at Week 8 (Response Defined as a >=50% Reduction in the HAM-D-24 Total Score)
NCT00811252 (13) [back to overview]	Change From Baseline in CGI-S Score After 8 Weeks of Treatment
NCT00811252 (13) [back to overview]	Change From Baseline in MADRS Total Score After 8 Weeks of Treatment
NCT00811252 (13) [back to overview]	Change From Baseline in HAM-D-24 Total Score After 6 Weeks of Treatment
NCT00811252 (13) [back to overview]	Change From Baseline in HAM-D-24 Total Score After 4 Weeks of Treatment
NCT00811252 (13) [back to overview]	Change From Baseline in HAM-D-24 Total Score After 2 Weeks of Treatment
NCT00811252 (13) [back to overview]	Change From Baseline in HAM-D-24 Total Score After 1 Week of Treatment
NCT00811252 (13) [back to overview]	Proportion of Remitters at Week 8 (Remission Defined as a MADRS Total Score <=10)
NCT00844194 (98) [back to overview]	Change of Pulse Rate From Baseline at Week 12
NCT00844194 (98) [back to overview]	Change of Systolic Blood Pressure From Baseline at Week 12
NCT00844194 (98) [back to overview]	Patient Global Impression - Improvement (PGI-I) at Week 12
NCT00844194 (98) [back to overview]	Patient Global Impression - Improvement (PGI-I) at Week 2
NCT00844194 (98) [back to overview]	Patient Global Impression - Improvement (PGI-I) at Week 6
NCT00844194 (98) [back to overview]	Change in HADS Anxiety Total Score From Baseline to Week 6
NCT00844194 (98) [back to overview]	Change in HADS Depression Total Score From Baseline to Week 12
NCT00844194 (98) [back to overview]	Change in HADS Depression Total Score From Baseline to Week 2
NCT00844194 (98) [back to overview]	Change in HADS Depression Total Score From Baseline to Week 6
NCT00844194 (98) [back to overview]	Suicidal Thoughts or Behaviours by HAMD-17 at Week 12
NCT00844194 (98) [back to overview]	Suicidal Thoughts by BDI-II at Week 6
NCT00844194 (98) [back to overview]	Suicidal Thoughts by BDI-II at Week 2
NCT00844194 (98) [back to overview]	Suicidal Thoughts by BDI-II at Week 12
NCT00844194 (98) [back to overview]	Number of Patients With a Reduction in BPI Average Pain at Week 6
NCT00844194 (98) [back to overview]	Number of Patients With a Reduction in BPI Average Pain at Week 2
NCT00844194 (98) [back to overview]	Number of Patients With a Reduction in BPI Average Pain at Week 12
NCT00844194 (98) [back to overview]	Change in Multidimensional Pain Inventory (MPI): Life Control From Baseline to Week 12
NCT00844194 (98) [back to overview]	Change in Interference of Pain With General Activity (BPI) From Baseline to Week 6
NCT00844194 (98) [back to overview]	Change in Interference of Pain With Mood (BPI) From Baseline to Week 12
NCT00844194 (98) [back to overview]	Suicidal Thoughts or Behaviours by HAMD-17 at Week 6
NCT00844194 (98) [back to overview]	Suicidal Thoughts or Behaviours by HAMD-17 at Week 2
NCT00844194 (98) [back to overview]	Change in Interference of Pain With Mood (BPI) From Baseline to Week 2
NCT00844194 (98) [back to overview]	Change in Interference of Pain With Mood (BPI) From Baseline to Week 6
NCT00844194 (98) [back to overview]	Change in Interference of Pain With Normal Work (BPI) From Baseline to Week 12
NCT00844194 (98) [back to overview]	Change in Interference of Pain With Normal Work (BPI) From Baseline to Week 2
NCT00844194 (98) [back to overview]	Change in Interference of Pain With Normal Work (BPI) From Baseline to Week 6
NCT00844194 (98) [back to overview]	Change in Interference of Pain With Relations to Other People (BPI) From Baseline to Week 12
NCT00844194 (98) [back to overview]	Change in Interference of Pain With Relations to Other People (BPI) From Baseline to Week 2
NCT00844194 (98) [back to overview]	Change in Interference of Pain With Relations to Other People (BPI) From Baseline to Week 6
NCT00844194 (98) [back to overview]	Change in Interference of Pain With Sleep (BPI) From Baseline to Week 12
NCT00844194 (98) [back to overview]	Change in Interference of Pain With Sleep (BPI) From Baseline to Week 2
NCT00844194 (98) [back to overview]	Change in Interference of Pain With Sleep (BPI) From Baseline to Week 6
NCT00844194 (98) [back to overview]	Change in Interference of Pain With Walking Ability (BPI) From Baseline to Week 12
NCT00844194 (98) [back to overview]	Change in Interference of Pain With Walking Ability (BPI) From Baseline to Week 2
NCT00844194 (98) [back to overview]	Change in Interference of Pain With Walking Ability (BPI) From Baseline to Week 6
NCT00844194 (98) [back to overview]	Change in Least Pain (BPI) From Baseline to Week 12
NCT00844194 (98) [back to overview]	Change in Least Pain (BPI) From Baseline to Week 2
NCT00844194 (98) [back to overview]	Change in Least Pain During Treatment (BPI) From Baseline to Week 6
NCT00844194 (98) [back to overview]	Change in Multidimensional Pain Inventory (MPI): Affective Distress From Baseline to Week 12
NCT00844194 (98) [back to overview]	Change in Multidimensional Pain Inventory (MPI): Affective Distress From Baseline to Week 6
NCT00844194 (98) [back to overview]	Change in Multidimensional Pain Inventory (MPI): Degree to Which Significant Others Display Distracting Responses to the Patient's Pain Behaviors and Complaints From Baseline to Week 12
NCT00844194 (98) [back to overview]	Change in Multidimensional Pain Inventory (MPI): Degree to Which Significant Others Display Distracting Responses to the Patient's Pain Behaviors and Complaints From Baseline to Week 6
NCT00844194 (98) [back to overview]	Change in Multidimensional Pain Inventory (MPI): General Activities From Baseline to Week 12
NCT00844194 (98) [back to overview]	Change in Multidimensional Pain Inventory (MPI): General Activities From Baseline to Week 6
NCT00844194 (98) [back to overview]	Change in Multidimensional Pain Inventory (MPI): Household Chores From Baseline to Week 12
NCT00844194 (98) [back to overview]	Change in Multidimensional Pain Inventory (MPI): Household Chores From Baseline to Week 6
NCT00844194 (98) [back to overview]	Change in Multidimensional Pain Inventory (MPI): Interference of Pain (With Subjective Well-being) From Baseline to Week 6
NCT00844194 (98) [back to overview]	Change in Multidimensional Pain Inventory (MPI): Interference of Pain From Baseline to Week 12
NCT00844194 (98) [back to overview]	Change in Multidimensional Pain Inventory (MPI): Life Control From Baseline to Week 6
NCT00844194 (98) [back to overview]	Change in Multidimensional Pain Inventory (MPI): Negative Responses From Baseline to Week 12
NCT00844194 (98) [back to overview]	Change in Multidimensional Pain Inventory (MPI): Negative Responses From Baseline to Week 6
NCT00844194 (98) [back to overview]	Change in Multidimensional Pain Inventory (MPI): Outdoor Work From Baseline to Week 12
NCT00844194 (98) [back to overview]	Change in Multidimensional Pain Inventory (MPI): Outdoor Work From Baseline to Week 6
NCT00844194 (98) [back to overview]	Change in Multidimensional Pain Inventory (MPI): Pain Severity From Baseline to Week 12
NCT00844194 (98) [back to overview]	Change in Multidimensional Pain Inventory (MPI): Pain Severity From Baseline to Week 6
NCT00844194 (98) [back to overview]	Change in Multidimensional Pain Inventory (MPI): Social Activities From Baseline to Week 12
NCT00844194 (98) [back to overview]	Change in Multidimensional Pain Inventory (MPI): Social Activities From Baseline to Week 6
NCT00844194 (98) [back to overview]	Change in Pain (BPI) From Baseline to Week 6
NCT00844194 (98) [back to overview]	Change in Multidimensional Pain Inventory (MPI): Solicitous Responses From Baseline to Week 12
NCT00844194 (98) [back to overview]	Change in HADS Anxiety Total Score From Baseline to Week 12
NCT00844194 (98) [back to overview]	Change in Clinical Global Impression - Severity Pain From Baseline to Week 6
NCT00844194 (98) [back to overview]	Change in Clinical Global Impression - Severity Pain From Baseline to Week 2
NCT00844194 (98) [back to overview]	Change in Clinical Global Impression - Severity Pain From Baseline to Week 12
NCT00844194 (98) [back to overview]	Change in BPI Worst Pain During Treatment From Baseline to Week 2
NCT00844194 (98) [back to overview]	Change in Interference of Pain With General Activity (BPI) From Baseline to Week 2
NCT00844194 (98) [back to overview]	Change in Multidimensional Pain Inventory (MPI): Solicitous Responses From Baseline to Week 6
NCT00844194 (98) [back to overview]	Change in Interference of Pain With General Activity (BPI) From Baseline to Week 12
NCT00844194 (98) [back to overview]	Change in Interference of Pain With Enjoyment of Life (BPI) From Baseline to Week 6
NCT00844194 (98) [back to overview]	Change in Interference of Pain With Enjoyment of Life (BPI) From Baseline to Week 2
NCT00844194 (98) [back to overview]	Change in Hospital Anxiety and Depression Scale (HADS) Anxiety Total Score From Baseline to Week 2
NCT00844194 (98) [back to overview]	Change in Hamilton Depression Score From Baseline to Week 6
NCT00844194 (98) [back to overview]	Change in Hamilton Depression Score From Baseline to Week 2
NCT00844194 (98) [back to overview]	Change in Hamilton Depression Score From Baseline to Week 12
NCT00844194 (98) [back to overview]	Change in Beck Depression Inventory Total Score (BDI-II) From Baseline to Week 6
NCT00844194 (98) [back to overview]	Change in Beck Depression Inventory Total Score (BDI-II) From Baseline to Week 2
NCT00844194 (98) [back to overview]	Change in Beck Depression Inventory Total Score (BDI-II) From Baseline to Week 12
NCT00844194 (98) [back to overview]	Change in Average Pain During Treatment (BPI) From Baseline to Week 6
NCT00844194 (98) [back to overview]	Change in Average Pain (BPI) From Baseline to Week 2
NCT00844194 (98) [back to overview]	Change in Average Pain (BPI) From Baseline to Week 12
NCT00844194 (98) [back to overview]	Change in Multidimensional Pain Inventory (MPI): Support From Baseline to Week 6
NCT00844194 (98) [back to overview]	Change in Multidimensional Pain Inventory (MPI): Support Which the Patient Received From Baseline to Week 12
NCT00844194 (98) [back to overview]	Change in Pain During Treatment (BPI) From Baseline to Week 12
NCT00844194 (98) [back to overview]	Change in Pain During Treatment (BPI) From Baseline to Week 2
NCT00844194 (98) [back to overview]	Change in Relief of Pain (BPI) From the Week Before Baseline to the Week Before Week 12
NCT00844194 (98) [back to overview]	Change in Relief of Pain (BPI) From the Week Before Baseline to the Week Before Week 2
NCT00844194 (98) [back to overview]	Change in Relief of Pain (BPI) From the Week Before Baseline to the Week Before Week 6
NCT00844194 (98) [back to overview]	Change in Short Form Health Survey (SF-12) - Mental Component Summary From Baseline to Week 12
NCT00844194 (98) [back to overview]	Change in Short Form Health Survey (SF-12) - Mental Component Summary From Baseline to Week 6
NCT00844194 (98) [back to overview]	Change in Short Form Health Survey (SF-12) - Physical Component Summary From Baseline to Week 12
NCT00844194 (98) [back to overview]	Change in Short Form Health Survey (SF-12) - Physical Component Summary From Baseline to Week 6
NCT00844194 (98) [back to overview]	Change in Worst Pain (BPI) From Baseline to Week 12
NCT00844194 (98) [back to overview]	Change in Worst Pain (BPI) From Baseline to Week 6
NCT00844194 (98) [back to overview]	Change of Brief Pain Inventory (BPI) Average Interference Score From Baseline to Week 12
NCT00844194 (98) [back to overview]	Change of Brief Pain Inventory (BPI) Average Interference Score From Baseline to Week 6
NCT00844194 (98) [back to overview]	Change of Diastolic Blood Pressure From Baseline at Week 12
NCT00844194 (98) [back to overview]	Change of Fasting Blood Glucose From Baseline at Week 12
NCT00844194 (98) [back to overview]	Change of Glycosylated Hemoglobin A1c (HbA1c) From Baseline at Week 12
NCT00844194 (98) [back to overview]	Change in Interference of Pain With Enjoyment of Life (BPI) From Baseline to Week 12
NCT00849693 (12) [back to overview]	Change From Baseline in Clinical Global Impressions of Severity (CGI-Severity) Scale at Week 10 Endpoint
NCT00849693 (12) [back to overview]	Change From Baseline in Children's Depression Rating Scale-Revised (CDRS-R) Total Score at Week 10 Endpoint
NCT00849693 (12) [back to overview]	Percentage of Participants With Potentially Clinically Significant (PCS) Changes in Systolic Blood Pressure (BP), Diastolic BP, Pulse, and Weight Any Time Week 10 Through Week 36
NCT00849693 (12) [back to overview]	Change From Week 10 in Children's Depression Rating Scale-Revised (CDRS-R) Total Score at Week 36 Endpoint
NCT00849693 (12) [back to overview]	Number of Participants With Suicidal Ideation or Suicidal Behavior Baseline Through Week 10
NCT00849693 (12) [back to overview]	Change From Week 10 in Clinical Global Impressions of Severity (CGI-Severity) Scale at Week 36 Endpoint
NCT00849693 (12) [back to overview]	Number of Participants With Suicidal Ideation or Suicidal Behavior Week 10 Through Week 36
NCT00849693 (12) [back to overview]	Change From Baseline in Children's Depression Rating Scale-Revised (CDRS-R) Subscale Score at Week 10 Endpoint
NCT00849693 (12) [back to overview]	Change From Week 10 in Children's Depression Rating Scale-Revised (CDRS-R) Subscale Score at Week 36 Endpoint
NCT00849693 (12) [back to overview]	Percentage of Participants With Potentially Clinically Significant (PCS) Changes in Systolic Blood Pressure (BP), Diastolic BP, Pulse, and Weight Any Time Baseline Through Week 10
NCT00849693 (12) [back to overview]	Number of Participants With Potentially Clinically Significant Hepatic Laboratory Results Any Time Baseline Through Week 10
NCT00849693 (12) [back to overview]	Number of Participants With Potentially Clinically Significant Hepatic Laboratory Results Any Time Week 10 Through Week 36
NCT00849901 (12) [back to overview]	Change From Baseline in Children's Depression Rating Scale-Revised (CDRS-R) Total Score at Week 10 Endpoint
NCT00849901 (12) [back to overview]	Change From Baseline in Clinical Global Impressions of Severity (CGI-Severity) Scale at Week 10 Endpoint
NCT00849901 (12) [back to overview]	Number of Participants With Suicidal Ideation or Suicidal Behavior Baseline Through Week 10
NCT00849901 (12) [back to overview]	Change From Week 10 in Children's Depression Rating Scale-Revised (CDRS-R) Total Score at Week 36 Endpoint
NCT00849901 (12) [back to overview]	Change From Week 10 in Clinical Global Impressions of Severity (CGI-Severity) Scale at Week 36 Endpoint
NCT00849901 (12) [back to overview]	Change From Baseline in Children's Depression Rating Scale-Revised (CDRS-R) Subscale Score at Week 10 Endpoint
NCT00849901 (12) [back to overview]	Change From Week 10 in Children's Depression Rating Scale-Revised (CDRS-R) Subscale Score at Week 36 Endpoint
NCT00849901 (12) [back to overview]	Number of Participants With Potentially Clinically Significant Hepatic Laboratory Results Any Time Baseline Through Week 10
NCT00849901 (12) [back to overview]	Number of Participants With Potentially Clinically Significant Hepatic Laboratory Results Any Time Week 10 Through Week 36
NCT00849901 (12) [back to overview]	Number of Participants With Suicidal Ideation or Suicidal Behavior Week 10 Through Week 36
NCT00849901 (12) [back to overview]	Percentage of Participants With Potentially Clinically Significant (PCS) Changes in Systolic Blood Pressure (BP), Diastolic BP, Pulse, and Weight Any Time Baseline Through Week 10
NCT00849901 (12) [back to overview]	Percentage of Participants With Potentially Clinically Significant (PCS) Changes in Systolic Blood Pressure (BP), Diastolic BP, Pulse, and Weight Any Time Week 10 Through Week 36
NCT00863057 (10) [back to overview]	Number of Participants With 30% or More Improvement in Mean Pain Score on an 11-point Likert Scale
NCT00863057 (10) [back to overview]	Number of Participants With 50% or More Improvement in Mean Pain Score on an 11-point Likert Scale
NCT00863057 (10) [back to overview]	Number of Participants With Treatment-emergent Grade 2 to 4 Adverse Events
NCT00863057 (10) [back to overview]	Pain-related Interference Measured by the Brief Pain Inventory (BPI) Interference Items
NCT00863057 (10) [back to overview]	Weekly Mean Pain Score Derived From Self-reported Average Daily Pain Intensity on an 11-point Likert Scale
NCT00863057 (10) [back to overview]	Patient and Clinician Global Impression of Change (PGIC and CGIC) on a 7-point Likert Scale
NCT00863057 (10) [back to overview]	Emotional Functioning as Measured by the Center for Epidemiologic Studies Depression Scale (CES-D)
NCT00863057 (10) [back to overview]	Maximum Tolerated Dose of Duloxetine and Methadone
NCT00863057 (10) [back to overview]	Mean Nighttime Pain Measure on an 11-point Likert Scale
NCT00863057 (10) [back to overview]	Use of Rescue Medication (Acetaminophen)
NCT00929344 (3) [back to overview]	Change From Baseline in Drinking Quantity and Frequency Using Drinks Per Week at Week 12
NCT00929344 (3) [back to overview]	Change From Baseline in Drinking Quantity and Frequency Using Drinking Days Per Week at Week 12
NCT00929344 (3) [back to overview]	Change From Baseline in Drinking Quantity and Frequency Using Drinks Per Drinking Day at Week 12
NCT00945945 (2) [back to overview]	Number of Participants With Suicidal Behaviors and Ideations From the Columbia Suicide Severity Rating Scale
NCT00945945 (2) [back to overview]	"Change From Baseline to 13 Week Endpoint (Baseline Observation Carried Forward [BOCF]) in Brief Pain Inventory (BPI) 24-Hour Average Pain Item (Question 3) of the BPI-Modified Short Form Score"
NCT00960986 (16) [back to overview]	Patient Global Impression of Improvement (PGI-I) at 1 Week and 8 Weeks
NCT00960986 (16) [back to overview]	Mean Change From Baseline to 1-Week and 8-Week Endpoints in 17-Item Hamilton Depression Rating Scale (HAMD-17) Sleep Subscale
NCT00960986 (16) [back to overview]	Mean Change From Baseline to 1-Week and 8-Week Endpoints in 17-Item Hamilton Depression Rating Scale (HAMD-17) Retardation/Somatization Subscale
NCT00960986 (16) [back to overview]	Mean Change From Baseline to 1-Week and 8-Week Endpoints in 17-Item Hamilton Depression Rating Scale (HAMD-17) Maier Subscale
NCT00960986 (16) [back to overview]	Mean Change From Baseline to 8-Week Endpoint in Association for Methodology and Documentation in Psychiatry (AMDP-5) Adverse Event (AE) Scale Item 112 (Nausea)
NCT00960986 (16) [back to overview]	Mean Change From Baseline to 1-Week and 8-Week Endpoints in 17-Item Hamilton Depression Rating Scale (HAMD-17) Core Mood Subscale
NCT00960986 (16) [back to overview]	Percentage of Patients Achieving Remission
NCT00960986 (16) [back to overview]	Mean Change From Baseline to 1-Week and 8-Week Endpoints in Association for Methodology and Documentation in Psychiatry (AMDP-5) Measure: Common Adverse Events (AEs) Score
NCT00960986 (16) [back to overview]	Percentage of Participants Achieving Response
NCT00960986 (16) [back to overview]	Time to Resolve Nausea
NCT00960986 (16) [back to overview]	Mean Change From Baseline to 1-Week and 8-Week Endpoints in 17-Item Hamilton Depression Rating Scale (HAMD-17) Anxiety/Somatization Subscale
NCT00960986 (16) [back to overview]	Time to Onset of Nausea
NCT00960986 (16) [back to overview]	Mean Maximum Nausea Severity, Association for Methodology and Documentation in Psychiatry (AMDP-5) Adverse Event (AE) Scale Item 112 (Nausea)
NCT00960986 (16) [back to overview]	Mean Change From Baseline to 1-Week and 8-Week Endpoints in Clinical Global Impressions of Severity (CGI-S)
NCT00960986 (16) [back to overview]	Mean Change From Baseline to 1-Week and 8-Week Endpoints in Association for Methodology and Documentation in Psychiatry (AMDP-5) Measure: Gastric Events Score
NCT00960986 (16) [back to overview]	Mean Change From Baseline to 1-Week and 8-Week Endpoints in 17-Item Hamilton Depression Rating Scale (HAMD-17) Total Score
NCT00961298 (4) [back to overview]	Clinical Global Impression Scale
NCT00961298 (4) [back to overview]	Irritable Bowel Syndrome-Quality of Life Scale
NCT00961298 (4) [back to overview]	Irritable Bowel Syndrome Severity Scoring System
NCT00961298 (4) [back to overview]	Hamilton Anxiety Rating Scale
NCT00965081 (9) [back to overview]	Number of Participants With Suicidal Behaviors and Ideations Collected by Columbia -Suicide Severity Rating Scale (C-SSRS)
NCT00965081 (9) [back to overview]	Change From Baseline to 12-Week Endpoint 36-Item Short-Form Health Survey (SF-36)
NCT00965081 (9) [back to overview]	Change From Baseline to 12-Week Endpoint Beck Depression Inventory-II (BDI-II)
NCT00965081 (9) [back to overview]	"Change From Baseline to 12-Week Endpoint in the Brief Pain Inventory (BPI) 24-Hour Average Pain Item (Question 3) of the BPI-Modified Short Form Score"
NCT00965081 (9) [back to overview]	Change From Baseline to 12-Week Endpoint Beck Anxiety Inventory (BAI)
NCT00965081 (9) [back to overview]	Clinical Global Impression of Improvement (CGI-I) for Depression at Endpoint
NCT00965081 (9) [back to overview]	Change From Baseline to 12-Week Endpoint Fibromyalgia Impact Questionnaire (FIQ)
NCT00965081 (9) [back to overview]	Change From Baseline to 12-Week Endpoint in the Brief Pain Inventory (BPI) - Modified Short Form
NCT00965081 (9) [back to overview]	Patient Global Impression - Improvement (PGI-I) at Endpoint
NCT00981149 (2) [back to overview]	Spontaneous Pain as Measured by Visual Analog Scale at Baseline and at End of 6 Weeks.
NCT00981149 (2) [back to overview]	Evoked Pain Via Algometry .
NCT00985504 (11) [back to overview]	Percentage of Participants Who Relapsed During 8 Weeks
NCT00985504 (11) [back to overview]	Percentage of Participants Who Discontinue Due to Lack of Efficacy During 8 Weeks
NCT00985504 (11) [back to overview]	Patient's Global Impressions of Improvement Scale (PGI-I) Rating Scale Score at Week 8
NCT00985504 (11) [back to overview]	Change From Baseline in the Clinical Global Impression of Severity (CGI-S) Rating Scale at Week 8
NCT00985504 (11) [back to overview]	Change From Baseline in the Apathy Evaluation Scale - Clinician Rated Version (AES-C) Total Score at Week 8
NCT00985504 (11) [back to overview]	Number of Days From Baseline to Relapse as Defined by Montgomery-Asberg Depression Rating Scale (MADRS) Total Score ≥16 During 8 Weeks
NCT00985504 (11) [back to overview]	Change From Baseline in the Rothschild Scale for Antidepressant Tachyphylaxis (RSAT) Total and Individual Item Scores at Week 8
NCT00985504 (11) [back to overview]	Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score and Item 8 (Inability to Feel) at Week 8
NCT00985504 (11) [back to overview]	Change From Baseline in the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (MGH-CPFQ) Total and Item Scores at Week 8
NCT00985504 (11) [back to overview]	Change From Baseline in the Apathy Evaluation Scale-Clinician Rated Version (AES-C) Subscale Scores at Week 8
NCT00985504 (11) [back to overview]	Change From Baseline in the Sheehan Disability Scale (SDS) Total and Individual Scores at Week 8
NCT00989157 (5) [back to overview]	T1/2
NCT00989157 (5) [back to overview]	AUCo-inf,
NCT00989157 (5) [back to overview]	Cmax
NCT00989157 (5) [back to overview]	Tmax
NCT00989157 (5) [back to overview]	Emesis
NCT01000805 (14) [back to overview]	Change From Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score at Week 2
NCT01000805 (14) [back to overview]	Change From Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score at Week 4
NCT01000805 (14) [back to overview]	Change From Baseline in the Brief Pain Inventory-Short Form (BPI-SF) Average Pain Score During the 8-week Treatment Period
NCT01000805 (14) [back to overview]	Change From Baseline in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score at Week 8
NCT01000805 (14) [back to overview]	Change From Baseline in the Sheehan Disability Scale (SDS) Total and Item Scores at Week 8
NCT01000805 (14) [back to overview]	Change From Baseline in the Brief Pain Inventory Severity and Interference Scores (BPI-S/BPI-I) at Week 8
NCT01000805 (14) [back to overview]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Up to Week 8
NCT01000805 (14) [back to overview]	Change From Baseline in Pulse Rate up to Week 8
NCT01000805 (14) [back to overview]	Percentage of Participants Achieving Remission up to Week 8
NCT01000805 (14) [back to overview]	Patient's Global Impressions of Improvement Scale (PGI-I) at Week 8
NCT01000805 (14) [back to overview]	Number of Participants With Abnormal Laboratory Values During the Double-blind Treatment Phase - High Alanine Amino Transferase/Serum Glutamate Pyruvate Transaminase (ALT/SGPT)
NCT01000805 (14) [back to overview]	Change From Baseline in the Percentage of Participants Achieving Remission up to Week 8
NCT01000805 (14) [back to overview]	Number of Participants With Suicidal Behaviors, Ideations, and Acts Based on the Columbia Suicide Severity Rating Scale (C-SSRS) During the Double-blind Treatment Phase
NCT01000805 (14) [back to overview]	Change From Baseline in Weight up to Week 8
NCT01018680 (18) [back to overview]	Change From Baseline in the Brief Pain Inventory Severity and Interference Scores (BPI-S/BPI-I) Scores at 8 Weeks
NCT01018680 (18) [back to overview]	Percentage of Responders as Assessed by the Osteoarthritis Research Society International (OARSI) Response Criteria up to 8 Weeks
NCT01018680 (18) [back to overview]	Percentage of Participants With Abnormal Pulse Rate up to 10 Weeks
NCT01018680 (18) [back to overview]	Percentage of Participants With Abnormal High Hemoglobin A1c (HbA1c) up to 10 Weeks
NCT01018680 (18) [back to overview]	Percentage of Participants Who Discontinued Due to an Adverse Event During the 10-Week Treatment Period
NCT01018680 (18) [back to overview]	Percentage of Participants Using Acetaminophen Weekly During the 10-Week Treatment Period
NCT01018680 (18) [back to overview]	Patient Global Impression of Improvement (PGI-I) at 8 Weeks
NCT01018680 (18) [back to overview]	Change From Baseline in the Weekly Mean of the 24-Hour Average Pain Score at 8 Weeks
NCT01018680 (18) [back to overview]	Change From Baseline in the Patient Global Assessment of Illness (PGAI) at 8 Weeks
NCT01018680 (18) [back to overview]	Change From Baseline in the Clinical Global Impression of Severity (CGI-S) at 8 Weeks
NCT01018680 (18) [back to overview]	Change From Baseline in the Weekly Mean of the 24-Hour Night Pain and Worst Pain Scores at 8 Weeks
NCT01018680 (18) [back to overview]	Change From Baseline in the Profile of Mood States-Brief Form (BPOMS) Total and Subscale Scores at 8 Weeks
NCT01018680 (18) [back to overview]	Percentage of Participants With Abnormal Weight Gain and Weight Loss up to 10 Weeks
NCT01018680 (18) [back to overview]	Percentage of Participants With Abnormal Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) up to 10 Weeks
NCT01018680 (18) [back to overview]	Percentage of Participants With a Change of Better, Worse, or No Change in Health Outcomes as Measured by Resource Utilization (REU) up to 10 Weeks
NCT01018680 (18) [back to overview]	Percentage of Participants Who Achieved a 30 Percent or 50 Percent Reduction in the Weekly Mean of the 24-Hour Average Pain Score up to 8 Weeks
NCT01018680 (18) [back to overview]	Percentage of Participants Who Achieved a 30 Percent or 50 Percent Reduction in the Brief Pain Inventory-Severity (BPI-S) Average Pain Score up to 8 Weeks
NCT01018680 (18) [back to overview]	Change From Baseline in the Western Ontario and McMaster Universities Index of Osteoarthritis (WOMAC) Pain, Stiffness, and Physical Function Subscale Scores at 8 Weeks
NCT01028352 (2) [back to overview]	Decrease in Average Pain With 8 Weeks of Duloxetine Therapy. (Sustained)
NCT01028352 (2) [back to overview]	Percentage of Patients Who Experience 30% Reduction in Average Pain Score From Baseline to 8 Weeks Due to Duloxetine Therapy.
NCT01051466 (15) [back to overview]	Sheehan Disability Scale (SDS)
NCT01051466 (15) [back to overview]	Clinical Global Impressions of Severity Scale (CGI-S)
NCT01051466 (15) [back to overview]	Change From Baseline to 12-Week Endpoint in Activation [Blood Oxygenation-Level-Dependent (BOLD) Response to Implicit Processing of Sad Faces] for Each of the 3 Brain Regions
NCT01051466 (15) [back to overview]	Translocation of Gs Alpha (Gsα) From Lipid Rafts in the Cell Membranes of Red Blood Cells (RBCs), White Blood Cells (WBCs) and Platelets Compared With Baseline
NCT01051466 (15) [back to overview]	Change From Baseline to 12-Week Endpoint in Brain-Derived Neurotrophic Factor (BDNF) and the Precursor of BDNF (proBDNF) Receptors
NCT01051466 (15) [back to overview]	Change From Baseline to 12-Week Endpoint in the Functional Magnetic Resonance Imaging (fMRI) Mean Blood Oxygenation-Level-Dependent (BOLD) Response in the Amygdalae
NCT01051466 (15) [back to overview]	Percentage of Participants With 17-Item Hamilton Depression Rating Scale (HAMD17) Remission
NCT01051466 (15) [back to overview]	Percentage of Participants With 17-Item Hamilton Depression Rating Scale (HAMD17) Response
NCT01051466 (15) [back to overview]	17-Item Hamilton Depression Rating Scale (HAMD17)
NCT01051466 (15) [back to overview]	Change From Baseline to 12-Week Endpoint in Brain-Derived Neurotrophic Factor (BDNF) and the Precursor of BDNF (proBDNF)
NCT01051466 (15) [back to overview]	Change From Baseline to 12-Week Endpoint in Proinflammatory Cytokines [Tumor Necrosis Factor Alpha (TNFα), Interleukin 1 (IL-1), and Interleukin 6 (IL-6)]
NCT01051466 (15) [back to overview]	Change From Baseline to 12-Week Endpoint in Volume of Subgenual Anterior Cingulate, Amygdalae, and Hippocampus
NCT01051466 (15) [back to overview]	Patient's Global Impressions of Improvement (PGI-I) Scale
NCT01051466 (15) [back to overview]	Hamilton Anxiety Rating Scale (HAMA)
NCT01051466 (15) [back to overview]	Incidence of Suicidal Behavior and Suicidal Ideation as Measured by the Columbia Suicide Severity Rating Scale (C-SSRS)
NCT01070329 (14) [back to overview]	Change From Baseline in the Brief Pain Inventory Severity and Interference Scores (BPI-S/BPI-I) at Week 8
NCT01070329 (14) [back to overview]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Up to Week 8
NCT01070329 (14) [back to overview]	Change From Baseline in Pulse Rate up to Week 8
NCT01070329 (14) [back to overview]	Percentage of Participants Achieving Remission up to Week 8
NCT01070329 (14) [back to overview]	Patient Global Impression of Improvement (PGI-I) Score at Week 8
NCT01070329 (14) [back to overview]	Number of Participants With Abnormal Laboratory Values During the Double-Blind Treatment Phase - High Creatinine
NCT01070329 (14) [back to overview]	Change From Baseline in the Percentage of Participants Achieving Remission up to Week 8
NCT01070329 (14) [back to overview]	Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 2
NCT01070329 (14) [back to overview]	Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 8
NCT01070329 (14) [back to overview]	Change From Baseline in the Brief Pain Inventory-Short Form (BPI-SF) Average Pain Score During the 8-Week Treatment Period
NCT01070329 (14) [back to overview]	Change From Baseline in the Sheehan Disability Scale (SDS) Total and Item Scores at Week 8
NCT01070329 (14) [back to overview]	Change From Baseline in Weight up to Week 8
NCT01070329 (14) [back to overview]	Number of Participants With Suicidal Behaviors, Ideations, and Acts Based on the Columbia Suicide Severity Rating Scale (C-SSRS) During the Double-Blind Treatment Phase
NCT01070329 (14) [back to overview]	Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 4
NCT01089556 (31) [back to overview]	Change From Week 8 to Week 16 Endpoint in 24 Hour Average Pain Item Score on the Brief Pain Inventory (BPI) Modified Short Form
NCT01089556 (31) [back to overview]	Resource Utilization (Number of Days Hospitalized, Number of Days of Sick Leave) Baseline Through Week 8
NCT01089556 (31) [back to overview]	Percentage of Participants With a Reduction of Greater Than or Equal to 30% on Brief Pain Inventory (BPI) Modified Short Form 24-Hour Average Pain Item Score at Week 16 Endpoint
NCT01089556 (31) [back to overview]	Average Number of Hours Worked for Pay Per Week Week 8 Through Week 16
NCT01089556 (31) [back to overview]	Patient Global Impression of Improvement (PGI-I) Score at Week 16 Endpoint
NCT01089556 (31) [back to overview]	Mean Change From Baseline to Week 8 Endpoint in 24 Hour Average Pain Item Score on the Brief Pain Inventory (BPI) Modified Short Form
NCT01089556 (31) [back to overview]	Clinical Global Impression of Improvement (CGI-I) at Week 8 Endpoint
NCT01089556 (31) [back to overview]	Clinical Global Impression of Improvement (CGI-I) at Week 16 Endpoint
NCT01089556 (31) [back to overview]	Mean Change in Blood Pressure (BP) From Week 8 to Week 16 Endpoint
NCT01089556 (31) [back to overview]	Number of Participants Who Discontinued From Study Between Week 8 and Week 16 Endpoint
NCT01089556 (31) [back to overview]	Number of Participants With Treatment Emergent Adverse Events (TEAE) Between Baseline and Week 8 Endpoint
NCT01089556 (31) [back to overview]	Number of Participants With Treatment Emergent Adverse Events (TEAEs) Between Week 8 and Week 16 Endpoint
NCT01089556 (31) [back to overview]	Number of Participants Who Discontinued From Study Between Baseline and Week 8 Endpoint
NCT01089556 (31) [back to overview]	Mean Change From Baseline to Week 8 Endpoint in Sheehan Disability Scale (SDS)
NCT01089556 (31) [back to overview]	Patient Global Impression of Improvement (PGI-I) Score at Week 8 Endpoint
NCT01089556 (31) [back to overview]	Percentage of Participants With a Decrease of Greater Than or Equal to 2 Points on Brief Pain Inventory (BPI) Modified Short Form 24-Hour Average Pain Item Score at Week 16 Endpoint
NCT01089556 (31) [back to overview]	Percentage of Participants With a Decrease of Greater Than or Equal to 2 Points on Brief Pain Inventory (BPI) Modified Short Form 24-Hour Average Pain Item Score at Week 8 Endpoint
NCT01089556 (31) [back to overview]	Average Number of Hours Worked for Pay Per Week Baseline Through Week 8
NCT01089556 (31) [back to overview]	Percentage of Participants With a Reduction of Greater Than or Equal to 30% on Brief Pain Inventory (BPI) Modified Short Form 24-Hour Average Pain Item Score at Week 8 Endpoint
NCT01089556 (31) [back to overview]	Percentage of Participants With a Reduction of Greater Than or Equal to 50% on Brief Pain Inventory (BPI) Modified Short Form 24-Hour Average Pain Item Score at Week 16 Endpoint
NCT01089556 (31) [back to overview]	Percentage of Participants With a Reduction of Greater Than or Equal to 50% on Brief Pain Inventory (BPI) Modified Short Form 24-Hour Average Pain Item Score at Week 8 Endpoint
NCT01089556 (31) [back to overview]	Mean Change From Baseline to Week 8 Endpoint in Hospital Anxiety and Depression Scale (HADS)
NCT01089556 (31) [back to overview]	Resource Utilization (Number of Days Hospitalized, Number of Days of Sick Leave) Week 8 Through Week 16
NCT01089556 (31) [back to overview]	Mean Change From Week 8 to Week 16 Endpoint in Hospital Anxiety and Depression Scale (HADS)
NCT01089556 (31) [back to overview]	Mean Change in Blood Pressure (BP) From Baseline to Week 8 Endpoint
NCT01089556 (31) [back to overview]	Mean Change From Baseline to Week 8 Endpoint on the Neuropathic Pain Symptom Inventory (NPSI) Questionnaire
NCT01089556 (31) [back to overview]	Mean Change From Week 8 to Week 16 Endpoint in Items of the Brief Pain Inventory (BPI) Modified Short Form Worst Pain Score
NCT01089556 (31) [back to overview]	Mean Change From Week 8 to Week 16 Endpoint in Sheehan Disability Scale (SDS)
NCT01089556 (31) [back to overview]	Mean Change From Week 8 to Week 16 Endpoint on the Neuropathic Pain Symptom Inventory (NPSI) Questionnaire
NCT01089556 (31) [back to overview]	Mean Change in Heart Rate From Baseline to Week 8 Endpoint
NCT01089556 (31) [back to overview]	Mean Change in Heart Rate From Week 8 to Week 16 Endpoint
NCT01117857 (5) [back to overview]	Change in Overall Well Being Measured by the Clinical Global Impression Scale (CGI)
NCT01117857 (5) [back to overview]	Change in Depression Scores as Measured by the Hamilton Rating Scale for Depression
NCT01117857 (5) [back to overview]	Change in Menopause Symptoms as Measured by the Greene Climacteric Scale
NCT01117857 (5) [back to overview]	Change in Hot Flash Interference With Daily Activities and Quality of Life as Measured by the Hot Flash Related Daily Interference Scale (HFRDIS)
NCT01117857 (5) [back to overview]	Change in Anxiety as Measured by the Generalized Anxiety Disorder Questionnaire (GAD-7)
NCT01118780 (21) [back to overview]	Percentage of Participants With Response or Remission at Week 10 (Response and Remission Rates)
NCT01118780 (21) [back to overview]	Percentage of Participants With Sustained Improvement (Sustained Improvement Rate)
NCT01118780 (21) [back to overview]	Time to First Response
NCT01118780 (21) [back to overview]	Clinical Global Impressions of Improvement Scale (CGI-Improvement) at Week 10
NCT01118780 (21) [back to overview]	Change From Baseline to Week 10 in Sheehan Disability Scale (SDS) Global Functional Impairment Score
NCT01118780 (21) [back to overview]	Change From Baseline to Week 10 in Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) Total Score
NCT01118780 (21) [back to overview]	Patient's Global Impressions of Improvement Scale (PGI-Improvement) at Week 10
NCT01118780 (21) [back to overview]	Percentage of Participants Reporting Falling Down
NCT01118780 (21) [back to overview]	Time to First Functional Remission
NCT01118780 (21) [back to overview]	Time to First Improvement
NCT01118780 (21) [back to overview]	Change From Baseline to Week 10 in Hamilton Anxiety Rating Scale (HAMA) Total Score
NCT01118780 (21) [back to overview]	Time to Sustained Improvement Overall
NCT01118780 (21) [back to overview]	Change From Baseline to Week 10 Endpoint in Hospital Anxiety Depression Scale (HADS) Subscale Scores
NCT01118780 (21) [back to overview]	Change From Baseline to Week 10 in Brief Pain Inventory-Modified Short Form (BPI-SF) Pain Severity and Interference Subscales
NCT01118780 (21) [back to overview]	Change From Baseline to Week 10 in Hamilton Anxiety Rating Scale (HAMA) (Psychic Anxiety Factor Score, Somatic Anxiety Factor Score, and Individual Item Scores: Anxious Mood Item and Tension Item)
NCT01118780 (21) [back to overview]	Change From Baseline to Week 10 in Sheehan Disability Scale (SDS) Work/School, Social Life, and Family/Home Management Individual Impairment Scores
NCT01118780 (21) [back to overview]	Number of Participants Experiencing a Treatment-Emergent Adverse Event (AE) During the Taper Period
NCT01118780 (21) [back to overview]	Adverse Events (AEs) Leading to Discontinuation From Study
NCT01118780 (21) [back to overview]	Percentage of Participants With Functional Remission at Week 10 (Functional Remission Rate)
NCT01118780 (21) [back to overview]	Number of Participants With Treatment-Emergent Suicide-Related Ideation and Behavior Based on the Columbia Suicide Severity Rating Scale (C-SSRS)
NCT01118780 (21) [back to overview]	Time to First Remission
NCT01140906 (8) [back to overview]	Change in Clinical Status Using CGI-I Score at Week 8
NCT01140906 (8) [back to overview]	Potential Discontinuation Symptoms After Abrupt Discontinuation of Treatment With Vortioxetine
NCT01140906 (8) [back to overview]	Proportion of Remitters at Week 8 (Remission Defined as a MADRS Total Score <=10)
NCT01140906 (8) [back to overview]	Change From Baseline in ASEX Total Score After 8 Weeks of Treatment
NCT01140906 (8) [back to overview]	Change From Baseline in MADRS Total Score After 8 Weeks of Treatment in Patients With Baseline HAM-A Total Score ≥20
NCT01140906 (8) [back to overview]	Change From Baseline in MADRS Total Score After 8 Weeks of Treatment.
NCT01140906 (8) [back to overview]	Proportion of Responders at Week 8 (Response Defined as a >=50% Decrease in the MADRS Total Score From Baseline)
NCT01140906 (8) [back to overview]	Change From Baseline in SDS Total Score After 8 Weeks of Treatment
NCT01145755 (3) [back to overview]	MADRS Remission
NCT01145755 (3) [back to overview]	MADRS Total Score Change From Baseline to Week 6
NCT01145755 (3) [back to overview]	MADRS Response
NCT01153009 (6) [back to overview]	Percentage of Participants With a MADRS Response at Week 8
NCT01153009 (6) [back to overview]	Change From Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
NCT01153009 (6) [back to overview]	Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 8
NCT01153009 (6) [back to overview]	Change From Baseline in MADRS Total Score at Week 8 in Participants With Baseline Hamilton Anxiety Scale (HAM-A) Total Score ≥20
NCT01153009 (6) [back to overview]	Mean Clinical Global Impression Scale - Improvement (CGI-I) Score at Week 8
NCT01153009 (6) [back to overview]	Percentage of Participants in MADRS Remission at Week 8
NCT01179672 (10) [back to overview]	Mean Change From Baseline at 12-Week Endpoint in Weekly Mean of Night Pain and Worst Pain
NCT01179672 (10) [back to overview]	Mean Change From Baseline at 12 Week Endpoint in the SDS Total Score
NCT01179672 (10) [back to overview]	Percentage of Participants Who Experienced Equal to or Greater Than 30%, 50% or 75% Reduction From Baseline at 12-week Endpoint in BPI-Severity Average Pain Score
NCT01179672 (10) [back to overview]	Percentage of Participants Who Experience Equal to or Greater Than 30%, 50% or 75% Reduction From Baseline at 12-Week Endpoint in Weekly Mean of Average Daily Pain
NCT01179672 (10) [back to overview]	Patient Global Impression of Improvement (PGI-I) Scale at 12-Week Endpoint
NCT01179672 (10) [back to overview]	Mean Change From Baseline at 12-Week Endpoint in the Weekly Mean of Pain Severity Score
NCT01179672 (10) [back to overview]	Mean Change From Baseline at 12-Week Endpoint in the Sensory Subscale of the SF-MPQ
NCT01179672 (10) [back to overview]	Mean Change From Baseline at 12-Week Endpoint in the CGI-S Scale
NCT01179672 (10) [back to overview]	Mean Change From Baseline at 12-Week Endpoint in the BPI-Severity Scale
NCT01179672 (10) [back to overview]	Mean Change From Baseline at 12-week Endpoint in the BPI Interference Score
NCT01226511 (14) [back to overview]	Percentage of Participants During the 18-Week Extension Period With Treatment-Emergent (New or Worsening) Suicidal Behavior as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)
NCT01226511 (14) [back to overview]	Percentage of Participants During the 10-Week Period With Treatment-Emergent (New or Worsening) Suicidal Ideation as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)
NCT01226511 (14) [back to overview]	Percentage of Participants During the 10-Week Period With Treatment-Emergent (New or Worsening) Suicidal Behavior as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)
NCT01226511 (14) [back to overview]	Change From Baseline to 10-Week Endpoint on the Pediatric Anxiety Rating Scale (PARS) Severity Total Score Evaluated for All Symptoms Identified on the PARS Symptom Checklist Symptoms
NCT01226511 (14) [back to overview]	Change From Baseline to 10-Week Endpoint in the Pediatric Anxiety Rating Scale (PARS) Severity Score Evaluated for Symptoms Identified on the Generalized Anxiety Subsection of the PARS Symptom Checklist
NCT01226511 (14) [back to overview]	Change From Baseline to 10-Week Endpoint in the Children's Global Assessment Scale (CGAS)
NCT01226511 (14) [back to overview]	Response Rate at Endpoint for Generalized Anxiety Disorder (GAD) Using Pediatric Anxiety Rating Scale (PARS) Severity Score for GAD
NCT01226511 (14) [back to overview]	Change From 10-Week to 28-Week Endpoint on the Pediatric Anxiety Rating Scale (PARS) Severity Total Score Evaluated for All Symptoms Identified on the PARS Symptom Checklist Symptoms
NCT01226511 (14) [back to overview]	Change From 10-Week to 28-Week Endpoint on the Clinical Global Impression of Severity (CGI-S) Scale
NCT01226511 (14) [back to overview]	Change From 10-Week to 28-Week Endpoint in the Pediatric Anxiety Rating Scale (PARS) Severity Score Evaluated for Symptoms Identified on the Generalized Anxiety Subsection of the PARS Symptom Checklist
NCT01226511 (14) [back to overview]	Change From 10-Week to 28-Week Endpoint in the Children's Global Assessment Scale (CGAS)
NCT01226511 (14) [back to overview]	Change From Baseline to 10-Week Endpoint on the Clinical Global Impression of Severity (CGI-S) Scale
NCT01226511 (14) [back to overview]	Remission Rate at Endpoint for Generalized Anxiety Disorder (GAD) Using Clinical Global Impressions of Severity (CGI-S) Scale
NCT01226511 (14) [back to overview]	Percentage of Participants During the 18-Week Extension Period With Treatment-Emergent (New or Worsening) Suicidal Ideation as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)
NCT01237587 (20) [back to overview]	Change From Baseline in Functional Disability Inventory Parent Form (FDI-parent)
NCT01237587 (20) [back to overview]	Change From Baseline in Functional Disability Inventory Parent Form (FDI-Parent)
NCT01237587 (20) [back to overview]	Change From Baseline to 13 Week Endpoint in Brief Pain Inventory (BPI) Modified Short Form-adolescent Version 24 Hour Average Pain Severity Item
NCT01237587 (20) [back to overview]	Maintenance Effect in Acute Phase Responders on the Brief Pain Inventory (BPI) Modified Short Form-adolescent Version 24 Hour Average Pain Severity Item
NCT01237587 (20) [back to overview]	Number of Participants With Greater Than or Equal to 30% Reduction From Baseline in BPI 24 Hour Average Pain Severity Score at 13 Weeks
NCT01237587 (20) [back to overview]	Number of Participants With Greater Than or Equal to 50% Reduction From Baseline in BPI 24 Hour Average Pain Severity Score at 13 Weeks
NCT01237587 (20) [back to overview]	Change From Baseline in Multidimensional Anxiety Scale for Children (MASC)
NCT01237587 (20) [back to overview]	Change From Baseline in Multidimensional Anxiety Scale for Children (MASC)
NCT01237587 (20) [back to overview]	Change From Baseline in Pediatric Pain Questionnaire (PPQ) Item Scores
NCT01237587 (20) [back to overview]	Change From Baseline to 13 Week Endpoint in Brief Pain Inventory (BPI) Modified Short Form-Adolescent Version Severity and Interference Items
NCT01237587 (20) [back to overview]	Change From Baseline to 39 Week Endpoint in Brief Pain Inventory (BPI) Modified Short Form-adolescent Version Severity and Interference Items
NCT01237587 (20) [back to overview]	Change From Baseline in Pediatric Pain Questionnaire (PPQ) Item Scores
NCT01237587 (20) [back to overview]	Change From Baseline in Children's Depression Inventory (CDI)
NCT01237587 (20) [back to overview]	Change From Baseline in Children's Depression Inventory (CDI)
NCT01237587 (20) [back to overview]	Change From Baseline in Clinical Global Impression (CGI) Severity: Mental Illness Score
NCT01237587 (20) [back to overview]	Change From Baseline in Clinical Global Impression (CGI) Severity: Mental Illness Score
NCT01237587 (20) [back to overview]	Change From Baseline in Clinical Global Impression (CGI) Severity: Overall Illness Score
NCT01237587 (20) [back to overview]	Change From Baseline in Functional Disability Inventory Child Form (FDI-child)
NCT01237587 (20) [back to overview]	Change From Baseline in Clinical Global Impression (CGI) Severity: Overall Illness Score
NCT01237587 (20) [back to overview]	Change From Baseline in Functional Disability Inventory Child Form (FDI-Child)
NCT01288079 (1) [back to overview]	Change in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score From Randomization to End of Treatment
NCT01360866 (5) [back to overview]	Change From Baseline in the Inventory of Depressive Symptomatology - Self Report (IDS-SR) Total Score
NCT01360866 (5) [back to overview]	Change From Baseline in Mean Clinical Global Impression - Improvement (CGI-I) Score
NCT01360866 (5) [back to overview]	Mean Change From Baseline in Clinical Global Impression - Severity (CGI-S) of Illness Score
NCT01360866 (5) [back to overview]	Summary of Mean Change From Baseline in Sheehan Disability Scale (SDS) Mean Score
NCT01360866 (5) [back to overview]	Adverse Events (AEs) - All Participants
NCT01451606 (2) [back to overview]	Change in Rating of Spontaneous Pelvic Pain (0 -10 Scale).
NCT01451606 (2) [back to overview]	Change in Endometriosis Health Profile - 30 Subscale for Functional Limitations Due to Pain
NCT01552057 (14) [back to overview]	Change From Baseline to 14-Week Endpoint in Beck Depression Inventory-II (BDI-II)
NCT01552057 (14) [back to overview]	Change From Baseline to 14-Week Endpoint in Fibromyalgia Impact Questionnaire (FIQ)
NCT01552057 (14) [back to overview]	Change From Baseline to 14-Week Endpoint in the BPI 24-Hour Average Pain Severity Item of the BPI-Modified Short Form Score (MMRM)
NCT01552057 (14) [back to overview]	Change From Baseline to 2 Weeks in the BPI 24-Hour Average Pain Severity Item of the BPI-Modified Short Form Score (MMRM)
NCT01552057 (14) [back to overview]	Change From Baseline to 4 Weeks in the BPI 24-Hour Average Pain Severity Item of the BPI-Modified Short Form Score (MMRM)
NCT01552057 (14) [back to overview]	Change From Baseline to 10 Weeks in the BPI 24-Hour Average Pain Severity Item of the BPI-Modified Short Form Score (MMRM)
NCT01552057 (14) [back to overview]	Change From Baseline to 14-Week Endpoint in Widespread Pain Index (WPI) and Symptom Severity (SS) in American College of Rheumatology (ACR) Fibromyalgia Diagnostic Criteria 2010
NCT01552057 (14) [back to overview]	Change From Baseline to 14-Week Endpoint in Brief Pain Inventory-Severity (BPI-S) and Brief Pain Inventory-Interference (BPI-I) Scores on the BPI-Modified Short Form
NCT01552057 (14) [back to overview]	Change From Baseline to 14-Week Endpoint in Average Pain and Worst Pain Severity Score Within 24-Hours in Participant Diary
NCT01552057 (14) [back to overview]	Change From Baseline to 14-Week Endpoint in 36-Item Short-Form (SF-36) Health Survey Domain Scores
NCT01552057 (14) [back to overview]	Patients Global Impression of Improvement (PGI-I) at Endpoint
NCT01552057 (14) [back to overview]	Clinical Global Impression of Improvement (CGI-I) at Endpoint
NCT01552057 (14) [back to overview]	Change From Baseline up to 14-Week Endpoint in the BPI 24-Hour Average Pain Severity Item of the BPI-Modified Short Form Score (ANCOVA)
NCT01552057 (14) [back to overview]	Change From Baseline to 6 Weeks in the BPI 24-Hour Average Pain Severity Item of the BPI-Modified Short Form Score (MMRM)
NCT01558700 (2) [back to overview]	Change in Brain Gray Matter Volume
NCT01558700 (2) [back to overview]	Change in Pain Magnitude
NCT01564862 (15) [back to overview]	Change From Baseline to Week 8 in the Identification Task (IT)
NCT01564862 (15) [back to overview]	Change From Baseline to Week 8 in the Clinical Global Impressions-Severity (CGI-S) Score
NCT01564862 (15) [back to overview]	Change From Baseline to Week 8 in the MADRS Total Score
NCT01564862 (15) [back to overview]	Change From Baseline to Week 8 in the Trail Making Test B (TMT-B)
NCT01564862 (15) [back to overview]	Change From Baseline to Week 8 in the Trail Making Test (TMT-A)
NCT01564862 (15) [back to overview]	Clinical Global Impressions-Improvement (CGI-I) Score at Week 8
NCT01564862 (15) [back to overview]	Percentage of Participants in MADRS Remission at Week 8
NCT01564862 (15) [back to overview]	Percentage of Participants With MADRS Response at Week 8
NCT01564862 (15) [back to overview]	Change From Baseline to Week 8 in the One-Back Task
NCT01564862 (15) [back to overview]	Change From Baseline to Week 8 in the Groton Maze Learning Test (GMLT)
NCT01564862 (15) [back to overview]	Change From Baseline to Week 8 in the Digit Symbol Substitution Test (DSST)
NCT01564862 (15) [back to overview]	Change From Baseline to Week 8 in the Detection Task (DT)
NCT01564862 (15) [back to overview]	Proportion of Cognitive Dysfunction Improvement Due to Improvement of Depression
NCT01564862 (15) [back to overview]	Change From Baseline to Week 8 in the Perceived Deficits Questionnaire (PDQ) Attention/Concentration and Planning/Organization Subscore
NCT01564862 (15) [back to overview]	Change in Time From Baseline to Week 8 in the Stroop Test
NCT01598298 (3) [back to overview]	Worst Joint Pain According to the BPI-SF
NCT01598298 (3) [back to overview]	Average Joint Pain According to BPI-SF
NCT01598298 (3) [back to overview]	Pain Interference According to the BPI-SF
NCT01621191 (8) [back to overview]	Change From Baseline to 50-Week Endpoint in Beck Depression Inventory-II (BDI-II)
NCT01621191 (8) [back to overview]	Clinical Global Impression-Improvement (CGI-I) at Endpoint
NCT01621191 (8) [back to overview]	Change From Baseline to 50-Week Endpoint in Fibromyalgia Impact Questionnaire (FIQ)
NCT01621191 (8) [back to overview]	Change From Baseline to 50-Week Endpoint in Widespread Pain Index (WPI) and Symptom Severity (SS) in American College of Rheumatology (ACR) Fibromyalgia Diagnostic Criteria 2010
NCT01621191 (8) [back to overview]	Change From Baseline to 50-Week Endpoint in Brief Pain Inventory-Severity (BPI-S) and Brief Pain Inventory-Interference (BPI-I) Scores on the BPI-Modified Short Form
NCT01621191 (8) [back to overview]	Change From Baseline to 50-Week Endpoint in 36-Item Short-Form (SF-36) Health Survey Domain Scores
NCT01621191 (8) [back to overview]	Patient Global Impression-Improvement (PGI-I) at Endpoint
NCT01621191 (8) [back to overview]	Number of Participants Who Experienced an Adverse Event (AE)
NCT01754493 (5) [back to overview]	Montgomery-Asberg Depression Rating Scale (MADRS)
NCT01754493 (5) [back to overview]	Visual Analogue Scales (VAS)
NCT01754493 (5) [back to overview]	Somatization Module of the Patient's Health Questionnaire (PHQ-15)
NCT01754493 (5) [back to overview]	Gastrointestinal Symptoms Rating Scale (GSRS)
NCT01754493 (5) [back to overview]	Clinician-Rated Global Impression Scales (CGI)
NCT01852383 (4) [back to overview]	Change in Cornell Dysthymia Rating Scale Scores From Week 0 to Week 12
NCT01852383 (4) [back to overview]	Maximum Duloxetine Oral Dose
NCT01852383 (4) [back to overview]	Change in the Treatment Emergent Symptom Scale (TESS) Total Score From Week 0 to Week 12.
NCT01852383 (4) [back to overview]	Change in Hamilton Rating Scale for Depression (HAM-D, 24-item) From 0 Weeks to 12 Weeks.
NCT01855919 (14) [back to overview]	Percentage of Participants With Reduction of ≥30% and ≥50% in BPI Average Pain Score at Week 14
NCT01855919 (14) [back to overview]	Number of Participants With Suicidal Thoughts And Behaviors During Study [Columbia Suicide Severity Rating Scale (C-SSRS)]
NCT01855919 (14) [back to overview]	Change From Baseline in Work Productivity and Activity Impairment (WPAI) Instrument to Week 14
NCT01855919 (14) [back to overview]	Change From Baseline in Weekly Mean of 24 Hour Average Pain and Worst Daily Pain Severity Scores to Week 14
NCT01855919 (14) [back to overview]	Change From Baseline in BPI Pain Severity Items (BPI-S) and Interference Items (BPI-I) Scores to Week 14
NCT01855919 (14) [back to overview]	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) to Week 14
NCT01855919 (14) [back to overview]	Percentage of Participants With Sustained Pain Reduction in BPI Average Pain Score
NCT01855919 (14) [back to overview]	Percentage of Participants With Fall Events in Fall Questionnaire
NCT01855919 (14) [back to overview]	Patient Global Impression of Improvement (PGI-I) at Week 14
NCT01855919 (14) [back to overview]	Change From Baseline to Week 14 in Brief Pain Inventory (BPI) 24-Hour Average Pain Severity Item
NCT01855919 (14) [back to overview]	Change From Baseline in Roland Morris Disability Questionnaire (RMDQ-24) to Week 14
NCT01855919 (14) [back to overview]	Change From Baseline in European Quality of Life Questionnaire-5 Dimension (EQ-5D) to Week 14
NCT01855919 (14) [back to overview]	Change From Baseline in Clinical Global Impression of Severity (CGI-Severity) to Week 14
NCT01855919 (14) [back to overview]	Change From Baseline in Beck Depression Inventory-II (BDI-II) to Week 14
NCT01912612 (38) [back to overview]	Change in Cognitive Difficulties - Attention/Concentration Between Baseline and 5 Weeks of Treatment With Duloxetine
NCT01912612 (38) [back to overview]	Change in Cognitive Difficulties - Attention/Concentration Between Baseline and 5 Weeks of Treatment With Duloxetine
NCT01912612 (38) [back to overview]	Change in Cognitive Difficulties - Language Between Baseline and 5 Weeks of Treatment With Duloxetine
NCT01912612 (38) [back to overview]	Change in Objectively Assessed Pain Sensitivity Between Baseline and 5 Weeks of Treatment With Duloxetine
NCT01912612 (38) [back to overview]	Change in Cognitive Difficulties - Verbal Memory Between Baseline and 5 Weeks of Treatment With Duloxetine
NCT01912612 (38) [back to overview]	Change in Cognitive Difficulties - Verbal Memory Between Baseline and 5 Weeks of Treatment With Duloxetine
NCT01912612 (38) [back to overview]	Change in Cognitive Difficulties - Visual-Perceptual Ability Between Baseline and 5 Weeks of Treatment With Duloxetine
NCT01912612 (38) [back to overview]	Change in Cognitive Difficulties - Visual-Perceptual Ability Between Baseline and 5 Weeks of Treatment With Duloxetine
NCT01912612 (38) [back to overview]	Change in PainDETECT Score Between Baseline and 5 Weeks of Treatment With Duloxetine
NCT01912612 (38) [back to overview]	Change in Cognitive Difficulties - Language Between Baseline and 5 Weeks of Treatment With Duloxetine
NCT01912612 (38) [back to overview]	Change in Sleep Disturbance Between Baseline and 5 Weeks of Treatment With Duloxetine
NCT01912612 (38) [back to overview]	Change in Sleep Disturbance Between Baseline and 5 Weeks of Treatment With Duloxetine
NCT01912612 (38) [back to overview]	Change in Physical Function Between Baseline and 5 Weeks of Treatment With Duloxetine
NCT01912612 (38) [back to overview]	Change in Physical Function Between Baseline and 5 Weeks of Treatment With Duloxetine
NCT01912612 (38) [back to overview]	Change in Patient-reported Worst Pain Between Baseline and 5 Weeks of Treatment With Duloxetine
NCT01912612 (38) [back to overview]	Change in Patient-reported Worst Pain Between Baseline and 5 Weeks of Treatment With Duloxetine
NCT01912612 (38) [back to overview]	Change in Patient-reported Average Pain Between Baseline and 5 Weeks of Treatment With Duloxetine
NCT01912612 (38) [back to overview]	Change in Patient-reported Average Pain Between Baseline and 5 Weeks of Treatment With Duloxetine
NCT01912612 (38) [back to overview]	Change in PainDETECT Score Between Baseline and 5 Weeks of Treatment With Duloxetine
NCT01912612 (38) [back to overview]	Change in Pain Interference Between Baseline and 5 Weeks of Treatment With Duloxetine
NCT01912612 (38) [back to overview]	Change in Pain Interference Between Baseline and 5 Weeks of Treatment With Duloxetine
NCT01912612 (38) [back to overview]	Change in Objectively Assessed Pain Sensitivity Between Baseline and 5 Weeks of Treatment With Duloxetine
NCT01912612 (38) [back to overview]	Change in Objectively Assessed Conditioned Pain Modulation Between Baseline and 5 Weeks of Treatment With Duloxetine
NCT01912612 (38) [back to overview]	Change in Objectively Assessed Conditioned Pain Modulation Between Baseline and 5 Weeks of Treatment With Duloxetine
NCT01912612 (38) [back to overview]	Change in Number of Sites of Pain Between Baseline and 5 Weeks of Treatment With Duloxetine
NCT01912612 (38) [back to overview]	Change in Cognitive Difficulties - Visual-Spatial Memory Between Baseline and 5 Weeks of Treatment With Duloxetine
NCT01912612 (38) [back to overview]	Change in Number of Sites of Pain Between Baseline and 5 Weeks of Treatment With Duloxetine
NCT01912612 (38) [back to overview]	Change in Neuropathy Between Baseline and 5 Weeks of Treatment With Duloxetine
NCT01912612 (38) [back to overview]	Change in Neuropathy Between Baseline and 5 Weeks of Treatment With Duloxetine
NCT01912612 (38) [back to overview]	Change in Fibromyalgia Symptom Severity Score Between Baseline and 5 Weeks of Treatment With Duloxetine
NCT01912612 (38) [back to overview]	Change in Fibromyalgia Symptom Severity Score Between Baseline and 5 Weeks of Treatment With Duloxetine
NCT01912612 (38) [back to overview]	Change in Fatigue Between Baseline and 5 Weeks of Treatment With Duloxetine
NCT01912612 (38) [back to overview]	Change in Fatigue Between Baseline and 5 Weeks of Treatment With Duloxetine
NCT01912612 (38) [back to overview]	Change in Depression Between Baseline and 5 Weeks of Treatment With Duloxetine
NCT01912612 (38) [back to overview]	Change in Depression Between Baseline and 5 Weeks of Treatment With Duloxetine
NCT01912612 (38) [back to overview]	Change in Cognitive Difficulties - Visual-Spatial Memory Between Baseline and 5 Weeks of Treatment With Duloxetine
NCT01912612 (38) [back to overview]	Change in Anxiety Between Baseline and 5 Weeks of Treatment With Duloxetine
NCT01912612 (38) [back to overview]	Change in Anxiety Between Baseline and 5 Weeks of Treatment With Duloxetine
NCT01914666 (10) [back to overview]	Number of Participants With Fall Events From Fall Questionnaire
NCT01914666 (10) [back to overview]	Change From Baseline in Beck Depression Inventory-II (BDI-II) to Week 50
NCT01914666 (10) [back to overview]	Change From Baseline in Clinical Global Impression of Severity (CGI-Severity) to Week 50
NCT01914666 (10) [back to overview]	Change From Baseline in European Quality of Life Questionnaire-5 Dimension (EQ-5D) to Week 50
NCT01914666 (10) [back to overview]	Patient Global Impression of Improvement (PGI-Improvement) to Week 50
NCT01914666 (10) [back to overview]	Change From Baseline in Roland Morris Disability Questionnaire (RMDQ-24) to Week 50
NCT01914666 (10) [back to overview]	Number of Participants With Drug Related Adverse Events (AEs) or Any Serious AE's
NCT01914666 (10) [back to overview]	Change From Baseline in Columbia Suicide Severity Rating Scale (C-SSRS) to Week 52
NCT01914666 (10) [back to overview]	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) to Week 50
NCT01914666 (10) [back to overview]	Change From Baseline in Brief Pain Inventory (BPI) Pain Severity Item and Interference Item to Week 50
NCT01916824 (1) [back to overview]	Money Earned
NCT01931475 (10) [back to overview]	Change From Baseline in Western Ontario and McMaster Universities Arthritis Index (WOMAC) Total and Subscale Scores
NCT01931475 (10) [back to overview]	Percentage of Participants With Reduction of ≥30% and ≥50% in BPI Average Pain Score
NCT01931475 (10) [back to overview]	Change From Baseline in the Brief Pain Inventory (BPI) 24-hour Average Pain Score
NCT01931475 (10) [back to overview]	Change in Brief Pain Inventory (BPI) Average Pain Intensity Scores, Hospital Anxiety and Depression Scale (HADS) Depression Subscale (HADS-D) and HADS Anxiety Subscale (HADS-A)
NCT01931475 (10) [back to overview]	Change From Baseline in Clinical Global Impression of Severity (CGI-S) Score
NCT01931475 (10) [back to overview]	Patient Global Impressions of Improvement (PGI-I) Score
NCT01931475 (10) [back to overview]	Change From Baseline in Brief Pain Inventory (BPI) Interference
NCT01931475 (10) [back to overview]	Change From Baseline in Brief Pain Inventory (BPI) Severity
NCT01931475 (10) [back to overview]	Change From Baseline in Hospital Anxiety and Depression Scale-Depression (HADS-D) or HADS-Anxiety (HADS-A) Subscale Scores
NCT01931475 (10) [back to overview]	Percentage of Participants With Response to Treatment on Patient Global Impression-Improvement (PGI-I) at Endpoint
NCT01943435 (3) [back to overview]	Swiss Spinal Stenosis (SSS) Questionnaire Score
NCT01943435 (3) [back to overview]	Sense Wear Armband
NCT01943435 (3) [back to overview]	Self Paced Walking Test (SPWT)
NCT01973283 (15) [back to overview]	World Health Organization Disability Assessment 2.0 (36-item)--Stratified by Baseline Frailty
NCT01973283 (15) [back to overview]	World Health Organization Disability Assessment 2.0 (36-item)--Stratified by Baseline Frailty
NCT01973283 (15) [back to overview]	World Health Organization Disability Assessment 2.0 (36-item)--Stratified by Baseline Frailty
NCT01973283 (15) [back to overview]	World Health Organization Disability Assessment 2.0 (36-item)
NCT01973283 (15) [back to overview]	World Health Organization Disability Assessment 2.0 (36-item)
NCT01973283 (15) [back to overview]	World Health Organization Disability Assessment 2.0 (36-item)
NCT01973283 (15) [back to overview]	Hamilton Rating Scale for Depression (HRSD)
NCT01973283 (15) [back to overview]	Hamilton Rating Scale for Depression (HRSD)
NCT01973283 (15) [back to overview]	Hamilton Depression Rating Scale: Stratified by Baseline Frailty
NCT01973283 (15) [back to overview]	Hamilton Depression Rating Scale: Stratified by Baseline Frailty
NCT01973283 (15) [back to overview]	Hamilton Depression Rating Scale (HRSD)
NCT01973283 (15) [back to overview]	Hamilton Depression Rating Scale: Stratified by Baseline Frailty
NCT01973283 (15) [back to overview]	World Health Organization Disability Assessment 2.0 (36-item)--Stratified by Baseline Frailty
NCT01973283 (15) [back to overview]	Hamilton Depression Rating Scale: Stratified by Baseline Frailty
NCT01973283 (15) [back to overview]	World Health Organization Disability Assessment 2.0 (36-item)
NCT02005601 (3) [back to overview]	Total Daily Opioid Use (mg Oral Morphine Equivalents)
NCT02005601 (3) [back to overview]	NRS Pain With Ambulation at 2 Weeks
NCT02005601 (3) [back to overview]	Nausea Severity
NCT02229825 (26) [back to overview]	Change in Hamilton Scale of Anxiety (HAMA) Score From Baseline to Week 4
NCT02229825 (26) [back to overview]	Change in Hamilton Scale of Anxiety (HAMA) Score From Baseline to Week 8 - by Post-week 4 Treatment Groups
NCT02229825 (26) [back to overview]	Patient Global Impressions of Improvement (PGI-I) Score: Number of Patients Per Score at Week 1, 2, 3 and Week 4
NCT02229825 (26) [back to overview]	Clinical Global Impression of Improvement (CGI-I) Scale: Number of Patients Per Score at Week 6 and Week 8 - by Post-week 4 Treatment Groups
NCT02229825 (26) [back to overview]	Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Baseline to Week 4
NCT02229825 (26) [back to overview]	Number of Patients Withdrawn Due to Adverse Events
NCT02229825 (26) [back to overview]	Change From Baseline in Weight to Week 4 and Week 8
NCT02229825 (26) [back to overview]	Patient Global Impressions of Improvement (PGI-I) Score: Number of Patients Per Score at Week 6 and Week 8 - by Post-week 4 Treatment Groups
NCT02229825 (26) [back to overview]	Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Baseline to Week 1, 2 and Week 3
NCT02229825 (26) [back to overview]	Clinical Global Impressions Scales of Severity of Illness (CGI-SI): Number of Patients Per Score at Week 6 and Week 8 - by Post-week 4 Treatment Groups
NCT02229825 (26) [back to overview]	Clinical Global Impressions Scales of Severity of Illness (CGI-SI): Number of Patients Per Score at Baseline, Week 1, 2, 3 and Week 4
NCT02229825 (26) [back to overview]	Change in Hamilton Depression 6-item Scale (HAMD-6) Total Score From Baseline to Week 6 and Week 8 - by Post-week 4 Treatment Groups
NCT02229825 (26) [back to overview]	Change From Baseline in Blood Pressure to Week 4 and Week 8
NCT02229825 (26) [back to overview]	Reason for Living (RFL) Questionaire at Baseline
NCT02229825 (26) [back to overview]	Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Baseline to Week 6 and Week 8 - by Post-week 4 Treatment Groups
NCT02229825 (26) [back to overview]	Percentage of Responders at Week 6 and Week 8 According to Montgomery-Asberg Depression Rating Scale (MADRS) Scale - by Post-week 4 Treatment Groups
NCT02229825 (26) [back to overview]	Number of Patients With Treatment Emergent Adverse Event
NCT02229825 (26) [back to overview]	Change in Hamilton Depression 6-item Scale (HAMD-6) Total Score From Baseline to Week 1, 2, 3 and Week 4
NCT02229825 (26) [back to overview]	Number of Patients With Intake of Concomitant Medication for Anxiety and Sleep
NCT02229825 (26) [back to overview]	Number of Patients With Potentially Clinically Significant Laboratory Findings
NCT02229825 (26) [back to overview]	Percentage of Patients Reaching Remission at Week 8
NCT02229825 (26) [back to overview]	Percentage of Responders at Week 1, 2, 3 and Week 4 According to Hamilton Depression 6-item Scale (HAMD-6)
NCT02229825 (26) [back to overview]	Percentage of Responders at Week 1, 2, 3 and Week 4 According to Montgomery-Asberg Depression Rating Scale (MADRS) Scale
NCT02229825 (26) [back to overview]	Percentage of Responders at Week 6 and Week 8 According to Hamilton Depression 6-item Scale (HAMD-6) - by Post-week 4 Treatment Group
NCT02229825 (26) [back to overview]	Change From Baseline to Week 8 in Reason for Living (RFL) Questionnaire - by Post-week 4 Treatment Groups
NCT02229825 (26) [back to overview]	Clinical Global Impression of Improvement (CGI-I) Scale: Number of Patients Per Score at Week 1, 2, 3 and Week 4
NCT02248480 (16) [back to overview]	Change From Baseline on the WOMAC Questionnaire Physical Function Subscale
NCT02248480 (16) [back to overview]	Change From Baseline on the WOMAC Questionnaire Stiffness Subscale
NCT02248480 (16) [back to overview]	Change From Baseline on the Clinical Global Impression of Severity (CGI-S)
NCT02248480 (16) [back to overview]	Percentage of Participants With a Responder Rate Based on OMERACT-OARSI Criteria
NCT02248480 (16) [back to overview]	Percentage of Participants With Reduction of ≥30% and ≥50% in BPI Average Pain Score
NCT02248480 (16) [back to overview]	Percentage of Participants With Fall Events From Fall Questionnaire
NCT02248480 (16) [back to overview]	Change From Baseline on the 36-Item Short-Form Health Survey (SF-36)
NCT02248480 (16) [back to overview]	Change From Baseline in Patient Global Impression of Improvement (PGI-Improvement)
NCT02248480 (16) [back to overview]	Change From Baseline on Weekly Mean of the 24-Hour Average Pain and Worst Pain Score
NCT02248480 (16) [back to overview]	Change in Baseline in Brief Pain Inventory Severity and Interference Scores (BPI-S, BPI-I) Change From Baseline in BPI Pain Severity Items and Interference Items Score
NCT02248480 (16) [back to overview]	Change From Baseline on the 5 Dimension (EQ-5D) Version of the European Quality of Life Instrument
NCT02248480 (16) [back to overview]	Percentage of Participants With a 30% and 50% Reduction in Average Pain Score on Weekly Mean of the 24-Hour Average Pain Score on the 11-Point Numeric Rating Scale
NCT02248480 (16) [back to overview]	Change From Baseline on the Beck Depression Inventory (BDI-II) Total Score
NCT02248480 (16) [back to overview]	Change From Baseline on the Brief Pain Inventory (BPI) 24-Hour Average Pain Score
NCT02248480 (16) [back to overview]	Change From Baseline on the Western Ontario and McMaster Osteoarthritis Index (WOMAC) Questionnaire Total Score
NCT02248480 (16) [back to overview]	Change From Baseline on the WOMAC Questionnaire Pain Subscale
NCT02260388 (4) [back to overview]	PROMIS Fatigue Short Form v1.0 8a
NCT02260388 (4) [back to overview]	PROMIS Pain Interference Short Form v1.0 8a T Score
NCT02260388 (4) [back to overview]	PROMIS Sleep Disturbance Short Form v1.0 8a
NCT02260388 (4) [back to overview]	SF12 Health Composite Scores
NCT02335346 (9) [back to overview]	Percentage of Participants With Fall Events From Fall Questionnaire
NCT02335346 (9) [back to overview]	Change From Baseline to 50 Weeks on the 36-Item Short-Form Health Survey (SF-36)
NCT02335346 (9) [back to overview]	Percentage of Participants With Drug Related Adverse Events (AEs) or Any Serious Adverse Events (SAEs)
NCT02335346 (9) [back to overview]	Change From Baseline to 50 Weeks on the Brief Pain Inventory-Severity and Interference Rating Short Form (BPI-SF)
NCT02335346 (9) [back to overview]	Change From Baseline in Clinical Global Impression of Severity (CGI-S) to Week 50
NCT02335346 (9) [back to overview]	Change From Baseline to 50 Weeks on the 5 Dimension (EQ-5D) Version of the European Quality of Life Instrument
NCT02335346 (9) [back to overview]	Change From Baseline to 50 Weeks on the Beck Depression Inventory (BDI-II) Total Score
NCT02335346 (9) [back to overview]	Change From Baseline to 50 Weeks on the Western Ontario and McMaster Osteoarthritis Index (WOMAC) Questionnaire Total Score
NCT02335346 (9) [back to overview]	Patient Global Impression-Improvement (PGI-I) at 50 Weeks
NCT02417064 (16) [back to overview]	Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Day 28 of Double- Blind Induction Phase- Mixed- Effects Model Using Repeated Measures (MMRM) Analysis
NCT02417064 (16) [back to overview]	Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- ANCOVA Analysis
NCT02417064 (16) [back to overview]	Percentage of Participants With Onset of Clinical Response by Day 2 and Day 8
NCT02417064 (16) [back to overview]	Percentage of Participants Who Achieved at Least 50% Reduction From Baseline in MADRS Total Score at the Endpoint (Double-blind Induction Phase [Day 28]) (LOCF Data)
NCT02417064 (16) [back to overview]	Percentage of Participants Who Achieved at Least 50% Reduction From Baseline in MADRS Total Score at Day 28 of Double-blind Induction Phase (Observed Data)
NCT02417064 (16) [back to overview]	Change From Baseline in Patient Health Questionnaire-9 (PHQ-9) Total Score up to Day 28 of Double-blind Induction Phase- MMRM Analysis
NCT02417064 (16) [back to overview]	Percentage of Participants in Remission (MADRS<=12) at the Endpoint (Double-blind Induction Phase [Day 28])- ANCOVA Analysis (LOCF Data)
NCT02417064 (16) [back to overview]	Change From Baseline in Sheehan Disability Scale (SDS) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- ANCOVA Analysis
NCT02417064 (16) [back to overview]	Change From Baseline in Patient Health Questionnaire-9 (PHQ-9) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- ANCOVA Analysis
NCT02417064 (16) [back to overview]	Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score up to Endpoint (Double-blind Induction Phase [Day 28])
NCT02417064 (16) [back to overview]	Percentage of Participants in Remission (MADRS<=12) at Day 28 of Double-blind Induction Phase (Observed Data)
NCT02417064 (16) [back to overview]	Change From Baseline in Sheehan Disability Scale (SDS) Total Score up to Day 28 of Double-blind Induction Phase- MMRM Analysis
NCT02417064 (16) [back to overview]	Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) up to End of Double-blind Induction Phase (Day 28): EQ-VAS
NCT02417064 (16) [back to overview]	Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) up to End of Double-blind Induction Phase (Day 28): Health Status Index
NCT02417064 (16) [back to overview]	Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) up to End of Double-blind Induction Phase (Day 28): Sum Score
NCT02417064 (16) [back to overview]	Change From Baseline in Generalized Anxiety Disorder-7 Item (GAD-7) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])
NCT02417935 (10) [back to overview]	Change From Baseline to 12 Weeks on the Neuropathic Pain Symptom Inventory (NPSI)
NCT02417935 (10) [back to overview]	Change From Baseline to 12 Weeks in the Weekly Mean of the 24-Hour Average Pain Score on the 11-Point Numeric Rating Scale (NRS)
NCT02417935 (10) [back to overview]	Number of Participants With a 30% and 50% Reduction in the Weekly Mean of the 24-Hour Average Pain Score on the 11-Point NRS at 12 Weeks
NCT02417935 (10) [back to overview]	Change From Baseline to 12 Weeks on the Brief Pain Inventory-Severity and Interference Rating Short Form (BPI-SF)
NCT02417935 (10) [back to overview]	Patient Global Impression of Improvement (PGI-I) at 12 Weeks
NCT02417935 (10) [back to overview]	Clinical Global Impression of Improvement (CGI-I) at 12 Weeks
NCT02417935 (10) [back to overview]	Change From Baseline to 12 Weeks on the EuroQol 5 Dimension (EQ-5D)
NCT02417935 (10) [back to overview]	Change From Baseline to 12 Weeks in the Weekly Mean of Night Pain Scores on the 11-Point NRS
NCT02417935 (10) [back to overview]	Change From Baseline to 12 Weeks in the Weekly Mean of the 24-Hour Worst Pain Scores on the 11-Point NRS
NCT02417935 (10) [back to overview]	Change From Baseline to 12 Weeks on the Beck Depression Inventory-II (BDI-II) Total Score
NCT02418585 (16) [back to overview]	Change From Baseline in Clinical Global Impression-Severity (CGI-S) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])
NCT02418585 (16) [back to overview]	Percentage of Participants in Response (SDS Total Score <=12 and Individual Item Scores Each <=4) at the End of 4-Week Double-blind Induction Phase (Day 28)
NCT02418585 (16) [back to overview]	Percentage of Participants With Onset of Clinical Response on Day 2 and Day 8
NCT02418585 (16) [back to overview]	Percentage of Participants Who Achieved >=50% Reduction From Baseline in MADRS Total Score at the Endpoint (Double-blind Induction Phase [Day 28])
NCT02418585 (16) [back to overview]	Percentage of Participants in Remission (MADRS<=12) at the Endpoint (Double-blind Induction Phase [Day 28])
NCT02418585 (16) [back to overview]	Change From Baseline in Sheehan Disability Scale (SDS) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- ANCOVA Analysis
NCT02418585 (16) [back to overview]	Change From Baseline in Sheehan Disability Scale (SDS) Total Score up to Day 28 of Double-blind Induction Phase- MMRM Analysis
NCT02418585 (16) [back to overview]	Change From Baseline in Patient Health Questionnaire - 9-Item Depression Module (PHQ-9) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- ANCOVA Analysis
NCT02418585 (16) [back to overview]	Change From Baseline in Patient Health Questionnaire - 9-Item Depression Module (PHQ-9) Total Score up to Day 28 of Double-blind Induction Phase- MMRM Analysis
NCT02418585 (16) [back to overview]	Change From Baseline in EQ 5D-5L- European Quality of Life - Visual Analogue Scale (EQ-VAS) to End of Double-blind Induction Phase (Day 28)
NCT02418585 (16) [back to overview]	Percentage of Participants in Remission (SDS Total Score <=6 and Individual Item Scores Each <=2) at the End of 4-Week Double-blind Induction Phase (Day 28)
NCT02418585 (16) [back to overview]	Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- Analysis of Covariance (ANCOVA) Analysis
NCT02418585 (16) [back to overview]	Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Day 28 in the Double-blind Induction Phase- Mixed-Effects Model Using Repeated Measures (MMRM) Analysis
NCT02418585 (16) [back to overview]	Change From Baseline in Generalized Anxiety Disorder (GAD-7) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])
NCT02418585 (16) [back to overview]	Change From Baseline in EQ 5D-5L-Health Status Index to End of Double-blind Induction Phase (Day 28)
NCT02418585 (16) [back to overview]	Change From Baseline in EQ 5D-5L- Sum Score to End of Double-blind Induction Phase (Day 28)
NCT02422186 (8) [back to overview]	Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) to Endpoint (Double-blind Induction Phase [Day 28]): EQ-VAS
NCT02422186 (8) [back to overview]	Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) to Endpoint (Double-blind Induction Phase [Day 28]): Sum Score
NCT02422186 (8) [back to overview]	Change From Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score to Endpoint (Double-blind Induction Phase [Day 28])- Analysis of Covariance (ANCOVA) Analysis
NCT02422186 (8) [back to overview]	Change From Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- Mixed-Effects Model Using Repeated Measures (MMRM) Analysis
NCT02422186 (8) [back to overview]	Percentage of Participants in Remission (MADRS<=12) at Endpoint (Double-blind Induction Phase [Day 28]) (LOCF Data)
NCT02422186 (8) [back to overview]	Percentage of Participants Who Achieved >=50% Reduction From Baseline in MADRS Total Score at Endpoint (Double-blind Induction Phase [Day 28]) (LOCF Data)
NCT02422186 (8) [back to overview]	Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) to Endpoint (Double-blind Induction Phase [Day 28]): Health Status Index
NCT02422186 (8) [back to overview]	Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score to Endpoint (Double-blind Induction Phase [Day 28])- ANCOVA Analysis on Ranks
NCT02493868 (18) [back to overview]	Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Endpoint in Participants With Stable Remission (Maintenance Phase)
NCT02493868 (18) [back to overview]	Change From Baseline in PHQ-9 Total Score at Endpoint in Participants With Stable Response (But Not in Stable Remission) (Maintenance Phase)
NCT02493868 (18) [back to overview]	Change From Baseline in Patient Health Questionnaire-9 (PHQ-9) Total Score at Endpoint in Participants With Stable Remission (Maintenance Phase)
NCT02493868 (18) [back to overview]	Change From Baseline in MADRS Total Score at Endpoint in Participants With Stable Response (But Not in Stable Remission) (Maintenance Phase)
NCT02493868 (18) [back to overview]	Change From Baseline in MADRS Total Score at Endpoint in Participants With Stable Remission (Maintenance Phase)
NCT02493868 (18) [back to overview]	Change From Baseline in Generalized Anxiety Disorder-7 Items Total Score at Endpoint in Participants With Stable Response (But Not in Stable Remission) (Maintenance Phase)
NCT02493868 (18) [back to overview]	Change From Baseline in Generalized Anxiety Disorder-7 Items (GAD-7) Total Score at Endpoint in Participants With Stable Remission (Maintenance Phase)
NCT02493868 (18) [back to overview]	Change From Baseline in EuroQol-5 Dimension-5 Level Sum Score at Endpoint in Participants With Stable Response (But Not in Stable Remission) (Maintenance Phase)
NCT02493868 (18) [back to overview]	Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) Sum Score at Endpoint in Participants With Stable Remission (Maintenance Phase)
NCT02493868 (18) [back to overview]	Change From Baseline in EQ-5D-5L Health Status Index at Endpoint in Participants With Stable Response (But Not in Stable Remission) (Maintenance Phase)
NCT02493868 (18) [back to overview]	Change From Baseline in EQ-5D-5L Health Status Index at Endpoint in Participants With Stable Remission (Maintenance Phase)
NCT02493868 (18) [back to overview]	Change From Baseline in EQ-5D-5L EQ Visual Analogue Scale Score at Endpoint in Participants With Stable Response (But Not in Stable Remission) (Maintenance Phase)
NCT02493868 (18) [back to overview]	Change From Baseline in EQ Visual Analogue Scale Score at Endpoint in Participants With Stable Remission (Maintenance Phase)
NCT02493868 (18) [back to overview]	Change From Baseline in Clinical Global Impression-Severity Score at Endpoint in Participants With Stable Response (But Not in Stable Remission) (Maintenance Phase)
NCT02493868 (18) [back to overview]	Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score at Endpoint in Participants With Stable Remission (Maintenance Phase)
NCT02493868 (18) [back to overview]	Time to Relapse in Participants With Stable Remission (Maintenance Phase)
NCT02493868 (18) [back to overview]	Time to Relapse in Participants With Stable Response (But Not in Stable Remission) (Maintenance Phase)
NCT02493868 (18) [back to overview]	Change From Baseline in Sheehan Disability Total Score at Endpoint in Participants With Stable Response (But Not in Stable Remission) (Maintenance Phase)
NCT02497287 (34) [back to overview]	Change From Baseline to Endpoint in MADRS Total Score During Optimization/Maintenance (OP/MA) Phase
NCT02497287 (34) [back to overview]	Change From Baseline to Endpoint in Montgomery Asberg Depression Rating Scale (MADRS) Total Score During Induction (IND) Phase
NCT02497287 (34) [back to overview]	Change From Baseline to Endpoint in Generalized Anxiety Disorder (GAD-7) Total Score During IND Phase
NCT02497287 (34) [back to overview]	Change From Baseline to Endpoint in GAD-7 Total Score During OP/MA Phase
NCT02497287 (34) [back to overview]	Change From Baseline to Endpoint in European Quality of Life (EuroQol) 5-Dimension, 5-Level (EQ 5D-5L) During OP/MA Phase: Sum Score
NCT02497287 (34) [back to overview]	Change From Baseline to Endpoint in European Quality of Life (EuroQol) 5-Dimension, 5-Level (EQ 5D-5L) During IND Phase: Sum Score
NCT02497287 (34) [back to overview]	Change From Baseline to Endpoint in EQ-5D-5L Score During OP/MA Phase: EQ-VAS
NCT02497287 (34) [back to overview]	Change From Baseline to Endpoint in EQ-5D-5L Score During IND Phase: EQ-VAS
NCT02497287 (34) [back to overview]	Change From Baseline to Endpoint in EQ-5D-5L Scale Score During OP/MA Phase: Health Status Index
NCT02497287 (34) [back to overview]	Change From Baseline to Endpoint in EQ-5D-5L Scale Score During IND Phase: Health Status Index
NCT02497287 (34) [back to overview]	Change From Baseline to Endpoint in Clinical Global Impression of Severity (CGI-S) Scale Score During IND Phase
NCT02497287 (34) [back to overview]	Change From Baseline in Sheehan Disability Scale Total Score During OP/MA Phase
NCT02497287 (34) [back to overview]	Change From Baseline in Sheehan Disability Scale (SDS) Total Score During IND Phase
NCT02497287 (34) [back to overview]	Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) Score: Total Recall
NCT02497287 (34) [back to overview]	Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) Score: Recognition Discrimination Index
NCT02497287 (34) [back to overview]	Change From Baseline to Endpoint in Patient Health Questionnaire - 9 (PHQ-9) Total Score During IND Phase
NCT02497287 (34) [back to overview]	Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) Score: Number of Words Recalled
NCT02497287 (34) [back to overview]	Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) Score: Delayed Recall
NCT02497287 (34) [back to overview]	Change From Baseline in Cognitive Test Battery: One Card Learning Test (OCL) Score
NCT02497287 (34) [back to overview]	Change From Baseline in Cognitive Test Battery: One Back Test (ONB) Score
NCT02497287 (34) [back to overview]	Change From Baseline in Cognitive Test Battery: Identification Test (IDN) Score
NCT02497287 (34) [back to overview]	Change From Baseline in Cognitive Test Battery: Groton Maze Learning Test (GMLT) Score
NCT02497287 (34) [back to overview]	Percentage of Participants With an Increase Score From Predose at Any Time in CADSS Total Score During OP/MA Phase
NCT02497287 (34) [back to overview]	Percentage of Participants With an Increase Score From Predose at Any Time in Clinician-Administered Dissociative States Scale (CADSS) Total Score During IND Phase
NCT02497287 (34) [back to overview]	Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)
NCT02497287 (34) [back to overview]	Percentage of Participants With Cystitis, Urinary Tract Infections, Renal and Urinary Tract Symptoms, Renal and Urinary Disorders
NCT02497287 (34) [back to overview]	Percentage of Participants With Remission as Assessed by MADRS Total Score During IND Phase
NCT02497287 (34) [back to overview]	Percentage of Participants With Remission as Assessed by PHQ-9 Total Score During IND Phase
NCT02497287 (34) [back to overview]	Percentage of Participants With Response as Assessed by MADRS Total Score During IND Phase
NCT02497287 (34) [back to overview]	Percentage of Participants With Response as Assessed by PHQ-9 Total Score During IND Phase
NCT02497287 (34) [back to overview]	Percentage of Participants With Treatment-Emergent Acute Hypertension (Systolic and Diastolic) During IND and OP/MA Phases
NCT02497287 (34) [back to overview]	Change From Baseline in Cognitive Test Battery: Detection Test (DET) Score
NCT02497287 (34) [back to overview]	Change From Baseline to Endpoint in CGI-S Scale Score During OP/MA Phase
NCT02497287 (34) [back to overview]	Change From Baseline to Endpoint in PHQ-9 Total Score During OP/MA Phase
NCT02535000 (2) [back to overview]	Self Reported Pain Score Range From 0 (no Pain) to 10 (Worst Possible Pain).
NCT02535000 (2) [back to overview]	Total Consumption of Fentanyl (in Micrograms) Self-administered by the Patient and Accessed at 24 and 48 Hours After Spine Surgery.
NCT02655354 (13) [back to overview]	Change From Baseline PTSD Checklist- Civilian (PCL-C) Over the Course of the Year After Injury
NCT02655354 (13) [back to overview]	Change From Baseline Short Form (SF)-12/36 Physical Function Over the Course of the Year After Injury
NCT02655354 (13) [back to overview]	TSOS Patient Satisfaction: Mental Health Care
NCT02655354 (13) [back to overview]	Number of Participants Endorsing a Single Item That Assesses Marijuana Use
NCT02655354 (13) [back to overview]	Number of Participants Endorsing a Single Item That Assesses Opioid Use
NCT02655354 (13) [back to overview]	Number of Participants Endorsing a Single Item That Assesses Stimulant Use
NCT02655354 (13) [back to overview]	Number of Participants With Suicidal Ideation
NCT02655354 (13) [back to overview]	SF-36 Quality of Life
NCT02655354 (13) [back to overview]	Cognitive Impairment Scale
NCT02655354 (13) [back to overview]	Brief Pain Inventory
NCT02655354 (13) [back to overview]	Change From Baseline Alcohol Use Disorders Identification Over the Course of the Year After Injury
NCT02655354 (13) [back to overview]	Change From Baseline Patient Health Questionnaire 9 Item Depression Scale Over the Course of the Year After Injury
NCT02655354 (13) [back to overview]	TSOS Patient Satisfaction: Overall Health Care
NCT02903238 (2) [back to overview]	Brain Regional Gray Matter Density
NCT02903238 (2) [back to overview]	WOMAC Pain Index
NCT03038867 (55) [back to overview]	Prolactin Level at 10 Weeks
NCT03038867 (55) [back to overview]	Prolactin Level at 2 Weeks
NCT03038867 (55) [back to overview]	Prolactin Level at 6 Weeks
NCT03038867 (55) [back to overview]	Prolactin Level at 8 Weeks
NCT03038867 (55) [back to overview]	Sperm Concentration at 0 Weeks
NCT03038867 (55) [back to overview]	Sperm Concentration at 10 Weeks
NCT03038867 (55) [back to overview]	Sperm Concentration at 2 Weeks
NCT03038867 (55) [back to overview]	Sperm Concentration at 6 Weeks
NCT03038867 (55) [back to overview]	Sperm Concentration at 8 Weeks
NCT03038867 (55) [back to overview]	Sperm Head Defects at 0 Weeks
NCT03038867 (55) [back to overview]	Sperm Head Defects at 10 Weeks
NCT03038867 (55) [back to overview]	Sperm Head Defects at 2 Weeks
NCT03038867 (55) [back to overview]	Sperm Head Defects at 6 Weeks
NCT03038867 (55) [back to overview]	Sperm Head Defects at 8 Weeks
NCT03038867 (55) [back to overview]	Sperm Motility at 0 Weeks
NCT03038867 (55) [back to overview]	Sperm Motility at 10 Weeks
NCT03038867 (55) [back to overview]	Sperm Motility at 2 Weeks
NCT03038867 (55) [back to overview]	Sperm Motility at 6 Weeks
NCT03038867 (55) [back to overview]	Sperm Motility at 8 Weeks
NCT03038867 (55) [back to overview]	Sperm Neck Defects at 0 Weeks
NCT03038867 (55) [back to overview]	Sperm Neck Defects at 10 Weeks
NCT03038867 (55) [back to overview]	Sperm Neck Defects at 2 Weeks
NCT03038867 (55) [back to overview]	Sperm Neck Defects at 6 Weeks
NCT03038867 (55) [back to overview]	Sperm Neck Defects at 8 Weeks
NCT03038867 (55) [back to overview]	Sperm Tail Defects at 0 Weeks
NCT03038867 (55) [back to overview]	Sperm Tail Defects at 10 Weeks
NCT03038867 (55) [back to overview]	Sperm Tail Defects at 2 Weeks
NCT03038867 (55) [back to overview]	Sperm Tail Defects at 6 Weeks
NCT03038867 (55) [back to overview]	Sperm Tail Defects at 8 Weeks
NCT03038867 (55) [back to overview]	Testosterone Level at 0 Weeks
NCT03038867 (55) [back to overview]	Testosterone Level at 10 Weeks
NCT03038867 (55) [back to overview]	Testosterone Level at 2 Weeks
NCT03038867 (55) [back to overview]	Testosterone Level at 6 Weeks
NCT03038867 (55) [back to overview]	Testosterone Level at 8 Weeks
NCT03038867 (55) [back to overview]	Estrogen Level at 0 Weeks
NCT03038867 (55) [back to overview]	Luteinizing Hormone Level at 10 Weeks
NCT03038867 (55) [back to overview]	Estrogen Level at 10 Weeks
NCT03038867 (55) [back to overview]	Estrogen Level at 2 Weeks
NCT03038867 (55) [back to overview]	Estrogen Level at 6 Weeks
NCT03038867 (55) [back to overview]	Estrogen Level at 8 Weeks
NCT03038867 (55) [back to overview]	Follicle Stimulating Hormone Level at 0 Weeks
NCT03038867 (55) [back to overview]	Follicle Stimulating Hormone Level at 10 Weeks
NCT03038867 (55) [back to overview]	Follicle Stimulating Hormone Level at 2 Weeks
NCT03038867 (55) [back to overview]	Follicle Stimulating Hormone Level at 6 Weeks
NCT03038867 (55) [back to overview]	Follicle Stimulating Hormone Level at 8 Weeks
NCT03038867 (55) [back to overview]	Luteinizing Hormone Level at 0 Weeks
NCT03038867 (55) [back to overview]	Luteinizing Hormone Level at 2 Weeks
NCT03038867 (55) [back to overview]	Luteinizing Hormone Level at 6 Weeks
NCT03038867 (55) [back to overview]	Luteinizing Hormone Level at 8 Weeks
NCT03038867 (55) [back to overview]	Number of Participants With Abnormal Sperm DNA Fragmentation at 0 Weeks
NCT03038867 (55) [back to overview]	Number of Participants With Abnormal Sperm DNA Fragmentation at 10 Weeks
NCT03038867 (55) [back to overview]	Number of Participants With Abnormal Sperm DNA Fragmentation at 2 Weeks
NCT03038867 (55) [back to overview]	Number of Participants With Abnormal Sperm DNA Fragmentation at 6 Weeks
NCT03038867 (55) [back to overview]	Number of Participants With Abnormal Sperm DNA Fragmentation at 8 Weeks
NCT03038867 (55) [back to overview]	Prolactin Level at 0 Weeks
NCT03271151 (3) [back to overview]	Opioid Use
NCT03271151 (3) [back to overview]	Pain Scores
NCT03271151 (3) [back to overview]	Pain Phenotype
NCT03315793 (5) [back to overview]	Change From Baseline on Clinical Global Impression-Severity (CGI-S)
NCT03315793 (5) [back to overview]	Change From Baseline on the Children's Depression Rating Scale-Revised (CDRS-R) Total Score
NCT03315793 (5) [back to overview]	Percentage of Participants Whose CDRS-R Total Score Decreased by More Than 50% From Baseline
NCT03315793 (5) [back to overview]	Percentage of Participants Whose Children's Depression Rating Scale-Revised (CDRS-R) Total Score Decreased by More Than 30% From Baseline
NCT03315793 (5) [back to overview]	Percentage of Participants With Total Children's Depression Rating Scale-Revised (CDRS-R) Score ≤ 28
NCT03321006 (3) [back to overview]	Clinical Global Impression Severity and Improvement (CGI)
NCT03321006 (3) [back to overview]	Hamilton Rating Score for Depression (HRSD)
NCT03321006 (3) [back to overview]	Social Adjustment Scale Self-Report (SAS-SR) Score
NCT03395353 (4) [back to overview]	Change From Baseline on the Children's Depression Rating Scale-Revised (CDRS-R)
NCT03395353 (4) [back to overview]	Change From Baseline on the Clinical Global Impression-Severity of Illness (CGI-S)
NCT03395353 (4) [back to overview]	Pharmacokinetics (PK): Trough Concentration of Duloxetine
NCT03395353 (4) [back to overview]	Percentage of Participants With Adverse Events (AEs), Drug Related Adverse Events (ADRs) or Any Serious Adverse Events (SAEs)
NCT03434041 (12) [back to overview]	Change From Baseline in Participant-Reported Health Status as Assessed by EuroQol-5 Dimension-5 Level (EQ-5D-5L) Score up to the Endpoint (Double-blind Treatment Phase [Day 28]): Visual Analogue Scale (VAS)
NCT03434041 (12) [back to overview]	Change From Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score to the End of Double-blind Treatment Phase (Day 28)
NCT03434041 (12) [back to overview]	Change From Baseline in Generalized Anxiety Disorder 7-item (GAD-7) Scale Score up to the Endpoint (Double-blind Treatment Phase [Day 28])
NCT03434041 (12) [back to overview]	Change From Baseline in Depressive Symptoms as Measured by the MADRS Total Score to 24 Hours Post First Dose (Day 2)
NCT03434041 (12) [back to overview]	Percentage of Participants in Remission at the End of Double-blind Treatment Phase (Day 28)
NCT03434041 (12) [back to overview]	Change From Baseline in Sheehan Disability Scale (SDS) Total Score to the End of Double-blind Treatment Phase (Day 28)
NCT03434041 (12) [back to overview]	Change From Baseline in Participant-Reported Health-Related Quality of Life as Assessed by EuroQol-5 Dimension-5 Level (EQ-5D-5L) Score up to the Endpoint (Double-blind Treatment Phase [Day 28]): Health Status Index
NCT03434041 (12) [back to overview]	Change From Baseline in Clinical Global Impression Severity (CGI-S) Scale Score up to the Endpoint (Double-blind Treatment Phase [Day 28])
NCT03434041 (12) [back to overview]	Change From Baseline in Participant-Reported Health Status as Assessed by EuroQol-5 Dimension-5 Level (EQ-5D-5L) up to the Endpoint (Double-blind Treatment Phase [Day 28]): Sum Score
NCT03434041 (12) [back to overview]	Percentage of Participants With Onset of Clinical Response
NCT03434041 (12) [back to overview]	Percentage of Participants With Sustained Remission
NCT03434041 (12) [back to overview]	Percentage of Responders at the End of Double-blind Treatment Phase (Day 28)
NCT04178993 (36) [back to overview]	Subjective Effects of Methamphetamine (20 mg) Administration Following Methylphenidate (0 mg) Maintenance.
NCT04178993 (36) [back to overview]	Subjective Effects of Methamphetamine (10 mg) Administration Following Methylphenidate (60 mg) Maintenance.
NCT04178993 (36) [back to overview]	Subjective Effects of Methamphetamine (10 mg) Administration Following Methylphenidate (40 mg) Maintenance.
NCT04178993 (36) [back to overview]	Subjective Effects of Methamphetamine (10 mg) Administration Following Methylphenidate (20 mg) Maintenance.
NCT04178993 (36) [back to overview]	Subjective Effects of Methamphetamine (10 mg) Administration Following Methylphenidate (0 mg) Maintenance.
NCT04178993 (36) [back to overview]	Subjective Effects of Methamphetamine (0 mg) Administration Following Methylphenidate (60 mg) Maintenance.
NCT04178993 (36) [back to overview]	Subjective Effects of Methamphetamine (0 mg) Administration Following Methylphenidate (40 mg) Maintenance.
NCT04178993 (36) [back to overview]	Subjective Effects of Methamphetamine (0 mg) Administration Following Methylphenidate (20 mg) Maintenance.
NCT04178993 (36) [back to overview]	Subjective Effects of Methamphetamine (0 mg) Administration Following Methylphenidate (0 mg) Maintenance.
NCT04178993 (36) [back to overview]	Snaith-Hamilton-Pleasure Scale to Measure Anhedonia (Inability to Experience Pleasure)
NCT04178993 (36) [back to overview]	Reinforcing Effects of Methamphetamine Following Methylphenidate (40 mg) Maintenance.
NCT04178993 (36) [back to overview]	Reinforcing Effects of Methamphetamine Following Methylphenidate (20 mg) Maintenance.
NCT04178993 (36) [back to overview]	Reinforcing Effects of Methamphetamine Following Methylphenidate (0 mg; Placebo) Maintenance.
NCT04178993 (36) [back to overview]	Reinforcing Effects of Methamphetamine Following Methylphenidate (60 mg) Maintenance.
NCT04178993 (36) [back to overview]	Heart Rate After Methamphetamine Administration Following Methylphenidate (60 mg) Maintenance.
NCT04178993 (36) [back to overview]	Heart Rate After Methamphetamine Administration Following Methylphenidate (40 mg) Maintenance.
NCT04178993 (36) [back to overview]	Heart Rate After Methamphetamine Administration Following Methylphenidate (20 mg) Maintenance.
NCT04178993 (36) [back to overview]	Heart Rate After Methamphetamine Administration Following Methylphenidate (0 mg) Maintenance.
NCT04178993 (36) [back to overview]	Diastolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (60 mg) Maintenance.
NCT04178993 (36) [back to overview]	Diastolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (40 mg) Maintenance.
NCT04178993 (36) [back to overview]	Diastolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (20 mg) Maintenance.
NCT04178993 (36) [back to overview]	Systolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (0 mg) Maintenance.
NCT04178993 (36) [back to overview]	Subjective Effects of Methamphetamine (20 mg) Administration Following Methylphenidate (60 mg) Maintenance.
NCT04178993 (36) [back to overview]	Subjective Effects of Methamphetamine (20 mg) Administration Following Methylphenidate (40 mg) Maintenance.
NCT04178993 (36) [back to overview]	Diastolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (0 mg) Maintenance.
NCT04178993 (36) [back to overview]	Delay Discounting for Money
NCT04178993 (36) [back to overview]	Delay Discounting for Methamphetamine
NCT04178993 (36) [back to overview]	Attentional Bias
NCT04178993 (36) [back to overview]	Subjective Effects of Methamphetamine (20 mg) Administration Following Methylphenidate (20 mg) Maintenance.
NCT04178993 (36) [back to overview]	Temperature After Methamphetamine Administration Following Methylphenidate (60 mg) Maintenance.
NCT04178993 (36) [back to overview]	Temperature After Methamphetamine Administration Following Methylphenidate (40 mg) Maintenance.
NCT04178993 (36) [back to overview]	Temperature After Methamphetamine Administration Following Methylphenidate (20 mg) Maintenance.
NCT04178993 (36) [back to overview]	Temperature After Methamphetamine Administration Following Methylphenidate (0 mg) Maintenance.
NCT04178993 (36) [back to overview]	Systolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (60 mg) Maintenance.
NCT04178993 (36) [back to overview]	Systolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (40 mg) Maintenance.
NCT04178993 (36) [back to overview]	Systolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (20 mg) Maintenance.
NCT04476030 (16) [back to overview]	Percentage of Participants With CGI-I Response, at Day 3 and Day 15
NCT04476030 (16) [back to overview]	Percentage of Participants With MADRS Response at Day 15
NCT04476030 (16) [back to overview]	Percentage of Participants With MADRS Remission at Day 15
NCT04476030 (16) [back to overview]	Change From Baseline in the HAMD-17 Total Score Over the Double-Blind Treatment Period
NCT04476030 (16) [back to overview]	Change From Baseline in CGI-S Score at Day 15
NCT04476030 (16) [back to overview]	Change From Baseline in HAM-A Total Score at Day 15
NCT04476030 (16) [back to overview]	Change From Baseline in MADRS Total Score at Day 15
NCT04476030 (16) [back to overview]	Change From Baseline in the HAMD-17 Total Score Around End of Blinded Treatment
NCT04476030 (16) [back to overview]	Change From Baseline in the HAMD-17 Total Score at Day 3
NCT04476030 (16) [back to overview]	Percentage of Participants With HAMD-17 Remission at Day 15 and Day 42
NCT04476030 (16) [back to overview]	Percentage of Participants With HAMD-17 Response at Day 15 and Day 42
NCT04476030 (16) [back to overview]	Percentage of Participants With TEAEs, Graded by Severity
NCT04476030 (16) [back to overview]	Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
NCT04476030 (16) [back to overview]	Change From Baseline in Depressive Symptoms at Day 15, as Assessed by PHQ-9
NCT04476030 (16) [back to overview]	Time to First HAMD-17 Response
NCT04476030 (16) [back to overview]	Change From Baseline in the HAMD-17 Total Score at Days 15 and 42
NCT04697693 (1) [back to overview]	Change in Hamilton Rating Score for Depression (HRSD) From Baseline to Week 8

Change From Baseline to Endpoint in Arizona Sexual Experience Scale (ASEX) - Acute and Continuation Phases (Males)

A 5-item patient-rated scale measuring 5 domains: sexual drive, arousal (subjective excitement), lubrication/erection (physiological excitement), ability to reach orgasm, orgasm satisfaction. Higher score means worse dysfunction. Total score range is 5-30. (NCT00105989)
Timeframe: Week 0 and Week 10 (Acute) and Week 34 (Continuation)

Intervention	units on a scale (Mean)
	Sum Items 1 to 5 Baseline (N=117,N=97)	Sum Items 1 to 5 Change to Endpoint	Sum Items 1&2 Baseline (N=135, N=109)	Sum Items 1&2 Change to Endpoint	Item 1-Sex Drive Baseline (N=136,N=109)	Item 1-Sex Drive Change to Endpoint	Item 2-Arousal Baseline (N=135, N=109)	Item 2-Arousal Change to Endpoint	Item 3-Lubrication/Erection Baseline (N=124,N=99)	Item 3-Lubrication Change to Endpoint	Item 4-Orgasm Baseline (N=120,N=98)	Item 4-Orgasm Change to Endpoint	Item 5-Satisfaction Baseline (N=118,N=97)	Item 5-Satisfaction Change to Endpoint
Duloxetine - Acute Phase	17.57	0.13	7.47	-0.19	3.91	-0.15	3.56	-0.02	3.43	-0.02	3.38	0.32	3.36	0.05
Duloxetine - Continuation Phase	17.26	-0.67	7.16	-0.39	3.68	-0.21	3.48	-0.18	3.27	-0.04	3.60	-0.15	3.32	-0.15

Intervention	kilograms (Mean)
	Weight Baseline	Weight Change from Baseline to Endpoint
Duloxetine - Acute Phase	74.74	-0.69
Duloxetine - Continuation Phase	74.22	0.88

Intervention	beats per minute (Mean)
	Pulse Baseline	Pulse Change from Baseline to Endpoint
Duloxetine - Acute Phase	71.76	1.42
Duloxetine - Continuation Phase	72.79	1.75

Intervention	mm Hg (Least Squares Mean)
	Change from Baseline: Systolic Blood Pressure	Change from Baseline: Diastolic Blood Pressure
Duloxetine	1.70	-0.23
Placebo	-1.11	-0.11

Intervention	mm Hg (Mean)
	Systolic Blood Pressure Baseline	Systolic Blood Pressure Change to Endpoint	Diastolic Blood Pressure Baseline	Diastolic Blood Pressure Change to Endpoint
Duloxetine - Acute Phase	125.03	0.25	77.52	0.72
Duloxetine - Continuation Phase	124.72	0.77	78.28	-0.57

Intervention	participants (Number)
	Patients with >= 1 Adverse Event	Headache	Nasopharyngitis	Hyperhidrosis	Back pain	Diarrhoea
Duloxetine 120 mg	59	6	9	5	8	2
Duloxetine 60 mg	102	21	7	8	7	10
Duloxetine 90 mg	83	12	10	12	4	6

Intervention	participants (Number)
	Patients with >= 1 Adverse Event	Nausea	Headache	Dry mouth	Hyperhidrosis	Fatigue	Constipation	Dizziness	Diarrhoea	Vomiting	Insomnia	Decreased appetite
Duloxetine - Acute Phase	349	150	79	76	76	60	48	41	38	28	27	26

Intervention	micromoles per Liter (Mean)
	Baseline	Change to Endpoint
Duloxetine - Acute Phase	297.05	-10.64

Intervention	millimoles per Liter (Mean)
	Fasting Glucose Baseline (N=120,N=112)	Fasting Glucose Change to Endpoint	Non-Fasting Glucose Baseline (N=41,N=39)	Non-Fasting Glucose Change to Endpoint
Duloxetine	5.40	0.07	5.68	-0.20
Placebo	5.47	0.03	5.74	0.62

Intervention	visits (Least Squares Mean)
	Primary Health Care Provider Visits (N=47,N=47)	Psychiatrist Visits (N=33,N=23)	Psychologist/Therapist Visits (N=8,N=7)	Other Specialist Physician Visits (N=25,N=25)	Other (Specified by Patient) Visits (N=5,N=3)
Duloxetine	-0.00	-0.01	-0.02	0.00	0.04
Placebo	-0.00	-0.01	-0.01	-0.00	0.00

Intervention	visits (Mean)
	Primary Health Care Provider Visits (N=94,N=99)	Psychiatrist Visits (N=91,N=65)	Psychologist/Therapist Visits (N=19,N=11)	Other Specialist Physician Visits (N=42,N=38)	Other (Specified by Patient) Visits (N=3,N=3)
Duloxetine - Acute Phase	-0.00	0.03	0.01	-0.00	0.04
Duloxetine - Continuation Phase	-0.00	-0.03	-0.00	0.01	-0.07

Intervention	hours (Mean)
	Number of Missed Paid Work Hours Baseline	Change in Number of Missed Paid Work Hours
Duloxetine - Acute	1.77	0.46
Duloxetine - Continuation Phase	2.67	-0.52

Intervention	hours (Mean)
	Average Number of Hours Worked In a Week Baseline	Change in Average Number of Hours Worked In a Week
Duloxetine - Acute Phase	0.36	0.00
Duloxetine - Continuation Phase	0.36	0.01

Intervention	percentage of participants (Number)
	t=7 days (N=142, N=140)	t=14 days (N=140, N=138)	t=21 days (N=136, N=130)	t=28 days (N=132, N=125)	t=56 days (N=124, N=105)	t=84 days (N=114, N=88)	t=112 days (N=105, N=81)	t=140 days (N=100, N=72)	t=168 days (N=95, N=70)	t=196 days (N=93, N=67)	t=224 days (N=90, N=65)	t=252 days (N=84, N=60)	t=280 days (N=81, N=60)	t=308 days (N=78, N=59)	t=336 days (N=77, N=56)	t=364 days (N=75, N=51)
Duloxetine	2.07	3.45	5.53	7.63	11.89	16.99	21.48	23.02	24.61	26.19	28.57	31.04	31.88	31.88	31.88	33.65
Placebo	1.41	1.41	7.12	9.30	22.57	31.86	35.07	40.82	42.47	44.14	45.80	45.80	45.80	46.71	49.42	51.33

Intervention	percentage of participants (Number)
	t=7 days (N=145, N=139)	t=14 days (N=143, N=138)	t=21 days (N=141, N=137)	t=28 days (N=140, N=135)	t=56 days (N=136, N=120)	t=84 days (N=131, N=106)	t=112 days (N=122, N=96)	t=140 days (N=119, N=89)	t=168 days (N=115, N=86)	t=196 days (N=111, N=86)	t=224 days (N=108, N=85)	t=252 days (N=105, N=82)	t=280 days (N=99, N=77)	t=308 days (N=96, N=75)	t=336 days (N=95, N=74)	t=364 days (N=93, N=73)
Duloxetine	0.68	1.37	1.37	2.07	4.19	6.33	8.58	9.34	10.89	11.69	12.50	13.32	13.32	13.32	14.23	16.03
Placebo	2.11	2.11	2.82	3.54	12.97	21.15	25.79	28.98	28.98	28.98	29.80	32.28	34.00	34.86	34.86	35.74

Intervention	units on a scale (Least Squares Mean)
	Change from Baseline to Endpoint in Overall Pain	Change from Baseline to Endpoint in Headache	Change from Baseline to Endpoint in Back Pain	Change from Baseline to Endpoint in Shoulder Pain	Change: Interference with Daily Activities	Change from Baseline in Pain While Awake
Duloxetine	3.92	4.77	1.77	0.51	3.16	3.64
Placebo	4.57	2.80	3.40	3.02	2.81	4.69

Intervention	units on a scale (Mean)
	Overall Pain Baseline (N=450, N=410)	Overall Pain Change from Baseline to Endpoint	Headache Baseline (N=450, N=410)	Headache Change from Baseline to Endpoint	Back Pain Baseline (N=450, N=410)	Back Pain Change from Baseline to Endpoint	Shoulder Pain Baseline (N=446, N=410)	Shoulder Pain Change from Baseline to Endpoint	Interference-DailyActivities Baseline(N=445,N=410)	Intereference Change from Baseline to Endpoint	Pain While Awake Baseline (N=446, N=410)	Pain While Awake Change from Baseline to Endpoint
Duloxetine - Acute Phase	34.36	-16.34	29.74	-14.83	28.79	-13.64	24.06	-10.47	33.28	-16.79	38.18	-17.66
Duloxetine - Continuation Phase	17.29	1.16	14.80	0.04	15.61	-0.00	13.49	-0.39	15.59	1.00	19.22	0.06

Intervention	units on a scale (Mean)
	Baseline	Change from Baseline to Endpoint
Duloxetine - Acute Phase	12.64	-5.37
Duloxetine - Continuation Phase	6.88	-0.35

Intervention	units on a scale (Least Squares Mean)
	Change from Baseline to Endpoint in Global Score	Change from Baseline to Endpoint in Work/School	Change from Baseline to Endpoint in Social Life	Change from Baseline to Endpoint in Family Life
Duloxetine	-0.05	0.03	0.02	-0.10
Placebo	2.06	0.83	0.56	0.67

Intervention	units on a scale (Mean)
	Global Score Baseline (N=449,N=378)	Global Score Change from Baseline to Endpoint	Work/School Item Baseline (N=452,N=378)	Work/School Item Change from Baseline to Endpoint	Social Life Item Baseline (N=452,N=378)	Social Life Item Change from Baseline to Endpoint	Family Life Item Baseline (N=452,N=378)	Family Life Item Change from Baseline to Endpoint
Duloxetine - Acute Phase	19.30	-7.88	6.52	-2.61	6.45	-2.69	6.35	-2.59
Duloxetine - Continuation Phase	10.72	-2.01	3.64	-0.71	3.50	-0.64	3.54	-0.63

Intervention	units on a scale (Least Squares Mean)
	Change from Baseline to Endpoint in Anxiety	Change from Baseline to Endpoint in Core	Change from Baseline to Endpoint in Maier	Change from Baseline to Endpoint in Retardation	Change from Baseline to Endpoint in Sleep	Change from Baseline to Endpoint in Depressed Mood
Duloxetine	0.46	0.75	0.91	0.59	0.13	0.27
Placebo	1.54	1.74	2.25	1.49	0.71	0.67

duloxetine hydrochloride

Description

Cross-References

Synonyms (126)

Research Excerpts

Overview

Effects

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (1)

Drug Classes (1)

Protein Targets (51)

Potency Measurements

Inhibition Measurements

Biological Processes (282)

Molecular Functions (86)

Ceullar Components (55)

Bioassays (48)

Research

Studies (1,745)

Market Indicators

Research Demand Index: 72.57

Study Types

Clinical Trials (352)

Trial Overview

Trial Outcomes

Change From Baseline to Endpoint in Arizona Sexual Experience Scale (ASEX) - Acute and Continuation Phases (Males)

Recurrence Count

Mean Values at Endpoint in Patient's Global Impressions of Improvement (PGI-I) - Maintenance Phase

Vital Signs - Change From Baseline to Endpoint in Weight - Acute and Continuation Phases

Vital Signs - Change From Baseline to Endpoint in Pulse - Acute and Continuation Phases

Vital Signs - Change From Baseline to Endpoint in Blood Pressure - Maintenance Phase

Vital Signs - Change From Baseline to Endpoint in Blood Pressure - Acute and Continuation Phases

Treatment-Emergent Adverse Events Occurring in at Least 5 Percent of the Participants -- Open-Label Continuation Phase

Treatment-Emergent Adverse Events Occurring in at Least 5 Percent of Participants -- Open-Label Acute Therapy Phase

Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Uric Acid - Acute Phase

Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Total Protein - Continuation Phase

Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Total Protein - Acute Phase

Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Sodium - Acute Phase

Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Platelet Count - Acute Phase

Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Monocytes - Continuation Phase

Mean Values at Endpoint in Patient's Global Impressions of Improvement (PGI-I) - Acute and Continuation Phases

Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Chloride - Acute Phase

Loss of Response at Any Time

Change From Baseline to Endpoint in Symptom Questionnaire-Somatic Subscale (SQ-SS) - Maintenance Phase

Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Mean Cell Volume (MCV) - Continuation Phase

Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Mean Cell Hemoglobin - Continuation Phase

Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Low Density Lipoprotein (LDL) Cholesterol (Direct) - Continuation Phase

Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Leukocyte Count - Continuation Phase

Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Hemoglobin - Continuation Phase

Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Hemoglobin - Acute Phase

Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Hematocrit - Continuation Phase

Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Hematocrit - Acute Phase

Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Glucose - Maintenance Phase

Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Gamma-Glutamyl Transferase - Continuation Phase

Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Gamma-Glutamyl Transferase - Acute Phase

Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Erythrocyte Count - Continuation Phase

Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Eosinophils - Acute Phase

Change From Baseline to Endpoint in Clinical Global Impressions (CGI) Severity Scale - Maintenance Phase

Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Calcium - Maintenance Phase

Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Calcium - Continuation Phase

Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Calcium - Acute Phase

Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Bilirubin, Total - Continuation Phase

Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Bilirubin, Direct - Continuation Phase

Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Bicarbonate, HCO3 - Continuation Phase

Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Albumin - Continuation Phase

Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Albumin - Acute Phase

Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Alanine Aminotransferase (ALT) - Maintenance Phase

Resource Utilization and Hospitalization Module - Visits to Health Care Providers - Maintenance Phase

Resource Utilization and Hospitalization Module - Visits to Health Care Providers - Acute and Continuation Phases

Resource Utilization and Hospitalization Module - Change From Baseline to Endpoint in Number of Missed Paid Work Hours - Acute and Continuation Phase

Resource Utilization and Hospitalization Module - Change From Baseline to Endpoint in Average Number of Hours Worked in a Week - Acute and Continuation Phases

Percentage of Participants With Greater Than or Equal to 50% Worsening After Time (t) in Days

Percentage of Participants With Depressive Recurrence After Time (t) in Days

Change From Baseline to Endpoint in Visual Analog Scales (VAS) for Pain - Maintenance Phase

Change From Baseline to Endpoint in Visual Analog Scales (VAS) for Pain - Acute and Continuation Phase

Change From Baseline to Endpoint in Symptom Questionnaire-Somatic Subscale (SQ-SS) - Acute and Continuation Phases

Intervention	units on a scale (Mean)
	Anxiety Baseline	Anxiety Change from Baseline to Endpoint	Core Baseline	Core Change from Baseline to Endpoint	Maier Baseline	Maier Change from Baseline to Endpoint	Retardation Baseline	Retardation Change from Baseline to Endpoint	Sleep Baseline	Sleep Change from Baseline to Endpoint	Depressed Mood Baseline	Depressed Mood Change from Baseline to Endpoint
Duloxetine - Acute Phase	7.71	-4.52	8.81	-5.97	11.44	-7.46	7.76	-4.61	3.80	-2.37	2.78	-1.86
Duloxetine - Continuation Phase	2.51	-0.11	2.00	-0.29	2.91	-0.29	2.43	-0.48	1.11	-0.07	0.64	-0.05

Intervention	units on a scale (Least Squares Mean)
	Change from Baseline: Sum Items 1 to 5 (N=35,N=29)	Change from Baseline: Sum Items 1&2 (N=39,N=29)	Item 1-Sex Drive (N=39,N=29)	Item 2-Arousal (N=39,N=29)	Item 3-Lubrication/Erection (N=38,N=29)	Item 4-Orgasm (N=36,N=29)	Item 5-Satisfaction (N=35,N=29)
Duloxetine	-0.97	-0.25	-0.17	-0.09	-0.32	-0.08	-0.13
Placebo	-0.77	0.03	-0.02	0.07	-0.10	-0.43	-0.04

Intervention	units on a scale (Least Squares Mean)
	Change from Baseline:Sum Items 1 to 5 (N=63,N=66)	Change from Baseline:Sum Items 1&2 (N=77,N=79)	Item 1 - Sex Drive (N=77,N=79)	Item 2 - Arousal (N=77,N=79)	Item 3 - Lubrication/Erection (N=63,N=67)	Item 4 - Orgasm (N=63,N=67)	Item 5 - Satisfaction (N=63,N=67)
Duloxetine	-0.65	-0.19	-0.08	-0.12	-0.21	-0.10	-0.05
Placebo	-0.47	0.34	0.18	0.16	-0.15	-0.15	-0.40

Intervention	units on a scale (Mean)
	Sum Items 1 to 5 Baseline (N=220,N=197)	Sum Items 1 to 5 Change to Endpoint	Sum Items 1&2 Baseline (N=285,N=239)	Sum Items 1&2 Change to Endpoint	Item 1-Sex Drive Baseline (N=286,N=239)	Item 1-Sex Drive Change to Endpoint	Item 2-Arousal Baseline (N=286,N=239)	Item 2-Arousal Change to Endpoint	Item 3-Lubrication/Erection Baseline (N=224,N=198)	Item 3-Lubrication/Erection Change to Endpoint	Item 4-Orgasm Baseline (N=224,N=198)	Item4-Orgasm Change to Endpoint	Item 5-Satisfaction Baseline (N=226,N=198)	Item 5-Satisfaction Change to Endpoint
Duloxetine - Acute Phase	21.41	-1.31	9.31	-0.69	4.92	-0.46	4.40	-0.22	3.97	-0.19	4.33	-0.13	3.93	-0.18
Duloxetine - Continuation Phase	19.31	-0.99	8.42	-0.56	4.34	-0.31	4.08	-0.25	3.57	-0.10	4.06	-0.28	3.58	-0.10

Intervention	units on a scale (Least Squares Mean)
	Change from Baseline-Physical Component Summary	Change from Baseline-Mental Component Summary	Change from Baseline-Physical Functioning	Change from Baseline-Bodily Pain	Change from Baseline-Role Limitations: Physical	Change from Baseline-Role Limitations: Emotional	Change from Baseline-General Health Perceptions	Change from Baseline-Mental Health	Change from Baseline-Social Function	Change from Baseline-Vitality	Change from Baseline-Rate Current Health	Change from Baseline-Health Compared to Year Ago
Duloxetine	-0.45	-1.11	0.06	-0.42	0.01	-0.03	-0.23	-0.44	-0.14	-0.77	0.03	0.19
Placebo	0.33	-5.74	-0.07	-0.19	-0.41	-0.46	-0.61	-2.60	-0.50	-1.38	0.08	0.34

Intervention	units on a scale (Mean)
	Physical Component Summary Baseline (N=455,N=377)	Physical Component Summary Change to Endpoint	Mental Component Summary Baseline (N=455,N=377)	Mental Component Summary Change to Endpoint	Physical Functioning Baseline (N=457,N=377)	Physical Functioning Change to Endpoint	Bodily Pain Baseline (N=460,N=377)	Bodily Pain Change from Baseline to Endpoint	Role Limitations:Physical Baseline (N=457,N=377)	Role Limitations:Physical Change to Endpoint	Role Limitations:Emotional Baseline (N=456,N=377)	Role Limitations:Emotional Change to Endpoint	General Health Perceptions Baseline(N=456,N=377)	General Health Perceptions Change to Endpoint	Mental Health Baseline (N=456,N=377)	Mental Health Change from Baseline to Endpoint	Social Function Baseline (N=460,N=377)	Social Function Change from Baseline to Endpoint	Vitality Baseline (N=457,N=377)	Vitality Change from Baseline to Endpoint	Rate Current Health Baseline (N=460,N=377)	Rate Current Health Change to Endpoint	Health Compared to Year Ago Baseline (N=460,N=377)	Health Compared to Year Ago Change to Endpoint
Duloxetine - Acute Phase	43.55	3.86	23.93	14.67	23.59	2.39	6.83	1.61	5.24	1.06	3.42	1.11	13.66	2.93	12.62	6.45	4.77	2.12	8.85	4.51	3.88	-0.72	3.67	-1.18
Duloxetine - Continuation Phase	48.05	0.03	39.83	3.98	26.28	0.28	8.61	0.07	6.48	0.20	4.65	0.34	17.03	0.58	19.60	1.30	7.05	0.65	13.84	0.84	3.03	-0.01	2.37	-0.34

Intervention	Scores on a scale (Mean)
Duloxetine 60mg/Day + Placebo for 18 Weeks (Phase 2)	67.9
Duloxetine 120mg/Day for 18 Weeks (Phase 2)	53.7

Intervention	Scores on a scale (Mean)
Duloxetine 60mg/Day + Placebo for 18 Weeks (Phase 2)	4.42
Duloxetine 120mg/Day for 18 Weeks (Phase 2)	3.60

Intervention	Percentage of participants (Number)
	Baseline (N=33; N=34)	Year 1 (N=23; N=25)	Year 2 (N=11; N=17)
Donepezil	54.10	62.16	36.67
Placebo	61.82	54.35	47.22

Intervention	Z-score (Mean)
	Baseline (N=67;N=63)	Year 1 (N=45; N=57)	Year 2 N=42; N=49)
Donepezil	-0.47	-0.23	-0.31
Placebo	-0.47	-0.65	-0.56